

EXHIBIT 5

In The Matter Of:
In Re: CR Bard 200

Daniel Elliott, M.D.

November 15, 2014

Tiffany Alley Global Reporting & Video

730 Peachtree Street NE

Suite 470

Atlanta, GA 30308

770.343.9696

www.tiffanyalley.com



IN THE UNITED STATES DISTRICT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
CHARLESTON DIVISION

IN RE: C.R. BARD, INC.,
PELVIC REPAIR SYSTEM PRODUCTS
LIABILITY LITIGATION

THIS DOCUMENT RELATES TO ALL
CASES IN MDL NO. 2187 AND
SPECIFICALLY TO:

ROSAIDA ALONSO,
Plaintiff, Civil Action File
No. 2:14-cv-07112

vs.

C.R. BARD, INC.,
Defendant.

PATRICIA BOLYARD, et al.,
Plaintiffs, Civil Action File
No. 2:12-cv-00126

vs.

C.R. BARD, INC.,
Defendant,

MARTINA WHEELER,
Plaintiff, Civil Action File
No. 2:12-cv-04580

vs.

C.R. BARD, INC.,
Defendant.

The videotaped deposition of DANIEL S. ELLIOTT, M.D.,

November 15, 2014

Wexler Wallace, 55 West Monroe Street, Suite
3300, Chicago, Illinois, commencing at 9:23 a.m.

Reporter: Jennifer L. Bernier

.

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 2</p> <p>1 APPEARANCES:</p> <p>2 WAGSTAFF & CARTMELL</p> <p>3 MR. THOMAS CARTMELL</p> <p>4 MR. JEFFREY M. KUNTZ</p> <p>5 4740 Grand Avenue</p> <p>6 Suite 300</p> <p>7 Kansas City, Missouri 64112</p> <p>8 Phone: (816) 701-1100</p> <p>9 E-Mail: tcartmell@wccllp.com</p> <p>10 jkuntz@wccllp.com</p> <p>11 -AND-</p> <p>12 AYLSTOCK, WITKIN, KREIS & OVERHOLTZ, PLLC</p> <p>13 MS. P. ANN GAYLE</p> <p>14 MR. BRANDON S. MORRIS</p> <p>15 17 East Main Street</p> <p>16 Suite 200</p> <p>17 Pensacola, Florida 32502</p> <p>18 Phone: (850) 202-1010</p> <p>19 E-mail: agayle@awkolaw.com</p> <p>20 bmmorris@awkolaw.com</p> <p>21 On behalf of the Plaintiffs;</p> <p>22 REED SMITH</p> <p>23 MS. MELISSA GEIST</p> <p>24 136 Main Street</p> <p>25 Suite 250</p> <p>Princeton Forrestal Village</p> <p>Princeton, New Jersey 08540</p> <p>Phone: (609) 514-5978</p> <p>E-mail: Mgeist@reedsmith.com</p> <p>On behalf of the Defendant.</p> <p>ALSO PRESENT:</p> <p>John Doody, Videographer</p>	<p style="text-align: right;">Page 4</p> <p>1 VIDEO TECHNICIAN: We're now on the record. The</p> <p>2 time is approximately 9:23 a.m. This is the beginning</p> <p>3 of Disc 1 for the video deposition of Dr. Daniel S.</p> <p>4 Elliot.</p> <p>5 Will counsel please identify yourselves for</p> <p>6 the record and state who you represent.</p> <p>7 MR. CARTMELL: Tom Cartmell for the plaintiffs.</p> <p>8 MR. KUNTZ: Jeff Kuntz for the plaintiffs.</p> <p>9 MS. GEIST: Melissa Geist for the defendant, C.R.</p> <p>10 Bard.</p> <p>11 VIDEO TECHNICIAN: Would the court reporter please</p> <p>12 swear in the witness.</p> <p>13 (Witness sworn.)</p> <p>14 WHEREUPON:</p> <p>15 DANIEL S. ELLIOTT, M.D.,</p> <p>16 called as a witness herein, having been first duly</p> <p>17 sworn, was examined and testified as follows:</p> <p>18 DIRECT EXAMINATION</p> <p>19 BY MS. GEIST:</p> <p>20 Q. Good morning, Dr. Elliott.</p> <p>21 A. Good morning.</p> <p>22 Q. We met just before the deposition, correct?</p> <p>23 A. Correct.</p> <p>24 Q. As I told you then, my name is Melissa Geist.</p> <p>25 I'm with the law firm of Reed Smith and we represent</p>
<p style="text-align: right;">Page 3</p> <p>1 WITNESS I N D E X</p> <p>2 PAGE</p> <p>3 DANIEL S. ELLIOTT, M.D.</p> <p>4 Examination by Ms. Geist 4, 139</p> <p>5 Examination By Mr. Cartmell 347</p> <p>6 E X H I B I T S</p> <p>7</p> <p>8 ELLIOTT DEPOSITION EXHIBITS</p> <p>9 PAGE</p> <p>10 No. #1 Notice 5</p> <p>11 No. #2 Expert Report 5</p> <p>12 No. #3 Blandon Article 118</p> <p>13 No. #4 Linder Article 171</p> <p>14 No. #5 AJOG Accepted Manuscript 180</p> <p>15 No. #6 Position Statement 187</p> <p>16 No. #7 Abed Article 198</p> <p>17 No. #8 Withagen Article 203</p> <p>18 No. #9 Carey Article 216</p> <p>19 No. #10 Nieminen Article 223</p> <p>20 No. #11 Nieminen Article 230</p> <p>21 No. #12 Nygaard Article 249</p> <p>22 No. #13 Murphy Article 253</p> <p>23 No. #14 Public Citizen 267</p> <p>24 No. #15 Elliott Current Opinion 273</p> <p>25 No. #16 Elliott Letter to Gov Agency 279</p> <p>No. #17 Levin Papantonio Web Page 283</p> <p>No. #18 Jane Akre 285</p> <p>No. #19 Mayo Clinic POP 287</p> <p>No. #20 De Tayrac Article 311</p> <p>No. #21 Clifton Article 314</p> <p>No. #22 Nilsson Article 316</p> <p>No. #23 AUGS Position Statement 319</p> <p>No. #24 Dora Article 324</p> <p>No. #25 Krambeck Article 329</p> <p>No. #26 Dietz Article 332</p> <p>No. #27 Reliance Documents 358</p> <p>No. #28 Notice 358</p>	<p style="text-align: right;">Page 5</p> <p>1 C.R. Bard in the MDL proceeding in West Virginia</p> <p>2 entitled C.R. Bard Repair System Products Liability</p> <p>3 Litigation. And you've been designated by the</p> <p>4 plaintiffs in that litigation as an expert witness with</p> <p>5 respect to certain general liability opinions, correct?</p> <p>6 A. Correct.</p> <p>7 Q. And you understand we're here today to take</p> <p>8 your deposition in that litigation?</p> <p>9 A. Correct.</p> <p>10 Q. And it's my understanding that today, Doctor,</p> <p>11 we'll focus on your general liability report, and then</p> <p>12 tomorrow we'll focus on your case-specific opinions that</p> <p>13 you've rendered in three cases. Is that your</p> <p>14 understanding as well?</p> <p>15 A. Yes.</p> <p>16 (Elliott Exhibit Nos. 1 & 2 were</p> <p>17 marked for identification.)</p> <p>18 BY MS. GEIST:</p> <p>19 Q. I've marked, as Exhibit 1 to your deposition,</p> <p>20 Doctor, the notice for today's deposition. Do you see</p> <p>21 that?</p> <p>22 A. Yes, I do.</p> <p>23 Q. And I've also marked, as Exhibit 2, a copy of</p> <p>24 your general liability expert report in this litigation.</p> <p>25 And do you see that as well?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 6</p> <p>1 A. Yes, I do.</p> <p>2 Q. That -- that expert report you have in front</p> <p>3 of you, Doctor, that's the only expert report you've</p> <p>4 provided in this litigation other than the three</p> <p>5 case-specific reports, correct?</p> <p>6 A. Correct.</p> <p>7 Q. Does it contain a complete statement of all of</p> <p>8 the opinions you hold in the litigation?</p> <p>9 A. As of this point right now.</p> <p>10 Q. Do you intend to offer any opinions that are</p> <p>11 not set forth in your expert report that's been marked</p> <p>12 as Exhibit 2?</p> <p>13 A. Only if new information were to become</p> <p>14 available to me.</p> <p>15 Q. But at least as of this point, as we're</p> <p>16 sitting here today, all of the opinions that you intend</p> <p>17 to give, if you were called as a witness in this trial,</p> <p>18 for example, are contained in that report; is that fair</p> <p>19 to say?</p> <p>20 A. Correct. And, again, unless you ask another</p> <p>21 question that has not been addressed in this, yes.</p> <p>22 Q. Are all of the facts and the data that you</p> <p>23 considered in reaching your opinions in this litigation</p> <p>24 also contained in that report or in the Materials Relied</p> <p>25 section of that report?</p>	<p style="text-align: right;">Page 8</p> <p>1 A. Yes, I do.</p> <p>2 Q. Is that there on your laptop?</p> <p>3 A. No. The laptop has the Dropbox accounts of</p> <p>4 all of the internal documents. The document I brought</p> <p>5 here, which is the updated bibliography, is exactly what</p> <p>6 you have.</p> <p>7 Q. Okay. So you have it there in front of you in</p> <p>8 paper copy?</p> <p>9 A. Correct.</p> <p>10 Q. So why was there an update in the last couple</p> <p>11 of days?</p> <p>12 A. Because I'm constantly doing research. I'm</p> <p>13 constantly going to meetings. I'm constantly in</p> <p>14 conversations with colleagues. So there's constant</p> <p>15 progression of knowledge.</p> <p>16 Q. So when did you read all of the new materials</p> <p>17 that are set forth in your updated reliance list?</p> <p>18 A. At some point in time between when this was</p> <p>19 turned in until now. So that was October 8th, when this</p> <p>20 was turned in originally, until -- well, I'm constantly</p> <p>21 doing research just as part of my normal workday.</p> <p>22 Q. So between October 8th and now, which is</p> <p>23 November 15th, right?</p> <p>24 A. Yes.</p> <p>25 Q. So in the last four or five weeks or so, you</p>
<p style="text-align: right;">Page 7</p> <p>1 A. As far as the internal documentation, yes.</p> <p>2 That's all. I've read all of those documents. However,</p> <p>3 as far as experience, personal conversations, surgical</p> <p>4 experience, you know, that's not going to necessarily be</p> <p>5 accurately reflected in the -- in my CV or in these</p> <p>6 reliance issues.</p> <p>7 Q. Yep, and that's fair, Doctor. But my question</p> <p>8 really is, all of the documents, the literature and</p> <p>9 other documents that you considered in reaching your</p> <p>10 opinions, are all of those set forth in the reliance</p> <p>11 list that's attached to your report?</p> <p>12 A. I'd say that's a fairly accurate issue. I</p> <p>13 can't attest that there hasn't been some other document,</p> <p>14 medical research literature, that I've read at some</p> <p>15 point in time that's not included in here. But as far</p> <p>16 as to answer your question, this is a very complete list</p> <p>17 of medical literature.</p> <p>18 Q. Yesterday or the day before yesterday -- well,</p> <p>19 certainly in the last couple of days -- we received an</p> <p>20 updated reliance list containing another 120-or-so</p> <p>21 medical articles that counsel stated also formed --</p> <p>22 helped you form the opinions you reached in this</p> <p>23 litigation. Are you aware of that?</p> <p>24 A. Yes, I am.</p> <p>25 Q. And do you have that updated list with you?</p>	<p style="text-align: right;">Page 9</p> <p>1 reviewed an additional, by my count, at least 120 new</p> <p>2 articles?</p> <p>3 A. Sounds about right. But I'm a reviewer for 15</p> <p>4 different journals, national/international journals, and</p> <p>5 I attended a meeting between that time. So that's about</p> <p>6 average.</p> <p>7 Q. So I just want to make sure you answered my</p> <p>8 question. All of the articles that were included in</p> <p>9 your updated reliance list, and, by my count -- and this</p> <p>10 is an estimate. I'll let you know that, Doctor --</p> <p>11 there's about, at least, 120 new articles?</p> <p>12 A. Again, that sounds about right, but the total</p> <p>13 is 509 articles.</p> <p>14 Q. So for the 120-or-so new articles, you read</p> <p>15 those in the last four weeks or so?</p> <p>16 A. Yes.</p> <p>17 Q. How did you come across the new articles?</p> <p>18 A. PubMed searches or as journals come out, the</p> <p>19 International Urogyn Journal comes out, the Journal of</p> <p>20 Urology comes out. I looked an article and that has</p> <p>21 references. A good example of that would have been the</p> <p>22 Zimmerman article, because then that spurs more ideas in</p> <p>23 looking at what their references are.</p> <p>24 Q. So you'll agree with me, I'm sure, Doctor,</p> <p>25 that some of the 120 or so new articles are not new</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 10</p> <p>1 publications, right?</p> <p>2 A. Correct.</p> <p>3 Q. They go back to 2006, 2008, and earlier for</p> <p>4 some of them?</p> <p>5 A. Correct.</p> <p>6 Q. Did -- and you said you did this during your</p> <p>7 own PubMed search?</p> <p>8 A. Correct.</p> <p>9 Q. And did you do a PubMed search prior to the</p> <p>10 time you rendered your expert opinions in this report?</p> <p>11 A. Oh, absolutely. I've used PubMed. There's 24</p> <p>12 million articles in it, so we're using it. That's my</p> <p>13 main search engine.</p> <p>14 Q. So I'm trying to understand why all of the new</p> <p>15 articles weren't included on your original reliance</p> <p>16 list.</p> <p>17 A. Because I'm constantly working on this. This</p> <p>18 is what I do day in and day out as far as taking care of</p> <p>19 patients. Patients come in with new problems. I attend</p> <p>20 meetings. I just got back from a meeting, the South</p> <p>21 Central Section of Urology. There's presentations. So</p> <p>22 it's not a stagnant. We are constantly trying to learn</p> <p>23 to better handle this problem.</p> <p>24 Q. So let me make sure I understand that. Like</p> <p>25 we just agreed, some of the articles date back a long</p>	<p style="text-align: right;">Page 12</p> <p>1 time you do one of those searches -- remember, search 24</p> <p>2 million articles, okay. So each time I do a variant of</p> <p>3 that search, just like you do a Google search with</p> <p>4 different changing words, different articles will pop</p> <p>5 up.</p> <p>6 Q. Well, did the search terms you used during</p> <p>7 this recent PubMed search differ from the original</p> <p>8 search terms you used?</p> <p>9 A. There may be different ones there. But if</p> <p>10 PubMed is screening all journals from around the world,</p> <p>11 journal articles will be popping up differently. So</p> <p>12 it's not a stagnant. Knowledge is not stagnant. It's</p> <p>13 constantly progressing forward.</p> <p>14 Q. Well, you would agree with me, Doctor, that</p> <p>15 the knowledge, as you say, included in some of these</p> <p>16 articles date back more than ten years ago, right?</p> <p>17 A. Some date back to the '70s. Some date back</p> <p>18 probably even earlier than that.</p> <p>19 Q. Did your review of the additional publications</p> <p>20 change or amend or revise your opinions in this</p> <p>21 litigation in any way?</p> <p>22 A. They probably will reinforce or further --</p> <p>23 further deepen the knowledge of the subject. But the</p> <p>24 human pelvis is incredibly complicated. The neurologic</p> <p>25 aspects are incredibly complicated. So, again, it's a</p>
<p style="text-align: right;">Page 11</p> <p>1 time ago, right?</p> <p>2 A. Correct.</p> <p>3 Q. Did you miss them during your original PubMed</p> <p>4 review?</p> <p>5 A. No. That's a very unfair statement to say,</p> <p>6 I've missed something. These are new articles that have</p> <p>7 come out. Like Dr. Zimmerman's article, Mickey Karram's</p> <p>8 article. And they make references to other articles,</p> <p>9 and so we go back and look at that literature.</p> <p>10 Q. So all of the new articles that were added to</p> <p>11 your updated list are here because they were all</p> <p>12 referenced in brand-new publications that you hadn't</p> <p>13 found during your first search.</p> <p>14 A. That's not what I'm saying. As far as this is</p> <p>15 a vast topic, a lot of people are writing on it,</p> <p>16 national and international. And so we can't, on the</p> <p>17 first search through, get every single article. Also,</p> <p>18 as we go along, we start learning about pain. I start</p> <p>19 going into -- I'm a member of the International Pelvic</p> <p>20 Pain Society, okay. So that gets more articles and more</p> <p>21 reading.</p> <p>22 Q. Did you focus on any particular topic or</p> <p>23 subject area when you did your updated PubMed search?</p> <p>24 A. Pelvis, pelvic pain, pelvic pain management,</p> <p>25 pelvic mesh management, pelvic complications. So each</p>	<p style="text-align: right;">Page 13</p> <p>1 deepening of the knowledge.</p> <p>2 Q. Did -- did you feel that you had missed</p> <p>3 anything the first time around?</p> <p>4 A. No. I wouldn't say I missed anything; but,</p> <p>5 again, it's adding to that, the body of knowledge.</p> <p>6 Q. Do you feel that you needed to go back and do</p> <p>7 additional research or reading on any particular topic</p> <p>8 or subject area?</p> <p>9 A. I wouldn't say that, but I'm always open. If</p> <p>10 there's new data that comes out, I'm always open. I'm</p> <p>11 not going to keep a closed mind about anything.</p> <p>12 Q. Did you review all of the articles and</p> <p>13 literature that are contained on your original and</p> <p>14 updated reliance list?</p> <p>15 A. Yes.</p> <p>16 Q. And there is also some depositions listed on</p> <p>17 your reliance list, correct, Doctor?</p> <p>18 A. Yes.</p> <p>19 Q. Did you review the entirety of those</p> <p>20 depositions or did you review excerpts?</p> <p>21 A. I would scan over the entire documents.</p> <p>22 Certain aspects of them are applicable to me, and then</p> <p>23 also these documents are, some of them, 500-or-more</p> <p>24 pages long. So I can't say I read every single word,</p> <p>25 but I would scan through them or find keywords that I</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 14</p> <p>1 was searching for.</p> <p>2 Q. So you didn't read the entirety of the</p> <p>3 deposition transcripts that are listed on your reliance</p> <p>4 list?</p> <p>5 A. I can say I scanned over every single page of</p> <p>6 those documents. Did I read every single word? The</p> <p>7 answer to that is, no.</p> <p>8 Q. But when you say scan, what are we talking</p> <p>9 about? You flipped through and you looked for certain</p> <p>10 keywords?</p> <p>11 A. I'm saying I have it on the desktop and I go</p> <p>12 through the keywords. I search for keywords. I search</p> <p>13 for various different phrases. As you know, certain of</p> <p>14 these depositions, they will go on for 20 or 30 pages</p> <p>15 talking about this type of stuff, which I don't -- I</p> <p>16 don't read every word of.</p> <p>17 Q. So you didn't actually sit down and review or</p> <p>18 read the transcripts. You used your computer and you</p> <p>19 picked out certain search terms. And then when those</p> <p>20 search terms hit in the transcript, those are the pages</p> <p>21 you looked at?</p> <p>22 MR. CARTMELL: Object to the form.</p> <p>23 BY THE WITNESS:</p> <p>24 A. Yeah. That's not what I said. I said I sat</p> <p>25 down. Whether I do it with a paper copy or on a</p>	<p style="text-align: right;">Page 16</p> <p>1 A. Correct.</p> <p>2 Q. So did you read every single exhibit for all</p> <p>3 of the depositions listed on your reliance list, or no?</p> <p>4 A. I can't recall. There's too many there.</p> <p>5 Q. You don't remember if you read every single</p> <p>6 one or not?</p> <p>7 A. No, I can't recall that.</p> <p>8 Q. That was something that was added to your</p> <p>9 updated reliance list, correct, the list of exhibits?</p> <p>10 A. Correct. Yes. And the added ones I know</p> <p>11 because they came in relatively recently. I've gone</p> <p>12 through every single one. I can't speak to all of them</p> <p>13 in the entirety of this whole project, though.</p> <p>14 Q. Well, before you originally provided your</p> <p>15 expert report with your reliance list, you didn't</p> <p>16 include, as part of the documents you relied on, the</p> <p>17 exhibits to the depositions, right?</p> <p>18 A. Again, I have not gone back and compared the</p> <p>19 one prior to October 8th and then the present. So I</p> <p>20 don't know which ones were there. So I can't answer</p> <p>21 your question accurately.</p> <p>22 MR. CARTMELL: And just so you know, Melissa, that,</p> <p>23 I believe, was because obviously we, as lawyers, helped</p> <p>24 put that together, and that was, I think, an omission by</p> <p>25 us.</p>
<p style="text-align: right;">Page 15</p> <p>1 computer -- I suspect you don't print out every single</p> <p>2 deposition and neither do I. So I go through every</p> <p>3 single page.</p> <p>4 Q. And were you given the entirety of the</p> <p>5 transcripts?</p> <p>6 A. As far as I know. I see a beginning and an</p> <p>7 end and where they sign off.</p> <p>8 Q. How about the exhibits to the depositions?</p> <p>9 Did you review all of the exhibits to the depositions?</p> <p>10 A. Yeah. Either I have reviewed the exact</p> <p>11 document or where it's referenced in the deposition</p> <p>12 where they discuss it.</p> <p>13 Q. So are you telling me you didn't necessarily</p> <p>14 review the exhibit, itself, if it was referenced in the</p> <p>15 deposition testimony?</p> <p>16 A. If all there is is a quick reference to</p> <p>17 something, a manuscript, well, then I'll review that one</p> <p>18 in detail. If it's an e-mail where they're using a</p> <p>19 specific quote, I'll review that, the e-mail before and</p> <p>20 the e-mail afterwards, so I can't pick. You know, as</p> <p>21 you know, there's thousands of pages of depositions</p> <p>22 there. Okay. I have looked at them all. I can't</p> <p>23 remember them all by any means.</p> <p>24 Q. So my question actually referred to the</p> <p>25 exhibits.</p>	<p style="text-align: right;">Page 17</p> <p>1 MS. GEIST: So -- thank you, Counsel.</p> <p>2 BY MS. GEIST:</p> <p>3 Q. So let me ask you that, Doctor. How did your</p> <p>4 reliance list come to be prepared? Did you prepare it</p> <p>5 yourself?</p> <p>6 A. The bibliography, the manuscripts reviewed, I</p> <p>7 completed that one completely myself. The documents,</p> <p>8 the internal documents with the Bates numbers, those</p> <p>9 were provided to me. And then how they organized them,</p> <p>10 I did not do that.</p> <p>11 Q. Okay. Well, you have it in front of you,</p> <p>12 don't you, Doctor?</p> <p>13 A. Yes.</p> <p>14 Q. Let's -- and you can look at your updated one.</p> <p>15 It doesn't matter to me which one you look at.</p> <p>16 A. The reliance list I don't have with me. I'll</p> <p>17 go off of this copy here.</p> <p>18 Q. Okay. Let's just go through it sort of</p> <p>19 methodically, shall we? Do you have it there in front</p> <p>20 of you, Doctor?</p> <p>21 A. Yes, I do. Yeah. I have the reliance list</p> <p>22 starting with the Bard documents.</p> <p>23 Q. Great. Okay. So the reliance list starts</p> <p>24 with a list of Bard documents, as you've just indicated,</p> <p>25 and most of them are preceded with what we call a Bates</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 18</p> <p>1 stamp, right, an AVA number?</p> <p>2 A. Correct.</p> <p>3 Q. Do you see that? And the list goes on for a</p> <p>4 few pages, right?</p> <p>5 A. Correct.</p> <p>6 Q. So all of the -- all of the documents that are</p> <p>7 reflected here, on this part of your reliance list, were</p> <p>8 provided to you by counsel, correct?</p> <p>9 A. Well, yes. It has a Bates number on it. I</p> <p>10 would have no access to that otherwise.</p> <p>11 Q. Okay.</p> <p>12 A. So, yeah, that was provided by the lawyers.</p> <p>13 Q. Okay. So fair to say that the lawyers</p> <p>14 selected which of the Bard documents that you were</p> <p>15 reviewing in order to inform your opinions?</p> <p>16 A. No. That would be incorrect. I asked -- I</p> <p>17 was very clear with the lawyers. I wanted provided all</p> <p>18 information, pro and con, concerning the situation at</p> <p>19 hand with the mesh product, the Avaulta mesh. These</p> <p>20 were provided to me by the lawyers. So I can't say.</p> <p>21 Again, that's what I asked. This is what was provided.</p> <p>22 Q. After you reviewed the documents that were</p> <p>23 selected for your review by counsel, did you ask for any</p> <p>24 additional Bard documents?</p> <p>25 A. Absolutely.</p>	<p style="text-align: right;">Page 20</p> <p>1 MSDS issues, so to speak, in some of the documents you</p> <p>2 were provided initially, correct?</p> <p>3 A. Correct.</p> <p>4 Q. And then, in response to that, you said, Hey,</p> <p>5 Counsel, give me everything on this issue. I want to</p> <p>6 review the whole topic. Is that fair to say?</p> <p>7 A. Partially. I reviewed the issue. I wanted to</p> <p>8 make sure I had all of the documents, whether or not</p> <p>9 more were there and not provided yet or if I did have</p> <p>10 all of the documents, because I never know if I'm</p> <p>11 getting all of the documents. I don't know what else is</p> <p>12 out there. That's why I always ask for all.</p> <p>13 Q. Right. So that was my question. You don't</p> <p>14 know if you have all of the documents on the issue,</p> <p>15 correct?</p> <p>16 A. Well, of course not. I don't know if I have</p> <p>17 all, but I have asked for all.</p> <p>18 Q. You've asked for all?</p> <p>19 A. Correct.</p> <p>20 Q. Okay. Any other topics, like the MSDS topic,</p> <p>21 that you can think of that you asked for additional</p> <p>22 information about?</p> <p>23 A. Actually, yes. I can think of another one</p> <p>24 pertaining to pore size. Again, it was the same as the</p> <p>25 other issue. I asked for all documents, what they had,</p>
<p style="text-align: right;">Page 19</p> <p>1 Q. And do you know, from looking at this list,</p> <p>2 which of the documents you asked for?</p> <p>3 A. Well, no. Not -- based upon these numbers,</p> <p>4 no, I would not be able to tell that.</p> <p>5 Q. Okay. How about generally speaking? Do you</p> <p>6 remember sitting here today, after you reviewed the</p> <p>7 initial set of Bard documents that were provided to you</p> <p>8 by the plaintiffs' lawyers, what else did you ask to</p> <p>9 look at?</p> <p>10 A. Again, this has been going on for, what, four</p> <p>11 or five months now, so I can't speak specifically to all</p> <p>12 that I asked for. Most specifically, from my expert</p> <p>13 report concerning the MSDS, I wanted to review in detail</p> <p>14 all of the internal documents pertaining to the e-mails</p> <p>15 exchanged concerning the resin toxin, et cetera. So</p> <p>16 that's the one I can think of off the top of my head. I</p> <p>17 can't think of all of the others. This has been going</p> <p>18 on too long to know all of the specifics, but that one I</p> <p>19 know I did ask for.</p> <p>20 Q. All right. So you asked for additional</p> <p>21 information, internal e-mails, on the MSDS issue?</p> <p>22 A. I asked for all of the available information</p> <p>23 on this situation. So let's put it that way. And that</p> <p>24 was what was provided to me.</p> <p>25 Q. Okay. So just so I understand, you saw the</p>	<p style="text-align: right;">Page 21</p> <p>1 based upon the internal documentation of the pore size</p> <p>2 of the mesh of the Avaulta Plus, the Avaulta Solo.</p> <p>3 Also, on the -- what was known. I wanted to know all of</p> <p>4 the issues. There's biocompatibility studies pertaining</p> <p>5 to the products, all of the Bard products.</p> <p>6 And as I go down my list -- oh, and, also, the</p> <p>7 last one, as far as the IFUs, I wanted to be provided</p> <p>8 all of the IFUs, not just a specific year. Because,</p> <p>9 again, I don't know what versions of IFUs are out there,</p> <p>10 so I asked for all of the IFUs regardless of date.</p> <p>11 Q. So just to recap, in addition to the MSDS</p> <p>12 issue, you wanted to make sure, before you informed your</p> <p>13 opinions, that you had all of the documents on the pore</p> <p>14 size issue, correct?</p> <p>15 A. Well, on that one specific issue, yes. I just</p> <p>16 wanted to be provided with everything.</p> <p>17 Q. And the same with biocompatibility? You</p> <p>18 wanted to look at all of the studies relating to</p> <p>19 biocompatibility for the Bard products?</p> <p>20 A. Correct, related to its 510(k) submission.</p> <p>21 Q. And the same thing with the IFUs, Doctor? You</p> <p>22 wanted to see all versions of the IFUs for both the</p> <p>23 Avaulta anterior and posterior products?</p> <p>24 A. Yeah, all of the Avaulta products, yes. And</p> <p>25 the ones that I listed there are the ones I can think of</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 22</p> <p>1 off the top of my head. If I were to go through the</p> <p>2 entire expert report, we'd probably come up with more.</p> <p>3 Q. And were you provided additional information</p> <p>4 as you asked for it?</p> <p>5 A. If it had been available. Sometimes I already</p> <p>6 had all of the information.</p> <p>7 Q. Now, flipping with me, Doctor, to the section</p> <p>8 of your reliance list entitled Depositions-Testimony.</p> <p>9 A. I have the section. It doesn't have a page</p> <p>10 number, but it just says, Depositions.</p> <p>11 Q. Okay. And, Doctor, you're looking at what</p> <p>12 we've marked as Exhibit 2, which is your generic expert</p> <p>13 report, correct?</p> <p>14 A. Correct.</p> <p>15 Q. And with that report came the original</p> <p>16 reliance list, right?</p> <p>17 A. Correct.</p> <p>18 Q. And you have in front of you there a paper</p> <p>19 version of the updated reliance list, correct?</p> <p>20 A. What you've provided me today, yeah. I don't</p> <p>21 have a personal copy of the updated one.</p> <p>22 Q. Oh, I thought you said you had it there.</p> <p>23 A. No, no. My records, that I brought with me, I</p> <p>24 do not have an updated reliance. I have what you</p> <p>25 provided today, or whoever provided it. I don't know</p>	<p style="text-align: right;">Page 24</p> <p>1 that's the only exhibits that are listed with this one.</p> <p>2 Q. Did you ask for any of the exhibits that were</p> <p>3 marked at all of the other depositions?</p> <p>4 A. Oh, I can't, I mean --</p> <p>5 MR. CARTMELL: Well, again, I think I told you, for</p> <p>6 your clarification, that I think not including the</p> <p>7 exhibits in the first round was the lawyers' fault.</p> <p>8 That's my understanding.</p> <p>9 BY MS. GEIST:</p> <p>10 Q. Okay. So let me just ask you. When you</p> <p>11 originally formed your opinions in this case and</p> <p>12 provided your expert report, had you already had all of</p> <p>13 the exhibits to the depositions that are listed here?</p> <p>14 A. Yes. I had what is listed here; and in the</p> <p>15 various different depositions, I would have used those.</p> <p>16 Q. And it appears to me, from looking at the</p> <p>17 updated reliance list, Dr. Elliott, that you also looked</p> <p>18 at one additional transcript from the time you provided</p> <p>19 your expert report; is that right?</p> <p>20 A. I don't understand what you mean a transcript.</p> <p>21 You mean a deposition?</p> <p>22 Q. Yeah. Well, let me -- let me ask it</p> <p>23 differently. After you reviewed the depositions that</p> <p>24 are listed on your reliance list, did you ask to see any</p> <p>25 other depositions that were taken in the Bard</p>
<p style="text-align: right;">Page 23</p> <p>1 who provided it.</p> <p>2 Q. Okay. So --</p> <p>3 MR. CARTMELL: Does Exhibit --</p> <p>4 THE WITNESS: Exhibit 2.</p> <p>5 MR. CARTMELL: -- 2 have an updated reliance list?</p> <p>6 MS. GEIST: It does not. Exhibit 2 is the</p> <p>7 originally provided expert report with the original</p> <p>8 reliance list.</p> <p>9 BY THE WITNESS:</p> <p>10 A. Then I do not have an updated reliance list.</p> <p>11 Q. Okay. I misunderstood. I thought you said</p> <p>12 you had it there.</p> <p>13 A. No. I'm sorry. I have my bibliography, but</p> <p>14 the reliance list -- well, which is part of the reliance</p> <p>15 list, obviously. But I did not bring the Bates numbers,</p> <p>16 depositions, exhibits, I did not bring an updated one of</p> <p>17 those.</p> <p>18 Q. Okay. Well, let me ask you this. So, in your</p> <p>19 original Materials Relied list, there is a list of</p> <p>20 depositions that you're looking at there, right, Doctor?</p> <p>21 A. That is correct.</p> <p>22 Q. And it doesn't have with that a list of any</p> <p>23 exhibits to those depositions, correct?</p> <p>24 A. Well, it has exhibits listed down below from</p> <p>25 Dr. Ross's deposition. But Dr. Ross -- that appears</p>	<p style="text-align: right;">Page 25</p> <p>1 litigation?</p> <p>2 A. I did ask. I can't recall who it was.</p> <p>3 Because as I read depositions, in there they will make</p> <p>4 reference to other depositions. I would be able to</p> <p>5 think of a specific example of that one back to SDMS</p> <p>6 (sic) issue where they made a reference to a Chevron or</p> <p>7 Phillips employee. I wanted to see what his comments</p> <p>8 were, so I requested that.</p> <p>9 Q. Okay. That employee's name is Frank. And</p> <p>10 I'll --</p> <p>11 A. Zakrzewski, or something like that, yeah.</p> <p>12 Q. Right, Z-A-K-R-Z-E-W-S-K-I. So that was on</p> <p>13 your updated reliance list?</p> <p>14 A. Correct. That was just an example of it.</p> <p>15 Again, I can't -- because, you know, these are hundreds</p> <p>16 of pages long. There's references around, so I'll ask</p> <p>17 for clarification. I might not ask for the entire</p> <p>18 document. I might say, Pertaining to this specific,</p> <p>19 what was said?</p> <p>20 Q. So when you asked for the deposition of the</p> <p>21 Phillips Sumika representative on the MSDS issue, did</p> <p>22 you review the entire transcript?</p> <p>23 A. No. I asked -- I wanted to know the specific</p> <p>24 comments that were made, so I did not review the entire</p> <p>25 document.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 26</p> <p>1 Q. So did you get the entire document or did you 2 just get excerpts?</p> <p>3 A. I got excerpts.</p> <p>4 Q. Did you ask to see the entire document?</p> <p>5 A. I don't recall what I asked for. I had a 6 specific question about a specific reference from a 7 deposition, so I wanted to know specifically what was 8 going on. So I didn't ask for the entire document, I 9 don't recall.</p> <p>10 Q. Do you know what pages you got from that 11 deposition?</p> <p>12 A. No, I do not.</p> <p>13 Q. You have your laptop here with you, right?</p> <p>14 A. Yes, I do.</p> <p>15 Q. Do you have it there on your laptop?</p> <p>16 A. I would have, probably, an e-mail, an internal 17 correspondence with the lawyers, but then it wouldn't 18 have any -- it would have, again, the specifics. I 19 don't know if it would have a date on there or anything.</p> <p>20 Q. So you don't have the excerpts of the --</p> <p>21 A. Oh, I have the excerpts. I have the expert 22 was -- here, I can provide that for you, if you'd like 23 that.</p> <p>24 Q. Well, I'm trying to find out, Doctor, what 25 portions of that Phillips Sumika witness testimony you</p>	<p style="text-align: right;">Page 28</p> <p>1 BY MS. GEIST:</p> <p>2 Q. Did you only review the two pages of the 3 deposition?</p> <p>4 A. That's all I recall reviewing.</p> <p>5 Q. And then, Doctor, the -- what I'll call the 6 third part of your reliance list relates to literature, 7 articles, or I think you called it your bibliography, 8 right?</p> <p>9 A. Correct.</p> <p>10 Q. And when you say bibliography -- and you have 11 a hard copy there in front of you?</p> <p>12 A. That's correct, yes.</p> <p>13 Q. -- we're talking about the same thing, right?</p> <p>14 A. The same -- same thing. That is correct. I 15 just called it a bibliography, though.</p> <p>16 Q. All right. And you already told me that, for 17 each and every article cited here, there are a total of 18 509?</p> <p>19 A. Correct.</p> <p>20 Q. And you read all of them?</p> <p>21 A. I read most every bit of all of 22 them.</p> <p>23 Q. Every page of every article?</p> <p>24 A. I said most every bit of all of them.</p> <p>25 Q. Do you know which articles you skimmed and</p>
<p style="text-align: right;">Page 27</p> <p>1 reviewed.</p> <p>2 A. Okay. I'll give it to you. Zakrzewski, 3 Z-A-K-R-Z-E-W-S-K-I, deposition. I don't have the date, 4 but page No. 204 and 205.</p> <p>5 Q. So you reviewed two pages of the deposition 6 from the Phillips Sumika representative on the MSDS 7 topic?</p> <p>8 A. That is correct.</p> <p>9 Q. Do you think that was enough for you to get 10 the full picture of what that company representative had 11 to say on the issue?</p> <p>12 A. I don't know. If you have more information on 13 it, I would like to hear it.</p> <p>14 MR. CARTMELL: Just so you know, he was provided 15 the whole deposition.</p> <p>16 MS. GEIST: Well, I -- I'm going to object to any 17 testimony by counsel. I mean, he's already said he 18 looked at two pages.</p> <p>19 MR. CARTMELL: Do you want him to be accurate on 20 what he was provided? He can tell you what he's 21 reviewed; but, I mean, I think you would want it to be 22 accurate on what he was provided.</p> <p>23 I'm just telling you he was given the 24 entire deposition. He may not remember it, but he 25 was.</p>	<p style="text-align: right;">Page 29</p> <p>1 which you thoroughly reviewed?</p> <p>2 A. I do not recall.</p> <p>3 Q. Do you know what percentage of the articles 4 listed here you reviewed in their entirety versus 5 skimming?</p> <p>6 A. As I said, I'm a reviewer for 15 journals. 7 Two years in a row I was best reviewer for Journal of 8 Urology and Female Urology section. So I do this for a 9 living. And so I read almost everything of almost all 10 of the articles. All of them I can't recall the 11 specifics.</p> <p>12 Q. So almost everything of almost all of the 13 articles; is that your answer?</p> <p>14 A. That is correct.</p> <p>15 Q. Doctor, we'll obviously talk a lot today about 16 your opinions that you've rendered in this litigation on 17 behalf the plaintiffs, but let me ask you a couple of 18 questions about what you're not going to opine about. 19 Okay?</p> <p>20 A. Okay.</p> <p>21 Q. You're not offering any opinions relating to 22 Bard's products as being less safe or more risky than 23 any other manufacturer's product used to treat pelvic 24 organ prolapse; is that correct?</p> <p>25 MR. CARTMELL: Object to the form.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 30</p> <p>1 BY THE WITNESS:</p> <p>2 A. I'd have to kind of, maybe, have you rephrase</p> <p>3 the question. I don't quite understand.</p> <p>4 Q. Sure.</p> <p>5 A. Please just ask it again.</p> <p>6 Q. Sure. Are you offering any opinions that</p> <p>7 Bard's Avaulta products are less safe or more risky than</p> <p>8 any other manufacturer's mesh product used to treat</p> <p>9 pelvic organ prolapse?</p> <p>10 MR. CARTMELL: Same objection.</p> <p>11 BY THE WITNESS:</p> <p>12 A. Okay. I would have to say that I would offer</p> <p>13 an opinion that it would be at a higher risk for further</p> <p>14 complications based upon the product design and</p> <p>15 implantation.</p> <p>16 Q. So that's not in your expert report anywhere.</p> <p>17 MR. CARTMELL: Object to the form.</p> <p>18 BY MS. GEIST:</p> <p>19 Q. Do you have any statements, in your expert</p> <p>20 report, that Bard's Avaulta products are more risky or</p> <p>21 less safe than another manufacturer's pelvic organ</p> <p>22 prolapse product?</p> <p>23 A. Not directly. Indirectly it is.</p> <p>24 Q. So what's your opinion on that?</p> <p>25 A. That they're at higher risk based upon the</p>	<p style="text-align: right;">Page 32</p> <p>1 Q. And the basis for that opinion is, one, that</p> <p>2 the Bard products have four arms; is that right?</p> <p>3 A. No. Again, that's a summary of what is in my</p> <p>4 report. The report gives it more generally -- more</p> <p>5 specifically. But the arms are more dense, there is no</p> <p>6 plastic covering over the arms causing sawing is another</p> <p>7 one that's in there, and then the porcine collagen. And</p> <p>8 off the top of my head, without reviewing it page by</p> <p>9 page, those are the ones that come to mind.</p> <p>10 Q. Well, Doctor, you just said it's in my report.</p> <p>11 But there's nowhere in your report, is there, where you</p> <p>12 provide the opinion that Bard's products, Bard's Avaulta</p> <p>13 products, are more risky or less safe than the AMS,</p> <p>14 Boston Scientific, and Ethicon's pelvic organ prolapse</p> <p>15 products?</p> <p>16 A. Well --</p> <p>17 Q. It's nowhere in the report, correct?</p> <p>18 MR. CARTMELL: Object to form.</p> <p>19 BY THE WITNESS:</p> <p>20 A. That's because I'm not providing an opinion</p> <p>21 today on those other products. We're not doing a</p> <p>22 comparative. We're just doing --</p> <p>23 Q. Well, that's what I'm asking you.</p> <p>24 A. Well, number one, you interrupted me.</p> <p>25 Q. I apologize. I don't mean to do that.</p>
<p style="text-align: right;">Page 31</p> <p>1 design of the product. And it's in my expert report,</p> <p>2 specifically in -- starting on page 21 where I talk</p> <p>3 about the arms of the Avaulta Solo and the Avaulta Plus</p> <p>4 being unreasonably dense. That is one section. Those</p> <p>5 arms are more dense than the other available products.</p> <p>6 Number two, on the mesh design where collagen</p> <p>7 is implanted, that makes it a different product than the</p> <p>8 other ones. It makes it unique. So I discuss it in</p> <p>9 there. I have what's on page 23, using the porcine</p> <p>10 collagen greater inflammatory response.</p> <p>11 Off the top of my head, those are the two</p> <p>12 issues that would say, I would say, that it is at higher</p> <p>13 risk for complications than the other available</p> <p>14 products.</p> <p>15 Q. So when you talk about the other available</p> <p>16 products, what products are you talking about</p> <p>17 specifically?</p> <p>18 A. The -- well, to the best of my knowledge, none</p> <p>19 of them are available anymore. But AMS Apogee/Perigee,</p> <p>20 Boston Scientific Pinnacle, the Ethicon's Prolift</p> <p>21 Anterior/Posterior Total.</p> <p>22 Q. So it's your opinion that the Bard Avaulta</p> <p>23 products are more risky and less safe than the AMS,</p> <p>24 Boston Scientific, and Ethicon products?</p> <p>25 A. That's what I've indicated in my report, yes.</p>	<p style="text-align: right;">Page 33</p> <p>1 A. I was still talking.</p> <p>2 Q. Hold on. Hold on. We can't talk over one</p> <p>3 another. You're a fast talker, Doctor, and sometimes so</p> <p>4 am I. So I don't mean to be rude. I do apologize. I</p> <p>5 do want to let you finish your testimony, and I will try</p> <p>6 my best not to step on your words. So go ahead.</p> <p>7 A. Can you read back where I was?</p> <p>8 Q. Well, why don't we just start with a new</p> <p>9 question. I think it's the same question.</p> <p>10 What I was saying to you, Doctor, is, let me</p> <p>11 make sure you understand the process. Okay? In</p> <p>12 litigation when somebody is an expert witness, they give</p> <p>13 what's called the expert report. And you've been an</p> <p>14 expert witness before, correct?</p> <p>15 A. Yes.</p> <p>16 Q. You're sort of familiar with this process?</p> <p>17 A. On the periphery. I'm not a lawyer.</p> <p>18 Q. Understood. But us lawyers have certain</p> <p>19 rules, and we are entitled to notice about the issues</p> <p>20 and the opinions that an expert is going to give at a</p> <p>21 trial in the case. Do you understand that?</p> <p>22 A. Yes.</p> <p>23 Q. And the report --</p> <p>24 MR. CARTMELL: I would just object to the form.</p> <p>25</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 34</p> <p>1 BY MS. GEIST:</p> <p>2 Q. The report is supposed to contain all of the</p> <p>3 opinions that an expert is going to talk about at a</p> <p>4 trial. Okay. That's sort of the rules of the game, if</p> <p>5 you will. Do you understand that?</p> <p>6 MR. CARTMELL: Object to the form. And I'll move</p> <p>7 to strike the legal statements of counsel. Go ahead.</p> <p>8 BY MS. GEIST:</p> <p>9 Q. So that's what -- that's what I'm getting at,</p> <p>10 Doctor. I'm trying to understand, if you hold any</p> <p>11 opinions that the Bard Avaulta products are more risky</p> <p>12 or less safe than the AMS, Boston Scientific, and</p> <p>13 Ethicon products also used to repair pelvic organ</p> <p>14 prolapse.</p> <p>15 MR. CARTMELL: Okay. Is that a question?</p> <p>16 MS. GEIST: Yes.</p> <p>17 MR. CARTMELL: Okay. You've asked him that</p> <p>18 question and he's answered it. So objection, asked and</p> <p>19 answered.</p> <p>20 BY MS. GEIST:</p> <p>21 Q. So do you have an opinion, Doctor, that you</p> <p>22 plan on giving in this litigation that the Bard Avaulta</p> <p>23 products are more risky or less safe than the AMS,</p> <p>24 Boston Scientific, and Ethicon products?</p> <p>25 MR. CARTMELL: Same objection. Asked and answered.</p>	<p style="text-align: right;">Page 36</p> <p>1 more risky than the AMS, Boston Scientific, and Ethicon</p> <p>2 products? There's nowhere in the report that says that.</p> <p>3 There's no comparative analysis, correct?</p> <p>4 MR. CARTMELL: Object to the form.</p> <p>5 BY THE WITNESS:</p> <p>6 A. If you want -- I disagree. I wholeheartedly</p> <p>7 disagree.</p> <p>8 Q. Well, show me in your report where --</p> <p>9 A. You interrupted me again when you said you</p> <p>10 weren't.</p> <p>11 Q. I thought you were finished.</p> <p>12 MR. CARTMELL: Just let him finish.</p> <p>13 BY THE WITNESS:</p> <p>14 A. I'm right in the middle of a sentence.</p> <p>15 MR. CARTMELL: Just let him finish. Go ahead.</p> <p>16 BY THE WITNESS:</p> <p>17 A. Avaulta Plus porcine causes even greater</p> <p>18 response, inflammatory response, than the synthetic</p> <p>19 polypropylene mesh alone; AMS, synthetic mesh alone;</p> <p>20 Ethicon, synthetic mesh alone; Boston Scientific,</p> <p>21 synthetic mesh alone. That is a statement saying there</p> <p>22 is even greater inflammatory response.</p> <p>23 Q. Are you finished?</p> <p>24 A. Yes.</p> <p>25 Q. So that relates only to the Avaulta Plus</p>
<p style="text-align: right;">Page 35</p> <p>1 BY THE WITNESS:</p> <p>2 A. If I am asked that question, I will render</p> <p>3 that opinion. If I'm not asked that question, I won't.</p> <p>4 MR. CARTMELL: And you just asked him that.</p> <p>5 BY MS. GEIST:</p> <p>6 Q. So what I'm trying to find out now, okay,</p> <p>7 because this wasn't in your report -- it's not in your</p> <p>8 report, right, these statements you're telling me now?</p> <p>9 MR. CARTMELL: Object to the form.</p> <p>10 BY THE WITNESS:</p> <p>11 A. I've already answered that. It is -- it is</p> <p>12 stated in there. It's not stated in the exact words</p> <p>13 you're talking about. But we're saying in there,</p> <p>14 specifically, on page 23, Avaulta Plus porcine collagen</p> <p>15 caused even greater response than synthetic</p> <p>16 polypropylene mesh alone.</p> <p>17 Okay. That is an opinion against Avaulta</p> <p>18 that -- Avaulta Plus that causes higher complications</p> <p>19 than the other polypropylene meshes. So I have stated</p> <p>20 it. I just didn't use the exact words you want me to</p> <p>21 use.</p> <p>22 Q. Well, I don't want you to use any words,</p> <p>23 Doctor. I'm trying to understand exactly what your</p> <p>24 testimony would be at the trial. There is nowhere in</p> <p>25 your report that says Bard's products are less safe or</p>	<p style="text-align: right;">Page 37</p> <p>1 product, correct, the collagen polypropylene product?</p> <p>2 A. Correct. As stated there, yes.</p> <p>3 Q. What sort of comparative analysis have you</p> <p>4 done, Doctor, comparing Bard's Avaulta Plus porcine</p> <p>5 collagen product to other products?</p> <p>6 A. I compare it to the available literature out</p> <p>7 there; specifically, with the Prolift product because</p> <p>8 there is the most literature on that. Unfortunately,</p> <p>9 there is very, very little Avaulta data out there. But</p> <p>10 I also compare it to the available literature and</p> <p>11 experience dealing with porcine and collagen when placed</p> <p>12 transvaginally or in the abdominal wall for that matter,</p> <p>13 too.</p> <p>14 Q. So can you point me to any study where the</p> <p>15 Avaulta Plus collagen polypropylene product was compared</p> <p>16 to another mesh product?</p> <p>17 A. Paraiso, et al., Rectocele Repair: A</p> <p>18 Randomized Trial of Three Surgical Techniques Including</p> <p>19 Graft Augmentation, from 2006, where there they had a</p> <p>20 collagen graft with an increased failure rate that it</p> <p>21 was theorized due to impaired healing.</p> <p>22 Q. And which products were involved in that</p> <p>23 study?</p> <p>24 A. That was a collagen graft. I would have to go</p> <p>25 back and look at the exact study to find out what</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 38</p> <p>1 that -- what were involved.</p> <p>2 Q. Well, was it the Avaulta product?</p> <p>3 A. Again, I would have to -- I would have to go</p> <p>4 back and look at that study.</p> <p>5 Q. You can't tell me sitting here now?</p> <p>6 A. I cannot tell you sitting here now, no.</p> <p>7 Q. I'm looking for any study, Doctor, where the</p> <p>8 Avaulta product was specifically compared to the AMS,</p> <p>9 Boston Scientific, or Ethicon product and they did a</p> <p>10 comparative analysis of incident rates.</p> <p>11 A. When I searched PubMed, which is 24 million</p> <p>12 articles, and searched Avaulta, I don't believe I was</p> <p>13 able to find any study where that was done, which would</p> <p>14 have been a very nice study to have been done, to see if</p> <p>15 it was a better product.</p> <p>16 Q. Is there any study out there that looked at</p> <p>17 the comparative incident rates between the Bard products</p> <p>18 and these other products that you mentioned to me that</p> <p>19 you say are less safe or more risky?</p> <p>20 A. I do not recall, in those specific words, a</p> <p>21 randomized controlled trial of the other products with</p> <p>22 the Avaulta Plus.</p> <p>23 Q. So, in other words, Doctor, there is no study</p> <p>24 that has compared the incident rates, for example, of</p> <p>25 erosion, pain, or dyspareunia, of the Avaulta products</p>	<p style="text-align: right;">Page 40</p> <p>1 correct?</p> <p>2 MR. CARTMELL: Okay. Object to the form. That's</p> <p>3 argumentative and completely misstates his prior</p> <p>4 testimony related to the literature on that.</p> <p>5 BY MS. GEIST:</p> <p>6 Q. Correct?</p> <p>7 MR. CARTMELL: Same objection.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Incorrect. I disagree completely. I can</p> <p>10 point you to many studies talking about the Avaulta Plus</p> <p>11 or anything containing collagen transvaginal showing a</p> <p>12 higher impaired healing rate.</p> <p>13 Q. That's not my question, Doctor. My question</p> <p>14 is this. I asked you to tell me about a single solitary</p> <p>15 study, industry-sponsored or otherwise, that looked at</p> <p>16 the comparative incident rates of adverse events between</p> <p>17 the Avaulta Plus products and other mesh manufacturers'</p> <p>18 products and concluded that the Avaulta products were</p> <p>19 less safe or more risky. And you can't point me to a</p> <p>20 single solitary study that does that; isn't that true?</p> <p>21 MR. CARTMELL: Okay. Object to the form. Just for</p> <p>22 clarification, are you talking about a head-to-head RCT</p> <p>23 Avaulta Plus versus another product?</p> <p>24 MS. GEIST: I think my question is clear, and you</p> <p>25 have made your objection. It doesn't have to be a</p>
<p style="text-align: right;">Page 39</p> <p>1 to other mesh products; is that true?</p> <p>2 A. I am unaware, as we sit here now, of any</p> <p>3 randomized, controlled, non-industry-sponsored trial</p> <p>4 comparing those two products head to head.</p> <p>5 Q. How about any trial? Forget about randomized</p> <p>6 or industry sponsored. How about any trial? Can you</p> <p>7 point me to any study, whatsoever, that did this type of</p> <p>8 comparative analysis, the Bard product versus the other</p> <p>9 products, and concluded that the Bard products were less</p> <p>10 safe or more risky? Can you point me to one single</p> <p>11 solitary study?</p> <p>12 A. The studies I can quote to you are not a</p> <p>13 head-to-head comparison. They are either comparing the</p> <p>14 native tissue, native repairs, the Avaulta Plus, or just</p> <p>15 Avaulta Plus, period. You then have to look at the body</p> <p>16 of knowledge out there and the data and could then</p> <p>17 compare those to the erosion rate, the infection rate,</p> <p>18 the pain rate, delayed healing rate, the other products</p> <p>19 with the Avaulta Plus.</p> <p>20 Q. All right. So let me ask it a different way.</p> <p>21 Since there's no -- we know there's no head-to-head</p> <p>22 study that looked at the Bard products versus these</p> <p>23 other products that you say are more safe or less risky.</p> <p>24 There's no study out there. This is just your opinion</p> <p>25 unsupported by any single article or medical literature,</p>	<p style="text-align: right;">Page 41</p> <p>1 randomized controlled trial. Any study, any.</p> <p>2 MR. CARTMELL: Well, okay, it's been asked and</p> <p>3 answered.</p> <p>4 BY THE WITNESS:</p> <p>5 A. I think I can do better than that and compare</p> <p>6 it to the literally hundreds of pages of articles out</p> <p>7 there on other products and then comparing it to the</p> <p>8 very few on Avaulta Plus. To isolate it to just one</p> <p>9 randomized controlled trial, it would be helpful, but it</p> <p>10 does not exclude the knowledge gathered from the other</p> <p>11 studies.</p> <p>12 Q. Doctor, you're not answering my question. You</p> <p>13 know, I've asked it now three different times. And if</p> <p>14 you're having a hard time understanding me, then let me</p> <p>15 know.</p> <p>16 MR. CARTMELL: We're not --</p> <p>17 BY MS. GEIST:</p> <p>18 Q. I want to know --</p> <p>19 MR. CARTMELL: Melissa --</p> <p>20 BY MS. GEIST:</p> <p>21 Q. -- and I'd like to move on the articles --</p> <p>22 MR. CARTMELL: Listen -- no, no, no.</p> <p>23 MS. GEIST: You're interrupting me. You're</p> <p>24 interrupting me.</p> <p>25 MR. CARTMELL: I am interrupting you because here</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 42</p> <p>1 is the problem. Your statements by counsel, okay, that</p> <p>2 he's not answering your question, when you've asked</p> <p>3 multiple different questions, you keep saying it's the</p> <p>4 same one, but it's not, is unfair to the witness and</p> <p>5 harassing. All right. So he's answered your question</p> <p>6 multiple times. And I'll let you ask it one more time</p> <p>7 and then we're moving on. I'm not going to let him</p> <p>8 answer it.</p> <p>9 BY MS. GEIST:</p> <p>10 Q. So my question is, Doctor, you can't point me</p> <p>11 to a single study, whether it's industry-sponsored or</p> <p>12 otherwise, a single study that looked at the Avaulta</p> <p>13 Plus products compared to other mesh manufacturer</p> <p>14 products and concluded that the Avaulta products were</p> <p>15 more risky or less safe; isn't that true?</p> <p>16 MR. CARTMELL: Objection. Asked and answered.</p> <p>17 BY THE WITNESS:</p> <p>18 A. I can quote to you studies -- if you limit me</p> <p>19 as far as limiting all of the available knowledge in</p> <p>20 that fashion, then it would probably be difficult, but</p> <p>21 that's --</p> <p>22 Q. Well, Doctor --</p> <p>23 A. You're interrupting me again.</p> <p>24 MR. CARTMELL: Let him finish.</p> <p>25 BY MS. GEIST:</p>	<p style="text-align: right;">Page 44</p> <p>1 BY MS. GEIST:</p> <p>2 Q. You can't point me to a single study, can you?</p> <p>3 MR. CARTMELL: Object to the form. It's been asked</p> <p>4 and answered. He's just answered it. No more questions</p> <p>5 like that, please.</p> <p>6 BY MS. GEIST:</p> <p>7 Q. Well, I'm going to move on. I think it's</p> <p>8 pretty clear, from the record, you can't point me to a</p> <p>9 single study.</p> <p>10 MR. CARTMELL: Object to the statement of counsel</p> <p>11 and move to strike it.</p> <p>12 BY MS. GEIST:</p> <p>13 Q. How about -- how about this one? When we're</p> <p>14 talking about adverse events resulting from a</p> <p>15 complication from mesh, generally speaking, we're</p> <p>16 talking about things like erosion, inflammatory</p> <p>17 response, pain, and dyspareunia; fair summary? It's not</p> <p>18 supposed to be a complete summary, but those are some of</p> <p>19 the more frequent adverse events we're talking about,</p> <p>20 correct?</p> <p>21 A. Incorrect. I take care of patients daily with</p> <p>22 a myriad of complications. To even limit one time the</p> <p>23 number of complications these patients experience and</p> <p>24 the life-changing effects is unfair to them. So I'll</p> <p>25 disagree with your comment.</p>
<p style="text-align: right;">Page 43</p> <p>1 Q. I would like to move on. It's a yes or no.</p> <p>2 Is there a study or not?</p> <p>3 MR. CARTMELL: You want it to be a yes or no, but</p> <p>4 what -- he needs to answer your question and then you</p> <p>5 can move to strike it. Okay. Go ahead.</p> <p>6 BY MS. GEIST:</p> <p>7 Q. Doctor, I would like a yes or no. If you can</p> <p>8 point me to a study, let's talk about the study. If</p> <p>9 there is no such study, would you please just tell me</p> <p>10 there is no such study and then we can move on.</p> <p>11 MR. CARTMELL: Objection. Asked and answered. You</p> <p>12 can answer it again.</p> <p>13 BY THE WITNESS:</p> <p>14 A. There will be no yes-or-no answer. It's far</p> <p>15 more complicated than that. To limit the fund of</p> <p>16 knowledge out there to a yes or no is wrong and</p> <p>17 shortchanges the available knowledge. I can point you</p> <p>18 to studies -- I have them here -- showing that Avaulta</p> <p>19 Plus has higher inflammatory reaction, delayed healing.</p> <p>20 I can point you to other studies with polypropylene mesh</p> <p>21 that has a less reaction.</p> <p>22 Q. You're not going to answer my question,</p> <p>23 Doctor?</p> <p>24 MR. CARTMELL: Object to the form. It's</p> <p>25 argumentative.</p>	<p style="text-align: right;">Page 45</p> <p>1 Q. All right. I'm trying to summarize, Doctor,</p> <p>2 the adverse events or potential complications that a</p> <p>3 patient may experience after having mesh implanted for</p> <p>4 pelvic organ prolapse. I was trying to give you a</p> <p>5 summary.</p> <p>6 So my question is this, is there any study</p> <p>7 that looked at the incident rates of dyspareunia for</p> <p>8 patients experiencing that problem after having</p> <p>9 implanted -- after having been implanted with an Avaulta</p> <p>10 product versus a Boston Scientific or Ethicon product?</p> <p>11 MR. CARTMELL: Object and move to strike the</p> <p>12 statement of counsel before the question.</p> <p>13 BY THE WITNESS:</p> <p>14 A. I'm sorry. You're asking for a study</p> <p>15 comparing Avaulta versus native tissues or are you going</p> <p>16 back to the Avaulta versus the other mesh products?</p> <p>17 Q. I'm going by adverse events. So let me go --</p> <p>18 let me ask it again.</p> <p>19 Is there any study that looked at the adverse</p> <p>20 event of dyspareunia and concluded that there was a</p> <p>21 higher incident rate of dyspareunia with the Bard</p> <p>22 products compared to the AMS, Boston Scientific, and</p> <p>23 Ethicon products?</p> <p>24 A. You're going back to the same question we</p> <p>25 already went over and over and over.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 46</p> <p>1 Q. I'm asking specifically about dyspareunia. Is 2 there any study that looked at that particular adverse 3 event, potential complication resulting from a mesh 4 implant, and concluded that there was a higher incident 5 rate of dyspareunia with the Bard products compared to 6 other mesh manufacturers' products?</p> <p>7 A. I have studies stating that the Bard product 8 has higher complications than the native tissues.</p> <p>9 Q. I'm not talking about native tissues.</p> <p>10 A. And then limiting it to one of those 11 randomized control looking at dyspareunia alone, I don't 12 have that data with me.</p> <p>13 Q. Is there any data that looked at dyspareunia 14 and said there is a higher incident rate with the Bard 15 products compared to other mesh manufacturers' products?</p> <p>16 A. Well, I would have to say there probably is 17 not because, if you had that data, Bard would have 18 provided it for me. And this would be a very good 19 format, because you asked if I had been provided all of 20 the information available. I did the PubMed research. 21 I am taking care of patients on a daily basis. I'm 22 going to meetings and I'm asking for all of the data 23 available. That would have been a very nice piece of 24 data to have provided to me.</p> <p>25 Q. So you don't -- you don't have that data,</p>	<p style="text-align: right;">Page 48</p> <p>1 compared it to other mesh manufacturers' product and 2 said that there is an incident -- greater incident rate 3 of pain associated with the Bard products?</p> <p>4 MR. CARTMELL: Objection. Asked and answered.</p> <p>5 BY MS. GEIST:</p> <p>6 Q. Correct?</p> <p>7 MR. CARTMELL: You can answer it again.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Okay. Limiting it, in the severe fashion that 10 you're doing, I do not know of, right now, any study 11 that compared the head-to-head comparison of these, any 12 randomized, controlled, industry-sponsored, et cetera.</p> <p>13 Q. The same thing with erosion rates, Doctor?</p> <p>14 There is no study out there or article that concluded 15 that the Bard products have more incident rates of 16 erosion compared to other manufacturers' mesh products 17 used for pelvic organ prolapse?</p> <p>18 A. There are plenty of studies out there showing 19 it has a higher extrusion rate. You said erosion, which 20 would be the incorrect word, but extrusion rate compared 21 to the native tissues. I am unaware, sitting here now, 22 of any randomized controlled trial stating it has a 23 higher rate compared to other mesh products.</p> <p>24 Q. Do you consider yourself to be an expert on 25 Bard's Avaulta products, Doctor?</p>
<p style="text-align: right;">Page 47</p> <p>1 Doctor, and you've never seen that data, correct?</p> <p>2 A. Well, I have also had the opportunity of 3 reviewing the Bard depositions, and nowhere did they 4 present this data being available either.</p> <p>5 Q. You don't have that data, Doctor, and you've 6 never seen that data, correct?</p> <p>7 A. I've already answered this.</p> <p>8 Q. Okay. That's fine. How about things like 9 pelvic pain? Pelvic pain is a known complication that a 10 woman may experience after having a mesh implant, 11 correct?</p> <p>12 A. Correct.</p> <p>13 Q. Any study out there that has looked at the 14 incident rates of pelvic pain associated with the 15 Avaulta products and concluded that the incident rates 16 were greater with the Avaulta products compared to any 17 other mesh manufacturers' products?</p> <p>18 A. No. I can quote to you many studies showing 19 that the incidence of pelvic pain and dyspareunia is 20 higher. But when you limit it to comparing it to the 21 other products, we would -- there is no -- we can't have 22 a quality head-to-head comparison. We have to go based 23 upon the studies that are available.</p> <p>24 Q. Okay. So the answer to my question is 25 correct? No study that's looked at the Bard product,</p>	<p style="text-align: right;">Page 49</p> <p>1 A. Yes, I do.</p> <p>2 Q. How does a doctor like yourself, who is a 3 practicing urologist, how should a doctor like yourself 4 go about becoming an expert in a medical device product?</p> <p>5 MR. CARTMELL: I object to the form.</p> <p>6 BY THE WITNESS:</p> <p>7 A. You have to look at the totality of training: 8 six years of pelvic surgery training; one year of 9 advanced surgical training in pelvic floor dysfunction, 10 including surgery; and then becoming certified in female 11 pelvic medicine and reconstructive surgery, which is 12 approved by the American Board of GYN and American Board 13 of Urology; and then practicing for 15 years at a higher 14 level, a high-volume tertiary care center.</p> <p>15 Q. And how about, Doctor, if you want to become 16 an expert on this specific product, what should you do 17 to do that?</p> <p>18 A. Be aware of the FDA regulations involved in 19 submission and clearance of a product, be involved 20 looking at the warnings, the regulations, the labels of 21 that product, be involved in teaching residents or staff 22 how to implant or how to more -- more appropriately for 23 me taking care of the complications, also being daily 24 taking care of patients that deal with this. That 25 provides expertise that most don't have.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 50</p> <p>1 Q. So you should become familiar with how to</p> <p>2 implant the actual product. Is that what you said?</p> <p>3 A. I didn't say that. You need to be -- you need</p> <p>4 to be familiar with how the product goes in, you know,</p> <p>5 reviewing of videos, surgical videos, seminars at our</p> <p>6 national/international meetings, and then be familiar</p> <p>7 with transvaginal surgery.</p> <p>8 Q. Reviewing a video relating to the implantation</p> <p>9 of a medical device is not the same thing as actually</p> <p>10 doing it?</p> <p>11 A. No. And I've also been involved in cadaveric</p> <p>12 labs as far as implantation of meshes, polypropylene,</p> <p>13 pelvic organ prolapse meshes.</p> <p>14 Q. You agree with me, though, that reviewing a</p> <p>15 video instructing how to implant an Avaulta product is</p> <p>16 not the same thing as actually implanting an Avaulta</p> <p>17 product?</p> <p>18 A. Well, I said I did it in cadaverics, also.</p> <p>19 Q. How about in a live patient?</p> <p>20 A. Well, if you -- if you limit me to</p> <p>21 implantation only in living human beings, I have never</p> <p>22 once implanted transvaginally pelvic organ prolapse</p> <p>23 meshes by choice.</p> <p>24 Q. So you never once implanted the Bard products</p> <p>25 for which you're giving an opinion, correct?</p>	<p style="text-align: right;">Page 52</p> <p>1 published relating to that particular product. Do you</p> <p>2 agree with me it would be a good idea to review all of</p> <p>3 the literature out there on that particular product?</p> <p>4 MR. CARTMELL: Object to the form.</p> <p>5 BY THE WITNESS:</p> <p>6 A. I only just -- I just want to make sure I'm</p> <p>7 clear on what you're asking as far as the medical</p> <p>8 literature, medical manuscripts, abstract presentations</p> <p>9 at meetings, if that's what you're asking, then, by all</p> <p>10 means, it is essential as one of the components of</p> <p>11 gaining experience with the product.</p> <p>12 Q. It's essential to read all of the public</p> <p>13 literature about that product?</p> <p>14 MR. CARTMELL: Object to form.</p> <p>15 BY MS. GEIST:</p> <p>16 Q. Is that what you're telling me?</p> <p>17 A. I would never use the word all. I would say</p> <p>18 you better have a good grasp of the available trends of</p> <p>19 thought on a product.</p> <p>20 Q. Well, when you say a good grasp, what do you</p> <p>21 mean by that?</p> <p>22 A. A good grasp is going to be relative. Okay?</p> <p>23 I'm at a high-volume institution, a tertiary care</p> <p>24 center, so I'm taking care of these patients on a daily</p> <p>25 basis, so -- and with national and international</p>
<p style="text-align: right;">Page 51</p> <p>1 A. I have never implanted the Bard mesh; however,</p> <p>2 I have significant experience taking out the Bard mesh.</p> <p>3 Q. You've never implanted any type of pelvic</p> <p>4 organ prolapse kit from any manufacturer, true?</p> <p>5 A. Well, asking the way you did now, that is</p> <p>6 incorrect.</p> <p>7 Q. So which pelvic organ prolapse kit have you</p> <p>8 actually implanted in your career?</p> <p>9 A. That would be the AMS Interpro.</p> <p>10 Q. And when did you do that?</p> <p>11 A. The last one would have been about a week or</p> <p>12 two -- no, three weeks ago, something like that.</p> <p>13 Q. And that's a transvaginal procedure?</p> <p>14 A. No.</p> <p>15 Q. What type of procedure is that?</p> <p>16 A. A robotic sacrocolpopexy.</p> <p>17 Q. Is that -- is that product manufactured using</p> <p>18 polypropylene mesh?</p> <p>19 A. Yes.</p> <p>20 Q. How about reviewing public literature relating</p> <p>21 specifically to the product in which you're giving an</p> <p>22 opinion. Would it be a good idea to do that?</p> <p>23 A. By public literature, you mean, like, patient</p> <p>24 brochures? I just want clarification.</p> <p>25 Q. No. I mean, any literature or articles</p>	<p style="text-align: right;">Page 53</p> <p>1 meetings, I just got back from a meeting in Stockholm</p> <p>2 dealing with mesh problems, okay. So my grasp of it is</p> <p>3 a daily interaction.</p> <p>4 If you're talking about an individual out in</p> <p>5 private practice, in the middle of somewhere else,</p> <p>6 that's going to take a little bit more work to become</p> <p>7 involved, to have a good grasp of available knowledge.</p> <p>8 So, again, that's a relative statement.</p> <p>9 Q. Okay. Let me try and bring it back, Doctor,</p> <p>10 because what I'm talking about is, you told me you</p> <p>11 believe you're an expert on the Bard Avaulta product,</p> <p>12 correct?</p> <p>13 A. I am an expert on the Avaulta product, yes.</p> <p>14 Q. Okay. So my question is, is it a good idea to</p> <p>15 read all of the literature, the published literature,</p> <p>16 about the actual product in which you're claiming to be</p> <p>17 an expert?</p> <p>18 MR. CARTMELL: Object to the form. It's vague and</p> <p>19 ambiguous.</p> <p>20 BY THE WITNESS:</p> <p>21 A. I can state, without any shadow of a doubt,</p> <p>22 absolutely I have read all of the available documents</p> <p>23 that I know of, medical literature published and some in</p> <p>24 abstract form, on the Avaulta products.</p> <p>25 Q. How many published articles are there relating</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 54</p> <p>1 to the Avaulta products specifically, do you know?</p> <p>2 A. Yes.</p> <p>3 MR. CARTMELL: Object to the form. Go ahead.</p> <p>4 BY THE WITNESS:</p> <p>5 A. I can state of what I did on my search. This</p> <p>6 was not provided to me by counsel. This is my search</p> <p>7 that I came up with 17 articles.</p> <p>8 Q. And are all of those listed on your reliance</p> <p>9 list?</p> <p>10 A. Yes. And some of those will be from meetings</p> <p>11 where the general public won't have access to those</p> <p>12 because they're abstract forms that I have access to.</p> <p>13 Q. How about reviewing the regulatory submissions</p> <p>14 for the clearance to market a medical device? Is that a</p> <p>15 good idea to review that in order to become an expert on</p> <p>16 that device?</p> <p>17 MR. CARTMELL: Object to form.</p> <p>18 BY THE WITNESS:</p> <p>19 A. I think you have to have a good working</p> <p>20 knowledge of the requirements, regulations, the</p> <p>21 warnings, and the labels for a product.</p> <p>22 Q. I appreciate that answer, Doctor. But my</p> <p>23 question is, is it a good idea to read the regulatory</p> <p>24 submission to the FDA in order to become an expert about</p> <p>25 that medical device?</p>	<p style="text-align: right;">Page 56</p> <p>1 MS. GEIST: All right. You go first and then I</p> <p>2 will go.</p> <p>3 MR. CARTMELL: We're not going to proceed today</p> <p>4 where you ask a question and he answers it and you don't</p> <p>5 like his answer because it's not your yes or no, you</p> <p>6 know, in a question that can't be answered yes or no.</p> <p>7 So you do your little harassment statement like, Doctor,</p> <p>8 you haven't answered my question. I'm going to answer</p> <p>9 (sic) it again in hopes that he gives you exactly the</p> <p>10 answer you want. We're not going to do that for hour</p> <p>11 after hour after hour.</p> <p>12 We've been going for an hour now and you've</p> <p>13 done it about 30 percent of the time. So I want to make</p> <p>14 the record clear that you can ask him a question. I'm</p> <p>15 fine with it. If he gives you an answer, then you need</p> <p>16 to move on. If he doesn't answer it, I'm fine with you</p> <p>17 re-asking it. But when he does, in fairness to the</p> <p>18 witness, don't try to harass him into giving an answer</p> <p>19 that you think is right even though he's answered it</p> <p>20 already. That's my record.</p> <p>21 MS. GEIST: So my record is this, the objections</p> <p>22 during this type of deposition, like any other</p> <p>23 deposition taken according to the Federal Rules, are</p> <p>24 objections to form, not speaking objections. We've been</p> <p>25 going, I guess, about an hour and you have made multiple</p>
<p style="text-align: right;">Page 55</p> <p>1 MR. CARTMELL: Object to the form. Asked and</p> <p>2 answered. He just answered that exact question.</p> <p>3 MS. GEIST: No, he didn't.</p> <p>4 MR. CARTMELL: You can answer it again. Yes, he</p> <p>5 did.</p> <p>6 MS. GEIST: No, he didn't.</p> <p>7 MR. CARTMELL: Well, see, what you want to do</p> <p>8 is you want to --</p> <p>9 MS. GEIST: No, no, no.</p> <p>10 MR. CARTMELL: No, no.</p> <p>11 MS. GEIST: We're not -- hold on. Hold on. Wait</p> <p>12 for the record.</p> <p>13 MR. CARTMELL: Step out of the room.</p> <p>14 THE WITNESS: I'll step out.</p> <p>15 MR. CARTMELL: Go ahead and step out. Go ahead and</p> <p>16 step out.</p> <p>17 (Exit the witness.)</p> <p>18 MS. GEIST: We're not going to proceed today with</p> <p>19 speaking objections.</p> <p>20 MR. CARTMELL: We're not going to proceed like</p> <p>21 you're doing right now. Okay.</p> <p>22 MS. GEIST: Wait. Hold on. You have to let me</p> <p>23 finish.</p> <p>24 MR. CARTMELL: No. I'm talking right now. Go</p> <p>25 ahead. We are not going to proceed today --</p>	<p style="text-align: right;">Page 57</p> <p>1 speaking objections, which are against the rules. So</p> <p>2 I'd ask you to stop doing it.</p> <p>3 MR. CARTMELL: Okay.</p> <p>4 MS. GEIST: Make your objections to form for the</p> <p>5 record. The doctor -- and just for the -- just for the</p> <p>6 record about this last question, he did not answer my</p> <p>7 question.</p> <p>8 MR. KUNTZ: Let's go back and read that.</p> <p>9 MS. GEIST: I asked him --</p> <p>10 MR. KUNTZ: He absolutely did. Let's go -- let's</p> <p>11 go back and look at it.</p> <p>12 MS. GEIST: You're interrupting me.</p> <p>13 MR. CARTMELL: No.</p> <p>14 MR. KUNTZ: Because you're wrong. Pull it up and</p> <p>15 look at it while he's out of the room. You're not even</p> <p>16 close he answered it.</p> <p>17 MR. CARTMELL: Right.</p> <p>18 MR. KUNTZ: You're not even close.</p> <p>19 MS. GEIST: You're interrupting me. I asked him</p> <p>20 specifically about whether he should review, somebody</p> <p>21 who is claiming to be an expert on the product, whether</p> <p>22 they should review the regulatory submissions for that</p> <p>23 product. And he gave me a whole answer about you should</p> <p>24 be familiar with regulatory rules and everything else.</p> <p>25 The answer (sic) was, did he review the regulatory</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 58</p> <p>1 submission for this product or not? He hasn't answered 2 that question. 3 MR. KUNTZ: And he said, yes, three questions 4 before that. 5 MS. GEIST: No, he didn't. 6 MR. CARTMELL: You didn't ask him if he reviewed 7 the regulatory submission for this product. 8 MS. GEIST: I said, would it be a good idea -- 9 MR. CARTMELL: Hold on. 10 MS. GEIST: -- to review the regulatory submission 11 for the product in which you're claiming to be an 12 expert. 13 MR. CARTMELL: Okay. And his response was you need 14 to have a working knowledge of the regulatory 15 requirements for the product. He answered your 16 question. 17 MS. GEIST: No, that's not the -- let -- 18 MR. CARTMELL: If you -- 19 MS. GEIST: -- answer -- 20 MR. CARTMELL: Don't interrupt me. 21 MS. GEIST: You guys are interrupting me. It's 22 like a tag team here. 23 MR. CARTMELL: If you then ask him, Well, did you 24 review the regulatory submission for this product, 25 Doctor --</p>	<p style="text-align: right;">Page 60</p> <p>1 he's been in this room. This is the first time he's 2 been out of the room. So we'll just continue it and see 3 how it goes. 4 MR. CARTMELL: Okay. You can come in. 5 (Enter the witness.) 6 MR. CARTMELL: Can we, for the record, read your 7 last question and his response? 8 MS. GEIST: I agree with that. 9 MR. CARTMELL: Okay. 10 (Record read as requested.) 11 MS. GEIST: Right. 12 MR. CARTMELL: Thank you. 13 BY MS. GEIST: 14 Q. And I appreciate that, Doctor. But my 15 question is, should you review the regulatory 16 submission -- the submission, not the regulations that 17 you talked about and the other things you talked 18 about -- in order to become an expert on a particular 19 medical device, would it be a good idea to review the 20 submission to FDA for that product to be cleared? 21 MR. CARTMELL: Object to the form. 22 BY THE WITNESS: 23 A. Specifically, the 510(k) submission you're 24 referring to? 25 Q. Yes.</p>
<p style="text-align: right;">Page 59</p> <p>1 MS. GEIST: I will. 2 MR. CARTMELL: -- then that would be a different 3 question. But he answered your first question. 4 MS. GEIST: No, he didn't. 5 MR. CARTMELL: And you wanted him to say, yes, and 6 he told you that it was -- it would be required to have 7 a working knowledge. Now you're entitled to then 8 explore that, Melissa. I'm fine with that. But, you 9 know, the problem is you ask these questions that are 10 not precise, he answers them part- -- you know, 11 particularly the way he can based on your question 12 that's not precise, and you're offended by that and you 13 ask the exact same question. 14 That's the problem I have with it. That's it. 15 Now he's out of the room. That's why he's out of the 16 room, because I didn't want to do this, all of this 17 speaking stuff, in front of him. And I will continue to 18 send him out of the room when we get to situations where 19 you're just not being fair to the witness. That's the 20 only reason I want to make it clear on the record is my 21 speaking objections are going to be when he's out of the 22 room, but I am going to continue to do them as long as 23 you're unfair to the witness. 24 MS. GEIST: Well, I appreciate your comments. 25 You've been making plenty of speaking objections while</p>	<p style="text-align: right;">Page 61</p> <p>1 A. Yes. 2 Q. And did you do that in this case? 3 A. Yes, all 506 pages of it. 4 Q. Thank you. Is that 510(k) submission on your 5 reliance list, Doctor? 6 A. I'd have to look at the reliance list. I'm 7 not sure. 8 Q. But it's your testimony that you reviewed the 9 510(k) submission for the Avaulta products in its 10 entirety? 11 MR. CARTMELL: Object. Asked and answered. 12 BY MS. GEIST: 13 Q. I'm just trying to understand your testimony. 14 A. Okay. The document, as I recall, was, 15 roughly, 506 pages. I may be off on that, plus or minus 16 10 or 20 here and there. I went through and read over 17 almost every single page of that. I scanned every 18 single page. Some of them were duplicates. Some it was 19 regulatory data. So, yes, to answer your question. 20 Q. Thank you. Doctor, I know we just went off -- 21 well, we didn't go off the record, but you left the room 22 for a little bit on a break. Are you okay to keep going 23 right now, or do you need a -- 24 A. No. No. Keep going. 25 Q. -- bio break or anything? Okay. Great.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 62</p> <p>1 Let me have you look at your deposition notice</p> <p>2 for a second, Doctor, which we've marked as Exhibit 1 to</p> <p>3 your deposition. Have you seen this before --</p> <p>4 A. Yes.</p> <p>5 Q. -- Dr. Elliott?</p> <p>6 A. Yes.</p> <p>7 Q. Okay. It asks you to bring a number of things</p> <p>8 with you here to your deposition. Do you see that?</p> <p>9 A. Yes.</p> <p>10 Q. They're listed on Exhibit A?</p> <p>11 A. Correct.</p> <p>12 Q. The first thing is a copy of your CV. Do you</p> <p>13 see that, Doctor?</p> <p>14 A. Yes. Yes.</p> <p>15 Q. That's contained as part of your expert</p> <p>16 report, correct?</p> <p>17 A. Yes.</p> <p>18 Q. Is that an up-to-date version of your</p> <p>19 curriculum vitae and bibliography?</p> <p>20 A. It appears to be within the past month or so,</p> <p>21 so it would be fairly accurate.</p> <p>22 Q. Do you need to add anything or provide any</p> <p>23 addendum to that CV sitting here now?</p> <p>24 A. As I sit here now quickly going over it, I</p> <p>25 don't think anything significant needs to be added.</p>	<p style="text-align: right;">Page 64</p> <p>1 in the world to perform a robotic sacrocolpopexy and</p> <p>2 writing on that.</p> <p>3 Q. The robotic-assisted laparoscopic</p> <p>4 sacrocolpopexy?</p> <p>5 A. Correct.</p> <p>6 Q. That's one of the prime areas of your</p> <p>7 research; fair to say?</p> <p>8 A. I focus quite a bit on that, yeah.</p> <p>9 Q. How many times have you published on the area</p> <p>10 of mesh complications?</p> <p>11 A. One that I know of, that I can think of off</p> <p>12 the top of my head, and then another one is submitted</p> <p>13 but it has not been published yet.</p> <p>14 Q. And where on your CV is the one publication</p> <p>15 that you've done relating to mesh complications?</p> <p>16 A. Well, as far as specific -- excuse me. Let me</p> <p>17 go to my -- this is not in the format I'm usually used</p> <p>18 to looking at it.</p> <p>19 Q. Take your time.</p> <p>20 A. Speaking of mesh complications and papers that</p> <p>21 involve mesh complications, that would be No. 37,</p> <p>22 Robotics and Laparoscopy for Vaginal Prolapse and</p> <p>23 Incontinence.</p> <p>24 Q. That paper has to do with mesh complications?</p> <p>25 A. Correct.</p>
<p style="text-align: right;">Page 63</p> <p>1 I've given some recent talks at Minnesota's Urology's</p> <p>2 Society. That might not be on here, but that would be</p> <p>3 not pertaining to mesh products. The most important one</p> <p>4 is I sit on the education committee for Society of</p> <p>5 Urodynamics and Female Urology, and I need to make sure</p> <p>6 that's on here.</p> <p>7 Q. Okay. If it's not, as long as you just</p> <p>8 testified to that, that's fine.</p> <p>9 A. Yeah.</p> <p>10 Q. Anything else?</p> <p>11 A. And that would be -- and then papers, it</p> <p>12 appears to be accurate.</p> <p>13 Q. Referring to your papers for a minute, do you</p> <p>14 have any particular area of research that you</p> <p>15 concentrate on?</p> <p>16 A. The pelvis.</p> <p>17 Q. The pelvis, in general?</p> <p>18 A. Well, I mean, as far as research and</p> <p>19 incontinence, pelvic organ prolapse is where I focus on.</p> <p>20 Q. If someone were to ask you, well, you know,</p> <p>21 Doctor, what are you best known for, what's your claim</p> <p>22 to fame, what would you say?</p> <p>23 A. Probably dealing with mesh organ</p> <p>24 complications, dealing with complications, the surgical</p> <p>25 correction of those, male incontinence, being the first</p>	<p style="text-align: right;">Page 65</p> <p>1 Q. Okay. And what else?</p> <p>2 A. Then --</p> <p>3 Q. Is there anything else?</p> <p>4 A. Yes. And then No. 43, Shimko, Umbreit -- oh,</p> <p>5 it's my paper. I'm the senior author -- Long-Term</p> <p>6 Outcomes of Robotic-Assisted Laparoscopic</p> <p>7 Sacrocolpopexy. And then --</p> <p>8 Q. I'm sorry. That paper also has to do with</p> <p>9 complications associated with mesh implantation?</p> <p>10 A. Absolutely.</p> <p>11 Q. And what else?</p> <p>12 A. And I'm trying to get to the first article we</p> <p>13 wrote on this. I will get there in just one second.</p> <p>14 Here we go. Number 24, which I am the senior author,</p> <p>15 Robotic-Assisted Laparoscopic Sacrocolpopexy With</p> <p>16 Treatment of Vaginal Vault Prolapse.</p> <p>17 Q. All three of those articles focus primarily on</p> <p>18 your work and research relating to robotic-assisted</p> <p>19 laparoscopic sacrocolpopexy, correct?</p> <p>20 A. What I've mentioned so far has been, but I</p> <p>21 haven't gone through my CV completely.</p> <p>22 Q. Okay.</p> <p>23 A. Okay. Number 25 is, Time-Dependent Variations</p> <p>24 in Biochemical Properties of Cadaveric, Porcine Dermis,</p> <p>25 Porcine Small Intestine, and Polypropylene Mesh, and</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 66</p> <p>1 Autologous Fascia in a Rabbit Model. Number,</p> <p>2 Gynecologic Use of Robotic-Assisted Laparoscopic</p> <p>3 Sacrocolpopexy For the Treatment of High Vaginal Vault</p> <p>4 Prolapse.</p> <p>5 Q. Those -- those two articles, 25 and 26, have</p> <p>6 to do with mesh explant procedures?</p> <p>7 A. Mesh complications, mesh inflammatory process.</p> <p>8 Number 27, where I am the senior author, time --</p> <p>9 time-dependent variations in inflammation and scar</p> <p>10 formation in six different pubovaginal sling materials</p> <p>11 in a rabbit model, which polypropylene was one of those.</p> <p>12 Q. These three studies you just cited to me, 25,</p> <p>13 26, and 27, these were all animal studies, correct?</p> <p>14 A. No. Incorrect. One of those was human. 24</p> <p>15 was human.</p> <p>16 Q. Sorry. I was talking about 25, 26, and 27?</p> <p>17 A. Okay. 25, no. 26 is human. 28, Current</p> <p>18 Status of Robotics in Female Urology and Gynecology,</p> <p>19 focused on the complications and the management of</p> <p>20 complications.</p> <p>21 Q. For mesh?</p> <p>22 A. For mesh. Number 30, Long-Term Results of</p> <p>23 Robotic-Assisted Laparoscopic Sacrocolpopexy For the</p> <p>24 Treatment of High-Grade Vaginal Vault Prolapse.</p> <p>25 Number -- do you want me to go through the whole list,</p>	<p style="text-align: right;">Page 68</p> <p>1 Q. And that was -- that article relates to mesh</p> <p>2 implanted to treat stress urinary incontinence, right?</p> <p>3 A. Correct.</p> <p>4 Q. Or the sling procedure, in other words?</p> <p>5 A. Sling is a generic term for it; but, by and</p> <p>6 large, you're correct, yes.</p> <p>7 Q. Okay. And I am using a generic term. Have</p> <p>8 you published, Doctor, in the area of mesh complications</p> <p>9 resulting from transvaginal implant of mesh for the</p> <p>10 purpose of repairing pelvic organ prolapse?</p> <p>11 A. We have submitted manuscripts dealing with</p> <p>12 laser resection of pelvic -- of pelvic organ erosion</p> <p>13 from meshes involving not just incontinence procedures,</p> <p>14 but also pelvic organ prolapse. And I have been invited</p> <p>15 to speak at the SUFU meeting in February speaking with</p> <p>16 laser management of these complications. And that paper</p> <p>17 has also been submitted to the American Urologic</p> <p>18 Association meeting in May this year.</p> <p>19 Q. So you have a pretty extensive publication</p> <p>20 list on your CV. You agree with me on that, Doctor, I</p> <p>21 assume? We're not going to argue about that?</p> <p>22 A. I work hard on it.</p> <p>23 Q. Yeah. And you've done some pretty good and</p> <p>24 cutting-edge work in the areas of robotic-assisted</p> <p>25 laparoscopic sacrocolpopexy. Fair to say?</p>
<p style="text-align: right;">Page 67</p> <p>1 because it keeps going here.</p> <p>2 Q. Well, I'm sort of -- I'm sort of bewildered,</p> <p>3 Doctor, because I read all of these articles and they</p> <p>4 all deal with robotic-assisted laparoscopic</p> <p>5 sacrocolpopexy primarily. There may be a line or two in</p> <p>6 here about mesh complications. But I think it's a</p> <p>7 stretch to say any of these articles deal with mesh</p> <p>8 complications; do you disagree?</p> <p>9 MR. CARTMELL: Object. It's argumentative.</p> <p>10 BY THE WITNESS:</p> <p>11 A. I --</p> <p>12 Q. I'm not trying to be argumentative. I'm</p> <p>13 asking if you disagree.</p> <p>14 A. I completely disagree. Is it mesh? Yes. Is</p> <p>15 it for vaginal prolapse? Yes. Is there complications?</p> <p>16 Yes. So, unequivocally, yes, this is dealing with</p> <p>17 complications.</p> <p>18 Q. So maybe my question wasn't precise. Do any</p> <p>19 of these articles deal with mesh complications resulting</p> <p>20 from a transvaginal implant of polypropylene mesh?</p> <p>21 A. Yes. Number 54, does risk -- repeat risk --</p> <p>22 excuse me. Risk of Repeat Anti-Incontinence Surgery</p> <p>23 Following Sling Release, a review of 93 patients, which</p> <p>24 the majority of those were mesh obstructions and</p> <p>25 treatments.</p>	<p style="text-align: right;">Page 69</p> <p>1 A. We were the first in the world to do it and</p> <p>2 publish on it, yes.</p> <p>3 Q. Yep. But you don't have a single article yet</p> <p>4 published relating to mesh complications resulting from</p> <p>5 the use of transvaginal mesh for pelvic organ prolapse;</p> <p>6 is that true?</p> <p>7 A. Not yet. But we've spoken on it in national</p> <p>8 and international meetings and have manuscripts</p> <p>9 submitted.</p> <p>10 Q. Okay.</p> <p>11 A. But you are -- you are correct, limited to</p> <p>12 publications, no, I do not.</p> <p>13 Q. And you told me you have something in</p> <p>14 submission?</p> <p>15 A. Correct.</p> <p>16 Q. Does it have a title?</p> <p>17 A. Well, yes, it does have a title. I can't</p> <p>18 quote it exactly. It will be Holmium Laser Management</p> <p>19 of Transvaginal Mesh Erosion.</p> <p>20 Q. I'm sorry. What did -- what laser management?</p> <p>21 Can you say that for me?</p> <p>22 A. A Holmium, H-O-L-I-U-M (sic), Laser Management</p> <p>23 of Transvaginal Mesh Erosion. So that includes in there</p> <p>24 the pelvic organ prolapse erosions into the -- into the</p> <p>25 bladder, urethra.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 70</p> <p>1 Q. What is holium (sic) laser management?</p> <p>2 A. Holmium, it's just a type of laser. It's a</p> <p>3 specific product of laser. There's different types of</p> <p>4 lasers, green light laser, all of these different types</p> <p>5 of lasers. This happens to be one specific type of</p> <p>6 laser that we have found works quite well on dealing</p> <p>7 with some of these mesh problems.</p> <p>8 Q. Are you the lead author on the paper?</p> <p>9 A. I am the senior author.</p> <p>10 Q. Is there a difference?</p> <p>11 A. Lead author -- well, it depends how we were</p> <p>12 defining it.</p> <p>13 Q. I don't know. How are you defining it?</p> <p>14 Senior meaning old or --</p> <p>15 A. We have first author -- you have first author,</p> <p>16 second author, third author, fourth author, or however</p> <p>17 many authors there are, and then a lead or senior</p> <p>18 author. Lead or senior one means they're the boss.</p> <p>19 First author is the one who does the most as far as the</p> <p>20 data gathering or work on it.</p> <p>21 Q. And what -- what journal or journals have you</p> <p>22 submitted the article to?</p> <p>23 A. The Journal of Urology.</p> <p>24 Q. And who else was involved in the research on</p> <p>25 this article?</p>	<p style="text-align: right;">Page 72</p> <p>1 doing that is transvaginal and the urethra is shredded</p> <p>2 apart. The women is usually or can be totally</p> <p>3 incontinent the rest of her life. So we wanted to try a</p> <p>4 different way. So that was the impetus, the initial</p> <p>5 patient one. And then since then I've seen a fair</p> <p>6 number of these. We're up to about 15 or 20 of these</p> <p>7 types of --</p> <p>8 Q. Sorry. Let me interrupt you purposefully.</p> <p>9 When you said 15 or 20, so you've performed the holmium</p> <p>10 laser procedure on 15 or 20 patients?</p> <p>11 A. Correct.</p> <p>12 Q. Okay. Sorry. Go ahead.</p> <p>13 A. But we submit the paper and then we continued</p> <p>14 to gather data, so I can never remember what the numbers</p> <p>15 are because, again, we continue to add. So it's roughly</p> <p>16 20, and that's involving mainly -- well, it is</p> <p>17 essentially just the bladder and urethral injuries.</p> <p>18 Q. We're talking about women who have experienced</p> <p>19 visceral erosion?</p> <p>20 A. Well, into the bladder. The gynecologists at</p> <p>21 my institution will deal with the perforations -- well,</p> <p>22 actually, I'm sorry. I take that back. There was one</p> <p>23 woman who had a rectal perforation, so we dealt with</p> <p>24 that one, too. So -- but, mainly, mine our bladder and</p> <p>25 urethra. The gynecologists at my institution are</p>
<p style="text-align: right;">Page 71</p> <p>1 A. Well, we have a resident involved with it.</p> <p>2 Q. Is it you and a resident?</p> <p>3 A. Yeah. Myself and a resident, yeah. But there</p> <p>4 has been multiple residents over the years who have</p> <p>5 gathered data and things like that.</p> <p>6 Q. And, in a nutshell, what's the summary and</p> <p>7 conclusions of the paper?</p> <p>8 A. It is meant to address the problem of the mesh</p> <p>9 erosions, which early on in my career, we were -- I was</p> <p>10 doing a lot of major transabdominal procedures to get</p> <p>11 the mesh out. It was a very morbid or bloody and</p> <p>12 painful procedure. A colleague of mine uses holmium</p> <p>13 lasers to break apart stones, and we did some research</p> <p>14 and found that it works on polypropylene.</p> <p>15 So we had a woman who originally came in to us</p> <p>16 with a mesh that went through the urethra, which is very</p> <p>17 difficult to deal with, to take out. It's scarred in</p> <p>18 like crazy. So we decided to try it with her consent.</p> <p>19 That we -- it may or may not work. But if it works, it</p> <p>20 will save her major surgery. And so we were able to,</p> <p>21 with the laser, go in and cut the mesh off as it went</p> <p>22 through and through the urethra.</p> <p>23 Q. So is this a one-patient case study?</p> <p>24 A. No. That was a patient that prompted the</p> <p>25 dealing with it. But, again, the traditional way of</p>	<p style="text-align: right;">Page 73</p> <p>1 dealing with the ones involving other organs. We kind</p> <p>2 of agreed to divide up the -- so we can have more</p> <p>3 expertise in dealing with this.</p> <p>4 Q. So what was the outcome of using the</p> <p>5 holmium -- holmium laser to excise the mesh?</p> <p>6 A. We have, roughly, a 75 percent success with</p> <p>7 one treatment. Unfortunately, the ones who come back</p> <p>8 with a recurrent erosion, it requires multiple</p> <p>9 treatments to try and get those fixed and some of them</p> <p>10 we can't get fixed. I just saw one of them back last</p> <p>11 week and she has, now, a recurrence of her erosion into</p> <p>12 the bladder. The problem has continued to get worse.</p> <p>13 Q. Is this the only pending publication or</p> <p>14 manuscript submitted for publication relating to mesh</p> <p>15 extraction?</p> <p>16 A. I believe so, yes.</p> <p>17 Q. And is the laser procedure, I assume, a</p> <p>18 minimally invasive procedure?</p> <p>19 A. Well, minimally invasive is a relative term,</p> <p>20 also. It is less invasive than doing this with an</p> <p>21 incision. It is -- there are significant risks when we</p> <p>22 do this because any woman -- any woman who has an</p> <p>23 erosion, whether it be urethra or vagina into the</p> <p>24 bladder, the tissues are thin. And so, as we resect</p> <p>25 this, we can get into the vagina through and through and</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 74</p> <p>1 cause a fistula. So there are major risks with it. So</p> <p>2 I would be very hesitant to call it -- it's relative.</p> <p>3 It's relative to open surgery, it is minimally invasive.</p> <p>4 Relative to doing a bladder biopsy, it's significantly</p> <p>5 invasive. That's not to be evasive in the answer. It's</p> <p>6 just that it's subjective.</p> <p>7 Q. No. Understood. Okay. Doctor, going back,</p> <p>8 now, to Exhibit 1, which is your notice of deposition --</p> <p>9 A. Yes.</p> <p>10 Q. -- it asks you also for a list of all cases in</p> <p>11 which you have, during the past four years, served as an</p> <p>12 expert essentially?</p> <p>13 A. Correct.</p> <p>14 Q. So, in the past four years, have you served as</p> <p>15 an expert other than here in the Bard pelvic mesh</p> <p>16 litigation?</p> <p>17 A. Yes.</p> <p>18 Q. And can you let me know about those</p> <p>19 circumstances, please?</p> <p>20 A. Yes. What are we, 2014? So 2011 or '12, with</p> <p>21 Ethicon on the Prolift, I wrote up an expert report;</p> <p>22 however, I did not go to trial, or however you phrase --</p> <p>23 however you phrase that.</p> <p>24 Q. Have you ever testified at trial as an expert</p> <p>25 witness?</p>	<p style="text-align: right;">Page 76</p> <p>1 Q. When did you start getting involved working as</p> <p>2 an expert for plaintiffs in the mesh litigation; do you</p> <p>3 remember?</p> <p>4 A. I believe -- well, actually, I do know. It</p> <p>5 was in September or so of 2011.</p> <p>6 Q. And were you retained by plaintiff's counsel</p> <p>7 at that time in cases pending against Ethicon?</p> <p>8 A. I don't know the legal nomenclature. I mean,</p> <p>9 they -- I was contacted. They wanted to know my opinion</p> <p>10 on subjects, I told them, and then we went from there.</p> <p>11 So, as far as retained, I don't know that term.</p> <p>12 Q. Okay. I apologize for that. Let me just ask</p> <p>13 it this way. You started working with plaintiff's</p> <p>14 counsel back in September of 2011 in litigation or cases</p> <p>15 pending against Ethicon; is that a fair summary?</p> <p>16 A. Correct.</p> <p>17 Q. And who did you start working with?</p> <p>18 A. Mr. Ben Anderson.</p> <p>19 Q. And what firm is he with, do you know?</p> <p>20 A. Anderson Law Firm in Cleveland.</p> <p>21 Q. Had you had any prior experience with that law</p> <p>22 firm?</p> <p>23 A. None.</p> <p>24 Q. How about for the --</p> <p>25 VIDEO TECHNICIAN: Can you repeat that? Sorry.</p>
<p style="text-align: right;">Page 75</p> <p>1 A. One time.</p> <p>2 Q. And when was that?</p> <p>3 A. That was not related to mesh. That was a</p> <p>4 patent infringement case of generic medical devices</p> <p>5 versus Coloplast for their transobturator mesh sling.</p> <p>6 Well, I guess it was a mesh. It was a mesh sling. But</p> <p>7 that was patent infringement. It had nothing to do with</p> <p>8 complications. It was patent infringement. And that</p> <p>9 took place in Tacoma District Court, I believe.</p> <p>10 Q. How many times have you given a deposition as</p> <p>11 an expert witness?</p> <p>12 A. Three.</p> <p>13 Q. And were those all on behalf of the plaintiffs</p> <p>14 in a litigation?</p> <p>15 A. Correct.</p> <p>16 Q. And were those all against mesh manufacturers?</p> <p>17 A. Manufacturer, Ethicon.</p> <p>18 Q. So, prior to this, you gave three depositions</p> <p>19 on behalf of plaintiffs and against Ethicon in a mesh</p> <p>20 proceeding?</p> <p>21 A. I'm going to have to take that back. There</p> <p>22 was a deposition in November of '11 or '12, and then</p> <p>23 there was a deposition a few weeks ago. Both of those</p> <p>24 were with Ethicon and then you. So actually it's three</p> <p>25 total.</p>	<p style="text-align: right;">Page 77</p> <p>1 BY THE WITNESS:</p> <p>2 A. Just the Anderson Law Firm in Cleveland, and I</p> <p>3 had had no prior contact with them.</p> <p>4 Q. And how about for the Bard litigation? When</p> <p>5 did you start working for plaintiffs in the Bard</p> <p>6 litigation as an expert?</p> <p>7 A. Summer of 2014.</p> <p>8 Q. So pretty recent?</p> <p>9 A. Well, June or so, so five months ago.</p> <p>10 Q. And who approached you to work on this</p> <p>11 litigation?</p> <p>12 A. Mr. Anderson.</p> <p>13 Q. The same guy?</p> <p>14 A. Correct.</p> <p>15 Q. Did you bring, as requested in your deposition</p> <p>16 notice, any invoices or records relating to your</p> <p>17 compensation as an expert in the litigation?</p> <p>18 A. I don't have those with me, no.</p> <p>19 Q. What did you bring with you today, Doctor, in</p> <p>20 response to the notice? We already -- you have your</p> <p>21 bibliography, right?</p> <p>22 A. I have paper copies of my expert report, my</p> <p>23 bibliography, then the case-specific reports. And then</p> <p>24 I have electronic copies of -- as far as everything</p> <p>25 that's on my reliance list, and then most manuscripts.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 78</p> <p>1 Not all, but most manuscripts.</p> <p>2 Q. Okay. So sort of in front of you you have</p> <p>3 paper copies of your reports, your bibliography, and</p> <p>4 your reliance list. Everything else is accessible on</p> <p>5 your laptop?</p> <p>6 A. Correct. And, to be technical, in front of me</p> <p>7 includes Dropbox. I have everything.</p> <p>8 (Brief interruption.)</p> <p>9 MR. CARTMELL: Uh-ooh.</p> <p>10 MS. GEIST: How about can we take a five-minute bio</p> <p>11 break?</p> <p>12 MR. CARTMELL: Sure.</p> <p>13 MS. GEIST: Thanks.</p> <p>14 VIDEO TECHNICIAN: We're off the record. The time</p> <p>15 is 10:51 a.m.</p> <p>16 (A recess was had.)</p> <p>17 VIDEO TECHNICIAN: We're back on the record. The</p> <p>18 time is 11:06 a.m.</p> <p>19 BY MS. GEIST:</p> <p>20 Q. Doctor, referring again to the notice of</p> <p>21 deposition --</p> <p>22 VIDEO TECHNICIAN: Counsel, sorry, I can barely</p> <p>23 hear you.</p> <p>24 MS. GEIST: I'm sorry. I forgot to put on my</p> <p>25 microphone.</p>	<p style="text-align: right;">Page 80</p> <p>1 Q. Did you tell me earlier you started working on</p> <p>2 the litigation in or about June of 2014; is that right?</p> <p>3 A. More or less. It was during the summer. I</p> <p>4 don't recall exactly.</p> <p>5 Q. Okay. That's fine. And you invoice after</p> <p>6 every 30 days?</p> <p>7 A. At the end of the month, correct.</p> <p>8 Q. So there would be invoices from approximately</p> <p>9 July, August, September, October?</p> <p>10 A. Correct.</p> <p>11 Q. You don't have copies of those with you today?</p> <p>12 A. I do not, no.</p> <p>13 Q. Can you tell me how much time you spent</p> <p>14 working on the litigation so far?</p> <p>15 A. I don't recall an exact number, no.</p> <p>16 Q. How about an approximation?</p> <p>17 A. Greater than a hundred.</p> <p>18 Q. Greater than a hundred hours?</p> <p>19 A. Correct.</p> <p>20 Q. So are we talking a thousand hours or</p> <p>21 somewhere between a hundred and 200 hours?</p> <p>22 A. Again, this is pure speculation. I don't</p> <p>23 know. I can't recall the exact numbers. It would be</p> <p>24 greater than a hundred, less than two or 300.</p> <p>25 Q. All right. So somewhere between 100 to 300</p>
<p style="text-align: right;">Page 79</p> <p>1 BY MS. GEIST:</p> <p>2 Q. Doctor, you got your microphone on?</p> <p>3 A. (No verbal response.)</p> <p>4 Q. All right. I'm the only one who forgot.</p> <p>5 Doctor, referring, again, to your notice of</p> <p>6 deposition, if you flip with me to the second page, it</p> <p>7 looks like, of the notice, it asks you to bring with you</p> <p>8 correspondence or e-mails between you and plaintiffs'</p> <p>9 lawyers that relate to your compensation. Did you bring</p> <p>10 any of that with you here today?</p> <p>11 A. I don't have any e-mails related to</p> <p>12 compensation. I guess I don't -- what do you mean?</p> <p>13 Q. So are you being compensated for being an</p> <p>14 expert witness, I assume?</p> <p>15 A. Yes, I am.</p> <p>16 Q. You're being paid for your time?</p> <p>17 A. Yes.</p> <p>18 Q. Have you submitted any invoices so far for</p> <p>19 work on the cases?</p> <p>20 A. Yes.</p> <p>21 Q. How many invoices?</p> <p>22 A. Well, it started in the summer, this summer.</p> <p>23 I submit them at the end of the month. So I don't know</p> <p>24 exactly what month I submitted it, but there would be</p> <p>25 three or four invoices.</p>	<p style="text-align: right;">Page 81</p> <p>1 hours; is that a fair summary?</p> <p>2 A. Probably closer to 200 hours.</p> <p>3 Q. Okay. So somewhere between 100 to 200 hours?</p> <p>4 A. Correct.</p> <p>5 Q. And that time was spent reviewing all of those</p> <p>6 500-plus articles that are on your bibliography?</p> <p>7 A. That's --</p> <p>8 MR. CARTMELL: Object to form.</p> <p>9 BY THE WITNESS:</p> <p>10 A. That's part of what I was doing.</p> <p>11 Q. And what else?</p> <p>12 A. Reviewing patient records, reviewing internal</p> <p>13 documents.</p> <p>14 Q. So does the 100 to 200 hours include the work</p> <p>15 you did to form your opinions contained in your generic</p> <p>16 report as well as your case-specific reports?</p> <p>17 A. Correct.</p> <p>18 Q. Okay. Did you break your invoices out</p> <p>19 separately, invoices for the specific cases versus the</p> <p>20 invoices for the generic opinions?</p> <p>21 A. I submit to Mr. Anderson's office my hours</p> <p>22 spent. I don't know if it gets broken down after that.</p> <p>23 Q. So do you have detail about what you did in</p> <p>24 those hours, or is it just an invoice that says I spent</p> <p>25 50 hours?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 82</p> <p>1 A. No. It -- no, it will have a daily breakdown 2 of each day, deposition review, manuscript review. 3 MS. GEIST: Can we go off the record a second? 4 VIDEO TECHNICIAN: We're off the record. The time 5 is 11:10 a.m. 6 (A recess was had.) 7 VIDEO TECHNICIAN: We're back on the record. The 8 time is 11:11 a.m. 9 BY MS. GEIST: 10 Q. So, Doctor, just going back to your invoices 11 to plaintiffs' counsel, so there is sort of a narrative 12 for your time spent? 13 A. There is a brief description of what 14 activities; deposition review, manuscript review, 15 patient record review. 16 MS. GEIST: Okay. And, Counsel, I'll just ask that 17 those be provided to us since they were included in the 18 notice of deposition and they're not here today. 19 MR. CARTMELL: Okay. We'll track them down. 20 MS. GEIST: Thank you. 21 BY MS. GEIST: 22 Q. How much money have you made so far on the 23 litigation, Doctor? 24 A. Because I don't know the number of hours, I 25 can't tell you how much I've earned. So I don't have</p>	<p style="text-align: right;">Page 84</p> <p>1 Q. And it just says fee schedule is 700 an hour, 2 right? 3 A. Correct. 4 Q. Is the 700-dollar-an-hour fee for anything you 5 do in order to prepare your expert report? In other 6 words, does that cover review of medical records, review 7 of literature, research? 8 A. Correct. 9 Q. Do you have a different hourly rate for 10 testimony? 11 A. No, 700 flat fee. 12 Q. So, sitting here today, however long we're 13 here together today, it's 700 an hour? 14 A. Correct. 15 Q. You don't have a flat fee for an appearance at 16 a deposition or anything like that? 17 A. No, I do not. 18 Q. How about trial testimony? 19 A. 700 flat fee. 20 Q. How about travel? 21 A. \$700 an hour. 22 Q. So it's \$700 an hour whether you're 23 testifying, traveling, or reviewing medical records? 24 A. Correct. 25 Q. Was that the same rate that you charged</p>
<p style="text-align: right;">Page 83</p> <p>1 even a ballpark figure. 2 Q. Are you being paid as the invoices go in? 3 A. Yeah. I get paid a month to two months after 4 the invoice is submitted. 5 Q. And you don't know how much you've made so 6 far? 7 A. I don't keep record, no. 8 Q. Do you have a ballpark? 9 A. No, I don't, because I -- I don't even know 10 the number of hours I've spent, so I can't even 11 extrapolate from that. 12 Q. So you can't even give me an estimation of how 13 much money you've made and how much you've been 14 compensated for your work on behalf of plaintiffs in 15 this litigation? 16 A. Again, I can't. The invoices will spell it 17 out exactly, but I don't keep records like that. 18 Q. Well, Is it more than \$100,000? 19 A. Again, I don't -- I don't know. I know that 20 I've spent more than a hundred hours working on it. 21 But, again, I don't know how much. I don't keep -- have 22 any way of accurate records pertaining to that. 23 Q. So let me just look at your fee schedule, and 24 that was part of your expert report, right? 25 A. Correct.</p>	<p style="text-align: right;">Page 85</p> <p>1 plaintiffs' counsel when you were working as an expert 2 in the Ethicon litigation? 3 A. Correct. It's always been 700 hours -- \$700 4 an hour. 5 Q. Can you tell me how much you were compensated 6 for your work as an expert witness against Ethicon in 7 their pelvic mesh litigation? 8 A. Same answer, I don't know the number of hours. 9 It would be more than Bard, but -- because it was a lot 10 longer process, but I don't know the amount. 11 Q. Are we coming anywhere near a million dollars? 12 MR. CARTMELL: Object to form. 13 BY THE WITNESS: 14 A. I wouldn't think so, no; but, again, I don't 15 keep records like that. 16 Q. So you don't have any sense at all, even to 17 give me a ballpark estimate, of how much money you've 18 made as an expert witness on behalf of plaintiffs in the 19 pelvic mesh litigation? 20 A. No. It's been going on three years, and I 21 don't keep records. 22 Q. Can you tell me what percentage of your annual 23 income is derived from work as a plaintiff's expert in 24 the pelvic mesh litigation? 25 A. That would probably vary from year to year, a</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 86</p> <p>1 third, maybe.</p> <p>2 Q. Meaning?</p> <p>3 A. Again, I don't even know how much I get on my</p> <p>4 salary from my day job.</p> <p>5 Q. When you say your day job, you're talking</p> <p>6 about your job as an associate professor of urology?</p> <p>7 A. Correct.</p> <p>8 Q. At Mayo?</p> <p>9 A. Correct. I don't have records. It's a bank</p> <p>10 deposit and I don't even look at it. I don't know what</p> <p>11 my benefits are. I know what my retirement is, but</p> <p>12 I don't know what my daily salary is or monthly</p> <p>13 salary.</p> <p>14 Q. You don't know how much money you get from</p> <p>15 Mayo Clinic as an associate professor?</p> <p>16 A. No.</p> <p>17 Q. Really?</p> <p>18 A. It's -- the data is retrievable. I don't</p> <p>19 worry about it.</p> <p>20 Q. What about, a third of your income over the</p> <p>21 last three years has been from work as an expert witness</p> <p>22 on behalf of plaintiffs; is that right?</p> <p>23 MR. CARTMELL: Object to the form.</p> <p>24 BY MS. GEIST:</p> <p>25 Q. Well, is that what you just told me?</p>	<p style="text-align: right;">Page 88</p> <p>1 back in 2005, really. And so what they provided me</p> <p>2 would augment or increase my knowledge and</p> <p>3 understanding, but it didn't alter.</p> <p>4 Q. You already were sort of out there as a</p> <p>5 well-known doctor speaking against transvaginal mesh; is</p> <p>6 that fair to say?</p> <p>7 MR. CARTMELL: Object to the form.</p> <p>8 BY THE WITNESS:</p> <p>9 A. I was -- I was one of those speaking out</p> <p>10 against meshes, that's correct, the anti-mesh group.</p> <p>11 Q. You're one of leaders of the anti-mesh group?</p> <p>12 MR. CARTMELL: Object to form.</p> <p>13 BY THE WITNESS:</p> <p>14 A. Well, I don't know how you justify it. I may</p> <p>15 not quantify if I'm a leader or not. I've made --</p> <p>16 Q. Well, you're one of the -- I'm sorry. Go</p> <p>17 ahead.</p> <p>18 A. I've made public statements.</p> <p>19 Q. So you're one of the most outspoken physicians</p> <p>20 in terms of the anti-mesh group?</p> <p>21 MR. CARTMELL: Object to the form.</p> <p>22 BY MS. GEIST:</p> <p>23 Q. Is that fair to say?</p> <p>24 A. No. I wouldn't say I'm one of the most. I</p> <p>25 think there's some others out there who have been much</p>
<p style="text-align: right;">Page 87</p> <p>1 A. That would be rough. You know, going back to</p> <p>2 2011, it's probably going to be closer to 25 percent.</p> <p>3 But, again, that's a ballpark figure, because I don't --</p> <p>4 that's not something I keep track of.</p> <p>5 Q. Dr. Elliott, in reaching your opinions that</p> <p>6 you've rendered in this litigation, did you rely on any</p> <p>7 facts or data that were provided to you by counsel for</p> <p>8 plaintiffs?</p> <p>9 MR. CARTMELL: Object to the form. I don't</p> <p>10 understand the question.</p> <p>11 BY THE WITNESS:</p> <p>12 A. I mean, I thought that's data they had</p> <p>13 provided me. They provided me with what's on the</p> <p>14 reliance list as far as internal documents.</p> <p>15 Q. Did you rely on any summaries or information</p> <p>16 provided to you prepared by counsel?</p> <p>17 A. Well, they didn't provide me any summaries.</p> <p>18 They provided me documents.</p> <p>19 Q. Did -- did any of your opinions that you've</p> <p>20 reached in this litigation, were any of them based on</p> <p>21 assumptions that were provided to you by counsel?</p> <p>22 MR. CARTMELL: Object to the form.</p> <p>23 BY THE WITNESS:</p> <p>24 A. No. I had strong opinions regarding</p> <p>25 transvaginal mesh starting back prior to 2011, starting</p>	<p style="text-align: right;">Page 89</p> <p>1 louder in speaking against meshes.</p> <p>2 Q. Who has been much louder than you?</p> <p>3 MR. CARTMELL: Object to the form.</p> <p>4 BY THE WITNESS:</p> <p>5 A. Shlomo Raz at UCLA, Philippe Zimmern at UT</p> <p>6 Southwestern, Louis Wahl at St. Louis, Ostergard. I</p> <p>7 don't know where he's at, California somewhere. But I'm</p> <p>8 not denying it. I've been anti-mesh from the beginning.</p> <p>9 I'm not saying I'm not, but I'm not the only one out</p> <p>10 there.</p> <p>11 Q. Did you review any of the expert reports</p> <p>12 provided from some of the other doctors rendering</p> <p>13 reports on behalf of the plaintiffs?</p> <p>14 A. I'd have to look in the reliance list for all</p> <p>15 that I've reviewed. I have reviewed expert reports. I</p> <p>16 can't recall all of the ones I have reviewed.</p> <p>17 Q. Well, for this particular litigation, your</p> <p>18 opinions here, did you rely on any of the other reports</p> <p>19 provided on behalf of plaintiffs by other experts?</p> <p>20 A. It depends on how you're defining rely. I'm</p> <p>21 looking at them with an open mind seeing what they have</p> <p>22 to say and if it's consistent or inconsistent with my</p> <p>23 opinions. So, yes, I've looked at the materials</p> <p>24 expert's report. I don't recall his name. I'm not very</p> <p>25 good with names. So, again, my reliance report would</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 90</p> <p>1 have that on there. I don't know if we have an updated</p> <p>2 copy of that. That might be nice, too.</p> <p>3 Q. You understand there's a separate materials or</p> <p>4 biomaterials expert who has provided opinions in the</p> <p>5 litigation, correct?</p> <p>6 A. Correct. Yes.</p> <p>7 Q. And you're not a biomaterials expert, correct?</p> <p>8 MR. CARTMELL: Object to the form.</p> <p>9 BY THE WITNESS:</p> <p>10 A. Well, I wouldn't say that's correct. I have</p> <p>11 deal -- I deal with meshes. I deal with mesh</p> <p>12 complications. I've done research on meshes. I deal</p> <p>13 with the complications and transvaginal management of</p> <p>14 those things. I have two animal studies -- three animal</p> <p>15 studies, excuse me. I take that back. Two animal</p> <p>16 studies dealing with meshes. So I have basic science</p> <p>17 and human research on this.</p> <p>18 So I am a materials expert. Am I a Ph.D. or</p> <p>19 an engineer in biomaterials, no. But I do consider</p> <p>20 myself, from the urologic-GYN perspective, a</p> <p>21 biomaterials expert.</p> <p>22 Q. So that's a little different than what you</p> <p>23 said when you were deposed in the Ethicon proceeding; do</p> <p>24 you remember that?</p> <p>25 A. I don't recall.</p>	<p style="text-align: right;">Page 92</p> <p>1 Q. So do you have a background in polymer</p> <p>2 science?</p> <p>3 A. Well, I've taken organic chemistry and</p> <p>4 physics, so I do have a background in dealing with those</p> <p>5 products.</p> <p>6 Q. Do you consider yourself an expert in polymer</p> <p>7 science?</p> <p>8 A. As it pertains to the transvaginal application</p> <p>9 and the complications, I have a better working knowledge</p> <p>10 than the average with it.</p> <p>11 Q. No. That wasn't my question. Are you an</p> <p>12 expert in polymer science?</p> <p>13 A. Define --</p> <p>14 MR. CARTMELL: Object to the form.</p> <p>15 BY THE WITNESS:</p> <p>16 A. Define expert then.</p> <p>17 Q. So do you have any degrees in either polymer</p> <p>18 science or biomaterials?</p> <p>19 A. With those qualifiers, no, I do not have an</p> <p>20 advanced degree in polymer science.</p> <p>21 Q. Do you have any particular education in</p> <p>22 polymer science or biomaterials?</p> <p>23 A. I have a significant amount of education</p> <p>24 pertaining to those issues.</p> <p>25 Q. Tell me about that.</p>
<p style="text-align: right;">Page 91</p> <p>1 Q. Do you remember admitting, in that deposition,</p> <p>2 that you were not a biomaterials expert?</p> <p>3 A. I would have to --</p> <p>4 MR. CARTMELL: Object to form.</p> <p>5 BY THE WITNESS:</p> <p>6 A. I would have to see what I said. If you have</p> <p>7 that, I would like to see that.</p> <p>8 Q. You know what, Doctor, I can't find it right</p> <p>9 this minute, but I don't want to waste time. So I'll</p> <p>10 pull it up and look again.</p> <p>11 But do you recall giving a deposition in the</p> <p>12 litigation against Ethicon here at Wexler Wallace's</p> <p>13 office a couple months ago on September 13th, 2014?</p> <p>14 A. Yeah. I remember giving a deposition, yeah.</p> <p>15 Q. Do you remember that? And do you remember</p> <p>16 being asked about whether or not you were a biomaterials</p> <p>17 expert?</p> <p>18 A. I don't recall that specific question.</p> <p>19 Q. But it's your testimony here today that you</p> <p>20 are a biomaterials expert?</p> <p>21 MR. CARTMELL: Objection. Asked and answered. He</p> <p>22 just answered that same question.</p> <p>23 BY THE WITNESS:</p> <p>24 A. I agree with exactly what I just said this</p> <p>25 time with those qualifiers.</p>	<p style="text-align: right;">Page 93</p> <p>1 A. Okay. As far as dealing with meshes and their</p> <p>2 complications, reviews of the medical literature, both</p> <p>3 basic science and human research in vivo and in vitro.</p> <p>4 I would have to say in reviewing the internal documents,</p> <p>5 both with Bard and also with Ethicon.</p> <p>6 Q. So other than being engaged in explant</p> <p>7 procedures and reviewing documents, do you have any</p> <p>8 particular training or education in the area of</p> <p>9 biomaterials or polymer science?</p> <p>10 A. Oh, yeah. I've written two papers on that</p> <p>11 specifically dealing with the polypropylene meshes in</p> <p>12 the rabbit model, dealing with the forces involved with</p> <p>13 fracturing, the inflammation, dealing with the</p> <p>14 pathologists and engineers.</p> <p>15 Q. Did -- and it's those two papers on which you</p> <p>16 rely for your expertise on polymer science and</p> <p>17 biomaterials?</p> <p>18 A. Well, that's two of the ones that I rely upon,</p> <p>19 yeah, but that was pretty extensive work done.</p> <p>20 Q. Have you ever been qualified as a biomaterials</p> <p>21 or polymer science expert?</p> <p>22 A. I guess I don't understand that question.</p> <p>23 Again, I am not a Ph.D. in the subject. I'm not a Ph.D.</p> <p>24 in the subject. I don't carry that, but I am an expert</p> <p>25 dealing with the ramifications when implanted in the</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 94</p> <p>1 female body.</p> <p>2 Q. Do -- have you ever been qualified by a judge</p> <p>3 at a trial as an expert in polymer science or</p> <p>4 biomaterials?</p> <p>5 A. I have no way of answering. I don't know if I</p> <p>6 have it or have not.</p> <p>7 Q. Do you hold yourself out to your colleagues as</p> <p>8 an expert in polymer science or biomaterials?</p> <p>9 A. In biomaterials and mesh and mesh</p> <p>10 complications, I do hold myself out as an expert in it</p> <p>11 and they also hold me out as an expert by inviting me to</p> <p>12 speak this year at the National Female Urology Meeting</p> <p>13 on mesh complications and management of them, and that's</p> <p>14 all dealing with the biomaterials and complications.</p> <p>15 Q. Did -- have you conducted any type of</p> <p>16 laboratory or other type of testing on the Avaulta</p> <p>17 polypropylene mesh products?</p> <p>18 A. Not specific on the Avaulta polypropylene.</p> <p>19 I've done it on collagen, but not on polypropylene.</p> <p>20 Q. You've never tested the Avaulta products,</p> <p>21 correct?</p> <p>22 A. If you're talking -- you're meaning a basic</p> <p>23 science research? I guess, I don't know what you mean</p> <p>24 by that. Clarify what you mean.</p> <p>25 Q. Well, did you -- have you done -- have you</p>	<p style="text-align: right;">Page 96</p> <p>1 products that were explanted?</p> <p>2 A. For that paper, roughly, a third.</p> <p>3 Q. And how do you know that it was the Avaulta</p> <p>4 products you were involved in explanting using the</p> <p>5 laser?</p> <p>6 A. Because prior to me seeing any patient, I have</p> <p>7 to have the outside records, outside implantation</p> <p>8 records.</p> <p>9 Q. So you have them for all of the third of the</p> <p>10 15 to 20 women?</p> <p>11 A. Correct. I have them for all of the women and</p> <p>12 a third of them, roughly, were Avaulta products.</p> <p>13 Q. Other than this experience with the Avaulta</p> <p>14 products, have you done any testing or analysis on the</p> <p>15 Avaulta products?</p> <p>16 A. No. I've reviewed the testing of others.</p> <p>17 MR. CARTMELL: Sorry.</p> <p>18 BY MS. GEIST:</p> <p>19 Q. You haven't actually conducted any tests on</p> <p>20 the Avaulta products yourself, correct?</p> <p>21 A. Other than what I mentioned as far as the</p> <p>22 study, I personally, to the best of my knowledge, have</p> <p>23 not done a basic science study on it like you mentioned.</p> <p>24 Q. Okay. And we already talked before you've</p> <p>25 never implanted an Avaulta product, right?</p>
<p style="text-align: right;">Page 95</p> <p>1 published any paper relating to the Avaulta products?</p> <p>2 A. Okay. Specifically with the Avaulta product,</p> <p>3 yeah, our laser -- our laser resection paper is going to</p> <p>4 have an Avaulta product in it.</p> <p>5 Q. Have -- you've never done a study on Avaulta</p> <p>6 products, though, have you?</p> <p>7 A. Not limiting it to just Avaulta products, no.</p> <p>8 Q. Well, what studies have you done that involved</p> <p>9 Avaulta products?</p> <p>10 A. Well, I'm talking about the laser resection</p> <p>11 paper.</p> <p>12 Q. That's the one that you've submitted for</p> <p>13 publication?</p> <p>14 A. Correct.</p> <p>15 Q. It hasn't been approved or accepted for</p> <p>16 publication yet, correct?</p> <p>17 A. Correct.</p> <p>18 Q. And the extent of the discussion of the</p> <p>19 Avaulta products in that paper relate to the explant</p> <p>20 procedures you did -- you did using a laser?</p> <p>21 A. Correct.</p> <p>22 Q. And how many women, again, were involved in</p> <p>23 that paper?</p> <p>24 A. 15 to 20.</p> <p>25 Q. And how many of the 15 to 20 women had Avaulta</p>	<p style="text-align: right;">Page 97</p> <p>1 A. Correct.</p> <p>2 Q. Do you know any of the plaintiffs' experts in</p> <p>3 this litigation?</p> <p>4 A. I don't know who the plaintiffs' experts are</p> <p>5 other than, I believe, Dr. Wilkes. I think I saw his</p> <p>6 name, but I don't know him. But I don't know who their</p> <p>7 other experts are.</p> <p>8 Q. Did -- other than plaintiffs' counsel, did you</p> <p>9 talk to any other physicians about your opinions in this</p> <p>10 case?</p> <p>11 A. No.</p> <p>12 Q. Did you meet with any of the other plaintiffs'</p> <p>13 experts and talk about your opinions in this case?</p> <p>14 A. I don't even know who the other plaintiffs'</p> <p>15 experts are.</p> <p>16 Q. You understand that you're not being put</p> <p>17 forward as a biomaterials expert here, correct?</p> <p>18 MR. CARTMELL: Well, I object to the extent I don't</p> <p>19 think that's a correct statement. I mean --</p> <p>20 MS. GEIST: Well, you told me before --</p> <p>21 MR. CARTMELL: -- he -- he's clearly, in his</p> <p>22 report, giving biomaterials expert opinions. So I'm</p> <p>23 going to instruct him not to answer that question.</p> <p>24 That's based on a fact that's not true.</p> <p>25</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 98</p> <p>1 BY MS. GEIST:</p> <p>2 Q. You understand there is a separate</p> <p>3 biomaterials-designated expert on behalf of plaintiffs</p> <p>4 in this litigation as you've told me before, correct?</p> <p>5 A. I believe Dr. Wilkes is a biomaterials expert;</p> <p>6 but, again, I don't know.</p> <p>7 Q. Didn't you tell me that you reviewed some of</p> <p>8 the other expert reports and you reviewed the report of</p> <p>9 the biomaterials expert, whoever that may be?</p> <p>10 A. No. For clarification with that, I reviewed</p> <p>11 Wilkes' report. I don't know if I've reviewed any</p> <p>12 others in the process of this.</p> <p>13 Q. Did you review a report from a biomaterials</p> <p>14 expert?</p> <p>15 A. Well, I don't know what Dr. Wilkes' role is.</p> <p>16 So I would have to look up and see what his role is.</p> <p>17 That report I reviewed.</p> <p>18 Q. And what did that report talk about?</p> <p>19 A. It talked about the meshes, the complications,</p> <p>20 the pore sizes, the inflammation, collagen, interplay.</p> <p>21 Q. From a materials standpoint?</p> <p>22 A. That's what I'm saying. I don't know. I also</p> <p>23 talk about the same things.</p> <p>24 Q. In any of the reports that you reviewed, did</p> <p>25 you disagree with any of the conclusions reached by any</p>	<p style="text-align: right;">Page 100</p> <p>1 Q. Didn't they offer board certification in</p> <p>2 female pelvic medicine and reconstructive surgery</p> <p>3 beginning in 2013?</p> <p>4 A. Yeah. That's when I took the exam. Again, I</p> <p>5 just don't know if you --</p> <p>6 Q. So -- all right. So I don't understand why my</p> <p>7 question is difficult. So you took the exam in 2013?</p> <p>8 A. And passed. I mean, technically, you're right</p> <p>9 as far as calling it board certification. We don't go</p> <p>10 around saying we're board-certified in this. We're</p> <p>11 board-certified in urology. We're board-certified in</p> <p>12 GYN or dermatology, whatever. There is subspecialty</p> <p>13 certification that is approved by the board. So if we</p> <p>14 want to just for -- I'm not trying to be difficult, but</p> <p>15 you can call it board-certified by urology and GYN in</p> <p>16 female pelvic mesh and reconstructive surgery.</p> <p>17 Q. So you're not a board-certified</p> <p>18 urogynecologist, correct?</p> <p>19 A. Correct. I am not.</p> <p>20 Q. That's a subspecialty of obstetrics and</p> <p>21 gynecology?</p> <p>22 A. Correct.</p> <p>23 Q. What's the difference between a</p> <p>24 urogynecologist and a urologist?</p> <p>25 A. Well, a urogynecologist and a urologist is not</p>
<p style="text-align: right;">Page 99</p> <p>1 of the other experts?</p> <p>2 A. Again, the only report that I recall reviewing</p> <p>3 was Wilkes'. I don't recall reviewing the others. I</p> <p>4 may have. And with Mr. Wilkes or Dr. Wilkes -- again, I</p> <p>5 don't know what his title is -- I had no objection with</p> <p>6 what he had to say.</p> <p>7 Q. You're board-certified, Doctor, in urology,</p> <p>8 correct?</p> <p>9 A. Correct.</p> <p>10 Q. And female pelvic medicine and reconstructive</p> <p>11 surgery?</p> <p>12 A. Subspecialized in female pelvic mesh and</p> <p>13 reconstructive surgery by the Board of GYN and the Board</p> <p>14 of Urology.</p> <p>15 Q. So are you board-certified in female pelvic</p> <p>16 medicine reconstructive surgery?</p> <p>17 A. Correct. They don't really call it -- you</p> <p>18 would be technically correct. They don't really call it</p> <p>19 that. You're board-certified in urology or GYN. You</p> <p>20 then do subspecialty certification in female pelvic mesh</p> <p>21 and reconstructive surgery. That is a new development</p> <p>22 in this field in the past five to eight years. So those</p> <p>23 of us who did -- did residency and fellowship prior to</p> <p>24 the starting of that -- that subspecialty, then we had</p> <p>25 to go back and get further testing.</p>	<p style="text-align: right;">Page 101</p> <p>1 a fair comparison. I am a female urologist, okay.</p> <p>2 That's the comparison you want because both of us have</p> <p>3 advanced training in the female pelvis, and in urology</p> <p>4 we also have it in the male pelvis, too. So there's</p> <p>5 very -- once you have passed that female pelvic mesh and</p> <p>6 reconstructive certificate, you have that certificate,</p> <p>7 in the eyes of the boards, you are identical.</p> <p>8 Q. That's your opinion?</p> <p>9 A. That's the boards' opinion, the boards of</p> <p>10 urology and the boards of GYN.</p> <p>11 Q. You told me earlier that, in this study that's</p> <p>12 pending approval relating to the laser that you used to</p> <p>13 explant mesh, that about a third of the women had been</p> <p>14 implanted with Avaulta products; is that right?</p> <p>15 A. That's a rough estimate, yes.</p> <p>16 Q. Okay. So, I guess, five to six women based on</p> <p>17 the total women involved in the study; is that --</p> <p>18 A. Well, it's 15 to 20 patients.</p> <p>19 Q. Right. So I'm saying five to six --</p> <p>20 A. So five to seven.</p> <p>21 Q. Five to six, five to seven?</p> <p>22 A. Five to seven -- yeah, five to six, that's</p> <p>23 fair.</p> <p>24 Q. That's fine. We don't have to argue about</p> <p>25 those numbers.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 102</p> <p>1 What has been the totality of your experience</p> <p>2 in explanting mesh from women who were implanted with</p> <p>3 the Bard Avaulta products?</p> <p>4 A. I'm sorry, the -- from this --</p> <p>5 Q. How many?</p> <p>6 A. From this study?</p> <p>7 Q. Yeah. No, no, no. Not just the study.</p> <p>8 A. Oh.</p> <p>9 Q. So how many. Because you told --</p> <p>10 A. Sure.</p> <p>11 Q. -- we've already talked about the fact that</p> <p>12 you've never implanted an Avaulta product yourself,</p> <p>13 correct?</p> <p>14 A. Correct. Yep.</p> <p>15 Q. But part of the basis for your statement that</p> <p>16 you're an expert on the Avaulta product is based on your</p> <p>17 experience explanting the product, true?</p> <p>18 A. That's only partially true. That is part of</p> <p>19 my experience.</p> <p>20 Q. And that's what I meant to say.</p> <p>21 A. Okay.</p> <p>22 Q. So if I misspoke, that's fine. But part of</p> <p>23 the basis for you saying that you're an expert on the</p> <p>24 Avaulta product is due to your experience explanting the</p> <p>25 product, correct?</p>	<p style="text-align: right;">Page 104</p> <p>1 that statement?</p> <p>2 A. Because I keep track. I keep records of these</p> <p>3 things. And I keep track of who we're seeing on my</p> <p>4 clinic schedule, and I also have operative notes on</p> <p>5 essentially every single patient that comes through. I</p> <p>6 demand it before I see them.</p> <p>7 Q. So that's getting more to my question. For</p> <p>8 every patient that's referred to the Mayo Clinic that</p> <p>9 you see, do you determine which manufacturer's mesh</p> <p>10 product they had implanted?</p> <p>11 A. Well, I determine it because we review the</p> <p>12 medical records.</p> <p>13 Q. Are they all required to come with the medical</p> <p>14 records?</p> <p>15 A. Before. They're supposed to have it before</p> <p>16 they show up. And if they show up without it, then</p> <p>17 before we do anything we need to have them fax us the</p> <p>18 records.</p> <p>19 Q. And did you perform some sort of analysis or</p> <p>20 compilation to determine that 30 percent of the patients</p> <p>21 you've seen have had one of the Bard products implanted?</p> <p>22 A. Yeah. That's -- that's going to be a rough</p> <p>23 estimate because, also, we're going back to 2007, which</p> <p>24 was a smaller number of individuals, but we're keeping</p> <p>25 records then. And so I'm extrapolating that, but that</p>
<p style="text-align: right;">Page 103</p> <p>1 A. Correct. That is one segment of my</p> <p>2 experience.</p> <p>3 Q. Got it. How many times?</p> <p>4 A. I see, in a given week, four to five, six</p> <p>5 patients with mesh complications that started roughly in</p> <p>6 2007 or thereabouts, and then -- it started off slow and</p> <p>7 then it's increased. So I can't give you how many</p> <p>8 numbers, but then not all of those, in fact, the</p> <p>9 minority, are going to surgery because what I am seeing</p> <p>10 them mainly for is pelvic pain. And so I'm operating on</p> <p>11 only a minority of those individuals.</p> <p>12 So if you look at just the surgical, that's</p> <p>13 going to be a smaller number. If you look at the --</p> <p>14 you're just looking at the numerator. You have to look</p> <p>15 at the denominator, which is four to five patients a</p> <p>16 week. Let's just round it up to five patients a week.</p> <p>17 It's going to be, roughly, 60 -- let's see -- 60</p> <p>18 percent, roughly, are going to be AMS products, and then</p> <p>19 it's -- excuse me, 40 percent are AMS products, and,</p> <p>20 roughly, 30, 30 are, excuse me, Ethicon and Bard, and</p> <p>21 then I will see a smattering of the other percentages of</p> <p>22 the other products. The Boston Scientific we don't see</p> <p>23 very many. Also, the Cook product, I see those, also.</p> <p>24 So hundreds would be the answer to that.</p> <p>25 Q. So how do you know that? What's the basis for</p>	<p style="text-align: right;">Page 105</p> <p>1 is going to be a rough and fair estimate. AMS</p> <p>2 Apogee/Perigee is going to be the predominant product</p> <p>3 that I see. As I mentioned, they're roughly 40 percent.</p> <p>4 That's because AMS is based 100 miles north of</p> <p>5 Rochester. So we get a lot more patients who have that</p> <p>6 implanted.</p> <p>7 Q. So from 2007 to 2014, has it always been about</p> <p>8 the same number of referrals per week? You told me four</p> <p>9 to six or rounded to five patients per week?</p> <p>10 A. Start off slow starting in, roughly, 2007.</p> <p>11 Again, that's an estimate. That's looking back. We</p> <p>12 started seeing an uptick in patients. And then, as time</p> <p>13 progressed, then we started seeing more and more and</p> <p>14 more. And then in 2011, after that FDA release, that's</p> <p>15 when we really saw the increase. So, now, the four to</p> <p>16 five or four to six per week is current for the past</p> <p>17 three years. I can't speak with any accuracy going back</p> <p>18 to 2010 and prior.</p> <p>19 Q. What do you think was the reason why, in the</p> <p>20 last three years, you started getting more referrals?</p> <p>21 A. Very clear, because patients tell me,</p> <p>22 knowledge that this is occurring to other people besides</p> <p>23 themselves. That's the most common comment I get.</p> <p>24 Q. And where do they get that knowledge?</p> <p>25 A. Because they -- they read about and heard</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 106</p> <p>1 about the FDA warning, and then they are sitting out</p> <p>2 thinking they're alone, and then, all of a sudden, they</p> <p>3 find out there's more people who have the same problem.</p> <p>4 Q. Well, they're coming to you because they see</p> <p>5 lawyer advertisements on TV, right?</p> <p>6 MR. CARTMELL: Object to the form.</p> <p>7 BY MS. GEIST:</p> <p>8 Q. Isn't that how they get the knowledge?</p> <p>9 MR. CARTMELL: Object to the form. He's already</p> <p>10 answered that question.</p> <p>11 BY MS. GEIST:</p> <p>12 Q. Can you answer my question, Doctor?</p> <p>13 A. Yeah. I can't speak to where they're getting</p> <p>14 the information, but they're getting the information.</p> <p>15 Q. Do you ask them?</p> <p>16 A. I usually do not.</p> <p>17 Q. You just suddenly since 2011, since there has</p> <p>18 been a lot of advertising on television, you've had a</p> <p>19 huge uptick in plaintiffs coming or patients coming with</p> <p>20 mesh-related complications?</p> <p>21 MR. CARTMELL: Object to the form. I think he just</p> <p>22 told you about the FDA 2011 statement.</p> <p>23 MS. GEIST: You've got to stop with the statements.</p> <p>24 MR. CARTMELL: Well, when you totally leave out</p> <p>25 what he --</p>	<p style="text-align: right;">Page 108</p> <p>1 Q. All right.</p> <p>2 A. -- with surgery. I don't think surgery will</p> <p>3 fix it. Because when we have an individual who has</p> <p>4 devastating pelvic pain all over, okay, they can't sit,</p> <p>5 they can't walk, they can't lie down, and we do an exam</p> <p>6 and everything hurts, I do not -- I do not recommend</p> <p>7 surgery on them because I don't think it will fix it. I</p> <p>8 think it will make them worse.</p> <p>9 Q. How many of the patients that are referred to</p> <p>10 the Mayo Clinic that you've been treating, Doctor, how</p> <p>11 many of them are actually undergoing an explant or</p> <p>12 excision procedure?</p> <p>13 A. A percentage. Let's say -- let's say we see</p> <p>14 five a week times, what, 42 weeks a year. That's going</p> <p>15 to be difficult. That's too much math. A rough</p> <p>16 estimate would be about 20 percent of the individuals I</p> <p>17 see I feel are candidates for surgery. I have become</p> <p>18 more conservative in my surgeries. They have to meet</p> <p>19 very specific criteria because, otherwise, I don't think</p> <p>20 I do them any good.</p> <p>21 My GYN colleagues in the past have been much</p> <p>22 more aggressive than I am doing transabdominal repairs,</p> <p>23 and they have some success and have a lot of others that</p> <p>24 are not. Philippe Zimmerman (sic), a good friend of</p> <p>25 mine at UT Southwestern, was showing something like 35</p>
<p style="text-align: right;">Page 107</p> <p>1 MS. GEIST: Let the witness --</p> <p>2 MR. CARTMELL: Hold on. When you totally leave out</p> <p>3 what he just told you, change the question to include</p> <p>4 something else, that's unfair. So, in that</p> <p>5 circumstance, I'm not going to let you do it.</p> <p>6 MS. GEIST: You've got to make an objection to</p> <p>7 form; and, otherwise, you have to stop.</p> <p>8 BY THE WITNESS:</p> <p>9 A. Can you repeat the question? I'm sorry. Oh,</p> <p>10 I know your question. I can answer it without it.</p> <p>11 No. That's actually quite ridiculous to think</p> <p>12 that they're doing it based upon lawyers. We're seeing</p> <p>13 time progressing, so we're now having time for the</p> <p>14 complications to happen. Patients are becoming aware of</p> <p>15 it and, more importantly, I think doctors are becoming</p> <p>16 aware of it. Doctors did not know this was happening to</p> <p>17 the extent it was happening. And they're realizing that</p> <p>18 being a situation. We're also starting to write papers</p> <p>19 on it. So the knowledge is coming to the forefront.</p> <p>20 Q. How -- you told me, I think, before that the</p> <p>21 women coming to the Mayo Clinic that you've seen</p> <p>22 specifically do not all require some sort of excision or</p> <p>23 explant procedure; is that right?</p> <p>24 A. Well, to say require, that's not the right</p> <p>25 word. That means I can't fix them --</p>	<p style="text-align: right;">Page 109</p> <p>1 to 40 percent persistent pain after removal of pelvic</p> <p>2 meshes, and so I am very careful in who I select.</p> <p>3 Q. So how many times have you done an explant or</p> <p>4 excision procedure since 2007 that involved a patient</p> <p>5 who had a Bard Align -- pardon me, a Bard Avaulta</p> <p>6 product implanted?</p> <p>7 A. Well, that would be more starting with Bard</p> <p>8 starting in 2008, 2009, because we didn't see them</p> <p>9 initially. The same thing with Prolift. We didn't see</p> <p>10 those in 2005. We saw them in 2007.</p> <p>11 Again, we're going to look at it, if you do</p> <p>12 the math, we're roughly five patients a week, 30 percent</p> <p>13 of those are going to be a Bard product, and I'm going</p> <p>14 to be operating on 25 percent of those. So, again, we'd</p> <p>15 have to do the math of whatever those numbers are. But,</p> <p>16 again, that is not -- that's not counting all of the</p> <p>17 ones I see that I don't operate on. So just looking at</p> <p>18 the surgical numbers is unrealistic as far as the true</p> <p>19 nature of the extent of the problem.</p> <p>20 Q. Well, I'm trying to understand, if you can</p> <p>21 tell me sitting here today, how many times you've</p> <p>22 explanted mesh from a patient that you can tell me was</p> <p>23 from one of the Bard products?</p> <p>24 MR. CARTMELL: You mean just --</p> <p>25</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 110</p> <p>1 BY MS. GEIST:</p> <p>2 Q. To the best of his --</p> <p>3 MR. CARTMELL: -- Solo or Plus.</p> <p>4 MS. GEIST: To the best of his estimate, right.</p> <p>5 MR. CARTMELL: Do you mean any Bard product?</p> <p>6 MS. GEIST: Well, we're talking about the Avaulta</p> <p>7 products.</p> <p>8 BY MS. GEIST:</p> <p>9 Q. And I can see, Doctor, you're sitting there</p> <p>10 doing some math calculations; is that right?</p> <p>11 A. 310, estimate.</p> <p>12 Q. That's based on the mouth -- math calculations</p> <p>13 you just did now?</p> <p>14 A. Correct. Roughly, five per week times,</p> <p>15 roughly, 45 weeks per year, times, roughly, five or six</p> <p>16 years, and then, roughly, that's how many we're seeing</p> <p>17 as far as Avaulta products. And then, roughly, as far</p> <p>18 as surgeries, it comes out to, roughly, 312 surgeries if</p> <p>19 you want exact -- or if you want an educated, accurate</p> <p>20 answer.</p> <p>21 Q. So my question was, had you ever gone back</p> <p>22 before doing what you just did now here, some quick math</p> <p>23 based on assumptions, did you ever go back and take a</p> <p>24 look and say, Let me see if I can determine how many</p> <p>25 explant procedures I did that involved the Bard Avaulta</p>	<p style="text-align: right;">Page 112</p> <p>1 Q. All right. So what percentage of the 30</p> <p>2 percent actually have an explant or excision of the</p> <p>3 mesh?</p> <p>4 A. That's what I said, 25 percent of those.</p> <p>5 Q. So 25 percent of the 30 percent that you see</p> <p>6 have some sort of explant or excision procedure?</p> <p>7 A. Correct, that I feel meet, that their pain is</p> <p>8 isolated. Just like the woman I saw two weeks ago, the</p> <p>9 pain was isolated to the arms of the mesh in the</p> <p>10 transobturator region. She had pinpoint pain. I could</p> <p>11 touch it. I could feel a knot in there consistent with</p> <p>12 scarring and inflammation. Those are the individuals</p> <p>13 that will repair. I feel that can go for it for pain.</p> <p>14 But that's not also counting the extrusions. See, we</p> <p>15 see -- we have just many, many extrusions.</p> <p>16 Q. Is the -- is the 25 percent your best</p> <p>17 guesstimate sitting here today?</p> <p>18 A. Yes, and that's a fairly accurate estimate.</p> <p>19 Q. What's --</p> <p>20 A. Because, you know, we keep --</p> <p>21 Q. -- it based on?</p> <p>22 A. Our medical records, because I have a track of</p> <p>23 every single patient that I see, and then we have it</p> <p>24 broken down. I get -- every year I get a computer</p> <p>25 printout of every single patient and tallying those</p>
<p style="text-align: right;">Page 111</p> <p>1 products?</p> <p>2 A. Well, yeah. We keep -- as I mentioned, we</p> <p>3 didn't initially keep track. As the mesh problems</p> <p>4 started to manifest themselves, we were all caught</p> <p>5 off -- unaware because we were unfamiliar with this type</p> <p>6 of thing coming along, so we didn't initially keep</p> <p>7 track. And then prior to 2011 is when we started doing</p> <p>8 this math, and that's when we started realizing we've</p> <p>9 got a big problem here. So, yeah, that was -- again,</p> <p>10 that was before any of this litigation process was</p> <p>11 going.</p> <p>12 Q. Right. But that's my question. Before you</p> <p>13 sat here today and did that quick math that you just did</p> <p>14 for me, did you ever go back, in preparation for this</p> <p>15 deposition or in your expert report, and determine how</p> <p>16 many times you've done an explant or excision procedure</p> <p>17 that involved the Bard Avaulta product?</p> <p>18 A. Well, that's what I -- that's what I just told</p> <p>19 you. I said that, roughly, 30 percent of the patients</p> <p>20 that I see are Avaulta.</p> <p>21 Q. Right. But you told me -- you also told me</p> <p>22 that the 30 percent of the patients you see that are</p> <p>23 Avaulta product users do not all go through an explant</p> <p>24 or excision procedure, right?</p> <p>25 A. Correct.</p>	<p style="text-align: right;">Page 113</p> <p>1 patients up. I also get a record of every surgery that</p> <p>2 I do and tally them up. So I can't give you exact</p> <p>3 numbers, but I can give you very accurate numbers.</p> <p>4 Q. And -- and I assume you would agree with me,</p> <p>5 Doctor, that you don't have a denominator, if you will,</p> <p>6 for the women who were implanted with the Avaulta</p> <p>7 product, correct?</p> <p>8 MR. CARTMELL: Object to the form.</p> <p>9 BY MS. GEIST:</p> <p>10 Q. You don't know, in other words, how many women</p> <p>11 were implanted with the Avaulta product during this time</p> <p>12 period that you were excising or extracting mesh,</p> <p>13 correct?</p> <p>14 A. In my review of the Avaulta records, I have</p> <p>15 not seen a specific number. In my review of other</p> <p>16 companies' records, they have always refused to give</p> <p>17 those numbers out. So I would actually like to see.</p> <p>18 That would be very helpful for me to see because usually</p> <p>19 they won't tell me. They'll say we don't know.</p> <p>20 Q. So the answer to my question is, you don't</p> <p>21 know what the denominator is, so you can't determine</p> <p>22 what the incidence rate is, for example, for women</p> <p>23 requiring an explant or excision procedure after being</p> <p>24 implanted with the Avaulta product?</p> <p>25 MR. CARTMELL: Well, object to the form. Can I ask</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 114</p> <p>1 for clarification?</p> <p>2 BY MS. GEIST:</p> <p>3 Q. Right. So, Dr. Elliott --</p> <p>4 MR. CARTMELL: Are you saying you want him to</p> <p>5 create an incidence rate nationwide from his own</p> <p>6 practice with a denominator?</p> <p>7 BY MS. GEIST:</p> <p>8 Q. I'm asking you, Dr. Elliott, you can't tell me</p> <p>9 what percentage of women that you are seeing represents</p> <p>10 women who have been implanted with the Avaulta product?</p> <p>11 A. I see patients from all over the world, and so</p> <p>12 we have -- it's a unique practice that I have. I have</p> <p>13 yet to see, and I would like to see, Bard's numbers of</p> <p>14 exactly how many have been put in. That would be very</p> <p>15 helpful. But my practice is not going to reflect, you</p> <p>16 know, what that true incidence is. That just reflects</p> <p>17 what comes into my clinic.</p> <p>18 Q. Right. So you don't know what the incidence</p> <p>19 rate is, whether it's high, whether it's low, whether</p> <p>20 it's someplace in between, for the complications</p> <p>21 relating to the Bard Avaulta products?</p> <p>22 MR. CARTMELL: Object to the form.</p> <p>23 BY MS. GEIST:</p> <p>24 Q. You don't know what that incidence rate is,</p> <p>25 true?</p>	<p style="text-align: right;">Page 116</p> <p>1 MR. CARTMELL: Object to the form.</p> <p>2 BY MS. GEIST:</p> <p>3 Q. Is that an assumption?</p> <p>4 A. An assumption based upon experience, and I</p> <p>5 would -- I would really hope that Bard did the</p> <p>6 responsibility -- responsible thing and know how many</p> <p>7 products moved.</p> <p>8 Q. Based on what experience? Have you ever</p> <p>9 worked for a medical device company?</p> <p>10 A. I've been a consultant for some, yes.</p> <p>11 Q. Have you ever worked as an employee for a</p> <p>12 medical device company?</p> <p>13 A. Well, no. I've been a consultant for some in</p> <p>14 the past, so...</p> <p>15 Q. Have you ever been a consultant for a</p> <p>16 manufacturer of a pelvic mesh product?</p> <p>17 A. As a consultant, yeah. But we can just leave</p> <p>18 it on the table that it's acceptable for Bard not to</p> <p>19 know how many products have moved and have been</p> <p>20 implanted in women, if that's what you're telling me.</p> <p>21 Q. No. That's not what I'm telling you, Doctor.</p> <p>22 I'm asking you what your basis is for your statement</p> <p>23 that you think Bard can just give you the denominator?</p> <p>24 A. Bard knows how much money they made. Every</p> <p>25 company knows how much money they've made in the United</p>
<p style="text-align: right;">Page 115</p> <p>1 MR. CARTMELL: Object to the form.</p> <p>2 BY THE WITNESS:</p> <p>3 A. I have papers on Avaulta, Avaulta Plus,</p> <p>4 describing their complication rate, and so that's all I</p> <p>5 can go off of. If they're talking 11, 20, 30 percent on</p> <p>6 short-term studies, if we extrapolate that, and those</p> <p>7 are in the hands of highly trained individuals, so if we</p> <p>8 just take those conservative numbers on short-term</p> <p>9 studies, then I can give an estimate. But, again, we</p> <p>10 need to provide the denominator.</p> <p>11 Q. And we don't have that, correct?</p> <p>12 A. Oh, it's available. Bard has not given it to</p> <p>13 us.</p> <p>14 Q. Well, I'll just move to strike that. I don't</p> <p>15 know what that's based on.</p> <p>16 How do you know that it's available?</p> <p>17 A. You're telling me that a company in the United</p> <p>18 States that is designed to make money does not know how</p> <p>19 many products they sell and they're going to implant it?</p> <p>20 Then that sounds like a company that's not following</p> <p>21 their data very well. Cadillac knows how many cars move</p> <p>22 off their showroom.</p> <p>23 Q. So you're making certain assumptions about</p> <p>24 what Bard knows; is that fair to say, Doctor? You don't</p> <p>25 have any basis for saying that?</p>	<p style="text-align: right;">Page 117</p> <p>1 States. They file tax returns. They know how much</p> <p>2 money is made. They would know. They'd be able to</p> <p>3 follow their subsections. There's a line, Avaulta, et</p> <p>4 cetera. And they're going to know what products make</p> <p>5 money.</p> <p>6 Also, I read, in one of the depositions, that</p> <p>7 one of the individuals, when they're asked to file a 522</p> <p>8 for the federal government, that he said it's not making</p> <p>9 enough money to go through the extra work, so they know.</p> <p>10 Q. Do you -- do you understand, Doctor, there is</p> <p>11 a difference between products sold and products used or</p> <p>12 implanted?</p> <p>13 A. Mm-hmm. Yes, I do.</p> <p>14 Q. Do you know if Bard has the data you're</p> <p>15 talking about to even come up with the denominator?</p> <p>16 A. If they --</p> <p>17 Q. Do you know?</p> <p>18 A. Absolutely, they do.</p> <p>19 Q. What do you base that on?</p> <p>20 A. Experience, because I'm also involved with the</p> <p>21 buying and selling of products at my institution. And</p> <p>22 if a company sells a product to an institution and the</p> <p>23 hospital buys a certain number of products and then five</p> <p>24 months later they have to sell more products back, that</p> <p>25 means the product moved.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 118</p> <p>1 (Elliott Deposition Exhibit No. 3 was 2 marked for identification.) 3 BY MS. GEIST: 4 Q. Let me show you what I've marked as Exhibit 3 5 to your deposition, Dr. Elliott. And let me show it to 6 counsel first because, for whatever reason -- I 7 apologize -- I don't have another copy. 8 And, just for the record, Doctor, as Exhibit 9 3, I've handed you an article by Blandon and others 10 published in the Journal of International Urogynecology 11 in 2009. Do you see that? 12 A. Correct. 13 Q. And this was on your reliance list? 14 A. Correct. 15 Q. And, in this study, Doctor, this was actually 16 a Mayo Clinic study, correct? 17 A. Correct. 18 Q. And who are Dr. Blandon, Gebhart, Trabuto, 19 T-R-A-B-U- -- 20 A. Trabuco. 21 Q. Oh, I'm sorry. That's a C. T-R-A-B-U-C-O, 22 and -- 23 A. Klingele. 24 Q. Yeah, thank you. K-L-I-N-G-E-L-E. 25 A. Blandon was a fellow, John Gebhart is the --</p>	<p style="text-align: right;">Page 120</p> <p>1 Clinic from January 2003 through September 2007, 2 correct? 3 A. Incorrect. 4 Q. I'm sorry? 5 A. Incorrect. 6 Q. How is that incorrect? 7 A. You said these women were referred to the Mayo 8 Clinic. This is -- I mean, this is just into one 9 department and a few of the staff. So it's not 10 reflecting all of the patients that were sent in. 11 Q. Well, if you look at -- if you look at the 12 article, it states, We retrospectively identified 13 patients referred to our institution from January 2003 14 through September 2007 who had complications after 15 vaginal placement of mesh. Did I read that correctly? 16 A. Correct. 17 Q. So it's saying the institution. It's not 18 talking about a particular department, is it? 19 A. It is, because that's just reflecting their 20 practice and that were referred into their department. 21 Q. So this is -- this is limited to the 22 urogynecology division? 23 A. Pretty much, though I believe there is one 24 patient of mine in there. But most -- this does not 25 reflect my practice or the other female urologists in</p>
<p style="text-align: right;">Page 119</p> <p>1 in charge of urogyn. He's the chair of urogyn. Manny 2 Trabuco is a former Mayo fellow and urogyn and then 3 staff, and the same thing with Chris Klingele. 4 Q. So one of the lead authors of the article was 5 the chair of the urogynecology department at Mayo? 6 A. Correct. 7 Q. Is he still the chair of the department? 8 A. I think Klingele is now. 9 Q. And this paper is entitled, Complications From 10 Vaginally Placed Mesh in Pelvic Reconstructive Surgery, 11 correct? 12 A. Correct. 13 Q. And it refers to the experience these 14 physicians had with women who were referred to the Mayo 15 Clinic from all across the country, correct? 16 A. I can't speak to where they all came from. 17 Q. Referrals to the Mayo Clinic, I thought you 18 just told me earlier, come from all over the country? 19 A. That is correct. 20 Q. Okay. And this paper looked at a number of 21 different products that were used to correct pelvic 22 organ prolapse, correct? 23 A. Correct. 24 Q. And what the authors did in this paper was to 25 go back and take a look at women referred to the Mayo</p>	<p style="text-align: right;">Page 121</p> <p>1 our department. 2 Q. And over the four and a half -- approximate 3 four-and-a-half time period, there were 21 patients, in 4 that four and a half years, identified who had 5 complications after vaginal placement of mesh? 6 A. Correct. 7 Q. Is that right? 8 A. That's what they report, yes. 9 Q. So more than four years and only about 21 10 patients, so maybe five per year, referred to the Mayo 11 Clinic urogynecology department with mesh complications, 12 correct? 13 A. Yeah. Somewhat, but that's somewhat very 14 misleading. 15 Q. Well, is my math wrong? 16 MR. CARTMELL: Let him finish. Let him finish. Go 17 ahead. 18 BY THE WITNESS: 19 A. This is 2003 to 2007. Avaulta wasn't even on 20 the market. Most of the other ones weren't on the 21 market. It's only Prolift. Prolift came out on the 22 market in 2005. So this is dealing with the IVS tunnel 23 and all of those type of things. And this is -- 24 remember I mentioned there is delayed effect of the 25 complications. So this is right when 2007, 2008, when</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 122</p> <p>1 we're starting to see this uptick, and that's what this</p> <p>2 is reflecting.</p> <p>3 Q. So there is nothing inaccurate about what I</p> <p>4 just said, in terms of over a four-and-a-half-year</p> <p>5 period, there were 21 patients referred to Mayo for</p> <p>6 complications of mesh, approximately five per year</p> <p>7 during this time period?</p> <p>8 MR. CARTMELL: Object to form.</p> <p>9 BY THE WITNESS:</p> <p>10 A. That is still incorrect. It's from 2003 to</p> <p>11 2007. That does not reflect today's numbers.</p> <p>12 Q. I didn't say it did. I'm talking about a</p> <p>13 four-and-a-half-year time period, acknowledging it's</p> <p>14 2003 to 2007, there were approximately five patients per</p> <p>15 year referred to the urogynecology department at Mayo</p> <p>16 for mesh complications. Isn't that what this paper is</p> <p>17 looking at?</p> <p>18 A. Well, I don't know. I would have to look over</p> <p>19 the paper again. Is this reflecting all of the patients</p> <p>20 they saw during that or just the ones that went to</p> <p>21 surgery? So that would require me to read the paper.</p> <p>22 Q. Well, it's on your reliance list. Had you</p> <p>23 read it before?</p> <p>24 A. Of course I've read it. I've read it multiple</p> <p>25 times, but I can't remember every word that I read. So</p>	<p style="text-align: right;">Page 124</p> <p>1 dirty. In order to read a paper correctly, you have to</p> <p>2 read the entire paper.</p> <p>3 Q. Okay. Well, I'm trying to be efficient and</p> <p>4 move us along. If you think that that section, the</p> <p>5 quick-and-dirty section of the article, says something</p> <p>6 different than what's in the text --</p> <p>7 MR. CARTMELL: Just have him read it.</p> <p>8 BY MS. GEIST:</p> <p>9 Q. -- let me know.</p> <p>10 A. I will read the paper because, again, you</p> <p>11 can't just quote one line and then extrapolate. That's</p> <p>12 why you need to know the whole thing. So if you want, I</p> <p>13 can review it.</p> <p>14 MR. CARTMELL: Just go ahead and read it.</p> <p>15 BY MS. GEIST:</p> <p>16 Q. Well, let me ask you one question before you</p> <p>17 start reading it because I don't want to waste too much</p> <p>18 time. Under the Results section, it says, 16 patients</p> <p>19 were managed surgically.</p> <p>20 A. Okay. Again, that's the abstract. That's not</p> <p>21 the results section. That's the abstract section.</p> <p>22 That's the results section of the abstract. That's</p> <p>23 different. Remember, I'm on 16 journals that I review,</p> <p>24 and I was best reviewer two years in a row for female</p> <p>25 urology. This is what I do for a living.</p>
<p style="text-align: right;">Page 123</p> <p>1 in order to answer your question carefully -- and this</p> <p>2 is actually a very important point -- this may just</p> <p>3 reflect 21 that went to the OR.</p> <p>4 Q. Well, Doctor, it actually doesn't. And if you</p> <p>5 look with me on the results section on the very first</p> <p>6 page, it provides a nice summary. And, it says,</p> <p>7 Complications included mesh erosions in 12 women,</p> <p>8 dyspareunia in 10, and recurrent prolapse in nine?</p> <p>9 A. Okay. That still is not saying the</p> <p>10 denominator.</p> <p>11 MR. CARTMELL: Do you want him to read the whole</p> <p>12 thing and let you know the answer?</p> <p>13 BY THE WITNESS:</p> <p>14 A. Because it's going to be in the paper. That's</p> <p>15 a very important issue. Because you just raised the</p> <p>16 issue about Bard not knowing the denominator and the</p> <p>17 numerator. This, I don't know if this is the</p> <p>18 denominator, all patients who came in during that time</p> <p>19 period or just the ones that went to the OR, because</p> <p>20 that's completely different. Because, remember, in my</p> <p>21 practice, only 25 percent of the patients I see end up</p> <p>22 going to the OR because I can't fix the other ones.</p> <p>23 Q. Doctor, if you look at the results section --</p> <p>24 A. That's not the results section. You're</p> <p>25 reading the abstract. Okay. That's the quick and</p>	<p style="text-align: right;">Page 125</p> <p>1 Q. Yeah. I understand that. But how many times</p> <p>2 have you -- have you seen an abstract provide a summary</p> <p>3 like that specifically telling you 16 patients were</p> <p>4 managed surgically --</p> <p>5 A. Yeah.</p> <p>6 Q. -- and there's something different in the</p> <p>7 actual body of the paper?</p> <p>8 A. No. That part, one line, 16 managed</p> <p>9 surgically, is correct. But you're only given,</p> <p>10 probably, 150, 200 words to do it. So, again, I don't</p> <p>11 know what the denominator is going to be.</p> <p>12 And I'm more than happy to read the paper, and</p> <p>13 it's a very good paper. This is one of the first ones</p> <p>14 out there. But now there's been subsequent others, you</p> <p>15 know, Karram and Zimmerman and things like that, which</p> <p>16 have larger numbers than this. But this is one of the</p> <p>17 first ones to raise the awareness of this problem.</p> <p>18 Q. So my question is, Doctor, the paper, if you</p> <p>19 go to the discussion section of the paper, the authors</p> <p>20 conclude that the incidence rate of the complications is</p> <p>21 unknown, correct?</p> <p>22 A. I don't -- I don't know. I would have to see</p> <p>23 that line. It sounds like it would be -- you read</p> <p>24 accurately. I just want to know where you are, though.</p> <p>25 Q. Sure. I'm on page 527 under Discussion?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 126</p> <p>1 A. Okay.</p> <p>2 Q. I'm not in the abstract. I'm in the body of</p> <p>3 the paper.</p> <p>4 A. Okay.</p> <p>5 Q. The authors of the paper conclude that the</p> <p>6 incidence of the complications are unknown, correct?</p> <p>7 A. Yeah. Although -- let's see. I have to read</p> <p>8 the sentence before it. Okay. Yeah. As the use of</p> <p>9 synthetic materials in the pelvic reconstructive surgery</p> <p>10 increases, this is right when they came out and right</p> <p>11 when there is a big increase in numbers, so do the</p> <p>12 complications specific to their use. Although the</p> <p>13 incidence of these complications is unknown, our series</p> <p>14 demonstrates that, when they occur, multiple</p> <p>15 interventions may be required and bothersome and</p> <p>16 occasionally life-changing symptoms may persist.</p> <p>17 Q. And, at this point in time, there were four</p> <p>18 trocar-based implant systems marketed in the U.S.,</p> <p>19 including Bard's Avaulta product, correct, as noted in</p> <p>20 this paper on page 524?</p> <p>21 MR. CARTMELL: Is that Sofradim's Avaulta? Is that</p> <p>22 the one that Bard -- because I don't think Bard's</p> <p>23 product was on the market at that time.</p> <p>24 BY MS. GEIST:</p> <p>25 Q. Doctor, will you look with me at the second</p>	<p style="text-align: right;">Page 128</p> <p>1 Q. And the Avaulta product from Bard, correct?</p> <p>2 A. Correct.</p> <p>3 Q. And the authors of the paper did a</p> <p>4 retrospective study of all women referred to the</p> <p>5 urogynecology division from January 2003 to September</p> <p>6 2007 who had complications after procedures using</p> <p>7 transvaginal mesh. That's what this paper looked like,</p> <p>8 correct -- looked at, correct?</p> <p>9 A. That's what they state, yes.</p> <p>10 Q. And the paper also notes that the authors of</p> <p>11 the paper didn't perform the actual implant procedures.</p> <p>12 The women were referred from outside institutions,</p> <p>13 correct?</p> <p>14 A. Correct.</p> <p>15 Q. And the authors' review of the database, this</p> <p>16 retrospective review, identified 22 women who were</p> <p>17 referred to the department during that time period with</p> <p>18 complications, correct?</p> <p>19 A. Correct.</p> <p>20 Q. And if you look at Table 2 of the study, are</p> <p>21 you there with me, Doctor?</p> <p>22 A. Yes, I am.</p> <p>23 Q. It lists the type of mesh products that the</p> <p>24 women who experienced complications had implanted. Do</p> <p>25 you see that?</p>
<p style="text-align: right;">Page 127</p> <p>1 page of the article on page 524?</p> <p>2 A. I'm there.</p> <p>3 Q. If you go down towards the middle of that</p> <p>4 paragraph --</p> <p>5 A. Which column?</p> <p>6 Q. I'm on the --</p> <p>7 A. The first or second column?</p> <p>8 Q. I'm on the left-hand side, second paragraph,</p> <p>9 beginning with the word Options?</p> <p>10 A. Okay.</p> <p>11 Q. Okay. Are you with me?</p> <p>12 A. Yes, I am.</p> <p>13 Q. All right. In the middle of the paper, in the</p> <p>14 middle of that paragraph, rather, it says, Four trocar</p> <p>15 systems are currently marketed in the U.S. Do you see</p> <p>16 that? Doctor, do you see that?</p> <p>17 A. I'm looking.</p> <p>18 Q. And it lists the Gynecare product?</p> <p>19 A. I'm not there yet. Four -- okay. Four. Four</p> <p>20 trocar systems are currently marketed, correct.</p> <p>21 Q. And there's the Prolift product from Gynecare,</p> <p>22 right?</p> <p>23 A. Correct.</p> <p>24 Q. The Apogee product from AMS?</p> <p>25 A. Correct.</p>	<p style="text-align: right;">Page 129</p> <p>1 A. Yes, I do.</p> <p>2 Q. And of the 21 women listed who were referred</p> <p>3 to the Mayo Clinic, there is not a single patient on</p> <p>4 this list who had the Bard Avaulta product implanted; is</p> <p>5 that right?</p> <p>6 A. By the way they have it listed here, that is</p> <p>7 correct.</p> <p>8 Q. If you go with me to page 530 of the article,</p> <p>9 Doctor --</p> <p>10 A. Okay. I'm there.</p> <p>11 Q. -- the authors note that the questions of what</p> <p>12 degree of training is sufficient and who should be</p> <p>13 performing these types of procedures remain highly</p> <p>14 debated. Do you see that?</p> <p>15 A. Yes.</p> <p>16 Q. And do you agree with that?</p> <p>17 A. Yes.</p> <p>18 Q. Would you agree, Doctor, that such a surgical</p> <p>19 technique and surgeon training and experience are</p> <p>20 critically important in a good outcome for any surgical</p> <p>21 procedure?</p> <p>22 A. The -- within limits, the more expertise the</p> <p>23 data has shown that the results are better. That is</p> <p>24 correct.</p> <p>25 Q. And what about with transvaginal mesh in</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 130</p> <p>1 particular? Would you agree with me that surgical 2 technique and skill plays a very critical role in 3 determining whether or not a woman may have 4 complications? 5 A. I would somewhat disagree because there are 6 some high-volume, world class surgeons, I can think of 7 the French group and others for specifically with 8 prolapse who have implanted, you know, 700, 800, and 9 they still have an unacceptably high complication rate. 10 Q. Are you aware that there are very skilled and 11 highly reputable pelvic floor reconstructive surgeons 12 who still use transvaginal mesh today? 13 MR. CARTMELL: Object to the form. 14 BY THE WITNESS: 15 A. I'm not familiar. As far as the transvaginal 16 mesh or are you talking about the transvaginal kits? 17 Q. Transvaginal kits? 18 A. Transvaginal kits? Well, prolapse -- Prolift 19 is off the market, Avaulta is off the market, 20 Apogee/Perigee are off the market. I don't know about 21 Boston Scientific. So if they are still putting them 22 in, you know, I can't speak if they are. I have not 23 heard of anybody. 24 Q. You're not aware of anyone still using these 25 types of products?</p>	<p style="text-align: right;">Page 132</p> <p>1 see when Avaulta came onto the market. Because, 2 remember, the Prolift was 2005 and a lot more of those 3 got implanted. So I would have to see when Avaulta was 4 released and started to put in. Because then you have 5 to look at the study two, three, four years on down the 6 road. That's when we start seeing the complications. 7 Like Mickey Karram's paper and Philippe Zimmerman's 8 paper, okay, those ones would be a little bit more 9 reflective of complications. 10 Q. At least, based on this paper, though, Doctor, 11 there were no complications specific to the Avaulta 12 product that was seen by Mayo at this point in time, 13 correct? 14 A. Putting the qualifiers on there from January 15 2003, before it was even available, any of the mesh 16 products were available, as far as the large ones, to 17 2007, you are correct. Of the 21 selected individuals 18 who came in, there was not an Avaulta product on there. 19 Q. Well, and you keep saying available, Doctor. 20 But if we go back and we look at the page, the second 21 page of the article, the author specifically notes that 22 the four trocar systems currently marketed included the 23 Avaulta product; do you see that? 24 A. That is correct. They state that, but I don't 25 know when that was available. Because, remember, they</p>
<p style="text-align: right;">Page 131</p> <p>1 A. No. 2 Q. Would you agree with the conclusion by the 3 authors from the Mayo Clinic and this study, Doctor, 4 that there seems to be an inconsistency in the 5 techniques by implanters? 6 A. Yeah. I can't speak to that. I think it's a 7 valid point. Again, I can't speak to that with any 8 accuracy. 9 Q. You don't have any opinion on that? 10 A. Well, no. I do have an opinion. If they're 11 going to be following the IFU correctly and they're not 12 told how high to dissect or how deep to go in the 13 tissues, where to put the trocars, how much tension to 14 put the trocars in, there is going to be some 15 variability. So it seems to behoove the company to make 16 sure it's very, very clear on an innovative product like 17 this. 18 Q. At least based on this review from the doctors 19 at the Mayo Clinic, at this point in time, the other 20 products available on the market from Gynecare and other 21 manufacturers were presenting with more complications, 22 at least for women referred to Mayo? 23 A. Well, I mean, there is going to be a selection 24 bias here. This is just the people that have come in 25 with a retrospective view. I'd have to look back and</p>	<p style="text-align: right;">Page 133</p> <p>1 wrote this in 2009. So, again, you have to tell me when 2 Avaulta was released and the first product was sold, and 3 that would help me out tremendously. 4 Q. I'm just sticking with what the authors found 5 in this paper, Doctor. 6 MR. CARTMELL: Can I tell him the date it was 7 released? 8 MS. GEIST: No. If you want to do your own 9 examination, feel free -- 10 MR. CARTMELL: Okay. 11 MS. GEIST: -- when I'm done. 12 MR. CARTMELL: All right. 13 BY MS. GEIST: 14 Q. Okay. Doctor, you can put that aside. 15 Let me -- let me move, Doctor, to your expert 16 report and just start by asking you generally about 17 pelvic organ prolapse. And you have a discussion, don't 18 you, Doctor, generally of pelvic organ prolapse and some 19 of the different treatment options for women 20 experiencing that condition, approximately, page 5 to 12 21 of your report; is that right? 22 A. Correct. I wrote up a synopsis of 100 years 23 of knowledge about pelvic organ prolapse, the etiology, 24 et cetera, going through those pages you mentioned 25 there.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 134</p> <p>1 Q. And is it a fair summary that pelvic organ 2 prolapse is a condition where the organs of the pelvic 3 floor drop down from the usual supported positions into 4 or through the areas of weakness in the pelvic floor? 5 A. For women, yes. 6 Q. And we are speaking about women, right? 7 A. Correct. 8 Q. Typically, the organs that we're talking about 9 that prolapse are the bladder, the uterus, and the 10 rectum? 11 A. And intestines. 12 Q. And intestines. And pelvic floor damage 13 occurs, generally speaking, due to childbirth, correct? 14 A. Childbirth, age, obesity, chronic cough. 15 There are multiple factors that all play a role, but 16 childbirth would probably be the number one. 17 Q. Physical labor or chronic issues with 18 straining or constipation as well could be risk factors 19 for prolapse, true? 20 A. Correct. Anything that would be under the 21 criteria of Valsalva effort, which just means straining. 22 Q. And that results in a deficiency in the 23 support of the organs that we just finished talking 24 about, right? 25 A. It means that the musculature, the tendon</p>	<p style="text-align: right;">Page 136</p> <p>1 practice? 2 A. Yes. Since 2000, yes. 3 Q. And what percentage of your practice is 4 devoted to clinical experience in treating women versus 5 teaching? 6 A. Well, I'm -- I always have a resident with me. 7 So I'm 100 percent teacher, but I am 100 percent 8 clinical. So every other day I'm in the clinic and the 9 next day I'm in the operating room. 10 Q. And, based on your own experience, I assume 11 that you would agree with me that pelvic organ prolapse 12 can negatively affect a woman's life? 13 A. The quality of life can at times be impaired 14 with this, but it's important to stress that it is a 15 quality of life issue. 16 Q. It's not a life-threatening condition, 17 correct? 18 A. In the United States, that is exceedingly rare 19 for it to be life-threatening. I've only seen that one 20 time. 21 Q. But it can impact a woman in many different 22 ways in terms of symptomatology? 23 A. Correct. 24 Q. It's a very prevalent condition in the United 25 States, somewhere between 30 to 50 percent of all women</p>
<p style="text-align: right;">Page 135</p> <p>1 support, so to speak, are weakened with childbirth, and 2 then with time, age, et cetera, all of the factors we 3 mentioned, the structures slowly descend. 4 Q. Okay. And that's because, as I said, there is 5 sort of a deficiency in the support for those organs; is 6 that a fair summary? 7 A. I wouldn't say -- well, the fact that there is 8 a problem reflects that there is a deficiency, if you 9 want to call it that. But I wouldn't call it that. 10 It's that there is a weakness or a tearing. With 11 childbirth, there is an extreme amount of tearing. 12 That's why it hurts. Okay. If childbirth didn't hurt, 13 there wouldn't be the tearing of the muscles. So the 14 muscles are also a big part of the support of this, too. 15 Q. Okay. So there's -- the muscles are not as 16 strong, if you will, as before a woman had experienced 17 childbirth? 18 A. There's -- and, again, it's damage of the 19 whole pelvic structure, the support. So we can't think 20 of it in just muscles, just tendons, just collagen, et 21 cetera. It's the whole unit has been damaged. 22 Q. And do you treat women in your practice who 23 experience pelvic organ prolapse? 24 A. Daily. 25 Q. And has that always been part of your</p>	<p style="text-align: right;">Page 137</p> <p>1 are affected by some degree of prolapse; is that a fair 2 summary? 3 A. Well, that's going to be difficult to say 4 because there are -- it depends on how the study is run, 5 if it's anatomic prolapse versus subjective symptomatic 6 prolapse again. 7 So I don't know if we need to stop for out 8 there. 9 MR. CARTMELL: We don't. Go ahead. 10 BY THE WITNESS: 11 A. So I almost have to start over with that, 12 because that's very, very important, because just the 13 fact that there is an anatomic prolapse does not mean 14 there is a problem. You have to look at the subject of 15 everything. So I would be hesitant to say the number is 16 up to 30 to 50 percent. That would be pretty on the 17 high side. But, to answer your question, it is a 18 prevalent problem. 19 Q. Would you agree with me that, at least what 20 the literature tells us, is that maybe 300,000 women 21 undergo surgery a year for the repair of pelvic organ 22 prolapse? 23 A. Yeah. I have not heard. I have no reason to 24 doubt the accuracy of that. I have not heard a specific 25 number. It's a large number.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 138</p> <p>1 Q. Well, what are some of the signs and symptoms 2 that a woman may experience if she has pelvic organ 3 prolapse? 4 A. We have to break it down into -- well, there 5 is a lot of different types of symptoms and things: 6 fullness; something falling out; pressure, potentially; 7 pain very, very rarely. Pain is usually the exact 8 opposite. The higher the prevalence of pain, the lower 9 the incidence of pelvic organ prolapse. So pain is not 10 one of them usually. 11 Q. Pain usually indicates something other? 12 A. Something else, correct. I said fullness. 13 Can we stop? Because whatever is going on out there is 14 distracting me a whole bunch, the noise. 15 MS. GEIST: Yeah. Let's go off the record for a 16 minute. 17 VIDEO TECHNICIAN: We are off the record. The time 18 is 12:20 p.m. 19 (Whereupon, at 12:20 p.m., a recess 20 was had for lunch.) 21 22 23 24 25</p>	<p style="text-align: right;">Page 140</p> <p>1 something is actually falling out of her body? 2 A. Correct. With standing, lifting, as the day 3 goes on, that's the most common thing I hear is, again, 4 something is falling out. 5 Q. In some women who have a more severe type of 6 prolapse, you can actually visibly see something 7 extruding beyond the entrance of the vagina, correct? 8 A. Correct. In severe cases, it can actually 9 look like a baby's head crowning. 10 Q. And then some women have also -- I'm sure 11 you've heard in your own experience and practice -- talk 12 about a feeling of heaviness as well? 13 A. Yeah. That's the fullness, pressure. 14 Q. And some women, I'm sure you have known from 15 your practice, also have issues with being able to 16 urinate or void or defecate as well because of pelvic 17 organ prolapse? 18 A. Not necessarily. Urination symptoms, like not 19 being able to urinate, has been reported. That's rare. 20 Frequency, urgency, usually the bladder actually works 21 fairly well. Defecation, usually they're going to have 22 a problem -- the constipation is going to cause the 23 prolapse, not the prolapse cause the constipation. 24 Q. And some women, Doctor, I'm sure you've seen 25 in your practice, have issues with sexual intimacy,</p>
<p style="text-align: right;">Page 139</p> <p>1 AFTERNOON SESSION 2 VIDEO TECHNICIAN: We're back on the record. The 3 time is 12:58 p.m. 4 WHEREUPON: 5 DANIEL S. ELLIOT, M.D., 6 called as a witness herein, having been previously duly 7 sworn, was examined and testified as follows: 8 DIRECT EXAMINATION (Continued) 9 BY MS. GEIST: 10 Q. Dr. Elliott, before we took a break, we were 11 talking about the signs and symptoms that a woman might 12 experience when she's having pelvic organ prolapse. Do 13 you remember that? 14 A. Yes, I do. 15 Q. And you started telling me about some of the 16 signs and symptoms and said that pain is probably 17 indicative of some other medical problem or condition, 18 correct? 19 A. Pain -- pain is usually not consistent with 20 pelvic organ prolapse. 21 Q. And we talked about the feeling of like 22 something falling out? 23 A. Fullness, pressure, falling-out sensation. 24 Q. Falling-out sensation, we're specifically 25 talking about a woman's vagina, correct? She feels like</p>	<p style="text-align: right;">Page 141</p> <p>1 being able to experience sexual intercourse or wanting 2 to experience sexual intercourse with their partners, 3 true? 4 A. Correct. There could be physical barriers and 5 also psychological barriers with the prolapse, 6 embarrassment and things like that. 7 Q. And often, Doctor, but not always, there's 8 some sort of incontinence associated with pelvic organ 9 prolapse; is that also true? 10 A. There can be incontinence present before 11 surgery and also if it's not corrected after surgery. 12 It's called occult incontinence. 13 Q. And when a woman presents with these symptoms 14 and signs of pelvic organ prolapse, what are her options 15 to resolve the problem? 16 A. It depends upon the severity of the condition, 17 the health of the patient. There's multiple different 18 factors. 19 Q. So there is nonsurgical options, correct? 20 A. Correct. Nonsurgical, and there's 21 observation, nonsurgical and then surgical. 22 Q. So the observation is sort of the wait-and-see 23 approach, live with it, and see if you can deal with it 24 in your daily life on a daily basis? 25 A. If it's minimally symptomatic, there's nothing</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 142</p> <p>1 wrong with observation.</p> <p>2 Q. And some women choose that, correct?</p> <p>3 A. A large number do, yes.</p> <p>4 Q. After consultation and discussion with their</p> <p>5 physician?</p> <p>6 A. Yes. It should always be offered to the</p> <p>7 patient, yes.</p> <p>8 Q. And it's her decision ultimately?</p> <p>9 A. I can only speak to my personal practice, but</p> <p>10 I always leave it up to the woman to decide.</p> <p>11 Q. And then a nonsurgical option would be the use</p> <p>12 of a pessary; is that correct?</p> <p>13 A. Pessaries, pelvic floor strengthening</p> <p>14 exercises, vaginal estrogen replacement, the</p> <p>15 conservative options.</p> <p>16 Q. And what are sort of the -- pardon me. Strike</p> <p>17 that.</p> <p>18 What are some of the problems or potential</p> <p>19 side effects if a woman chooses to use a pessary?</p> <p>20 A. A pessary can have -- first of all, probably</p> <p>21 the most common thing is the pessary can fall out.</p> <p>22 There has to be maintenance for it. It has to be</p> <p>23 changed. It has to be cleaned, doctor visits, those</p> <p>24 types of things. If it's not taken care of</p> <p>25 appropriately, there could be vaginal erosion,</p>	<p style="text-align: right;">Page 144</p> <p>1 that through an anatomic repairing the prolapse and</p> <p>2 getting back to a normal anatomic position. But if I</p> <p>3 achieve just anatomic success, that does not necessarily</p> <p>4 correlate to subjective is the patient happy or not.</p> <p>5 Q. Is anatomic success important or not in terms</p> <p>6 of the goal of the pelvic organ prolapse surgery, repair</p> <p>7 surgery?</p> <p>8 A. For me, not to belabor the issue, but the goal</p> <p>9 is subjective relief. If I do a surgery and I take a</p> <p>10 woman with a Grade 4 prolapse and six months later she</p> <p>11 comes back and she has a Grade 2 prolapse, but she's</p> <p>12 thrilled with the results, she's relieved, that's a</p> <p>13 success.</p> <p>14 Q. So you're looking at both improvement in the</p> <p>15 anatomic structure as well as improvement in the</p> <p>16 symptomatology?</p> <p>17 A. I do it the other way around. Improvement of</p> <p>18 symptomatology, is the patient happy; and then,</p> <p>19 secondly, if the -- if there is an anatomic repair that</p> <p>20 is pleasing, the anatomic repair is pleasing to the</p> <p>21 surgeon, not necessarily to the patient.</p> <p>22 Q. Would you agree with me that both are goals of</p> <p>23 a pelvic organ prolapse procedure, a surgical procedure?</p> <p>24 A. This is a quality-of-life problem. So the</p> <p>25 goal is to improve the quality of life. If I've</p>
<p style="text-align: right;">Page 143</p> <p>1 discomfort.</p> <p>2 Q. Pain as well?</p> <p>3 A. Pain, yeah.</p> <p>4 Q. For some women?</p> <p>5 A. No, that definitely can happen.</p> <p>6 Q. And in terms of surgical options, Doctor, the</p> <p>7 goal of any surgical repair of pelvic organ prolapse is</p> <p>8 to provide some sort of support for the organs that have</p> <p>9 less support than they used to have?</p> <p>10 A. No. The goal of surgery is symptom relief.</p> <p>11 Q. The goal of pelvic organ prolapse is not to</p> <p>12 lift up or put the organs back to where they were</p> <p>13 originally?</p> <p>14 A. I think, if you look at studies out there,</p> <p>15 what the patient wants is they want relief of their</p> <p>16 symptoms that may be achieved either through counseling</p> <p>17 and reassurance or through surgery. Then when you do</p> <p>18 surgery, that will usually mean elevating the organs</p> <p>19 back up to a normal or closer to normal position, but it</p> <p>20 does not have to be anatomically perfect repair.</p> <p>21 Q. But, in order to relieve the symptoms and</p> <p>22 problems that a woman experiences, which is why she goes</p> <p>23 to see a doctor, you are trying to correct the anatomic</p> <p>24 defect; is that true?</p> <p>25 A. My goal is to relieve the symptoms. I may do</p>	<p style="text-align: right;">Page 145</p> <p>1 improved the anatomy but the patient is not happy,</p> <p>2 that's not successful surgery.</p> <p>3 Q. Well, the way to improve the quality of life,</p> <p>4 as you've just indicated, is to address and improve the</p> <p>5 symptoms, correct?</p> <p>6 A. Correct.</p> <p>7 Q. And in order to do that, you need to be</p> <p>8 addressing the anatomic defect or problem, true?</p> <p>9 A. Correct.</p> <p>10 Q. That's what you're doing in a surgery,</p> <p>11 correct?</p> <p>12 A. We are -- we are improving the support for the</p> <p>13 organs.</p> <p>14 Q. And there is different methods to go about</p> <p>15 improving the support of the organs, correct?</p> <p>16 A. Correct.</p> <p>17 Q. There's a number of different options?</p> <p>18 A. There are quite a few options, yes.</p> <p>19 Q. So let's talk about some of those options</p> <p>20 briefly. Native tissue repair is one of the options?</p> <p>21 A. Correct.</p> <p>22 Q. And have you done that in your own practice?</p> <p>23 A. That's the majority of what I do.</p> <p>24 Q. And has that always been the majority of what</p> <p>25 you've done in response to a woman who decides to have</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 146</p> <p>1 surgery to repair organ prolapse?</p> <p>2 A. Correct.</p> <p>3 Q. The majority of the prolapse cases that you've</p> <p>4 seen, Doctor, I assume relate to bladder prolapse or a</p> <p>5 cystocele?</p> <p>6 A. No. There's going to be a mix. There's going</p> <p>7 to be -- we won't necessarily call it cystocele. It</p> <p>8 would be an anterior, apical, or posterior prolapse.</p> <p>9 The only prolapse I do not do is when there is a</p> <p>10 concurrent uterine prolapse. My GYN colleagues take</p> <p>11 care of those.</p> <p>12 Q. It seems, based on my review of the</p> <p>13 literature, Doctor, that the anterior prolapse is the</p> <p>14 more prevalent or more frequently seen type of prolapse;</p> <p>15 is that right?</p> <p>16 A. That's probably fair. It's probably a little</p> <p>17 bit more symptomatic.</p> <p>18 Q. It's the reason why more women go to the</p> <p>19 doctor for any other type of prolapse, true?</p> <p>20 A. I would say that that's fair. The anterior</p> <p>21 compartment is the more problematic one.</p> <p>22 Q. It seems to be more susceptible to prolapse</p> <p>23 for whatever reason?</p> <p>24 A. Correct.</p> <p>25 Q. And what are some of the potential adverse</p>	<p style="text-align: right;">Page 148</p> <p>1 natively?</p> <p>2 A. It can happen, but that's why almost always</p> <p>3 I'm doing a concurrent sling at the same time of the</p> <p>4 anterior prolapse.</p> <p>5 Q. But it can happen, true?</p> <p>6 A. It can happen, yes.</p> <p>7 Q. In terms of other potential adverse events or</p> <p>8 complications from native tissue repair, I assume you</p> <p>9 would agree with me that there is also a risk of</p> <p>10 infection with any type of surgery we've been talking</p> <p>11 about?</p> <p>12 A. Vaginal infection you're referring to?</p> <p>13 Because I've never seen that with my patients.</p> <p>14 Q. Is that sort of well-established in the</p> <p>15 literature that there is a risk of infection with any</p> <p>16 surgery?</p> <p>17 A. Well, with any surgery, that's a possibility.</p> <p>18 Transvaginal surgery is a unique surgery with the vagina</p> <p>19 usually being fairly vascular. So an infection of the</p> <p>20 vaginal tissue is exceedingly rare. It could possibly</p> <p>21 happen. In my 15 years at a tertiary center, I've never</p> <p>22 had one patient develop a vaginal infection after one of</p> <p>23 my repairs.</p> <p>24 Q. But you're not disagreeing with me that</p> <p>25 infection is a potential adverse event of a pelvic -- of</p>
<p style="text-align: right;">Page 147</p> <p>1 events or risks or side effects if a woman chooses to</p> <p>2 have a native tissue repair for an anterior defect?</p> <p>3 A. An anterior repair, she could have</p> <p>4 postoperative bleeding is a possibility, development of</p> <p>5 urinary incontinence, recurrence of her prolapse is</p> <p>6 probably the most common ones.</p> <p>7 Q. So she could actually develop de novo</p> <p>8 incontinence after an anterior repair done natively?</p> <p>9 A. Not necessarily de novo. It's what's called</p> <p>10 occult incontinence, O-C-C-U-L-T. It means the</p> <p>11 incontinence was there prior to surgery. But because</p> <p>12 the bladder was falling down, it's not manifested. And</p> <p>13 then when you put the bladder up into a more anatomic</p> <p>14 position, incontinence is discovered. So it's not like</p> <p>15 we're causing it. We just uncover it.</p> <p>16 Q. Or sort of exacerbating it using the native</p> <p>17 tissue repair?</p> <p>18 A. No. We're just uncovering it. It was there.</p> <p>19 Because when the urethra is down like this, the woman</p> <p>20 doesn't leak. When we put it back up like this, the</p> <p>21 woman can leak. So it was there. That's what you're</p> <p>22 testing before surgery to make sure that does not happen</p> <p>23 after surgery.</p> <p>24 Q. So are there circumstances where there is de</p> <p>25 novo incontinence after an anterior repair done</p>	<p style="text-align: right;">Page 149</p> <p>1 a native tissue repair just like any other surgery?</p> <p>2 A. I'm saying that I'm not disagreeing with you,</p> <p>3 but I'm saying it can happen very, very rarely.</p> <p>4 Q. Okay.</p> <p>5 A. And I've never seen it.</p> <p>6 Q. And how about complications such as pelvic</p> <p>7 pain and dyspareunia? Can those also develop after a</p> <p>8 woman undergoes a native tissue repair?</p> <p>9 A. It's a possibility. I mean, in my experience</p> <p>10 in my personal practice, 15 years at a tertiary care</p> <p>11 center, I've had one patient, because we watch our</p> <p>12 patients very closely, with de novo dyspareunia</p> <p>13 afterwards, and we were able to then go after surgery</p> <p>14 and trim a suture and that resolved her dyspareunia.</p> <p>15 Q. But you're not disagreeing with me, Doctor,</p> <p>16 that pelvic pain and dyspareunia are known potential</p> <p>17 complications from a native tissue repair to improve</p> <p>18 pelvic organ prolapse?</p> <p>19 A. In the very rare circumstance and mild, it</p> <p>20 could possibly occur with those caveats.</p> <p>21 Q. Would you agree with me, Doctor, that, if a</p> <p>22 woman has diabetes or is a long-term smoker or has</p> <p>23 chronic obstructive pulmonary disease, among other</p> <p>24 comorbidities, she may be facing greater challenges with</p> <p>25 healing after a native tissue repair?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 150</p> <p>1 A. Well, you mentioned multiple different factors</p> <p>2 there. So we have to go one by one.</p> <p>3 Q. Okay. Let's go one by one.</p> <p>4 A. Diabetes, I don't know of anything in the</p> <p>5 literature relative to transvaginal surgery of increased</p> <p>6 risks or complications. I've never seen that, never</p> <p>7 heard it reported, never in any meetings or discussion</p> <p>8 with colleagues. COPD, COPD has an increased risk for</p> <p>9 recurrence of the prolapse, but not infections.</p> <p>10 Smoking, for native repairs, I've never seen one</p> <p>11 document saying that increases the risk for infection.</p> <p>12 Q. Do diabetics or smokers generally have more</p> <p>13 challenges or issues relating to healing after any type</p> <p>14 of surgery?</p> <p>15 A. Well, when you include any type of surgery,</p> <p>16 that's a different story. If you're talking</p> <p>17 transabdominal surgery with a major -- a morbidly obese</p> <p>18 patient who smokes, that's different than transvaginal</p> <p>19 surgery because then you have an extensive fat, adipose</p> <p>20 tissue, that does not heal well and then, by all means,</p> <p>21 they are at increased risk for infection. But</p> <p>22 transvaginal surgery, we don't have to deal with the fat</p> <p>23 and the poor healing.</p> <p>24 Q. So you don't agree with me that somebody who</p> <p>25 is a smoker, for example, or somebody who is a diabetic</p>	<p style="text-align: right;">Page 152</p> <p>1 abdominal route, yes.</p> <p>2 Q. And have you used that option yourself in your</p> <p>3 practice?</p> <p>4 A. Yes. That's what I was originally trained to</p> <p>5 do starting in 1999.</p> <p>6 Q. And that procedure involves the placement of a</p> <p>7 biologic or synthetic mesh via the abdominal route,</p> <p>8 correct?</p> <p>9 A. Correct. Though most of the time they're not</p> <p>10 using biologics anymore. They were shown not to work</p> <p>11 well.</p> <p>12 Q. So, in this particular discussion, biologics</p> <p>13 don't work as well as synthetic or polypropylene mesh;</p> <p>14 is that right?</p> <p>15 A. Well, no. I say that biologics do not work as</p> <p>16 well. There is a very nice paper from a Dr. Brubaker</p> <p>17 from 1999 or 2000 talking about using cadaveric tissue</p> <p>18 or biologics for sacrocolpopexy, and the failure rate</p> <p>19 was quite high. It wasn't strong enough to hold things</p> <p>20 up.</p> <p>21 Q. Right. They're not as strong as synthetic or</p> <p>22 polypropylene mesh, true?</p> <p>23 A. No. That is correct.</p> <p>24 Q. And that's borne out in the literature?</p> <p>25 A. That's a fair statement.</p>
<p style="text-align: right;">Page 151</p> <p>1 would have more challenges or problems healing after a</p> <p>2 vaginal surgery?</p> <p>3 A. I think that there is going to be limited data</p> <p>4 as far as a significant impact upon healing with native</p> <p>5 transvaginal repair with smoking, and I forget what the</p> <p>6 other one you said. It was COPD was -- COPD would be a</p> <p>7 nonfactor in that. COPD would be caused by the smoking.</p> <p>8 COPD has an increased risk for recurrence of prolapse.</p> <p>9 Oh, you said diabetes. I can't think, off the top of my</p> <p>10 head of a paper that shows an increased risk for vaginal</p> <p>11 infection.</p> <p>12 Q. Well, how about just a general healing? I'm</p> <p>13 trying to see if you agree with me that, as a general</p> <p>14 statement, smokers or diabetics have more challenges and</p> <p>15 problems healing after, for example, a native tissue</p> <p>16 repair?</p> <p>17 A. I'd disagree with that. I have no experience</p> <p>18 of ever seeing that, and 40 percent of my patients are</p> <p>19 obese with diabetes. And so I have not seen that with</p> <p>20 vaginal. But, again, if you open -- if you do an</p> <p>21 abdominal incision, that's a different story. Then I</p> <p>22 will agree with you, but not for transvaginal work.</p> <p>23 Q. In addition to native tissue repair, there is</p> <p>24 also the abdominal sacrocolpopexy, correct?</p> <p>25 A. That is another one of the options from an</p>	<p style="text-align: right;">Page 153</p> <p>1 Q. And then you need strength because you're</p> <p>2 trying to augment the lack of strength or the weakness</p> <p>3 in the ligature in the pelvic floor, correct?</p> <p>4 A. I would disagree. It needs strength because,</p> <p>5 when you do this procedure, you're holding the vagina up</p> <p>6 and sewing it to the sacrum. So you need to have</p> <p>7 strength to be able to hold that up. That's a</p> <p>8 completely different dynamic than the transvaginal work,</p> <p>9 which is working on suturing in different locations.</p> <p>10 This is holding up almost literally straight up to the</p> <p>11 sacrum.</p> <p>12 Q. Do you continue to place polypropylene mesh</p> <p>13 through the ASC procedure in your patients?</p> <p>14 A. The abdominal sacrocolpopexy route I still do.</p> <p>15 I have one on Monday, but it is the minority of my</p> <p>16 patients. Now, the majority are being done robotically.</p> <p>17 It's the same -- it's the same procedure, just with a</p> <p>18 different way of gaining access to the vagina and the</p> <p>19 sacrum.</p> <p>20 Q. And you also do that procedure</p> <p>21 laparoscopically, correct?</p> <p>22 A. Not anymore. It's -- originally the first</p> <p>23 one, when we started doing, it was</p> <p>24 laparoscopic-assisted. That was just a technical</p> <p>25 aspect. It's pure robotic now.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 154</p> <p>1 Q. You moved on from the traditional ASC -- ASC</p> <p>2 repair -- and I'm shortcutting just so I don't have to</p> <p>3 say it 5,000 times. You moved on from the traditional</p> <p>4 ASC repair to the laparoscopic approach to the robotic</p> <p>5 approach; is that a fair statement?</p> <p>6 A. No. When I was trained in 1999, I trained</p> <p>7 with a GYN department at Baylor College of Medicine in</p> <p>8 Houston. At that point in time, the standard of care</p> <p>9 was to do this abdominally. And, as I was fellow, I</p> <p>10 felt that this would be very amenable to doing this</p> <p>11 robotically. Other people had tried it</p> <p>12 laparoscopically, but it was very technically difficult,</p> <p>13 challenging work. But the robot bypasses that.</p> <p>14 So when I got back on staff in 2002, I</p> <p>15 approached my colleague who does robotics. So he's</p> <p>16 fellowship trained in robotics. And together we did the</p> <p>17 first one. The laparoscopic-assisted laparoscopy was</p> <p>18 only to gain access. It was kind of a -- it's</p> <p>19 essentially a nonentity in this procedure. It's pure --</p> <p>20 it's robotic.</p> <p>21 So I never had that laparoscopic middle point</p> <p>22 like you mentioned. And so now the overwhelming</p> <p>23 majority of them I do is robotic sacrocolpopexy unless</p> <p>24 there is factor that we can't do it robotically.</p> <p>25 Q. Okay. Understood. And would you agree with</p>	<p style="text-align: right;">Page 156</p> <p>1 A. That's true.</p> <p>2 Q. Like the ASC procedure, that was developed</p> <p>3 because of some of the problems that doctors were seeing</p> <p>4 with native tissue repair in terms of recurrence rates?</p> <p>5 MR. CARTMELL: Object to the form.</p> <p>6 BY THE WITNESS:</p> <p>7 A. I partially agree with that. You are correct,</p> <p>8 but some of it was the perceived problems of native</p> <p>9 repairs. But it was addressed to try and reduce the</p> <p>10 risk of recurrence.</p> <p>11 Q. All right. So let me make sure I understand.</p> <p>12 You agree with me that originally most doctors used the</p> <p>13 native tissue repair, and that goes back some time?</p> <p>14 A. The native tissue repairs have been around</p> <p>15 since surgeons have tried to fix vaginal prolapse.</p> <p>16 Q. And then, at some point in the mid-1990s, the</p> <p>17 ASC procedure became what I will refer to as the gold</p> <p>18 standard in repairing pelvic organ prolapse through</p> <p>19 surgery?</p> <p>20 A. I wouldn't be able to tell you. I mean, gold</p> <p>21 standards are relative. If you talk to somebody else,</p> <p>22 it won't be a gold standard. But in the 1990s, I don't</p> <p>23 know. There's work by Timmons and Addison at Duke going</p> <p>24 back to the '50s and '60s looking at sacrocolpopexies.</p> <p>25 So I think it is very fair to say that ASC is considered</p>
<p style="text-align: right;">Page 155</p> <p>1 me, Doctor, that, at one point in time for surgeons</p> <p>2 practicing in the area of pelvic reconstructive --</p> <p>3 female pelvic reconstructive surgery, most surgeons</p> <p>4 moved on from a native tissue approach to the ASC</p> <p>5 approach, the abdominal approach?</p> <p>6 A. I think there's going to be two big schools of</p> <p>7 treatment for prolapse, and it depends upon -- probably</p> <p>8 upon where you trained and the expertise of the people</p> <p>9 you trained under. Where I trained they felt that</p> <p>10 certain of the transvaginal repairs, sacro- --</p> <p>11 sacrospinous fixation maneuvers were dangerous and they</p> <p>12 wanted to do a transabdominal. Other GYNs will say the</p> <p>13 opposite. So I just happened to come up with one who</p> <p>14 did it transabdominally.</p> <p>15 Q. There is a number -- just by way of summary,</p> <p>16 there's a number of different surgical approaches to</p> <p>17 treating pelvic organ prolapse. Would you agree with</p> <p>18 that?</p> <p>19 A. There are quite a few, yes.</p> <p>20 Q. Different doctors use different approaches</p> <p>21 depending on their own experience, their own skill, and</p> <p>22 their preference, true?</p> <p>23 A. That is a fair statement.</p> <p>24 Q. And the transvaginal mesh was also developed</p> <p>25 as one of these options for doctors to use?</p>	<p style="text-align: right;">Page 157</p> <p>1 the highest anatomic success rate procedure. When that</p> <p>2 happened, I can't give you a date on that.</p> <p>3 Q. And then would you agree with me that doctors</p> <p>4 wanted to try and explore other options that were less</p> <p>5 invasive and had better outcomes than the ASC?</p> <p>6 A. I think it's fair to say that the ASC is a --</p> <p>7 it's a large surgery. There's a large incision made.</p> <p>8 There's a fair bit of recovery. The trans- -- and then,</p> <p>9 when people try transvaginal, there was a perceived --</p> <p>10 perceived higher failure rate with it. So some of the</p> <p>11 transvaginal mesh kits were designed to introduce that</p> <p>12 to hopefully reduce the morbidity or avoid the morbidity</p> <p>13 of the ASC.</p> <p>14 Q. And you understand that, that was the reason</p> <p>15 and the purpose behind the development of that type of</p> <p>16 technology in order to reduce the morbidities and issues</p> <p>17 seen with the ASC approach?</p> <p>18 A. Correct. And that's a laudable goal to be</p> <p>19 searching for a different way of doing it.</p> <p>20 Q. It's a good thing for medical device companies</p> <p>21 to explore other options for surgeons to use to treat</p> <p>22 their patients with pelvic organ prolapse?</p> <p>23 A. Yeah. I encourage innovation, safe</p> <p>24 innovation.</p> <p>25 Q. With -- we talked about some of the risks and</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 158</p> <p>1 side effects associated with native tissue. Is there 2 also the potential side effect that a native tissue 3 repair could create or cause a shortening and a 4 narrowing of the vagina? 5 A. If you're doing just an isolated compartment, 6 an anterior repair or posterior repair, that's unlikely. 7 If you're doing an anterior and a posterior repair, that 8 could happen. There could be some forced shortening of 9 the vagina. Other procedures, like a sacrospinous 10 fixation which is done transvaginally, the vagina would 11 not be shortened. And then -- I can't recall if you 12 asked this -- ASC does not shorten the vagina either. 13 Q. The ASC procedure, while it may have been more 14 successful in terms of anatomic success compared to the 15 native tissue, it was associated with more significant 16 complications because of the abdominal approach? 17 A. Yeah. It's a bigger surgery, abdominal 18 incision. So you could have abdominal wall infections 19 and problems with that, bowel problems. It's rare. In 20 our series of, now, almost exactly 100, we haven't had a 21 single one of those types of problems. But, yes, that 22 could happen. 23 Q. And there is a risk of mesh erosion associated 24 with the ASC procedure? 25 A. That has been reported in our series. And, as</p>	<p style="text-align: right;">Page 160</p> <p>1 one time. 2 Q. Have you seen that in the literature, though, 3 setting aside your own personal experience? 4 A. Yes. There is an extensive amount of 5 literature out there on the ASC procedure, and vaginal 6 pain or dyspareunia has been reported in a minority of 7 patients. 8 Q. And then, Doctor, I think, you know, in terms 9 of sort of a chronology, we saw sort of a movement 10 towards the laparoscopic sacrocolpopexy? 11 A. Well, the laparoscopic sacrocolpopexy is a 12 relatively minor, minorly (sic) performed procedure 13 because it is quite complicated. The robotic now is 14 doing the lion's share of those procedures. 15 Q. Are there complications, adverse events, risks 16 associated with either the laparoscopic sacrocolpopexy 17 and the robotic sacrocolpopexy? 18 A. Yeah. There are risks with those procedures. 19 Q. What are some of the risks, potential risks 20 and side effects associated with those procedures? 21 A. We warn individuals about the potential for 22 skin infections, injury to the bladder during 23 implantation, the potential for bleeding during the 24 procedure itself. 25 Q. And you're using mesh in these procedures, as</p>
<p style="text-align: right;">Page 159</p> <p>1 I mentioned, 100 patients, which we're writing up the 2 series on right now, we had, I believe, three in our 3 first ten patients and then none after that with 4 follow-up up to 12 years, 13 years now. 5 Q. So if a woman chooses the ASC procedure in 6 consultation with her doctor versus the transvaginal 7 mesh procedure, she could still experience an erosion of 8 mesh, true? 9 A. As I mentioned, in our experience, it is 10 highly unlikely, but something like that could happen. 11 Q. Similarly, there is a risk of pelvic pain and 12 dyspareunia and infection associated with the ASC 13 procedure as well, true? 14 A. It depends where you define it as far as 15 infection goes. 16 Q. Well, let's stick with pelvic pain and 17 dyspareunia. 18 A. Okay. 19 Q. The woman has the ASC procedure to treat her 20 pelvic organ prolapse. There's also a risk of pelvic 21 pain and dyspareunia associated with that procedure, 22 correct? 23 A. I assume something could be possible; but in 24 our series of now exactly 100, or almost 100 patients, 25 with follow-up as of right now, we have not seen that</p>	<p style="text-align: right;">Page 161</p> <p>1 well, right, Doctor? 2 A. We are using a Y-shaped polypropylene mesh. 3 Q. So it's polypropylene mesh as you've just 4 said, right? 5 A. Correct. 6 Q. And you're still doing that today. I think 7 you told me you put one in last week, correct? 8 A. A couple weeks ago. 9 Q. I apologize if I asked you this, Doctor. Even 10 though you're using the Y-shaped polypropylene mesh, as 11 you've just told me, for these procedures, is there 12 still a risk of mesh erosion associated with the 13 procedure? 14 A. In our hands, in the last 90, the answer would 15 be, no. In the first ten, yes. But that was a 16 technical issue. We were dissecting too thin. 17 Q. So -- 18 A. And then because -- I'm sorry to interrupt 19 you. 20 Q. No. That's all right. 21 A. And because the mesh is a Y-shape, it does not 22 have arms and we're able to lay it flat and it is 23 through sterile ports, I believe that's why we're not 24 seeing those problems. 25 Q. So in your first ten patients where you</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 162</p> <p>1 implanted Y-shaped polypropylene mesh using -- were</p> <p>2 these all the robotic approach or the laparoscopic?</p> <p>3 A. Robotic.</p> <p>4 Q. Robotic?</p> <p>5 A. Yeah, but it's there are a few in there that</p> <p>6 were robotic-assisted. But, again, robotic-assisted</p> <p>7 laparoscopic, but the laparoscopic, again, was just to</p> <p>8 gain access. So it's really -- the easiest way to think</p> <p>9 about it is just pure robotic.</p> <p>10 Q. Okay. So using the robotic approach to</p> <p>11 implant Y-shaped polypropylene mesh, the first ten</p> <p>12 patients experienced mesh erosion?</p> <p>13 A. No. No. Three out of those ten did.</p> <p>14 Q. Okay.</p> <p>15 A. And that was because --</p> <p>16 Q. So three -- I'm sorry. Go ahead.</p> <p>17 A. That was a surgical -- it was technical issue.</p> <p>18 We were dissecting too thin on the vagina. Because as I</p> <p>19 mentioned, we were the first in the world to do it, so</p> <p>20 we had to somewhat figure it out. But then, since then,</p> <p>21 zero, and that's with, again, with nearly 13 years of</p> <p>22 follow-up.</p> <p>23 Q. So just so I'm clear, out of the first ten</p> <p>24 patients, three out of the first ten experienced mesh</p> <p>25 erosion?</p>	<p style="text-align: right;">Page 164</p> <p>1 say?</p> <p>2 A. Again, I've answered it. I tell them exactly</p> <p>3 what I tell you now. The first ten, three patients did</p> <p>4 it. We altered how we did it, 90 patients, and zero.</p> <p>5 Q. So the answer to my question is, yes,</p> <p>6 you don't exclude the possibility that it could</p> <p>7 happen?</p> <p>8 MR. CARTMELL: Objection. Asked and answered three</p> <p>9 times.</p> <p>10 MS. GEIST: I don't think so.</p> <p>11 BY THE WITNESS:</p> <p>12 A. I'm very, very clear how I word it to the</p> <p>13 patient. I say it just that way. The first ten we had</p> <p>14 it in three and then after that zero.</p> <p>15 Q. So, in your practice today, you don't exclude</p> <p>16 the possibility that it may happen to another patient,</p> <p>17 true?</p> <p>18 MR. CARTMELL: Object to the form.</p> <p>19 BY THE WITNESS:</p> <p>20 A. Statistically speaking, if we were looking at</p> <p>21 it that way there's, in our hands, in the last 90,</p> <p>22 0 percent chance of having it, and that's what I tell</p> <p>23 the patient.</p> <p>24 Q. Well, then why do you include it on your</p> <p>25 informed consent? If there is zero chance that it's</p>
<p style="text-align: right;">Page 163</p> <p>1 A. Correct.</p> <p>2 Q. I assume you obtain informed consents from</p> <p>3 your patients when you performed these procedures?</p> <p>4 A. Correct.</p> <p>5 Q. Do you include mesh erosion as a potential</p> <p>6 side effect or adverse event or complication associated</p> <p>7 with the procedure?</p> <p>8 A. Yes. We discuss it with them. I tell them</p> <p>9 exactly what I just told you now. Because we look at</p> <p>10 our data very, very closely and follow these patients</p> <p>11 long-term, that, in the first ten, we had three and,</p> <p>12 since then, zero.</p> <p>13 Q. Notwithstanding your improvement in erosion</p> <p>14 incidents since you first started, you still include it</p> <p>15 as a potential side effect or complication when you</p> <p>16 inform your patients, true?</p> <p>17 A. We discuss it with the caveat of giving</p> <p>18 actually specific numbers and the risks.</p> <p>19 Q. So you still tell them about it?</p> <p>20 A. I tell them they have, in our series, you</p> <p>21 know, roughly, a 3 percent chance of it; however, if we</p> <p>22 look at the last 90, 0 percent chance.</p> <p>23 Q. You're not excluding the possibility that any</p> <p>24 one of your patients who undergo this particular</p> <p>25 procedure could experience mesh erosion; is that fair to</p>	<p style="text-align: right;">Page 165</p> <p>1 going to happen, why do you tell your patients about it</p> <p>2 at all? That doesn't make any sense, does it?</p> <p>3 MR. CARTMELL: Object to the form.</p> <p>4 BY THE WITNESS:</p> <p>5 A. Sure. I think it makes perfect sense. I</p> <p>6 believe in full disclosure to the patient. The patient</p> <p>7 needs to know everything and they also need to know the</p> <p>8 potential risk with percentages.</p> <p>9 Q. So, in other words, if it is -- if it is a</p> <p>10 true potential risk, not something hypothetical or</p> <p>11 something that could never occur, if it's a true</p> <p>12 potential risk, you tell them about it?</p> <p>13 A. Well, I also give them statistics.</p> <p>14 Q. I understand.</p> <p>15 A. So I don't -- I don't just say carte blanche</p> <p>16 there is a risk. I say what are her -- their odds.</p> <p>17 Patients aren't -- patients want to know what are their</p> <p>18 chances of complication.</p> <p>19 Q. You're not going to tell one of your patients,</p> <p>20 Doctor, about the risk of erosion if there is no chance</p> <p>21 it could ever happen? You wouldn't tell them about it</p> <p>22 if there was no chance?</p> <p>23 A. I tell them, in the last 90, zero. So the</p> <p>24 odds of her experiencing it in our hands, if they're</p> <p>25 involved in that last 90, is going to be zero.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 166</p> <p>1 Q. So, just so I understand, you -- sitting here</p> <p>2 today, you think there is zero chance of one of your</p> <p>3 patients experiencing mesh erosion from your current</p> <p>4 procedure?</p> <p>5 MR. CARTMELL: Object.</p> <p>6 BY MS. GEIST:</p> <p>7 Q. Zero, zero chance; is that right?</p> <p>8 MR. CARTMELL: Object. Misstates his testimony.</p> <p>9 MS. GEIST: No. I want to understand his</p> <p>10 testimony.</p> <p>11 BY THE WITNESS:</p> <p>12 A. No. I am very, very clear with the patients</p> <p>13 and fully open with all of the pros and cons, because,</p> <p>14 again, we follow these patients very carefully, so I</p> <p>15 know what happens with them so they don't wander off and</p> <p>16 have a complication elsewhere. So we're saying, in our</p> <p>17 hands, first ten, yes. The first ten, if you look at</p> <p>18 it, 30 percent. The second group of 90 patients,</p> <p>19 0 percent. And I say in our hands, when we do this,</p> <p>20 0 percent chance.</p> <p>21 Q. So you tell your patients about risks where</p> <p>22 there is a 0 percent chance?</p> <p>23 A. I believe in full disclosure about everything</p> <p>24 good and bad that's happened in the past and the future.</p> <p>25 That was during the part of an early learning curve,</p>	<p style="text-align: right;">Page 168</p> <p>1 BY MS. GEIST:</p> <p>2 Q. Hold on. Dr. Elliott, the court reporter is</p> <p>3 going to get mad at us. You talk about exposure or</p> <p>4 extrusion, right?</p> <p>5 A. I mention it with the caveats that I've</p> <p>6 mentioned several times now.</p> <p>7 Q. Okay. I assume you would agree with me,</p> <p>8 Dr. Elliott, that, in terms of options that a pelvic</p> <p>9 floor reconstructive surgeon has in his or her arsenal</p> <p>10 of things to offer to a patient, that there is no</p> <p>11 clear consensus among the medical community that one</p> <p>12 option is better than anything else for any given</p> <p>13 patient?</p> <p>14 MR. CARTMELL: Object to the form.</p> <p>15 BY THE WITNESS:</p> <p>16 A. You're referring to, I assume, transvaginal</p> <p>17 prolapse rate, specifically that? No, I would say that</p> <p>18 the consensus out there is that the sacrocolpopexy has</p> <p>19 the highest chance of a high quality permanent success.</p> <p>20 I don't think there's too many around there who are</p> <p>21 arguing about that.</p> <p>22 Q. When you say the sacrocolpopexy, are you</p> <p>23 talking about via the abdominal approach or the</p> <p>24 robotic-assisted procedure?</p> <p>25 A. Both, just the abdominal route.</p>
<p style="text-align: right;">Page 167</p> <p>1 too.</p> <p>2 Q. Do you tell your patients about other risks</p> <p>3 associated with the procedure when there is 0 percent</p> <p>4 chance of those risks occurring?</p> <p>5 A. I don't talk about dyspareunia because we've</p> <p>6 never seen it. In fact, in our series, we're seeing</p> <p>7 improvement of sexual functions.</p> <p>8 Q. So you don't -- you don't -- so dyspareunia is</p> <p>9 not included in the informed consent for your current</p> <p>10 procedure, correct?</p> <p>11 A. Because we have not seen it.</p> <p>12 Q. Right. And erosion is included because you</p> <p>13 have experienced it in your own patients?</p> <p>14 A. Not erosion, no. That's the wrong word.</p> <p>15 Q. Exposure, extrusion?</p> <p>16 A. Extrusion.</p> <p>17 Q. I think we're talking about the same thing,</p> <p>18 are we not?</p> <p>19 A. Well, no. But erosion -- erosion is into</p> <p>20 other organs. So I don't talk about that because we've</p> <p>21 never seen it, never experienced it.</p> <p>22 Q. All right. So that was my bad terminology.</p> <p>23 A. I talk about exposure.</p> <p>24 THE REPORTER: I'm sorry.</p> <p>25</p>	<p style="text-align: right;">Page 169</p> <p>1 Q. Do you -- you've published pretty extensively,</p> <p>2 as we've talked about earlier, right, Doctor?</p> <p>3 A. I've published quite a bit.</p> <p>4 Q. Yeah. And a lot of your publications relate</p> <p>5 to the robotic sacrocolpopexy as we went through</p> <p>6 earlier, right?</p> <p>7 A. Robotic and just abdominal, yes.</p> <p>8 Q. And you published on that procedure</p> <p>9 specifically how it compares with other prolapse repair</p> <p>10 techniques, true?</p> <p>11 A. Correct.</p> <p>12 Q. And, in your publications, you've noted that</p> <p>13 options for surgical treatment include a number of</p> <p>14 things, such as the ASC, the laparoscopic sacrocolpopexy</p> <p>15 or the robotic sacrocolpopexy, right?</p> <p>16 A. That sounds consistent with something I might</p> <p>17 say.</p> <p>18 Q. Okay. And you've concluded, in your own</p> <p>19 publications, that it's still not clear in the medical</p> <p>20 community which of these approaches is the best?</p> <p>21 A. I'd have to see that article and when we wrote</p> <p>22 that. You can just tell me the date.</p> <p>23 Q. Do you want to look it up, or do you want me</p> <p>24 to give you a copy?</p> <p>25 A. Well, if you have the copy right there, you</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 170</p> <p>1 can just say the date.</p> <p>2 Q. I don't have a copy. It's 2013, so just last</p> <p>3 year?</p> <p>4 A. Okay. So 2013, that reflects the thinking</p> <p>5 going on in, roughly, 2010 when we started doing</p> <p>6 research on that. And then we're probably considering</p> <p>7 or thinking about the robotics. But, again, the</p> <p>8 robotics, originally, no one was doing them, and then it</p> <p>9 slowly got hold and now, in certain regions in the</p> <p>10 United States, it is the most common type of abdominal</p> <p>11 approach. Again, I have to look at what we were</p> <p>12 thinking at the time and relative to what.</p> <p>13 Q. Well, this was -- this was just last year,</p> <p>14 right? It wasn't that long ago?</p> <p>15 A. No. But that's when the paper comes out.</p> <p>16 Q. Right.</p> <p>17 A. But we start writing that paper two years, at</p> <p>18 least, prior. We then submit it. It goes through</p> <p>19 multiple revisions, and then it gets accepted and then</p> <p>20 six months or so later it gets published. Now, you</p> <p>21 should have on there when it was submitted and when it</p> <p>22 was published. So from the time a project is started</p> <p>23 until it comes out in print is usually about two years</p> <p>24 or so.</p> <p>25 Q. Okay. Well, let me just mark this. I think</p>	<p style="text-align: right;">Page 172</p> <p>1 A. I know Howard very well.</p> <p>2 Q. Okay.</p> <p>3 A. We can say, it's fair to say, he has a dual</p> <p>4 appointment of some kind in Cleveland, but he's mainly</p> <p>5 at the other institution that's there.</p> <p>6 Q. He's pretty reputable in the area of pelvic</p> <p>7 floor repair?</p> <p>8 A. He -- he is a very, very good, thoughtful</p> <p>9 person. He is a -- tends to be a pro-mesh surgeon and</p> <p>10 transvaginal kits, but he is a good person.</p> <p>11 Q. Is he a good surgeon?</p> <p>12 A. I've never seen him operate. Unless I've seen</p> <p>13 somebody operate, I can't attest to that.</p> <p>14 Q. And you're aware that he still uses</p> <p>15 transvaginal mesh to repair pelvic organ prolapse?</p> <p>16 A. I haven't spoken to him for a year, so I don't</p> <p>17 know what he's using now.</p> <p>18 Q. At least, as of a year ago, were you aware</p> <p>19 that he was still using transvaginal mesh to repair</p> <p>20 pelvic organ prolapse in certain of his patients?</p> <p>21 A. I can't say that. I didn't ask him that</p> <p>22 specifically. I don't know if he does. I know in the</p> <p>23 past -- all I can say to have accuracy is, in the past,</p> <p>24 he did use mesh kits. I cannot say what he's done now.</p> <p>25 Q. If Dr. Goldman or any other pelvic floor</p>
<p style="text-align: right;">Page 171</p> <p>1 we're up to Exhibit 4, so I can ask you some questions</p> <p>2 about it.</p> <p>3 (Elliott Deposition Exhibit No. 4 was</p> <p>4 marked for identification.)</p> <p>5 MS. GEIST: Okay. I actually do have a copy this</p> <p>6 time. Doctor, here is yours. Counsel.</p> <p>7 MR. CARTMELL: Thanks.</p> <p>8 BY MS. GEIST:</p> <p>9 Q. Doctor, just for the record, I've handed you</p> <p>10 what we've marked as Exhibit 4. And this is a copy of</p> <p>11 your article published in --</p> <p>12 A. Yeah. This was in a requested opinion piece</p> <p>13 from Howard Goldman.</p> <p>14 Q. And who is Howard Goldman?</p> <p>15 A. He is a surgeon at -- in Cleveland.</p> <p>16 Q. At the Cleveland Clinic?</p> <p>17 A. Well, he's got a dual appointment there. I</p> <p>18 don't know how exactly it works. He's mainly -- I'm</p> <p>19 blanking on the place there in Cleveland. If Ben were</p> <p>20 here, he would know. I can't recall. Case Western?</p> <p>21 Q. He's a --</p> <p>22 A. No. That's in Chicago; isn't it?</p> <p>23 MR. CARTMELL: No. Case Western is in</p> <p>24 Cleveland.</p> <p>25 BY THE WITNESS:</p>	<p style="text-align: right;">Page 173</p> <p>1 reconstructive surgeon is using transvaginal mesh in</p> <p>2 some of their patients for a treatment of pelvic organ</p> <p>3 prolapse, are they acting within the standard of care?</p> <p>4 A. We would have to look at all of the parameters</p> <p>5 involved in that patient to be able to ask or answer</p> <p>6 that correctly. I do know of some in the past, of</p> <p>7 high-volume surgeons, that use mesh. And when we were</p> <p>8 at meetings, we would discuss it and I would be against</p> <p>9 their opinion, and they would be, obviously, for theirs.</p> <p>10 And if they put clarify -- clarifiers on</p> <p>11 there, on highly select, fully informed patients,</p> <p>12 perhaps, multiple revision patients who have failed</p> <p>13 everything else and are having a significant amount of</p> <p>14 problems and the patient knows all of the potential</p> <p>15 complications, there possibly would be a role for mesh</p> <p>16 in those types, but without mesh arms. So there's --</p> <p>17 there's a lot of qualifiers on there.</p> <p>18 Q. There are a lot of qualifiers on there.</p> <p>19 A. And that's why we talk, because this is</p> <p>20 complicated, and this is what we talk about at meetings,</p> <p>21 at the highest level of meetings. You don't get any</p> <p>22 higher than the International Incontinence Society and</p> <p>23 the SUFU in the United States, and this is what we talk</p> <p>24 about.</p> <p>25 Q. So, just so I understand, it's your opinion,</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 174</p> <p>1 Doctor, that there still -- still may be a role for the 2 use of transvaginal mesh to repair pelvic organ prolapse 3 depending on a number of particular patient factors -- 4 MR. CARTMELL: Wait. Let her finish. 5 BY MS. GEIST: 6 Q. I don't know if I'm finished yet. Hold on. 7 Let's strike that question and let me start again. 8 Would you agree with me, Doctor, there are 9 still today, notwithstanding the controversy and 10 discussion among the medical community, there still may 11 be a role for the use of transvaginal polypropylene 12 mesh to repair pelvic organ prolapse in certain 13 patients? 14 MR. CARTMELL: Object to the form. 15 BY THE WITNESS: 16 A. Okay. I don't feel comfortable answering that 17 question just as it is because I want those qualifiers 18 on there, and it has to be, again, a high-volume, highly 19 trained surgeon who is fully aware of the complications 20 who can deal with the complications, a patient who is 21 fully informed of the specific risks, the longevity, the 22 permanence of it, the delayed onset, and that has -- 23 she's tried and failed multiple other options, they have 24 failed, and she is severely symptomatic, in that one, 25 possibly, without arms.</p>	<p style="text-align: right;">Page 176</p> <p>1 talking. That's unfair. 2 BY THE WITNESS: 3 A. And I want my cookie, but they'll see crumbs 4 on my face. To answer your question, that's a very, 5 very good question. I think this was a very hot topic 6 in 2005, 2008, that time frame. And then, as the data 7 starts coming out, there was no question -- I will not 8 deny it -- a big wave of surgeons doing transvaginal 9 mesh kits, also a large wave of trainees only learning 10 how to do mesh kits. And the pendulum has swung. 11 So I -- in meetings now, again, I just got 12 back from a meeting, an international meeting in 13 Stockholm. The SUFU meeting was in February of this 14 year. It's not a discussion point now. There is not an 15 argument. There is no one coming up saying, We've got 16 to do meshes. Meshes are good for prolapse. 17 Q. So there's not one single solitary doctor that 18 you're aware of who treats women experiencing pelvic 19 organ prolapse who will still use transvaginal mesh? 20 A. Well, I can't speak for all of the surgeons 21 out there. As far as the ones I know, and I know a few 22 that in the past were very high-volume mesh kit 23 surgeons, they are not presenting data anymore on this 24 and they have changed. I can't speak for everybody out 25 there in the world. I'm saying for the ones that I know</p>
<p style="text-align: right;">Page 175</p> <p>1 Q. So if all of those criteria are met, and let's 2 just assume it's Dr. Goldman, who you know is a 3 reputable and very skilled surgeon in the area of 4 pelvic -- female pelvic reconstructive surgery, okay, 5 let's assume it's Dr. Goldman and all of those criteria 6 are met, if Dr. Goldman implants transvaginal mesh in 7 one of his patients to correct pelvic organ prolapse, is 8 that within the standard of care? 9 A. I think, if all of the aforementioned 10 criteria, that we won't go over again, assuming that is 11 consistent with this and he has a mesh without arms and 12 Dr. Goldman, again, a highly advanced tertiary care 13 center, thoughtful person, were to consider doing it, I 14 would not criticize him. I would manage the patient 15 differently. 16 Q. Is this one of those areas, Doctor, that we 17 sometimes see in medicine where there is a lot of debate 18 among physicians who practice in a particular area? 19 MR. CARTMELL: Object to the form. 20 BY THE WITNESS: 21 A. No. I disagree. I think that -- Tom wants to 22 get his cookie. 23 MR. CARTMELL: Sorry. I've got to get a piece of 24 my cookie. 25 MS. GEIST: I can't eat my cookie because I'm</p>	<p style="text-align: right;">Page 177</p> <p>1 at the high level they are not. 2 Q. But, as we've just discussed even today, with 3 the number of caveats and criteria that you mentioned 4 earlier, there would still be certain patients who would 5 be appropriate candidates for the use of transvaginal 6 mesh? 7 MR. CARTMELL: Objection. Asked and answered 8 multiple times. 9 BY THE WITNESS: 10 A. Okay. With all of those aforementioned, 11 incredibly important screening criteria, there may be a 12 possible -- I disagree with it -- but a possibility of 13 putting a transvaginal mesh without arms. But, again, 14 that's a tiny, tiny fraction of the patients out there. 15 Q. But they exist, don't they? 16 A. Well, you're talking about minotia. And -- 17 but, again, in my practice, zero. So I've got -- I've 18 got -- I take care of all of those people with all of 19 those things, multiple reoperations, multiple failures, 20 and I manage them successfully without putting in mesh. 21 Q. And I understand that, Doctor. We talked 22 about that, but you don't know what percentage. Your 23 only experience, you can't tell me what percentage of 24 those women -- strike that. 25 You can't tell me what percentage of women who</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 178</p> <p>1 have had mesh implanted, and, in particular, the Avaulta</p> <p>2 product, actually come to you with complications?</p> <p>3 A. We've already gone around that a bunch of</p> <p>4 times. I do not know the denominator of how many of</p> <p>5 these were implanted. All I know is what I see at my</p> <p>6 practice.</p> <p>7 Q. Okay. Well, let's -- you mentioned an article</p> <p>8 to me when we were having this discussion. So let me</p> <p>9 shift to that for a second. We looked at the Blandon</p> <p>10 article that was published by the chair of urogynecology</p> <p>11 at Mayo --</p> <p>12 A. No, it wasn't pub- -- no, it was --</p> <p>13 Q. -- among -- hold on. You're not letting me</p> <p>14 finish -- among other colleagues. Do you have something</p> <p>15 to say about that?</p> <p>16 A. Well, it was -- no, that's acceptable.</p> <p>17 Q. Okay. I just wanted to see if we had an</p> <p>18 argument there.</p> <p>19 A. No. I mean, in our language, we wouldn't say</p> <p>20 it was published by the chair because he wasn't the</p> <p>21 senior author.</p> <p>22 Q. Okay. Sorry.</p> <p>23 A. That's minor. I'll let you have that.</p> <p>24 Q. No. That's fine. That's a fair correction.</p> <p>25 And the complications that Mayo reviewed at that time</p>	<p style="text-align: right;">Page 180</p> <p>1 able to get the reference for you here.</p> <p>2 Q. That's all right. I think I have it.</p> <p>3 A. Abbott. Abbott, et al.</p> <p>4 Q. Yeah. There you go. So let's look at that</p> <p>5 article, because that was a more recent look, right?</p> <p>6 A. Correct.</p> <p>7 Q. At complications relating to mesh implants?</p> <p>8 A. Correct.</p> <p>9 Q. And that was what you had mentioned before,</p> <p>10 right?</p> <p>11 A. Yes, I had.</p> <p>12 MS. GEIST: Okay. So I just marked this as</p> <p>13 Exhibit --</p> <p>14 THE REPORTER: 5.</p> <p>15 MS. GEIST: -- 5 -- thank you, Madam Court</p> <p>16 Reporter -- to your deposition. Let me hand you that.</p> <p>17 (Elliott Deposition Exhibit No. 5 was</p> <p>18 marked for identification.)</p> <p>19 BY MS. GEIST:</p> <p>20 Q. Doctor, you don't have to look for it. I just</p> <p>21 handed you the hard copy.</p> <p>22 A. I have my copy that I've reviewed and read.</p> <p>23 Q. Well, let me ask you this. You're clicking</p> <p>24 away on your mouse there and you've got your laptop,</p> <p>25 right?</p>
<p style="text-align: right;">Page 179</p> <p>1 was from the 2003 to 2007 time period for patients who</p> <p>2 were referred to the clinic. And none of those women</p> <p>3 have had an Avaulta product. You remember that, right?</p> <p>4 A. Yeah. And it was -- it was a study -- that's</p> <p>5 a very good point, because it was January of 2003</p> <p>6 through September of 2007.</p> <p>7 Q. Right.</p> <p>8 A. That's my recollection. Avaulta didn't become</p> <p>9 available until a couple of months prior to that. So it</p> <p>10 had -- it would only include two months when the product</p> <p>11 was on the available list.</p> <p>12 Q. Right.</p> <p>13 A. So to answer your question, yeah, there are no</p> <p>14 Avaultas on here because Avaulta was essentially not</p> <p>15 even available during this time frame.</p> <p>16 Q. Well, it was available per the article,</p> <p>17 itself, right? We talked about that three different</p> <p>18 times. It's listed right in the article as one of the</p> <p>19 currently marketed POP products at this time?</p> <p>20 A. Incorrect. In 2009 when they submitted it,</p> <p>21 but this does not include -- this is January of 2003</p> <p>22 through September of 2007.</p> <p>23 Q. Doctor, my point was, you mentioned the Karram</p> <p>24 article, I think?</p> <p>25 A. Yeah. He was one of the authors. I would be</p>	<p style="text-align: right;">Page 181</p> <p>1 A. Yes.</p> <p>2 Q. So you didn't bring any of those papers with</p> <p>3 you in hard copy today to your deposition?</p> <p>4 A. Well, we're in the electronic era, so I didn't</p> <p>5 think I had to.</p> <p>6 Q. That's very green of you. But my only</p> <p>7 question is, do you have notes or comments or highlights</p> <p>8 on these articles?</p> <p>9 A. I have highlights, yes.</p> <p>10 Q. Do you have any notes or comments?</p> <p>11 A. No.</p> <p>12 Q. Underlining?</p> <p>13 A. We can -- I have highlight. No underlining,</p> <p>14 but I have highlights. We can go through every</p> <p>15 single --</p> <p>16 Q. Okay.</p> <p>17 A. What we could do -- how about this? I'll</p> <p>18 close this, you close your paper. Let's do it nose to</p> <p>19 nose on memory. Let's do that.</p> <p>20 Q. On memory?</p> <p>21 A. Because you are taking away this. This is my</p> <p>22 data and let's do it.</p> <p>23 MR. CARTMELL: Let her ask the questions.</p> <p>24 BY MS. GEIST:</p> <p>25 Q. Well, Doctor, see, let me explain how the</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 182</p> <p>1 deposition proceeds. I actually get to ask the</p> <p>2 questions and you get to answer the questions. So I</p> <p>3 appreciate the offer, but I'm going to decline.</p> <p>4 A. That's fine.</p> <p>5 Q. Let's -- so you have the paper in front of you</p> <p>6 with your highlights, correct?</p> <p>7 A. Correct.</p> <p>8 Q. And this was a review -- well, the paper is</p> <p>9 entitled, Evaluation and Management of Complications</p> <p>10 From Synthetic Mesh After Pelvic Reconstructive Surgery:</p> <p>11 A Multicenter Study. That was published just last year</p> <p>12 in 2013, correct?</p> <p>13 A. Correct.</p> <p>14 Q. Actually, you know what? I take that back. I</p> <p>15 have a copy of what is an accepted manuscript that was</p> <p>16 accepted in October of 2013 by the American Journal of</p> <p>17 Obstetrics and Gynecology.</p> <p>18 A. Yeah. You don't have the final article.</p> <p>19 Q. No. Do you?</p> <p>20 A. Yeah. I have the final article.</p> <p>21 Q. Okay. I'm looking at the accepted manuscript.</p> <p>22 So you can let me know if anything differs from the</p> <p>23 final as we go along. But the paper, Doctor, per the</p> <p>24 objective is to describe the evaluation and management</p> <p>25 of synthetic mesh-related complications after surgery</p>	<p style="text-align: right;">Page 184</p> <p>1 four select institutions.</p> <p>2 Q. So we don't know, from the 347 patients</p> <p>3 reviewed in this study that you mentioned earlier,</p> <p>4 whether any of them had complications relating from the</p> <p>5 Avaulta product; is that fair to say?</p> <p>6 A. I cannot. Because there are a certain number</p> <p>7 of patients here that did not -- it was not known what</p> <p>8 mesh, so I cannot say if Avaulta was there or not, but</p> <p>9 there was nothing reported on Avaulta.</p> <p>10 Q. And we also don't know anything in terms of</p> <p>11 the incidence rates. We don't know how many patients</p> <p>12 were implanted with mesh products, during this period of</p> <p>13 time, who actually experienced these complications?</p> <p>14 A. You're talking about all meshes?</p> <p>15 Q. Right.</p> <p>16 A. No. We do not know. This is, again, just</p> <p>17 representing the complications that come into these four</p> <p>18 institutions. So incidence, overall incidence, is not</p> <p>19 recorded in this study.</p> <p>20 Q. That's all I wanted to ask you about that</p> <p>21 paper, Doctor, if you want to put it aside.</p> <p>22 Doctor, I think we talked earlier a little bit</p> <p>23 about my suggestion to you that you are one of the more</p> <p>24 outspoken physicians in terms of being anti-mesh in the</p> <p>25 medical community?</p>
<p style="text-align: right;">Page 183</p> <p>1 for stress urinary incontinence and/or pelvic organ</p> <p>2 prolapse, correct?</p> <p>3 A. Correct.</p> <p>4 Q. And it was a multicenter retrospective</p> <p>5 analysis?</p> <p>6 A. This was the patient, four patient -- four</p> <p>7 tertiary care centers.</p> <p>8 Q. Okay. We're talking about -- they're looking</p> <p>9 at referrals of women from four different centers from</p> <p>10 January 2006 to December 2010, correct?</p> <p>11 A. Correct.</p> <p>12 Q. How many women that were referred to these</p> <p>13 centers for complications relating to mesh were</p> <p>14 implanted with the Avaulta product?</p> <p>15 A. From this paper, as far as I recall, they did</p> <p>16 not know the status of a fairly significant number of</p> <p>17 the patients, but they do not specifically single out</p> <p>18 Avaulta.</p> <p>19 Q. So this study doesn't tell us anything about</p> <p>20 the incidence rates or the frequency with which</p> <p>21 complications occurred in women implanted with the</p> <p>22 Avaulta products?</p> <p>23 A. No. It cannot state the frequency because</p> <p>24 they don't know the denominator either. This describes</p> <p>25 the severity of the complications that came into these</p>	<p style="text-align: right;">Page 185</p> <p>1 A. I would disagree with that. I think there's</p> <p>2 others out there who are a lot more vocal and adamant</p> <p>3 against meshes. I'm one of them. I'm not going to deny</p> <p>4 that.</p> <p>5 Q. There has been lots of opinions and</p> <p>6 discussions in the medical community, as we've just</p> <p>7 talked about, over the controversy relating to</p> <p>8 transvaginal mesh, true?</p> <p>9 A. Yes.</p> <p>10 MR. CARTMELL: Object to the form.</p> <p>11 BY MS. GEIST:</p> <p>12 Q. Would you agree with me, at least, that your</p> <p>13 opinions and stance on this issue is one of the more</p> <p>14 extreme?</p> <p>15 A. No.</p> <p>16 Q. You wouldn't?</p> <p>17 A. Not at all. Absolutely not. In 2005 had I</p> <p>18 made these statements, then you would have been correct.</p> <p>19 In 2008, no. They're starting to become the pendulum.</p> <p>20 In 2011, I'm one of the many. So, no.</p> <p>21 Q. You're not -- you're not one of the -- your</p> <p>22 opinions in 2011 were not extreme in your opinion?</p> <p>23 A. No. I don't think so at all. In our national</p> <p>24 meetings, when we're all together talking about this, I</p> <p>25 am one of the many. And there are others out there who</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 186</p> <p>1 are tremendously more outspoken than I am. I just</p> <p>2 happen to have a public forum based upon the institution</p> <p>3 that I work at.</p> <p>4 Q. So you wouldn't agree with me that you are</p> <p>5 sort of out there and on the fringe and that your</p> <p>6 opinions are inconsistent with some other physicians</p> <p>7 practicing in the area of female pelvic reconstructive</p> <p>8 surgery?</p> <p>9 MR. CARTMELL: Object to the form.</p> <p>10 BY THE WITNESS:</p> <p>11 A. Well, you're putting a lot of qualifiers out</p> <p>12 there. I can tell you the names of certain very</p> <p>13 high-profile, high-volume implanters, and we would be at</p> <p>14 meetings and I would moderate the sessions and we would</p> <p>15 talk about it. There was a scholarly discourse.</p> <p>16 There's no anger and there's no, you know, soapboxing.</p> <p>17 But I was -- I was -- again, if I did it in 2005, I</p> <p>18 would agree with you. Not now.</p> <p>19 Q. Not in 2011 either?</p> <p>20 A. No, not at all. I'm at these meetings.</p> <p>21 That's what I do for a living all over the world.</p> <p>22 Q. So your opinions back in 2011 were consistent</p> <p>23 with the leading physicians practicing in this area and</p> <p>24 with the medical organizations representing physicians</p> <p>25 who practice in the area of female pelvic reconstructive</p>	<p style="text-align: right;">Page 188</p> <p>1 A. Yes, I do. It's the AUGS report on surgical</p> <p>2 treatments.</p> <p>3 Q. All right. And you're -- you're familiar with</p> <p>4 this, I'm sure?</p> <p>5 A. Yes.</p> <p>6 Q. Correct?</p> <p>7 A. Yes, I am.</p> <p>8 Q. And you're a member of AUGS, which is</p> <p>9 shorthand for the American Urogynecologic Society,</p> <p>10 correct?</p> <p>11 A. I believe I am, yes. I have to look at my CV.</p> <p>12 Q. Do you know?</p> <p>13 A. I'm almost convinced I am, but I'm a member of</p> <p>14 the International Urogyn Society and AUG or AUGS, SUFU,</p> <p>15 so I'd have to say, yes, I am.</p> <p>16 Q. Okay. And AUGS, as indicated in the paper, is</p> <p>17 a nonprofit organization of thousands of physicians who</p> <p>18 specialize in treating pelvic floor disorders?</p> <p>19 A. Yeah. That would be fair to say.</p> <p>20 Q. So this is an organization for -- of health</p> <p>21 care providers, doctors. There's no lawyers in this</p> <p>22 organization, correct?</p> <p>23 MR. CARTMELL: Object to the form.</p> <p>24 BY THE WITNESS:</p> <p>25</p>
<p style="text-align: right;">Page 187</p> <p>1 surgery?</p> <p>2 A. Speaking within the confines of female</p> <p>3 urology --</p> <p>4 Q. Right.</p> <p>5 A. -- and the circle that I --</p> <p>6 Q. That's what we're talking about, right?</p> <p>7 A. In very, very high-profile female urologists,</p> <p>8 Shlomo Raz, arguably one of the bigger and better ones,</p> <p>9 Gerry Blaivas, oh, Greg Bales, University of Chicago,</p> <p>10 all of these types, no. We're -- this was a consistent,</p> <p>11 you know -- Philippe Zimmerman. Philippe Zimmerman, if</p> <p>12 you want somebody who is vocal, Philippe Zimmerman is.</p> <p>13 I've tried to retain a balance. And I have a problem.</p> <p>14 I'm taking care of women whose lives have been destroyed</p> <p>15 by a product and I'm trying to do something that's good</p> <p>16 for them.</p> <p>17 (Elliott Deposition Exhibit No. 6 was</p> <p>18 marked for identification.)</p> <p>19 BY MS. GEIST:</p> <p>20 Q. Doctor, let me hand you what I've marked as</p> <p>21 Exhibit 6 to your deposition. I'm sorry to throw it at</p> <p>22 you. I'm not really meaning to throw it at you.</p> <p>23 MR. CARTMELL: That's all right.</p> <p>24 BY MS. GEIST:</p> <p>25 Q. Do you have that in front of you, Doctor?</p>	<p style="text-align: right;">Page 189</p> <p>1 A. I can't speak to that, no.</p> <p>2 Q. You're not aware that there's any, right? I</p> <p>3 mean, these are doctors looking for the best things for</p> <p>4 women who are experiencing pelvic organ prolapse,</p> <p>5 correct?</p> <p>6 MR. CARTMELL: Object to the form.</p> <p>7 BY MS. GEIST:</p> <p>8 Q. That's what the purpose of the organization</p> <p>9 is?</p> <p>10 MR. CARTMELL: Object to form.</p> <p>11 BY THE WITNESS:</p> <p>12 A. Yeah. But as far as lawyer involvement, a</p> <p>13 lawyer reviewed this. They reviewed the ones for SUFU,</p> <p>14 so they reviewed this, I'm sure.</p> <p>15 Q. Okay. Well, this was -- this paper was put</p> <p>16 out as a physician statement by AUGS in response to the</p> <p>17 FDA safety communication in 2011, correct?</p> <p>18 A. That is correct.</p> <p>19 Q. So after FDA came out in 2011 and made a</p> <p>20 statement relating to transvaginal mesh for the use in</p> <p>21 POP, this group of physicians put out a position</p> <p>22 statement and response. Fair summary?</p> <p>23 A. That is correct.</p> <p>24 Q. And if you look with me on the third</p> <p>25 paragraph, the position statement says, The American</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 190</p> <p>1 Urogynecologic Society strongly opposes any restrictions</p> <p>2 by state or local medical organizations, health care</p> <p>3 systems, or insurance companies which ban currently</p> <p>4 available surgical options performed by qualified and</p> <p>5 credentialed surgeons on appropriately informed patients</p> <p>6 with pelvic floor disorders?</p> <p>7 A. That's what it states, yes.</p> <p>8 Q. Do you agree with that position?</p> <p>9 A. There are a lot of caveats in here. Number</p> <p>10 one, appropriately informed patients. If the patients</p> <p>11 aren't appropriately informed, the IFUs are incomplete,</p> <p>12 they can't be appropriately informed. So you have to</p> <p>13 assume, then, they have received all of the appropriate</p> <p>14 information. Qualified and credentialed. Credentialed</p> <p>15 means nothing. Qualified, okay. If you want to go on</p> <p>16 qualified, you're going to have to have high-volume,</p> <p>17 tertiary center individuals. So subsequently it's</p> <p>18 eliminated almost all of the private practice doctors</p> <p>19 from that group there.</p> <p>20 So -- and then I disagree as far as state and</p> <p>21 local medical organizations and health care systems and</p> <p>22 insurance companies getting involved. This is for the</p> <p>23 betterment of women. This is a women's rights issue.</p> <p>24 Women are being hurt by this product. I would want</p> <p>25 those organizations to have at least take a look.</p>	<p style="text-align: right;">Page 192</p> <p>1 treatment option for her particular clinical situation.</p> <p>2 Do you agree with that?</p> <p>3 A. To a certain extent, I do. If the physicians</p> <p>4 involved and medical organizations involved are not</p> <p>5 appropriately policing themselves and women are being</p> <p>6 permanently damaged sexually and physically, and I'm the</p> <p>7 one picking up the pieces, I disagree with this.</p> <p>8 I think that a ban, at the minimum, is the</p> <p>9 most appropriate thing until appropriate studies show</p> <p>10 that it's safe and that the benefits outweigh the risks.</p> <p>11 Currently, the risks far outweigh the benefits and</p> <p>12 that's a testament to what I see every day in my clinic.</p> <p>13 Q. So when you say the risks out see the</p> <p>14 benefits, the risks of what in particular?</p> <p>15 A. Okay. That is an excellent question.</p> <p>16 Q. Thank you.</p> <p>17 A. Number one -- I didn't mean that to be</p> <p>18 sarcastic. I'm saying that is actually a good question.</p> <p>19 Q. No. And I was thanking you legitimately. Go</p> <p>20 ahead.</p> <p>21 A. Okay. Pelvic organ prolapse and stress</p> <p>22 incontinence, but let's just deal with pelvic organ</p> <p>23 prolapse, is a quality-of-life issue. It does not kill</p> <p>24 patients. Okay. In all of my years, I've never --</p> <p>25 well, there's been one patient in California that had</p>
<p style="text-align: right;">Page 191</p> <p>1 Q. Well --</p> <p>2 A. And a healthy discourse and looking at this is</p> <p>3 not wrong.</p> <p>4 Q. I --</p> <p>5 A. Okay. Go ahead.</p> <p>6 Q. Sorry. Were you finished?</p> <p>7 MR. CARTMELL: Were you done?</p> <p>8 BY MS. GEIST:</p> <p>9 Q. I didn't want to interrupt you, Doctor. We</p> <p>10 had that issue earlier. Go ahead.</p> <p>11 A. No. I think this is -- there are -- I cannot</p> <p>12 fully agree or fully disagree with this. But you can't,</p> <p>13 as a blanket statement, say one or the other. Now, I'm</p> <p>14 done.</p> <p>15 Q. Okay. So I actually agree with you on one of</p> <p>16 the things you said, that this is a women's right --</p> <p>17 rights issue, Doctor. So do you agree with the other</p> <p>18 statements in this paper beginning on page 2?</p> <p>19 MR. CARTMELL: Take your time and look at it if you</p> <p>20 need to.</p> <p>21 BY MS. GEIST:</p> <p>22 Q. At the top, that a ban on alternative surgical</p> <p>23 treatment interferes with the patient/physician</p> <p>24 relationship and withholds FDA-acceptable options that</p> <p>25 the patient and her physician may decide is the best</p>	<p style="text-align: right;">Page 193</p> <p>1 erosion infection, but that's a unique situation.</p> <p>2 For the vast majority, it's quality of life.</p> <p>3 They come in with a sense of fullness, pressure, falling</p> <p>4 out, as we have covered very well before. They then get</p> <p>5 this procedure, and these women's lives, they are -- not</p> <p>6 just them, but their partner and their family, their</p> <p>7 children, their grandchildren, their parents, their</p> <p>8 lives are destroyed because this woman can't sit. She</p> <p>9 can't -- she can lie down sometimes, can't stand.</p> <p>10 So extreme views on severe damage and risks</p> <p>11 versus benefit? Take somebody with a quality-of-life</p> <p>12 issue and give them a permanent disability, the risk</p> <p>13 outweighs the benefit. If we have an individual who had</p> <p>14 a heart problem and there's some type of valve and</p> <p>15 they're going to die without it, a different ball game.</p> <p>16 But we're not. We're talking quality of life.</p> <p>17 Q. All right. So let me try and break it down a</p> <p>18 little bit. When we were talking about risks, you just</p> <p>19 gave me a very long answer, which I appreciate, but I</p> <p>20 would like to focus a little bit on what we're talking</p> <p>21 about. Are we talking about pelvic pain, dyspareunia,</p> <p>22 and erosion? Are those the three main risks that you</p> <p>23 say are unreasonably high with respect to transvaginal</p> <p>24 mesh?</p> <p>25 A. No. I'm talking about the severity and the</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 194</p> <p>1 frequency of pain, the location of the pain, buttock</p> <p>2 pain, obturator foramen pain, vaginal vault pain,</p> <p>3 adductor and abductor, A-B-D-U-C-T-O-R, and then,</p> <p>4 A-D-D-U-C-T-O-R, thigh pain, the mesh extrusion, the</p> <p>5 mesh erosion, the granulation tissue, chronic vaginal</p> <p>6 discharge, chronic inflammatory process, foreign body</p> <p>7 reaction, chronic severe debilitating vaginal pain,</p> <p>8 chronic severe debilitating pelvic pain, pain for the</p> <p>9 sexual partner, and a lifelong risk of this, and, very</p> <p>10 importantly, advanced level of complications requiring</p> <p>11 advanced level of surgeons to try and fix.</p> <p>12 Q. All right. So hold on a second.</p> <p>13 MR. CARTMELL: Were you done?</p> <p>14 THE WITNESS: Yes, I am.</p> <p>15 BY MS. GEIST:</p> <p>16 Q. So we're talking about pain. You're not going</p> <p>17 to dispute, are you, Doctor, that the pain you just</p> <p>18 described, all of the different types of pain you just</p> <p>19 described, may be experienced by a woman who has had a</p> <p>20 native tissue repair, or an ASC, to treat her pelvic</p> <p>21 organ prolapse? That is a known and well-established</p> <p>22 side effect in the literature for either one of those</p> <p>23 procedures, true?</p> <p>24 MR. CARTMELL: Object to the form.</p> <p>25 BY THE WITNESS:</p>	<p style="text-align: right;">Page 196</p> <p>1 can't even remotely fix. I'm done.</p> <p>2 Q. Okay. Thank you. I was just going to ask</p> <p>3 you. All right. So let me see where we agree and where</p> <p>4 we don't agree. Okay.</p> <p>5 A woman has a potential complication or side</p> <p>6 effect with pain with either native tissue, ASC, or</p> <p>7 transvaginal mesh. But it's your opinion that the pain</p> <p>8 is more significant or more severe with the mesh versus</p> <p>9 the other procedures. Did I get that right?</p> <p>10 A. Correct. And different onset and different</p> <p>11 location.</p> <p>12 Q. Okay. Same things with dyspareunia, a woman</p> <p>13 has a risk of a potential complication or adverse event</p> <p>14 of dyspareunia if she's had a native tissue repair or an</p> <p>15 ASC repair for her prolapse, but it's your opinion that</p> <p>16 the dyspareunia with transvaginal mesh is, what, more</p> <p>17 significant?</p> <p>18 A. Severe, relenting, progressive, and destroying</p> <p>19 of women's lives.</p> <p>20 Q. Okay. Same side effects and complications,</p> <p>21 but the severity is the difference among these different</p> <p>22 procedures. Is that what you're telling me?</p> <p>23 A. No. I disagree as far as with using the word</p> <p>24 same. These are not the same. This is what I do on a</p> <p>25 daily basis. And I see these women who can't even sit</p>
<p style="text-align: right;">Page 195</p> <p>1 A. I disagree, because we are -- we have to put</p> <p>2 qualifiers in there. In my 25 years of medical</p> <p>3 experience going back to medical school and OB/GYN,</p> <p>4 which was all native back then, my surgery training at a</p> <p>5 high-volume tertiary care center, advanced level</p> <p>6 training, I have never once seen the severe -- the</p> <p>7 severity of the location of the pain and the</p> <p>8 irreversibility of it and the ability for us not to be</p> <p>9 able to fix in the native transplants.</p> <p>10 Q. Well, and what about -- what about</p> <p>11 dyspareunia, in particular?</p> <p>12 A. As I'm --</p> <p>13 Q. Dyspareunia, in particular, I'm sure you're</p> <p>14 not going to disagree with me, is a known and</p> <p>15 well-established side effect with a native tissue repair</p> <p>16 or an ASC or even a laparoscopically performed</p> <p>17 sacrocolpopexy, true?</p> <p>18 A. Okay. I disagree because you have to put on</p> <p>19 with the qualifiers of the severity, the delayed onset,</p> <p>20 the ability to fix it. Remember, I mentioned, in my</p> <p>21 series, which I've watched very closely, I've had one</p> <p>22 patient who had severe dyspareunia after an anterior</p> <p>23 colporrhaphy. But we were able to cut the suture and</p> <p>24 the pain went away. But compare that to all of the</p> <p>25 other patients that I had with pelvic pain after mesh, I</p>	<p style="text-align: right;">Page 197</p> <p>1 down on my exam table. Not on my exam table, on the</p> <p>2 chair because of the severity of pain. I have never</p> <p>3 once seen that with a native repair. That's my own and</p> <p>4 the others coming in referred to me.</p> <p>5 Q. Okay.</p> <p>6 A. And if I'm at a tertiary care center, arguably</p> <p>7 one of the biggest volumes in the United States, and I</p> <p>8 have not seen one patient sent in to me with a native</p> <p>9 repair problem, but I see five a day of the other ones,</p> <p>10 we're talking a different type of problem.</p> <p>11 Q. Well, Doctor, you've said a couple of times</p> <p>12 you're referring back to your own experience with your</p> <p>13 patients at the Mayo Clinic, correct?</p> <p>14 A. No. That's not -- well, yes and no with that.</p> <p>15 I'm referring to my experience in the ones that I've</p> <p>16 seen. But, remember, I'm a referral center. So I'm</p> <p>17 getting patients from all over the United States sent in</p> <p>18 to me. And if transvaginal native repair problems,</p> <p>19 we're having all of these problems, I would be seeing</p> <p>20 them, but I'm not seeing them.</p> <p>21 Q. So I just want to explore the basis for the</p> <p>22 opinions you just gave on -- relating to pain and</p> <p>23 dyspareunia. All right. I also want to talk about</p> <p>24 erosion a little bit.</p> <p>25 Doctor, let me start with dyspareunia. Okay.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 198</p> <p>1 It's your opinion that women who have had transvaginal 2 mesh experience greater dyspareunia than women who have 3 had their prolapse repaired via another surgical 4 procedure; is that a fair summary? 5 A. I'm saying there's a qualitative difference 6 and a location difference, and that goes along with 7 severity and frequency. 8 MS. GEIST: I'm not doing this very well. So the 9 record is clear, I'm talking about the exhibit marker. 10 (Elliott Deposition Exhibit No. 7 was 11 marked for identification.) 12 BY MS. GEIST: 13 Q. Dr. Elliott, let me hand you what I've marked 14 as Exhibit 7. Again, I'm sorry, I'm not really trying 15 to throw it at you, but the table is kind of long. 16 Dr. Elliott, for the record, Exhibit 7 is an 17 article entitled, Incidence and Management of Graft 18 Erosion, Wound Granulation, and Dyspareunia Following 19 Vaginal Prolapse Repair With Graft Materials: 20 Systematic Review? 21 A. Correct. 22 Q. Do you see that, Doctor? 23 A. Yes, I do. 24 Q. And this was published in 2011 by Dr. Abed and 25 others for the symptomatic review group for the Society</p>	<p style="text-align: right;">Page 200</p> <p>1 A. Yeah. But they're put -- 2 Q. Okay. Hold on. 3 A. But you asked me -- no, you asked me a 4 question, though. 5 Q. Sorry. I wasn't finished. 6 A. You said correct, and correct means I'm 7 supposed to respond. 8 Q. Okay. You know what? Point -- point to you. 9 Go ahead and respond. 10 A. Okay. But, also, they're looking at from 1950 11 to 2005 a lot of other horrible products were put in 12 women's vaginas; Gortex, various other things, cotton, 13 all of that type of stuff. So it's not exactly -- we're 14 not comparing apples to apples. I've made my peace. 15 You can go ahead. 16 Q. Okay. Well, the study -- the study results 17 concluded that dyspareunia, which is pain during vaginal 18 intercourse, correct? 19 A. Correct. 20 Q. Okay. That was described in 7 -- 70, pardon 21 me. Dyspareunia was described in 70 of the studies that 22 were included in the systematic review, correct? 23 A. I don't see where you are, but I'll take your 24 word for it. 25 Q. I'm at the top --</p>
<p style="text-align: right;">Page 199</p> <p>1 of Gynecologic Surgeons? 2 A. Correct. 3 Q. Is that correct? 4 A. Correct. For the International Urogyn 5 Journal, which I'm a reviewer for. 6 Q. Did you review this paper in particular? 7 A. I don't recall doing that one, this one, no. 8 Q. And, as you can see, either in the abstract or 9 the introduction, the purpose of this study was to 10 describe the incidence of graft erosion, wound 11 granulation, and dyspareunia with adverse events 12 following vaginal repair. Do you see that? 13 A. Yeah, from 1950 to 2010. 14 Q. That's the time period for the review of 15 reports -- 16 A. Yeah, so 55 -- 17 Q. -- on these types of adverse events, correct? 18 A. Yeah. So 55 years of this is not considered 19 involvement with the mesh kits. 20 Q. I'm sorry? 21 A. 55 years of this paper of the 60 total are not 22 involving the mesh kits. 23 Q. Correct. But the paper went through and 24 looked at adverse events reported in Medline articles 25 through November 2010, correct?</p>	<p style="text-align: right;">Page 201</p> <p>1 A. In the abstract. 2 Q. Yeah. 3 A. Under Conclusions. 4 Q. It's above Conclusions. It says, Dyspareunia 5 was described in 70 studies. 6 A. Oh, here we go. 7 Q. Do you see that? 8 A. Yes. It was described in 70 studies for a 9 rate of 9.1 percent, correct. 10 Q. And dyspareunia was reported both in pelvic 11 organ prolapse repair surgeries and involved both 12 synthetic and biologic mesh, correct? 13 A. That's what it states, yeah. 14 Q. And the rate -- the incidence rate or the 15 reports of dyspareunia were greater in the women who had 16 had a biological implant or biological graft used in the 17 tissue repair versus the synthetic? 18 A. That's what the results are quoting from 1950 19 to 2010. They're talking about those biologicals being 20 at a slightly higher rate. I don't know if it was 21 statistically significant, though. 22 Q. Well, statistically significant or not, you 23 can see that the -- there were 8.9 -- 8.9 percent 24 reported dyspareunia when using -- when having -- when 25 having a synthetic versus 9.6 for biologic graft. Do</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 202</p> <p>1 you see that?</p> <p>2 A. I see it. But I think, for the record, we</p> <p>3 want to come on the record that you are stating</p> <p>4 statistical significance is not important. Is that what</p> <p>5 you're saying?</p> <p>6 Q. You can ignore that. I'm just saying, if you</p> <p>7 look at the -- you can ignore my statement about</p> <p>8 statistical significance.</p> <p>9 A. Okay. Then it's back on the playing field</p> <p>10 then, so this could just be by chance. We'd have to go</p> <p>11 in the paper and find out statistically significant.</p> <p>12 Regardless, it's still showing nearly 90 percent of the</p> <p>13 synthetics had problems, dyspareunia. It's still high.</p> <p>14 Q. But not any higher than the biologic grafts</p> <p>15 used to treat pelvic organ prolapse, true?</p> <p>16 A. Well, with biologics there's SIS, there's</p> <p>17 cadaveric tissue, there's porcine dermis. You know,</p> <p>18 that's immaterial comparing it to those. These aren't</p> <p>19 comparing it to natives, native repairs.</p> <p>20 Q. No. This is -- this is comparing the use of a</p> <p>21 biologic versus a synthetic --</p> <p>22 A. Okay. Then what --</p> <p>23 Q. -- graft, correct?</p> <p>24 A. I'm sorry. Yes. And what I will go on the</p> <p>25 record as agreeing with you that the synthetic in this,</p>	<p style="text-align: right;">Page 204</p> <p>1 A. Yes.</p> <p>2 Q. And this is on your reliance list, right?</p> <p>3 A. Correct. And there are no notes. This is</p> <p>4 just highlighted.</p> <p>5 Q. And this study concludes, does it not, Doctor,</p> <p>6 that vaginal mesh was introduced due to the high failure</p> <p>7 rates or recurrence rates seen in native tissue repairs?</p> <p>8 A. Yeah, but they're based upon that, their</p> <p>9 submission in 2011, which means, you know, earlier than</p> <p>10 that, on the anatomic and the perceived. This is</p> <p>11 somewhat the old era of thinking.</p> <p>12 Q. Well, this study, you say it's the old era of</p> <p>13 thinking, Doctor, but this study looks at not just</p> <p>14 anatomic success, but it also looks at quality-of-life</p> <p>15 issues, does it not?</p> <p>16 A. Correct. It does.</p> <p>17 Q. Because it looks at dyspareunia in particular,</p> <p>18 right?</p> <p>19 A. I'd have to look and see if it did. I would</p> <p>20 suspect it would talk about it, but I would have to find</p> <p>21 it.</p> <p>22 Q. Okay. Well, let's talk about -- let's talk</p> <p>23 about anatomic failure or success rates first. Okay.</p> <p>24 Is that all right with you, Dr. Elliot?</p> <p>25 A. That's fine. Sure.</p>
<p style="text-align: right;">Page 203</p> <p>1 whether it's statistical or not, is 0.7 percent less bad</p> <p>2 than biologics. It's still bad. It's just less bad</p> <p>3 than the biologics.</p> <p>4 Q. All right. You can put that one aside. Let</p> <p>5 me show you --</p> <p>6 MR. CARTMELL: Keep going.</p> <p>7 BY MS. GEIST:</p> <p>8 Q. Let me show you, Doctor, what we'll mark as</p> <p>9 Exhibit 8 to your deposition.</p> <p>10 (Elliott Deposition Exhibit No. 8 was</p> <p>11 marked for identification.)</p> <p>12 BY MS. GEIST:</p> <p>13 Q. Let me hand that to you. Now, this study, to</p> <p>14 your point, Doctor, actually looked at trocar-guided</p> <p>15 vaginal mesh compared with conventional or native tissue</p> <p>16 repair, correct? And, just for the record, this is the</p> <p>17 Withagen 2011 study entitled, Trocar-Guided Mesh</p> <p>18 Compared With Conventional Vaginal Repair and Recurrent</p> <p>19 Prolapse?</p> <p>20 A. Yeah. It's Withagen. He's Dutch.</p> <p>21 Q. Withagen. Thank you for that correction. Are</p> <p>22 you looking for the paper on your laptop?</p> <p>23 A. I have it. I have it right here. We can go</p> <p>24 through it again. It's highlighted. I've read it.</p> <p>25 Q. Okay. Good. So you read this one?</p>	<p style="text-align: right;">Page 205</p> <p>1 Q. Okay. Well, this -- this study looked at</p> <p>2 essentially where a woman -- where women were at 12</p> <p>3 months after either having a native tissue repair or a</p> <p>4 transvaginal mesh repair, right?</p> <p>5 A. Correct. I wanted to see which type of repair</p> <p>6 they did. Withagen usually uses Prolift, which is a</p> <p>7 different product. Yeah. They're using Prolift. So</p> <p>8 that's a different -- when we talked about it before,</p> <p>9 that's a different product than what we're talking about</p> <p>10 with Avaulta; different arms, collagen, density, high</p> <p>11 density, those types of things. But, yes, that is --</p> <p>12 that is --</p> <p>13 Q. It's still -- it's transvaginal mesh, though,</p> <p>14 right?</p> <p>15 A. Yeah. But before you didn't let me talk about</p> <p>16 these types of papers when we were talking about</p> <p>17 Avaulta. So now we're going to accept this data and</p> <p>18 correlate it to Avaulta.</p> <p>19 Q. Well, we're talking about trocar-guided</p> <p>20 transvaginal mesh, right?</p> <p>21 A. Okay. Good. So now -- all right. That's</p> <p>22 fine.</p> <p>23 Q. Hold on. That is one of your criticisms of</p> <p>24 the Avaulta product, which is why I brought out this</p> <p>25 paper, true?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 206</p> <p>1 A. Yes, but we didn't bring it out earlier when I 2 was trying to bring them out. So we're not being 3 consistent. 4 Q. Okay. Well -- 5 MR. CARTMELL: For the record, we're talking about 6 Avaulta products. 7 BY MS. GEIST: 8 Q. Well, my bad. I brought it out now. But the 9 point is, Doctor, it's talking about -- it's looking at 10 and comparing not just the success of women who have 11 undergone a transvaginal mesh procedure, a trocar-guided 12 transvaginal mesh procedure, but also looking at quality 13 of life issues, correct? 14 A. That is what it's doing, yeah. 15 Q. And the authors of this paper found that there 16 was a 45.2 percent anatomic failure rate in the native 17 tissue group after 12 months compared to a 9.6 percent 18 failure rate in the mesh group after 12 months. Is that 19 what they found in their study? 20 A. That is what they stated, and that's why I 21 earlier stated we're treating symptoms, not anatomy. 22 Q. And we'll get -- we'll get to that, Doctor? 23 A. Oh, I don't have a guarantee we will, but go 24 ahead. 25 Q. We will. And this -- so, based on this study,</p>	<p style="text-align: right;">Page 208</p> <p>1 women who underwent the native tissue repair, right? 2 A. Correct. 3 Q. And the paper concluded that the difference in 4 reported dyspareunia between groups was not significant 5 at the 12-month period, correct? 6 (Exit Mr. Jeffrey Kuntz.) 7 BY THE WITNESS: 8 A. And that is a very good point, also, yes. At 9 12 months, 51 of 97, 53 percent of the conventional 10 group and 53 of 93, 57 percent were sexually active and 11 the dyspareunias were equal at 12 months. However, we 12 know, from Klosterhalfen and others, mesh degradation 13 continues up to 15 years. So one-year data does not 14 help us out. However, to agree with you, that is their 15 findings at 12 months with the Prolift. 16 Q. Okay. And at 12 months we also know that 17 there were reports of de novo dyspareunia in both 18 groups, correct? In other words, de novo dyspareunia 19 means brand-new dyspareunia, did not -- did not exist 20 prior to the surgery? That's what de novo dyspareunia 21 means, correct? 22 A. No. I'm familiar with what de novo means. 23 Q. Well, I'm doing this for the purposes of the 24 jury and the lay people trying to understand this stuff. 25 A. Sure. Yes. At 12 months, which I've</p>
<p style="text-align: right;">Page 207</p> <p>1 Doctor, the women who proceeded with a native tissue 2 repair were five times more likely to have an anatomic 3 failure after surgery, correct? 4 A. Yes. 5 Q. In other words, a recurrence of the prolapse 6 that they wanted to fix in the first instance, five 7 times more likely in the native tissue group. Isn't 8 that what this study tells us? 9 A. It tells us that and that 80 percent were 10 happy just saying equal. So they were both happy in 11 each group. 12 Q. And we got five times more failure rate in the 13 native tissue, correct? 14 A. You're right. And then what I stated very, 15 very clearly, the majority of the time women don't care 16 about their anatomic success. They care about are their 17 symptoms relieved. 18 Q. Well, and let's go -- let's go to that right 19 now because I know that's what you want to talk about, 20 and I want to talk about it, too. So dyspareunia is one 21 of the problems we've been discussing today, right? 22 A. Correct. 23 Q. And Withagen's paper or study looked 24 specifically at dyspareunia reports of the women who had 25 both a trocar-guided transvaginal mesh inserted and</p>	<p style="text-align: right;">Page 209</p> <p>1 reiterated is -- or should reiterate is insufficient 2 because this is not 15 years on down the road. But 3 three out of 29, in the conventional 10 percent, and 4 three out of 37, 8 percent in the tension-free. So I 5 would -- statistically, those are going to be identical. 6 Q. Statistically identical. But, specifically, 7 as you've just said, 8 percent of women in the mesh 8 group reported de novo dyspareunia and 10 percent of the 9 women in the native tissue group reported de novo 10 dyspareunia, true? 11 A. Possibly, because, unfortunately, they did not 12 give us qualifiers on the severity of this pain. 13 They're stating pain, yes or no. It's like being 14 pregnant, yes or no, at three months is different than 15 at nine months. Okay. So, yes, this is what they 16 stated at 12 months without any qualifiers. 17 Q. Okay. The reports of dyspareunia, in both 18 groups, native tissue and trocar-guided transvaginal 19 mesh, were statistically the same at 12 months, correct? 20 A. I will agree with you as you state it, that at 21 12 months; but, again, that has no qualifier on the 22 severity. 23 Q. Well, we don't know from the study, and I'm 24 sure -- I'm sure you wouldn't guess, Doctor, that there 25 was any difference in the severity, right?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 210</p> <p>1 A. Absolutely, I would. Most questionnaires, if 2 you look at most studies, again, that's what I do for a 3 living. They're insufficient. And all they're saying 4 is, do you have sexual discomfort; yes, no? That is 5 nothing on the qualifier and the severity of it. 6 Q. All right. But you have no basis, based on 7 this study, to say that the women in the mesh group had 8 more significant dyspareunia than the women in the 9 native tissue group, true? 10 A. Well, with the Prolift product here -- I'm not 11 talking about Avaulta. So, really, this is kind of a 12 moot point to talk about this. In this study, they do 13 not give us those qualifiers. However, that is 14 inaccurate to say I don't have data to support that has 15 it higher from other studies that look at it with a 16 Visual Analog Scale and the severity of the pain. 17 So if we're going to start talking about lots 18 of papers -- let's go to the totality of knowledge out 19 there -- many papers talk about the severity of mesh 20 pain. My personal experience taking care of patients 21 daily talk about the severity. So, in this study, they 22 do not give us qualifiers to know the severity. 23 Q. So is that -- is that your criticism of 24 Withagen, that there's no qualifiers with respect to the 25 dyspareunia severity?</p>	<p style="text-align: right;">Page 212</p> <p>1 that the pain was any different in the mesh group versus 2 the native tissue group? 3 A. The authors do not provide us with enough 4 data. Had I reviewed this, I'd say we need to know that 5 data. 6 Q. Okay. But you can't? I mean, you're not 7 going to guess, I assume, right, Doctor? You're not 8 going to guess and just assume that the pain in the mesh 9 group was greater than the pain in the native tissue 10 group? You wouldn't do that, would you? 11 A. I'm not in the ball game of guessing. And 12 based upon my experience, it would be worse. And what's 13 it going to be five years from now, and that is worse. 14 Q. Well, we don't know that, though. There is 15 no -- there is no reanalysis of this data. There is no 16 update by Withagen and the other authors looking at what 17 happened over the next -- I think you said five years, 18 but the paper was in 2011, so three years. 19 We don't know that there is any change or 20 difference in the incident rates of dyspareunia in the 21 mesh group versus the native tissue group, do we? 22 MR. CARTMELL: Object to the form. 23 BY THE WITNESS: 24 A. Well, we do know from the other literature out 25 there. Again, I keep going back to Klosterhalfen</p>
<p style="text-align: right;">Page 211</p> <p>1 MR. CARTMELL: Other than the other things he's 2 told you? 3 MS. GEIST: Well, sure. 4 BY THE WITNESS: 5 A. Well, that would be one of them. And Mark 6 Vierhout I happen to know. I was just with him in a 7 meeting. And these are the things that we talk about, 8 that, when we look at studies and really do good 9 metaanalysis of studies, most of them are deficient and 10 this would be a deficiency. It doesn't mean it's a 11 worthless paper, but there's deficiencies. 12 Q. I just want to understand your reasons for not 13 finding this paper reliable, in your view, in terms of 14 the incidence rates of dyspareunia among mesh-implanted 15 patients versus native tissue repair. 16 A. Well, that somewhat misstates my statement 17 here or misstates what I said. I didn't say it was 18 unreliable. I said it's in- -- it's insufficient, 19 short, not enough -- not enough follow-up, a different 20 product -- Prolift, not Avaulta -- and what they don't 21 give me is the severity of this pain. There's no Visual 22 Analog Scale. There's no quality-of-life survey 23 relative to sexual discomfort. 24 Q. But you don't know, and I don't want to 25 belabor the point, but you don't know from this study</p>	<p style="text-align: right;">Page 213</p> <p>1 because it's a good one, but there's others. 2 Degradation, contraction of the mesh is progressive. 3 Klosterhalfen gave us up to 15 years. This is one year 4 in time. So all I'll agree with is what the authors 5 have stated here with my points that there is 6 insufficiency -- insufficiencies of this paper. 7 Q. That's fine. And, by the way, we'll talk 8 about degradation shortly. But are you -- are you 9 telling me that you believe that mesh degradation is 10 directly attributable to dyspareunia? 11 A. Yes. 12 Q. Polypropylene degradation results in 13 dyspareunia? 14 A. It can, yes. Definitely. That is one of the 15 cascades of the process to cause dyspareunia and 16 scarring. 17 Q. And this is your opinion, Doctor, even while 18 you still implant polypropylene mesh in your patients 19 today? 20 A. That is -- that is an unfair statement. I am 21 not putting in mesh kits with mesh arms that fold and 22 saw the tissues and are contaminated with bacteria and 23 candida species from the vagina. I'm putting it in 24 sterilely, lying it flat on the abdomen -- excuse me, in 25 the vagina, in sterile positions, suturing it down so it</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 214</p> <p>1 lays flat, and analyzing those patients over 12, 15</p> <p>2 years -- excuse me -- 13 years and not finding the</p> <p>3 problem.</p> <p>4 Q. So degradation of polypropylene mesh doesn't</p> <p>5 occur unless it's a four-armed product; is that what</p> <p>6 you're telling me?</p> <p>7 A. No.</p> <p>8 Q. So explain to me what you're talking about</p> <p>9 when you say degradation of polypropylene.</p> <p>10 A. Okay. That's outlined specifically in my</p> <p>11 notes, in my expert report. I mean, we are looking at</p> <p>12 the confluence of multiple different factors of</p> <p>13 transvaginal, contaminated mesh, plus or minus collagen</p> <p>14 on it, which impairs healing, torquing on this to go</p> <p>15 through the obturator foramen, rolling of the mesh arms,</p> <p>16 having them scar in place through the buttock muscles,</p> <p>17 the adductor muscles of the thigh, and that process is</p> <p>18 different than what I'm saying that occurs through the</p> <p>19 abdominal route. Those are completely separate</p> <p>20 surgeries.</p> <p>21 Q. So mesh implanted via the abdominal route</p> <p>22 doesn't have any risk of degradation?</p> <p>23 A. No. I would say it probably does degrade</p> <p>24 (sic) to a certain extent. Polypropylene is</p> <p>25 polypropylene no matter where it's put in the body.</p>	<p style="text-align: right;">Page 216</p> <p>1 greater the inflammatory process, the greater the</p> <p>2 rolling of the mesh; the greater the inflammation, the</p> <p>3 greater the release of peroxides, free radicals, the</p> <p>4 oxidation process starts, the mesh starts to degrade.</p> <p>5 The more the mesh degrades, the more the increased</p> <p>6 inflammation, subsequently pain. Pain happens down the</p> <p>7 vagina. And as it goes around the obturator foramen, it</p> <p>8 gets rock hard and it hurts like crazy and you can't get</p> <p>9 it out.</p> <p>10 Q. Okay. Doctor, thank you for that. We're</p> <p>11 going to go back to degradation, but I want to finish up</p> <p>12 on some of these other topics we started exploring.</p> <p>13 in particular, dyspareunia. Did -- in reaching your</p> <p>14 opinions, did you look at the Carey study?</p> <p>15 A. Yes. It depends which one you're talking</p> <p>16 about. He's been fairly prolific.</p> <p>17 Q. Agreed. I'm marking it as Exhibit 9.</p> <p>18 (Elliott Deposition Exhibit No. 9 was</p> <p>19 marked for identification.)</p> <p>20 BY THE WITNESS:</p> <p>21 A. Vaginal Repair With Mesh Versus Colporrhaphy</p> <p>22 For Prolapse?</p> <p>23 Q. Correct.</p> <p>24 A. Okay.</p> <p>25 (Enter Mr. Jeffrey Kuntz.)</p>
<p style="text-align: right;">Page 215</p> <p>1 However, there are multiple different factors.</p> <p>2 Polypropylene is put in for inguinal hernia repairs.</p> <p>3 It's put in the thoracic cavity. It's put in the eye</p> <p>4 and it's put in for sacrocolpopexies.</p> <p>5 Q. And --</p> <p>6 A. That's different than transvaginal.</p> <p>7 Q. And polypropylene, I assume you would agree</p> <p>8 with me, is a well-established material that is safe for</p> <p>9 implantation in the human body, true?</p> <p>10 MR. CARTMELL: Object to the form.</p> <p>11 BY THE WITNESS:</p> <p>12 A. That's too broad. If it's for inguinal</p> <p>13 hernias where there is no other treatment option, or</p> <p>14 thoracic wall hernias where there's no treatment option,</p> <p>15 I would say that is an acceptable risk-versus-benefit</p> <p>16 ratio. But, as we keep going back to, putting it</p> <p>17 through the vagina, a contaminated, lactobacillus,</p> <p>18 candida, et cetera, torquing on the arms, rolling on the</p> <p>19 arms, sawing back and forth, then, no.</p> <p>20 Q. What does sawing and torquing and the</p> <p>21 other things you just said have to do with</p> <p>22 degradation?</p> <p>23 A. A huge amount to do with degradation, okay.</p> <p>24 Because degradation occurs in the presence of</p> <p>25 inflammation and with bacterial contamination. The</p>	<p style="text-align: right;">Page 217</p> <p>1 BY MS. GEIST:</p> <p>2 Q. This is another study, Doctor, again comparing</p> <p>3 both anatomic success of transvaginal mesh versus native</p> <p>4 tissue repair and also looking at quality of life</p> <p>5 issues, to your point, right?</p> <p>6 A. Well, all they state their objective is to</p> <p>7 compare vaginal repairs with mesh and traditional with</p> <p>8 the prolapse. This is not an Avaulta study.</p> <p>9 Q. And, in this study, Doctor, first starting</p> <p>10 with anatomic success, 81 percent of the women in the</p> <p>11 mesh group achieved anatomic success after 12 months</p> <p>12 and 65 percent of the women in the native tissue</p> <p>13 group had anatomic success at the 12-month period,</p> <p>14 correct?</p> <p>15 (Exit Ms. Ann Gayle.)</p> <p>16 BY THE WITNESS:</p> <p>17 A. Which was not statistically significant. So,</p> <p>18 in other words, based upon statistics, they're</p> <p>19 identical. So there were no difference.</p> <p>20 Q. Okay. So the mesh was certainly -- looking at</p> <p>21 statistical significance, the mesh was certainly no</p> <p>22 worse, in terms of anatomic success, in this study than</p> <p>23 native tissue, correct?</p> <p>24 A. All you can say with this is it was an</p> <p>25 underpowered study, they didn't have enough patients in</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 218</p> <p>1 it, and that, based upon this, statistically they were 2 equal. 3 Q. And, in terms of dyspareunia, do you have 4 highlights on this study, too, Doctor? 5 A. Yes, I do. 6 Q. All right. In terms of dyspareunia, the same 7 exact number of women reported de novo dyspareunia at 8 the 12-month period, correct? 9 A. That is correct, limiting it to 12 months with 10 the Prolift. I imagine this is Prolift. Carey usually 11 writes about Prolift. That is what the findings were at 12 12 months. 13 Q. And even though it's the same number of women, 14 the incidence rate was actually higher in the native 15 tissue group, correct? 16 A. Yes, but statistically insignificant. 17 Q. Okay. But still higher? 18 A. But statistically insignificant. 19 Q. But still higher, right? Yes? 20 A. The percentages that they had were 21 statistically identical. 22 Q. 16.7 in the mesh group, 15.2 in the native 23 tissue group, correct? 24 A. That is what they state in this study. 25 Q. And --</p>	<p style="text-align: right;">Page 220</p> <p>1 A. I'm un- -- I don't -- no, I never heard of 2 them being on there. The Solo does not have it. 3 Q. Right. So you think that there might be a 4 difference between this product and the Solo based on 5 density? 6 A. I didn't say that. 7 Q. What did you say? 8 A. Excuse me. Yes, I did say that. 9 Q. I thought you said density made the 10 difference. 11 A. The arms of the Avaulta products are 12 heavyweight at, what, 95 grams-per-meter-squared 13 compared to the Prolift, which I believe was right 14 around 45 or so. I could be off on those numbers, but 15 that and in addition with the Plus having the collagen. 16 Q. All right. Let's set aside the collagen for a 17 second. All right. Let's just talk about the Solo, 18 which doesn't have collagen. Okay. 19 (Enter Ms. Ann Gayle.) 20 BY MS. GEIST: 21 Q. You think the reason why this study outcome 22 would be different for Avaulta is because of the arms 23 density of the product? 24 A. Yes. And that not having a plastic sheath 25 over it causing you to saw through the tissues because</p>
<p style="text-align: right;">Page 219</p> <p>1 A. Which were statistically insignificant. 2 Q. And, again, because this study looked at only 3 a 12-month period after the surgeries, you don't find 4 this study to be reliable in terms of the comparative 5 incident rates of dyspareunia in women having native 6 tissue repair versus mesh repair? 7 A. No. I think that -- I think this is an 8 important study, but there's limits to it. It's 9 under -- underpowered, meaning insufficient number of 10 patients, and not statistically different at 12 months. 11 Q. But like the Withagen study, Doctor, you would 12 agree with me, if you look at both of these studies, 13 both of these studies indicate that the dyspareunia 14 reports from women in the mesh group and the native 15 tissue group were the same? 16 MR. CARTMELL: Object to the form. 17 BY THE WITNESS: 18 A. For the Prolift product, which does not have 19 the ultra-dense, high-density arms, does not have 20 collagen, at 12 months, they were statistically the 21 same. 22 Q. What -- the Avaulta product, the Avaulta Plus 23 product, has collagen, correct? 24 A. That is correct. 25 Q. The other Avaulta products do not, correct?</p>	<p style="text-align: right;">Page 221</p> <p>1 both of those have to come into play. 2 Q. What studies do you rely on for your opinion 3 that the arms' density would have a greater impact on 4 dyspareunia rates? 5 A. Okay. I'm going to go to my expert report. I 6 talk through the density -- that's on page 21 -- where 7 the biggest studies I'd be quoting would be -- the 8 classic one would be Cobb, et al., talking about the 9 higher density, having more reaction, more inflammatory 10 response. Inflammatory response leads to degradation. 11 Degradation leads to increased inflammation, which leads 12 to scarring, which leads to incorporation of nerve 13 tissue and leads to pain. 14 Q. So we've got to make -- what did you just give 15 me, like five hops until we get to dyspareunia? 16 A. The body -- 17 MR. CARTMELL: Object to the form. 18 BY THE WITNESS: 19 A. Yeah. That is an incredible 20 oversimplification. If I were to cut my hand, there is 21 a cascade of clotting. There is like 12 different 22 steps. Things in the body lead to other things. It's 23 not just in isolation. You just don't have degradation. 24 That's it. It's a process and then you have to throw in 25 there the rolling of the arm, which then decreases the</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 222</p> <p>1 pore size, which then increases the inflammation. So,</p> <p>2 yeah, there's multiple steps. It's complicated, but</p> <p>3 it's logical.</p> <p>4 Q. Is there any study that actually looked at the</p> <p>5 density of the arms and different products and looked at</p> <p>6 the resulting dyspareunia rates?</p> <p>7 A. Worded that way, I can't think of a study off</p> <p>8 the top of my head right now looking at that</p> <p>9 implement -- implantation.</p> <p>10 Q. Let's -- since we're having such fun with</p> <p>11 these studies, let's look at another one on dyspareunia.</p> <p>12 Did you look at Nieminen --</p> <p>13 A. Yeah.</p> <p>14 Q. -- Nieminen when you formed your opinions,</p> <p>15 Doctor?</p> <p>16 A. Yes, I did. He has multiple papers, so</p> <p>17 it's --</p> <p>18 Q. Yep. So I'm looking at the 2010 one, and I</p> <p>19 think we're up to Exhibit 9.</p> <p>20 MR. CARTMELL: I think we're at 10.</p> <p>21 MS. GEIST: We're at 10?</p> <p>22 MR. CARTMELL: Yeah.</p> <p>23 MS. GEIST: I apologize.</p> <p>24 THE REPORTER: We were going too fast. I missed</p> <p>25 it.</p>	<p style="text-align: right;">Page 224</p> <p>1 Q. Okay.</p> <p>2 A. But they say at three years follow-up.</p> <p>3 Q. Yeah.</p> <p>4 A. Which is still short-term.</p> <p>5 Q. It's a lot longer than the 12-month studies we</p> <p>6 looked at. Fair?</p> <p>7 A. I disagree. If you put this in a 40-year-old</p> <p>8 woman who is going to live 40 years, three years is</p> <p>9 insufficient.</p> <p>10 Q. Okay. So you don't like this study either</p> <p>11 because it's insufficient in terms of time period after</p> <p>12 surgery to see what's going on?</p> <p>13 A. No. I'm saying it's definitely an</p> <p>14 improvement, but we have a permanent device to go into</p> <p>15 women and three years is, in this big spectrum of</p> <p>16 things, very small follow-up.</p> <p>17 Q. Well, this study established that three years</p> <p>18 after, there was a 41 percent recurrence of prolapse in</p> <p>19 the native tissue group versus a 13 percent recurrence</p> <p>20 of prolapse in the mesh group, correct?</p> <p>21 A. That's what they state, and we'd have to then</p> <p>22 find out how many of those were symptomatic with it.</p> <p>23 But that's what they state.</p> <p>24 Q. All right. But, again, this is the third</p> <p>25 study we've looked at together where anatomically mesh</p>
<p style="text-align: right;">Page 223</p> <p>1 (Elliott Deposition Exhibit No. 10</p> <p>2 was marked for identification.)</p> <p>3 BY MS. GEIST:</p> <p>4 Q. Okay. Dr. Elliott, I'm handing you what we've</p> <p>5 marked as Exhibit 10 to your deposition, a copy for</p> <p>6 counsel. And, as I stated to you, this is the Nieminen,</p> <p>7 N-I-E-M-I-N-E-N, study published in 2010 entitled,</p> <p>8 Outcomes After Anterior Vaginal Wall Repair With Mesh:</p> <p>9 A Randomized Controlled Trial With a Three-Year</p> <p>10 Follow-Up.</p> <p>11 So I think, Doctor, some of the criticisms</p> <p>12 you've stated to me earlier about some of the other</p> <p>13 studies you looked at, the Withagen and the Carey study,</p> <p>14 was that they only looked at what was going on with</p> <p>15 women after 12 months, right?</p> <p>16 A. Short-term.</p> <p>17 Q. Right. Too early. This study looks at what</p> <p>18 was going on with women after three years, right?</p> <p>19 A. They have it at 36 months. I don't know how</p> <p>20 many patients made it that far.</p> <p>21 Q. Okay. So 36 months is three years. We don't</p> <p>22 have a disagreement there?</p> <p>23 A. No. We don't, unless I need to know how many</p> <p>24 patients made it. That's the mean follow-up or if</p> <p>25 they -- what the variance is with that.</p>	<p style="text-align: right;">Page 225</p> <p>1 was clearly better than native tissue --</p> <p>2 A. No.</p> <p>3 Q. -- in repairing the defect, right?</p> <p>4 MR. CARTMELL: Object to the form.</p> <p>5 BY THE WITNESS:</p> <p>6 A. I'm sorry, no. That second one we looked at</p> <p>7 was statistically insignificant, okay, because it was an</p> <p>8 underpowered study. I would have to look at -- now,</p> <p>9 this has a P value showing that anatomically these women</p> <p>10 had the percentages that you referenced with anatomic</p> <p>11 improvement that, again, we are treating a</p> <p>12 quality-of-life problem. So we treat the subjective,</p> <p>13 not necessarily the anatomy.</p> <p>14 Q. And I hear you, Doctor, and this study looked</p> <p>15 at exactly that. Like the other studies we looked at,</p> <p>16 it looked at quality of life issues. The study looked</p> <p>17 at dyspareunia in particular. One of the main issues</p> <p>18 we've been talking about; so did this study. And this</p> <p>19 study also looked at the feeling of vaginal bulge as</p> <p>20 well, which is another symptom of prolapse, true?</p> <p>21 A. Correct.</p> <p>22 Q. So, in this study, the authors concluded that</p> <p>23 there was no difference in the reporting of dyspareunia</p> <p>24 in the mesh group versus the native tissue group?</p> <p>25 A. Had I reviewed this record, I would have said,</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 226</p> <p>1 How can you have 19 percent of the women have a mesh 2 extrusion and not have dyspareunia? Because it's like 3 barbed wire in there, so either the patient or spouse is 4 going to have it. So you're saying that -- so I would 5 say there's a major issue that they'd have to address. 6 What happened to those patients? So this would be 7 something that I would write the authors about if I were 8 doing a review. 9 Q. All right. So you'd have some questions -- 10 A. Their data does not jive. 11 Q. I'm sorry. You have some questions or you're 12 critical of the data in this study, right? 13 A. No, I didn't say I was critical of. I was 14 saying there are issues that would have to be resolved. 15 I would say these would be questions that would pop up 16 at meetings, those types of things. And this was from 17 April of 2003 to 2005. So, again, we're talking about a 18 different product. Again, we're probably -- I don't 19 know what product they would put in there. I don't even 20 know if it has arms in it either. 21 Q. Well, actually four-armed mesh products were 22 used in this study, Doctor. 23 A. Okay. Manufactured by who, what was the pore 24 size, what was the weight size, all of those types of 25 issues. So that would be important to know. And I'm</p>	<p style="text-align: right;">Page 228</p> <p>1 Q. Okay. But it's another one of those 2 awful four-armed products you're talking about, 3 right? 4 MR. CARTMELL: Object to the form. 5 BY MS. GEIST: 6 Q. It's a four-armed polypropylene mesh product 7 similar to the Avaulta product, true? 8 A. No. I can't say that. I don't know the 9 weight of this. 10 Q. Okay. But it is four-armed and it's 11 polypropylene, right? 12 A. Correct. They have a self-tailored, 13 four-armed light they call it. So we don't know the arm 14 lengths. As we've mentioned, it makes a big deal -- 15 Q. Well -- 16 A. -- if those arms are thick and heavy. 17 Q. -- you keep saying the arms are thick and 18 heavy with the Avaulta product. Isn't the Avaulta 19 product classified as Type 1, lightweight, monofilament, 20 macroporous mesh? 21 MR. CARTMELL: Object to the form. 22 BY MS. GEIST: 23 Q. Are they not? 24 A. You're using the Abed rating system from 1997. 25 Q. Well, it's still in effect, is it not?</p>
<p style="text-align: right;">Page 227</p> <p>1 going through the materials and methods. And it's in 2 Finland, so who knows what they have there in their 3 health system. 4 No. Here we go. There -- it's a 6-by-11 5 patch. I don't see anything about arms. Oh, here we 6 go, self-tailored arms. 7 Q. Four arms, do you see it on page -- 8 A. Yes. It's on 235.e.3. I see it. 9 Q. Right. Okay. So we can agree it's a 10 monofilament polypropylene four-armed mesh used in the 11 mesh group, correct? 12 A. Correct. 13 Q. And this study, at least, in 2010, tells us 14 that the dyspareunia reports in the mesh group versus 15 the native tissue group were the same at the three-year 16 period? 17 A. That was the findings of this study at that 18 time, yes. 19 Q. Okay. Well -- and you say at that time. I 20 mean, there was no update or reanalysis of this study 21 that you're aware of, is there? 22 A. And that is one of the major faults in these 23 studies. They don't follow up on the patients. So, in 24 this study, at three years, with a nonBard product, that 25 was the results they had.</p>	<p style="text-align: right;">Page 229</p> <p>1 A. No, it is not. That's archaic. 2 Q. So you think that the classification of the 3 Bard product as lightweight, Type 1, monofilament, 4 macroporous, polypropylene mesh is no longer true? 5 A. For 1997, when he came out with it, when 6 Abed came out with that. I would look more at the 7 Cobb study, which calls it heavyweight, 95 8 grams-per-perimeter-squared. And it calls the Prolift 9 medium at 45 and Ultrapro Light at 28 10 grams-per-meter-squared. 11 Q. At the point in time when the Bard products 12 were marketed and available on the market, were they 13 considered lightweight for the time? 14 A. What component are you talking about, because 15 they have a hybrid? They have thick arm meshes. The 16 arms are thicker than the body. So Cobb's -- Cobb's 17 article was in -- Cobb's article produced it in 2005. 18 Avaulta came on the market in the end of 2007 or the 19 beginning of '08. Polypropylene, 95 -- 95 20 grams-per-meter-squared; 45 was Prolene Soft, and 21 Ultralight was 28, and they called that lightweight. So 22 he calls it heavyweight. 23 Q. You're referring to Cobb? 24 A. Yes, I am, where he used the Bard product. 25 Q. And he calls it heavyweight?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 230</p> <p>1 A. He calls it heavyweight.</p> <p>2 Q. Anybody else call it heavyweight?</p> <p>3 A. I don't know. Klosterhalfen. Actually, I</p> <p>4 shouldn't say I don't know. Yes, Klosterhalfen.</p> <p>5 Q. Yes. Anybody else?</p> <p>6 A. Probably Klingele. I would have to look at</p> <p>7 the articles on that one.</p> <p>8 Q. I would bet you're right.</p> <p>9 MR. CARTMELL: Klinge.</p> <p>10 THE WITNESS: Klinge. Yeah, he's German.</p> <p>11 VIDEO TECHNICIAN: Can we jump off real quick?</p> <p>12 MS. GEIST: We need a break?</p> <p>13 VIDEO TECHNICIAN: I need to switch my card.</p> <p>14 MS. GEIST: Yeah. Sure. Let's take a break.</p> <p>15 VIDEO TECHNICIAN: We're off the record. The time</p> <p>16 is 2:49 p.m.</p> <p>17 (A recess was had.)</p> <p>18 (Exit Mr. Brandon Morris.)</p> <p>19 VIDEO TECHNICIAN: We're back on the record. The</p> <p>20 time is 3:03 p.m.</p> <p>21 (Elliott Deposition Exhibit No. 11</p> <p>22 was marked for identification.)</p> <p>23 BY MS. GEIST:</p> <p>24 Q. Doctor, let's continue our discussion, but I</p> <p>25 want to try and wrap it up shortly so we can move on.</p>	<p style="text-align: right;">Page 232</p> <p>1 A. Yeah. It's a randomized trial looking at</p> <p>2 those factors that you just mentioned.</p> <p>3 Q. Right. And this study actually looked at the</p> <p>4 incidence rate at the two-year follow-up. So it's</p> <p>5 longer than the 12-month studies we looked at before?</p> <p>6 A. No. They're -- no, that's not -- they're</p> <p>7 evaluated up to 12 months. So what I would have to do</p> <p>8 is look at the studies to find out how many made it</p> <p>9 two months -- 12 -- or, excuse me, 24 months. Because</p> <p>10 with that phrase there, that doesn't tell us how long</p> <p>11 they were studied. It's that some made it to 24 months.</p> <p>12 It would describe it in the results.</p> <p>13 Q. Okay. And let's look at that in a minute.</p> <p>14 But the conclusions of this study are, as you see at the</p> <p>15 top, that the dyspareunia score was statistically</p> <p>16 significantly lower in the mesh group?</p> <p>17 A. That is correct. That's what they report in</p> <p>18 this study with -- I'm trying to determine which product</p> <p>19 they were using. And, again, Nieminen tends to use</p> <p>20 Prolift.</p> <p>21 Q. So just so I understand, Doctor, some of these</p> <p>22 studies that we've looked at I think you were critical</p> <p>23 about the time in which women were followed. It was too</p> <p>24 short for some of the studies, right?</p> <p>25 A. There is no known study out there that is</p>
<p style="text-align: right;">Page 231</p> <p>1 But let me mark, as Exhibit 11, another study by</p> <p>2 Nieminen and ask you if had looked and considered this</p> <p>3 one. Again, this is on the issue of dyspareunia. I</p> <p>4 hand that to you, or throw that to you. Thank you.</p> <p>5 Again, Doctor, this study looked at women who</p> <p>6 had undergone a transvaginal mesh procedure to repair</p> <p>7 pelvic organ prolapse and women who had undergone a</p> <p>8 native tissue repair for their prolapse. Do you see</p> <p>9 that?</p> <p>10 A. Yes.</p> <p>11 Q. And, by the way, Doctor, this article notes</p> <p>12 that a posterior repair is associated with a higher risk</p> <p>13 and higher incidence of dyspareunia, generally speaking.</p> <p>14 Do you agree with that?</p> <p>15 A. That is the -- that is correct.</p> <p>16 Q. And that's what the literature tells us,</p> <p>17 right, not just this article? That's pretty</p> <p>18 well-established in the literature?</p> <p>19 A. That is that posterior repairs can be</p> <p>20 associated with more pain following surgery.</p> <p>21 Q. And in particular dyspareunia, right?</p> <p>22 A. Or dyspareunia has been reported, yes.</p> <p>23 Q. Okay. And the Nieminen 2008 study looks</p> <p>24 specifically at the incidence of dyspareunia in the mesh</p> <p>25 group versus the native tissue group, correct?</p>	<p style="text-align: right;">Page 233</p> <p>1 adequately valuing the risk of this product of the</p> <p>2 lifetime of a woman.</p> <p>3 Q. Okay. So there is no -- well, strike that.</p> <p>4 And this study, I assume you're going to tell</p> <p>5 me, well, it's sort of meaningless here because it</p> <p>6 didn't look at the Avaulta product in particular?</p> <p>7 A. No, absolutely not. This is -- I mean, Kari</p> <p>8 Nieminen and then the other one, Heinonen, the senior</p> <p>9 author I've met. No. They've done good work here.</p> <p>10 This is a contribution to literature.</p> <p>11 But what I'm saying is, if we're putting this</p> <p>12 in a 40- or a 50-year-old woman who has 40 or 50 years</p> <p>13 of life left in her, we don't know what happens. We do</p> <p>14 have animal data showing continued degradation as we've</p> <p>15 mentioned over and over. So at 24 months, that is good</p> <p>16 at 24 months, but what's going to happen on down the</p> <p>17 road?</p> <p>18 Q. And you can't -- we don't have any study that</p> <p>19 tells us exactly that? It would be guesswork or it</p> <p>20 would be speculative to guess, right?</p> <p>21 MR. CARTMELL: Object to form.</p> <p>22 BY THE WITNESS:</p> <p>23 A. Well, I wouldn't say it's going to be</p> <p>24 speculative. I mean, in the animal model, up to 15</p> <p>25 years we see degradation. And so there's no reason to</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 234</p> <p>1 think that degradation in humans, especially when it's</p> <p>2 contaminated or heavy -- heavyweight arms rolling, that</p> <p>3 this is going to continue.</p> <p>4 Q. Well, looking at -- looking at actual women in</p> <p>5 this study, we know that there was a statistically</p> <p>6 significant lower rate of dyspareunia in the mesh group</p> <p>7 after two years, correct?</p> <p>8 A. That is -- that is actually what they do</p> <p>9 report here. And, again, the mesh exposure rate of 8</p> <p>10 percent I would want to know were these women -- you</p> <p>11 know, was that included into it or not. So -- but you</p> <p>12 stated it accurately. Based upon the findings and what</p> <p>13 these people found at 24 months in this specific study,</p> <p>14 which is a nonAvaulta study, the dyspareunia score was</p> <p>15 lower in the mesh group.</p> <p>16 Q. There is no Avaulta-specific study that found</p> <p>17 a statistically significant difference in dyspareunia</p> <p>18 reports between the Avaulta mesh group and the native</p> <p>19 tissue group, true?</p> <p>20 MR. CARTMELL: Object. Object to the form.</p> <p>21 BY THE WITNESS:</p> <p>22 A. Culligan, et al., Evaluation of Transvaginal</p> <p>23 Mesh Delivery System For the Correction of Pelvic Organ</p> <p>24 Prolapse; Subjective and Objective Findings At Least One</p> <p>25 Year. From what I understand, that is an Avaulta study.</p>	<p style="text-align: right;">Page 236</p> <p>1 A. In a quick review of what I've got here, I</p> <p>2 don't see it. However, if -- in reviewing of the Bard</p> <p>3 depositions, I never saw anybody raise that, and that</p> <p>4 would be a very good one. I would like to see that if</p> <p>5 it exists.</p> <p>6 Q. Okay. But that was my question to you</p> <p>7 originally. We're looking at dyspareunia rates between</p> <p>8 women experiencing native tissue repair and transvaginal</p> <p>9 mesh repair, correct?</p> <p>10 A. That's what we've been looking at, yes.</p> <p>11 Q. That's what we've been looking at. And, you</p> <p>12 know, some of your criticisms of these studies are,</p> <p>13 well, it's not -- it's not a specific Avaulta study.</p> <p>14 But there is no Avaulta study that has looked at the</p> <p>15 comparative rates of dyspareunia between an Avaulta arm</p> <p>16 and a native tissue arm in the study, correct?</p> <p>17 A. I am unaware of any. And that seems to me to</p> <p>18 be a major fault of the product not doing that</p> <p>19 comparison. That's a very important study that should</p> <p>20 be done.</p> <p>21 Q. The two Nieminen or Nieminen --</p> <p>22 A. Mm-hmm.</p> <p>23 Q. Am I saying that correctly -- studies that</p> <p>24 we've looked at, the 2008 and 2010 studies, those --</p> <p>25 those both also looked at one of the quality of life</p>
<p style="text-align: right;">Page 235</p> <p>1 They had 11.7 percent extrusion and pain at 3.3 percent.</p> <p>2 Q. I asked about dyspareunia, Doctor.</p> <p>3 A. I would have to look at my studies here</p> <p>4 because I don't have them broken down. But they have</p> <p>5 Avaulta Plus Fractional -- Functional Results and</p> <p>6 Quality of Life, which that one you would think would</p> <p>7 have a discussion there of dyspareunia. So I have all</p> <p>8 of my studies, which are in my expert report. You</p> <p>9 should probably -- if you ask that question of which</p> <p>10 study has it, we need to go through it and find out.</p> <p>11 But here is one. Bondili, B-O-N-D-I-L-I, et</p> <p>12 al, Two-Year Follow Up of Sexual Function Symptoms and</p> <p>13 Quality of Life After Innovative Procedure Avaulta</p> <p>14 Synthetic For Pelvic Organ Prolapse, that was presented</p> <p>15 at the ICS, International Continence Society in 2010.</p> <p>16 That study would have the data in there.</p> <p>17 Q. Was there a comparison? Was there a nonmesh</p> <p>18 arm in that study?</p> <p>19 A. We would have to get that study and look at</p> <p>20 it.</p> <p>21 Q. Right. So that's what I'm trying to ask you.</p> <p>22 Do you have a study where there was a comparison between</p> <p>23 the -- a group of women implanted with the Avaulta</p> <p>24 product and a group of women who had prolapse repaired</p> <p>25 using a native tissue procedure?</p>	<p style="text-align: right;">Page 237</p> <p>1 issues we talked about before, which is the sensation of</p> <p>2 vaginal bulging?</p> <p>3 A. Correct. They discussed it in their reports.</p> <p>4 Q. Okay. Well, it was one of the -- they were</p> <p>5 looking at anatomic failure rates in those studies,</p> <p>6 right?</p> <p>7 A. Yeah. They looked at anatomic and I</p> <p>8 believe -- we'd have to go through the studies in</p> <p>9 detail -- I believe they were looking at quality of life</p> <p>10 as well.</p> <p>11 Q. Okay. So we just marked as Exhibit 11 the one</p> <p>12 Nieminen study, and we already marked as Exhibit 10 the</p> <p>13 other one. Do you have those in front of you, 10 and</p> <p>14 11?</p> <p>15 A. I have 11. I don't see 10. I would be able</p> <p>16 to look at 10 though. Okay.</p> <p>17 Q. Okay. Well, my only questions for you for</p> <p>18 these two studies, Doctor, is they both looked at</p> <p>19 anatomic success rates and both studies concluded that</p> <p>20 transvaginal mesh had a better anatomic success rate or</p> <p>21 less recurrence of prolapse symptoms, correct?</p> <p>22 A. I have to look at those. You're asking me to</p> <p>23 compare two different studies over different periods of</p> <p>24 times. I would -- I would bet -- how do I bet? I know</p> <p>25 these are comparing the same patients. This is actually</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 238</p> <p>1 one study that's extended out, I bet. So in these two</p> <p>2 studies were actually the same group of patients, the</p> <p>3 same group of patients. The findings you mentioned,</p> <p>4 that's what -- that's what their findings were on the</p> <p>5 non-Avaulta product.</p> <p>6 Q. Well, I don't think that's right, Doctor.</p> <p>7 Because if you look at the one study, Exhibit 10, it's</p> <p>8 talking about 202 women in a randomized controlled trial</p> <p>9 who underwent either native tissue repair or a</p> <p>10 transvaginal mesh procedure. And then, if you look at</p> <p>11 Exhibit 11, the other study, that's talking about 97</p> <p>12 patients in a randomized controlled trial?</p> <p>13 A. No. 97 and 105.</p> <p>14 MR. CARTMELL: Yeah.</p> <p>15 THE WITNESS: So together that equals --</p> <p>16 MR. CARTMELL: The same.</p> <p>17 THE WITNESS: -- 200 and what?</p> <p>18 MR. CARTMELL: 2.</p> <p>19 THE WITNESS: 2, which is interestingly, on this</p> <p>20 other paper, 202. This is the same, these people.</p> <p>21 BY MS. GEIST:</p> <p>22 Q. No. You're right, Doctor. I'm sorry. That</p> <p>23 was my mistake.</p> <p>24 A. Well, these people -- this was unethical, what</p> <p>25 they did. You have to acknowledge this is a</p>	<p style="text-align: right;">Page 240</p> <p>1 they did not, they've done something unethical.</p> <p>2 Q. That's fine, but that's sort of aside from the</p> <p>3 expert opinions you're offering in this litigation,</p> <p>4 right?</p> <p>5 A. No. Because I'm an expert as far as dealing</p> <p>6 with, also, paper journal review, because I do it for a</p> <p>7 lot of them.</p> <p>8 Q. I --</p> <p>9 A. And you're presenting -- you presented two</p> <p>10 separate studies claiming that they're different. I'm</p> <p>11 saying they're not different, and so all of this should</p> <p>12 be stricken.</p> <p>13 MR. CARTMELL: And you're cross-examining him with</p> <p>14 this.</p> <p>15 MS. GEIST: Well, I'm --</p> <p>16 MR. CARTMELL: I mean, he gets to point out the</p> <p>17 problems with the study. It's relevant.</p> <p>18 BY MS. GEIST:</p> <p>19 Q. The point is, Doctor, whether you want to say</p> <p>20 it's the same patient population or not, it doesn't</p> <p>21 matter to me. Because if it's the same population, they</p> <p>22 were followed longer than the original 2008 study?</p> <p>23 A. Yes. But you present it as two separate</p> <p>24 studies with two separate sets of data that both support</p> <p>25 that the product is good. And I'm saying, no, that's</p>
<p style="text-align: right;">Page 239</p> <p>1 continuation of a previous study. They are presenting</p> <p>2 this, and this is wrong and authors get caught up in</p> <p>3 this all of the time, and it's wrong, they are</p> <p>4 presenting this as two different study groups. Unless</p> <p>5 they state -- I would have to read this article very</p> <p>6 closely --</p> <p>7 Q. Well, let's not do that.</p> <p>8 A. No. You interrupted me.</p> <p>9 Q. Oh, sorry.</p> <p>10 MR. CARTMELL: Go ahead.</p> <p>11 BY THE WITNESS:</p> <p>12 A. Unless they state in here somewhere this is a</p> <p>13 continuation, they have done something that's unethical.</p> <p>14 They submitted it to, what journal here, International</p> <p>15 Urogyn and then they went over and submitted it to AJOG.</p> <p>16 Okay. Same authors. They're borderline unethical.</p> <p>17 Q. Well, Doctor, I'm sure you don't want to make</p> <p>18 that statement until you read either paper cover to</p> <p>19 cover to make sure they didn't disclose what they did.</p> <p>20 A. And what did they state? I'm sorry. I</p> <p>21 interrupted you.</p> <p>22 Q. I don't want to get into the ethics of the</p> <p>23 authors. My only question to you --</p> <p>24 A. Well, we should. We should. This is --</p> <p>25 you're talking on record, and I'm stating on record, if</p>	<p style="text-align: right;">Page 241</p> <p>1 not it. This is just the same continuation of people</p> <p>2 who have made questionable judgments.</p> <p>3 Q. Okay. Well, you know what? That aside, and</p> <p>4 I'm not making any representations about these studies.</p> <p>5 I'm showing you different studies that were on your</p> <p>6 review list and mine. So any statements about same</p> <p>7 study or different study, I'm talking about two separate</p> <p>8 papers. I'm not trying to misstate or mislead anything.</p> <p>9 But the point is, in both of these articles,</p> <p>10 and they may be the same patient population, in both of</p> <p>11 these articles, the authors concluded that they were</p> <p>12 better anatomical rates at the 12-month mark and then</p> <p>13 the three-year mark in the mesh group; is that correct?</p> <p>14 A. Well, no. I'm not going to get beyond that</p> <p>15 these are the same patients. It's too much of a</p> <p>16 coincidence to have 202 patients in both of them. So I</p> <p>17 see one study here that's probably a continuation. And</p> <p>18 the findings that you recorded, that's what they state.</p> <p>19 Q. Okay. So we'll just -- we'll ignore the</p> <p>20 earlier one. We'll just stick with the one that looked</p> <p>21 at women after three years and found that the recurrence</p> <p>22 rate of prolapse in the mesh group was only 13 percent</p> <p>23 compared to 41 percent in the native tissue group.</p> <p>24 That's what they found, correct?</p> <p>25 A. That's what they state in this non-Avaulta</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 242</p> <p>1 study, yes.</p> <p>2 Q. Okay. And -- and the mesh group did not have</p> <p>3 a higher incidence rate of dyspareunia after three</p> <p>4 years, correct?</p> <p>5 A. According to what they state in this</p> <p>6 non-Avaulta study, that is correct. However, as I</p> <p>7 mentioned before, the mesh erosion rate was 19 percent.</p> <p>8 I bet those women were not sexually active during that</p> <p>9 time, and so this is actually somewhat false findings,</p> <p>10 misleading findings.</p> <p>11 Q. And the other conclusion that the authors drew</p> <p>12 in this study was that the vaginal bulge symptom, which</p> <p>13 we talked about earlier, was statistically significantly</p> <p>14 lower in the mesh group. Do you see that in the 2010</p> <p>15 paper?</p> <p>16 A. Yeah. That is what they state in there. But,</p> <p>17 again, the worrisome fact of this is what's going to</p> <p>18 happen over time. If you look at Paper No. 1, exposure</p> <p>19 rate 8 percent. Paper No. 2, at three years, exposure</p> <p>20 rate was 19 percent. That is a progressive disease</p> <p>21 process. That is a defective product.</p> <p>22 Q. Do you say that, Doctor, even knowing that</p> <p>23 some of the mesh exposures that were reported in this</p> <p>24 study do not require any treatment?</p> <p>25 A. Yes, I do. That's a defective product.</p>	<p style="text-align: right;">Page 244</p> <p>1 Q. And your opinion to me just now is that the</p> <p>2 product is defective because there was exposure?</p> <p>3 MR. CARTMELL: Object to form.</p> <p>4 BY MS. GEIST:</p> <p>5 Q. Is that your opinion?</p> <p>6 A. My opinion is that we were seeing a</p> <p>7 progressive problem from 8 percent at one year to 19</p> <p>8 percent. With this particular non-Avaulta product,</p> <p>9 we're seeing this problem. Sacrocolpopexies, yes, they</p> <p>10 can have extrusions rarely. As I mentioned, for the</p> <p>11 past 90 patients, zero.</p> <p>12 Q. What's the incidence rate of mesh exposure for</p> <p>13 an ASC?</p> <p>14 A. We'd have to pull out the data on that one.</p> <p>15 Q. Okay. Let's do that, because I want to see</p> <p>16 what's your defining line of what makes a product</p> <p>17 defective or not defective based on the erosion rate.</p> <p>18 Doctor, let me ask you to put the Carey study</p> <p>19 in front of you. Do you have that? We've previously</p> <p>20 marked that.</p> <p>21 A. Yeah. I'll be able to find it. Carey,</p> <p>22 vaginal repair with mesh versus colporrhaphy.</p> <p>23 Q. Yeah. In that study, Doctor, there was a mesh</p> <p>24 exposure rate of 5.6 percent in the mesh group, correct?</p> <p>25 A. Well, this study is not comparing</p>
<p style="text-align: right;">Page 243</p> <p>1 Q. So hold on a second. That's an interesting</p> <p>2 point. So if there is a mesh exposure, even though it</p> <p>3 doesn't require any type of treatment, any type of</p> <p>4 surgical intervention, if that happens, that means the</p> <p>5 product is defective?</p> <p>6 A. Yes. It does. That's not a good product.</p> <p>7 That's a problem. Now, the severity of which, we can</p> <p>8 argue about that. But the native procedures do not have</p> <p>9 that. It's at zero percent.</p> <p>10 Q. But ASCs do, do they not? There are mesh</p> <p>11 exposures associated with an ASC for any other</p> <p>12 implantation of mesh?</p> <p>13 A. Yes. And the argument that's coming back on</p> <p>14 that is that 19 percent. The answer to that is, no.</p> <p>15 Q. Well, hold on. You just said any mesh</p> <p>16 exposure means the product is defective?</p> <p>17 MR. CARTMELL: Object to form. I think that</p> <p>18 misstates what he said. Do you mean mesh exposure?</p> <p>19 MS. GEIST: No. I don't -- I don't think it does.</p> <p>20 MR. CARTMELL: We were talking about 19 percent.</p> <p>21 BY MS. GEIST:</p> <p>22 Q. We just looked at a paper, five of the women</p> <p>23 who had mesh exposures didn't require any sort of</p> <p>24 surgical intervention, whatsoever?</p> <p>25 A. Correct.</p>	<p style="text-align: right;">Page 245</p> <p>1 sacrocolpopexies.</p> <p>2 Q. No. I know that.</p> <p>3 A. They're --</p> <p>4 Q. I'm just talking about -- I'm just talking</p> <p>5 about incidence of erosion rates using transvaginal</p> <p>6 mesh. The Carey study tells us and in that study there</p> <p>7 was 5.6 percent of the women in the mesh group who</p> <p>8 experienced erosion, correct?</p> <p>9 A. I would have to see where you're talking</p> <p>10 about. I just don't -- because we're talking about</p> <p>11 sacrocolpopexy, and so I don't see a reference in here</p> <p>12 of mesh extrusion with sacrocolpopexies.</p> <p>13 Q. No. And there is not. There is not. So let</p> <p>14 me restate it.</p> <p>15 A. Oh.</p> <p>16 Q. I want to show -- I want to talk about a</p> <p>17 couple of studies that looked at mesh erosion rates in</p> <p>18 the abdominal sacrocolpopexy.</p> <p>19 A. All right.</p> <p>20 Q. Okay. But in terms of what we see in the</p> <p>21 literature using transvaginal mesh, the Carey study</p> <p>22 tells us that there was 5.6 percent of the women in the</p> <p>23 mesh group had some mesh exposure?</p> <p>24 A. At 12 months, which is very much similar to</p> <p>25 the other, the Nieminen study, we just reviewed. So the</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 246</p> <p>1 question would be what is it at at 36 months. Is it up 2 to 18? I don't know. These patients weren't followed, 3 but that's what it states. 4 Q. Okay. And then the -- in the Withagen study 5 we looked at before, they also had an erosion rate in 6 that study. There were 14 patients in the mesh group 7 that had some degree of erosion. Do you see that in 8 Withagen? 9 A. 16.9 percent at 12 months. 10 Q. And the erosion rates in that study actually 11 varied significantly depending on what center the 12 patient had the surgery at, correct? 13 A. I would have to look through that. And, 14 actually, it was exposure rate, not erosion. 15 Q. Would you agree with me, Doctor, that 16 sometimes, in the literature, exposure, erosion, 17 extrusion are all used interchangeably? 18 A. Early on, but not currently. So I had to look 19 when this was originally written in 2011. Because these 20 complications are new and we didn't know how to 21 necessarily manage them early on, we still don't 22 necessarily know how to manage them. That remains to be 23 seen. There is confusion in the literature, but I'm 24 saying currently -- and they say exposure. That's why 25 I'm just making sure we're clear it's not erosion,</p>	<p style="text-align: right;">Page 248</p> <p>1 in Nieminen's -- Nieminen's 2010 study? 2 A. Well, again, those studies, at 12 months, it's 3 what you -- what you reported there. 4 MS. GEIST: And, sorry, the videographer is trying 5 to tell us something. What's wrong? 6 VIDEO TECHNICIAN: (Inaudible.) 7 BY MS. GEIST: 8 Q. Okay. Did you look at the Nygaard 2004 study? 9 A. I recognize the name. 10 Q. Okay. Let's take a look at that one. That 11 specifically looked at the erosion rate for mesh being 12 implanted using the abdominal approach, the ASC 13 approach, right? 14 A. Yeah. This is the Kari study, yes. 15 Q. Okay. So, in this study, we see a similar 16 erosion rate of 3.4 percent; is that correct? 17 A. I agree with you. Well, I don't see where 18 they say 3.4. I can't say that that is a similar rate, 19 but that's what they report in here. 20 Q. 3 -- I'm sorry. Go ahead. 21 A. In these other studies, and this is what's 22 important, is we'd have to look at the absolute numbers. 23 In the Kari study with Nygaard -- Nygaard, Brubaker, you 24 know, and Geoff Cundiff -- and I know a lot of these 25 people here -- that's 215 of one specific study or one</p>
<p style="text-align: right;">Page 247</p> <p>1 because that's obviously a different beast. 2 Q. In the Withagen study, though, they note that 3 some of the centers that performed the surgery had a 4 0 percent erosion or exposure rate, actually exposure 5 rate, and some of the centers had a greater rate, even 6 100 percent. Do you see that? 7 A. I don't -- I don't see it. I have heard it 8 elsewhere. 9 Q. Okay. Would that indicate to you, Doctor, 10 that the risk of exposure or erosion depends in a large 11 degree on the skill and technique used by the surgeon? 12 A. Well, that reflects in this study they had 13 that finding. But if you go to the other ones, you 14 know, the Carey, you know, this one is in Australia, 15 which is a large volume center. The other ones they 16 didn't report that. So all I can do is, based on your 17 question, in this one study, that is what they found. 18 The question is, was it statistically significant or 19 just by chance. 20 Q. Okay. 21 A. And so it was underpowered, so I'm sure they 22 wouldn't -- they wouldn't be able to do that. 23 Q. But in terms of trying to compare the 24 incidence rates between the ASC and transvaginal mesh, 25 we know from Carey it's 5.6 percent. It was 5 percent</p>	<p style="text-align: right;">Page 249</p> <p>1 specific type of surgery. 2 These other ones are going to be randomized, 3 so they have smaller numbers in their arms. So in 93 4 patients, in the Withagen paper, so, you know, half, 5 less than half was short follow-up, they had a higher 6 rate. So, again, you can't compare. It's not apples to 7 apples. You can't do that. 8 Q. Well, let me show you what I've marked as 9 Exhibit 12, which is the Nygaard study we just started 10 talking about. 11 (Elliott Deposition Exhibit No. 12 12 was marked for identification.) 13 BY THE WITNESS: 14 A. Yeah. 15 Q. Do you have it? 16 A. I have it here. 17 Q. All right. I'm just going to put it down 18 there for our pile anyway. 19 A. And I'm seeing what we have as far 20 as -- 21 MR. CARTMELL: We have a pile. 22 MS. GEIST: You have a pile, too? 23 MR. CARTMELL: Yeah. 24 BY MS. GEIST: 25 Q. All right. I'm getting the overall rate of</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 250</p> <p>1 mesh erosion at 3.4 percent from the section of the</p> <p>2 study on the left-hand side entitled, Tabulation,</p> <p>3 Integration, and Results?</p> <p>4 A. Yes. And in that -- yes, you are quoting that</p> <p>5 correctly, I believe. I still don't see the mesh</p> <p>6 erosion in there. But, important to note, this is five-</p> <p>7 and seven-year follow-up. We now have with Withagen or</p> <p>8 Nieminen, we have one-year follow-up at 8 percent; three</p> <p>9 years, 18-point something percent. Wasn't it? Or</p> <p>10 whatever. I don't -- I don't remember exactly what the</p> <p>11 number was.</p> <p>12 MR. CARTMELL: 19.</p> <p>13 BY THE WITNESS:</p> <p>14 A. 19 percent, and this is five to seven years</p> <p>15 with 3 percent. That is significant. Because we cannot</p> <p>16 compare the Kari study with the other ones until the</p> <p>17 other one gets to five to seven years.</p> <p>18 Q. So the Nieminen -- the Nieminen or Nieminen</p> <p>19 2010 study looked at the erosion rate at the three-year</p> <p>20 period, and that was 5 percent. Do you see that?</p> <p>21 A. I'm trying to find it. I've got papers</p> <p>22 everywhere. Nieminen, I have one of them here.</p> <p>23 Q. The 2010 one is the one I'm referring to,</p> <p>24 Doctor?</p> <p>25 A. Okay. Yeah. I'd have to pull that study back</p>	<p style="text-align: right;">Page 252</p> <p>1 see if you looked at the Wu 2006 study. That had a 5.4</p> <p>2 percent rate of mesh erosion for ASC procedures. I</p> <p>3 don't have a copy with me. I don't know if you have it.</p> <p>4 A. I don't -- do you know how to pronounce the</p> <p>5 last name?</p> <p>6 Q. No. It's, W-U?</p> <p>7 A. W-U, no. I do not have that one.</p> <p>8 Q. But I guess my question to you, Doctor, is,</p> <p>9 when we look at 5.4 percent or 3.4 percent and some of</p> <p>10 the other studies we looked at were 5 percent for</p> <p>11 transvaginal mesh, your criticism of those studies is</p> <p>12 that they didn't look at the erosion rates long enough?</p> <p>13 A. Absolutely. Because, again, look at the</p> <p>14 sacrocolpopexy, the Kari study. It's been a while since</p> <p>15 I've looked at this one. Five- to seven-year follow-up.</p> <p>16 That is incredible. Median follow-up, seven years. And</p> <p>17 if we're seeing a curved increase from one year at 8</p> <p>18 percent, three years at 19 percent, that's a curve</p> <p>19 that's going up. So what is it going to be at seven</p> <p>20 years? I don't know.</p> <p>21 Q. Well, it would be speculation to say whether</p> <p>22 it would be any higher, wouldn't it?</p> <p>23 A. The erosion -- the extrusion rate will not go</p> <p>24 down. Once a patient had exposure, you can't eliminate</p> <p>25 them from that. So it's only going to go up. That's</p>
<p style="text-align: right;">Page 251</p> <p>1 up here. That's a difficult name to spell, Outcomes</p> <p>2 after anterior vaginal, here we are.</p> <p>3 Q. I keep saying Nieminen, but maybe it's</p> <p>4 Nieminen?</p> <p>5 A. I've heard Kari speak, and I don't know how</p> <p>6 she pronounces her last name. At three years, it was 19</p> <p>7 percent. The same study at one year was 8 percent. So</p> <p>8 until they get out to five to seven years, we can't</p> <p>9 compare those two studies. And, if anything, this</p> <p>10 makes -- makes abdominal sacrocolpopexy look very, very</p> <p>11 good.</p> <p>12 Q. How about the Wu study from 2006? Did you</p> <p>13 look at that one?</p> <p>14 A. I do not recall that name.</p> <p>15 Q. Let me see if I have a copy of that. That's</p> <p>16 another study looking at erosion rate using the</p> <p>17 abdominal sacrocolpopexy.</p> <p>18 A. And with that said, that was perfectly</p> <p>19 acceptable. I'll really look forward to seeing it</p> <p>20 because I'm interested in this subject. But the Nygaard</p> <p>21 paper, the Kari study, is arguably the best, better than</p> <p>22 my studies, of looking at large volumes with multicenter</p> <p>23 and their results. So it would be interesting to</p> <p>24 compare a smaller study.</p> <p>25 Q. So I have to look at your reliance list and</p>	<p style="text-align: right;">Page 253</p> <p>1 basic statistics.</p> <p>2 Q. If new -- if new patients experience exposure</p> <p>3 or erosion?</p> <p>4 A. Or if a patient has been treated and she has a</p> <p>5 repeat exposure.</p> <p>6 Q. Let me -- let me flip for a second and show</p> <p>7 you what I'll mark as Exhibit 13.</p> <p>8 (Elliott Deposition Exhibit No. 13</p> <p>9 was marked for identification.)</p> <p>10 BY MS. GEIST:</p> <p>11 Q. Doctor, and for the record what I've marked as</p> <p>12 Exhibit 13 is an article entitled, Time to Rethink an</p> <p>13 Evidence-Based Response From Pelvic Surgeons to the FDA</p> <p>14 Safety Communication: Update on Serious Complications</p> <p>15 Associated With Transvaginal Placement of Surgical Mesh</p> <p>16 For Pelvic Organ Prolapse?</p> <p>17 A. Correct.</p> <p>18 Q. I hope I read that correctly.</p> <p>19 A. No. I'm familiar with this paper.</p> <p>20 Q. Okay.</p> <p>21 A. And I'm familiar with one, two, three, four,</p> <p>22 five of the authors.</p> <p>23 Q. Okay. These are all well-known reputable</p> <p>24 pelvic floor surgeons specializing in women suffering</p> <p>25 from pelvic organ prolapse; is that fair to say?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 254</p> <p>1 A. They're well-known.</p> <p>2 Q. Are some of them reputable, some of them are</p> <p>3 not?</p> <p>4 A. No. I'm saying that these are well -- some of</p> <p>5 these are very, very well-known to be making seven</p> <p>6 figures a year from industry, and that is a concern for</p> <p>7 me.</p> <p>8 Q. Who is making seven figures a year from</p> <p>9 industry on this paper?</p> <p>10 A. Lucente.</p> <p>11 Q. Anybody else?</p> <p>12 A. Murphy, possibly. I don't know how much --</p> <p>13 Q. So you don't know?</p> <p>14 A. I said some of them and Lucente would count as</p> <p>15 some. Murphy, I don't know how much he makes. I don't</p> <p>16 know how much Goldman makes.</p> <p>17 Q. You make money from the plaintiffs' bar, do</p> <p>18 you not, Doctor?</p> <p>19 MR. CARTMELL: Object to form.</p> <p>20 BY MS. GEIST:</p> <p>21 Q. Well, do you make money, a third of your</p> <p>22 income over the last three or four years, from the</p> <p>23 plaintiffs' bar?</p> <p>24 A. I make money -- you are correct. I do make</p> <p>25 money, but it's in the fight to protect women that I</p>	<p style="text-align: right;">Page 256</p> <p>1 well; isn't that fair?</p> <p>2 A. No. I think that's a mischaracterization.</p> <p>3 Q. Well, how is it different for you?</p> <p>4 A. Because my opinion -- I'm sorry. Go ahead.</p> <p>5 Q. No. But how is it different -- how is it</p> <p>6 different from you? You made a very strong statement</p> <p>7 against some very reputable, skilled surgeons who treat</p> <p>8 women suffering from pelvic organ prolapse about -- and,</p> <p>9 you know, you essentially implied that their -- their</p> <p>10 opinions are biased because they're paid by industry.</p> <p>11 How is it that you and other experts who are</p> <p>12 compensated by the plaintiffs' bar are not similarly</p> <p>13 biased?</p> <p>14 A. My opinions were established prior to this</p> <p>15 lawsuit, any of this litigation. Okay. I made comments</p> <p>16 with Public Citizens, Ralph Nader's group, about this</p> <p>17 prior to all of this. I was -- so I am not involved. I</p> <p>18 don't make a dime off of inserting something into a</p> <p>19 woman or not. I am trying to protect women that I see</p> <p>20 on a daily basis. That is different than writing a</p> <p>21 paper, studies, those types of things.</p> <p>22 Q. Do you think these doctors are not acting in</p> <p>23 the best interest of their patients?</p> <p>24 A. I can't answer as to all of them. I mean, I</p> <p>25 know Howard Goldman is very, very good doctor. I</p>
<p style="text-align: right;">Page 255</p> <p>1 have to deal with all -- every day. I do not make money</p> <p>2 in implantation of a defective device that ruins some</p> <p>3 women.</p> <p>4 Q. But that's your opinion, is it not, Doctor?</p> <p>5 A. It is my opinion based upon fact.</p> <p>6 Q. Well, before we looked at the AUGS position</p> <p>7 statement, and that position statement, as we discussed</p> <p>8 together, talks about the importance of allowing</p> <p>9 synthetic mesh materials to be accessible to women who</p> <p>10 need those materials to repair their pelvic organ</p> <p>11 prolapse. And there are physicians who believe in</p> <p>12 continuing to permit and allow that option to be</p> <p>13 available for women. Do you disagree with that?</p> <p>14 A. Well, we've gone over this already. And I'd</p> <p>15 have to state that, when a doctor, whoever he is, or any</p> <p>16 study that is industry-sponsored, there is an increased</p> <p>17 risk for there to be a bias introduced and favorable of</p> <p>18 that company, and those are all referenced in my</p> <p>19 bibliography, which I can't find a copy of right now.</p> <p>20 Q. Well, there is a risk of bias in any study,</p> <p>21 correct?</p> <p>22 A. Yes. But when money is involved, there is a</p> <p>23 reason why they have a phrase follow the money.</p> <p>24 Q. Well, so if there's money involved or paid to</p> <p>25 you, there is a risk of bias in things that you say as</p>	<p style="text-align: right;">Page 257</p> <p>1 respect him immensely. We have kindly debated this</p> <p>2 subject as of last year in May, okay. We talked about</p> <p>3 it at the SUFU meeting within the AUA. He's a very good</p> <p>4 person.</p> <p>5 The other ones, Murphy, Lucente, and van</p> <p>6 Raalte -- well, Kohli I also kind of know. I haven't</p> <p>7 talked to them. I don't know. But I'm not saying</p> <p>8 they're not good surgeons. Be very clear about that.</p> <p>9 They could be a very, very good surgeon. But when I see</p> <p>10 somebody who makes a lot of money and comes out in a</p> <p>11 statement that is in support of them making a lot of</p> <p>12 money, so be it. When all of this litigation stops, I</p> <p>13 go back to taking care of patients on a daily basis.</p> <p>14 Okay. So I see the possibility of bias.</p> <p>15 Q. So you discount the positions taken by these</p> <p>16 surgeons on behalf of the Pelvic Surgeons Network</p> <p>17 because you think they're all biased?</p> <p>18 A. The Pelvic Surgeons Network is a made-up</p> <p>19 group. That's not an organization. That came about --</p> <p>20 you have to look at the politics of that. That came</p> <p>21 about with all of this mesh litigation. They got</p> <p>22 together, everybody who puts in mesh, and said, Ooh,</p> <p>23 let's band together and make a statement.</p> <p>24 So that's not a preexisting that's been around</p> <p>25 for five, ten years that has fought through this. No.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 258</p> <p>1 Those are all people who -- and if you go down the list,</p> <p>2 I can't give you a specific number -- how many make</p> <p>3 money from industry. And that's a dangerous process.</p> <p>4 That's why manuscripts, everything, now have to do a</p> <p>5 full disclosure of how much money you make where.</p> <p>6 Q. So the 600 surgeons who take care of women</p> <p>7 suffering from pelvic organ prolapse that signed on to</p> <p>8 the response to the FDA safety communication, do you</p> <p>9 think they're all biased, too, and motivated by money</p> <p>10 they make from industry?</p> <p>11 A. I would never say all. I say there is the</p> <p>12 potential. And what would be very interesting, this</p> <p>13 statistic is available, how many make money from</p> <p>14 companies. And that is not disclosed on there, how many</p> <p>15 make money.</p> <p>16 Q. The AUGS statement that we referred to and</p> <p>17 discussed earlier together, do you have that in front of</p> <p>18 you yet?</p> <p>19 A. Sorry. I thought we were done with it, so I</p> <p>20 tossed it. Here. I have that now, yes.</p> <p>21 Q. Okay. Do you see on page 2, at the top, this</p> <p>22 is where we had stopped reading, page 2 at the top?</p> <p>23 A. Yes. I'm there.</p> <p>24 Q. If you go down to the fifth line of that</p> <p>25 paragraph --</p>	<p style="text-align: right;">Page 260</p> <p>1 across-the-board ban. I'm saying that, perhaps, in</p> <p>2 controlled circumstances, with controlled surgeons, with</p> <p>3 very unique situations, fully informed patients,</p> <p>4 randomized controlled trial, non-industry supported,</p> <p>5 then they could possibly, in those individuals, do some</p> <p>6 work. Okay. A full ban on just random use for</p> <p>7 everybody to put in any women, I do agree with that.</p> <p>8 Does that make sense?</p> <p>9 Q. No.</p> <p>10 A. No one, okay.</p> <p>11 Q. So -- no.</p> <p>12 A. Do you want me to start over?</p> <p>13 Q. No.</p> <p>14 A. Okay.</p> <p>15 Q. I'm trying to understand because, back in</p> <p>16 2011, you joined in the petition to the FDA for a</p> <p>17 complete and full ban of all pelvic organ prolapse mesh</p> <p>18 products, correct?</p> <p>19 A. Until further data is available and</p> <p>20 non-industry supported to support that it has some</p> <p>21 benefit.</p> <p>22 Q. But unless -- at the time, if there was an</p> <p>23 absence of that data, you were looking for a ban on the</p> <p>24 products at the time. So it wouldn't be available to</p> <p>25 this small percentage of women in the population that</p>
<p style="text-align: right;">Page 259</p> <p>1 A. The top paragraph?</p> <p>2 Q. Actually, you know what? Let's start on the</p> <p>3 third line. I forgot to ask you about this. On the</p> <p>4 third line of this paragraph, in the AUGS position</p> <p>5 statement, it says, A ban on the use of synthetic mesh</p> <p>6 materials would potentially prohibit many women from</p> <p>7 accessing the full range of treatment options available.</p> <p>8 Is that something you would like to see?</p> <p>9 MR. CARTMELL: Object to the form.</p> <p>10 BY THE WITNESS:</p> <p>11 A. I would have to read the whole document,</p> <p>12 because I don't know if they're talking about just POP</p> <p>13 or the slings because you're talking about a mixed bag</p> <p>14 here. According to this, effectiveness of POP mesh.</p> <p>15 Q. This is talking about POP mesh.</p> <p>16 A. Okay. If we are under the understanding that</p> <p>17 this is specifically POP mesh, so everything I'm going</p> <p>18 to state from this point on about this document is going</p> <p>19 to be on POP mesh, then I agree with that statement.</p> <p>20 Oh, excuse me. Excuse me.</p> <p>21 Q. You would with the ban --</p> <p>22 A. I agree with the ban, that's correct.</p> <p>23 Q. All right.</p> <p>24 A. Let me be very clear. I'll start over. I</p> <p>25 agree that a ban is the appropriate thing, but not an</p>	<p style="text-align: right;">Page 261</p> <p>1 you just described?</p> <p>2 A. No. I -- I am of the position. We have to be</p> <p>3 very clear about this. I stated it in the record</p> <p>4 already. The routine use of POP transvaginal mesh</p> <p>5 should be banned until there is further data available</p> <p>6 long term to say it's safe in women and that the</p> <p>7 benefits outweigh the risks. Right now there is not any</p> <p>8 data of that. You know, the FDA came back with that 522</p> <p>9 to all of the companies, as far as I know, Ethicon,</p> <p>10 Bard, and they were not able to produce data that met</p> <p>11 the FDA requirements for that 522.</p> <p>12 So that data is not available. I am</p> <p>13 definitely clearly against, based upon my experience</p> <p>14 from day-to-day dealing with patients, the international</p> <p>15 clinic, et cetera, et cetera, that routine use should be</p> <p>16 banned.</p> <p>17 Q. Do you agree with the statement in the AUGS</p> <p>18 paper that there are certain clinical situations where</p> <p>19 the use of transvaginal mesh would be preferred?</p> <p>20 A. Like I stated before, remember, I had all of</p> <p>21 those multiple different criteria.</p> <p>22 Q. Right.</p> <p>23 A. I probably won't remember all of them.</p> <p>24 Q. Right.</p> <p>25 MR. CARTMELL: Haven't we talked about that in</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 262</p> <p>1 depth?</p> <p>2 BY THE WITNESS:</p> <p>3 A. I -- I can go over it again. I don't mind.</p> <p>4 In highly advanced surgeons with a woman -- and, again,</p> <p>5 I'm not going to have all of the data, so we have to go</p> <p>6 back to my previous statements. A woman fully informed,</p> <p>7 in certain unique circumstances, it might possibly be</p> <p>8 acceptable. However, in my experience at one of the</p> <p>9 largest -- the largest institution in the United States,</p> <p>10 we have not needed -- we have never come to that.</p> <p>11 Q. Let me -- let me go back to the Time to</p> <p>12 Rethink article that I put in front of you, Doctor. The</p> <p>13 authors indicate that they performed a systematic review</p> <p>14 of the scientific literature from 1996 to 2011, similar</p> <p>15 to what FDA did; do you see that?</p> <p>16 A. Yeah. That is -- that is what they stated.</p> <p>17 Q. Any reason to believe they didn't do that?</p> <p>18 A. Well, I have no reason to support it or not.</p> <p>19 I looked at the bibliography, and it's 25 articles.</p> <p>20 There are hundreds and hundreds. I mean, I have 509 in</p> <p>21 mine. So they only have 25. So I can't state they did</p> <p>22 it. I have no reason to think they did not.</p> <p>23 Q. Would you -- let me see where you agree and</p> <p>24 disagree with some of the statements in this Time to</p> <p>25 Rethink article. Okay?</p>	<p style="text-align: right;">Page 264</p> <p>1 Q. Okay. Are you dismissing -- I just want to</p> <p>2 understand. Are you dismissing the conclusions reached</p> <p>3 by the authors here and the 600 surgeons who endorsed it</p> <p>4 because you think they're all biased in favor of</p> <p>5 industry?</p> <p>6 A. No, absolutely not. That's minimizing what I</p> <p>7 said and my experience. Two things, it's 600 surgeons</p> <p>8 out of how many? Number two, you're just taking the</p> <p>9 pelvic -- pelvic whatever network, which is a recently</p> <p>10 made-up thing. And so based upon what you're saying,</p> <p>11 yes, that is what this non-peer-reviewed article stated.</p> <p>12 Q. Now, I assume you agree with the statement</p> <p>13 that there is no question that mesh placed abdominally</p> <p>14 in the form of an abdominal sacrocolpopexy is an</p> <p>15 excellent procedure for treating POP?</p> <p>16 A. In certain patients, it is, yes.</p> <p>17 Q. And would you also agree that surgical</p> <p>18 technique appears to play a significant role in the rate</p> <p>19 of mesh erosion and the rate varies greatly between the</p> <p>20 studies?</p> <p>21 A. Some of the surgeons that I respect the most,</p> <p>22 the TBN group out of France, arguably the highest volume</p> <p>23 surgeons, they are reporting -- they are reporting</p> <p>24 extrusion rates 15 to 20 percent. So I agree that there</p> <p>25 is going to be variations in the exposure rate, but some</p>
<p style="text-align: right;">Page 263</p> <p>1 A. Okay.</p> <p>2 Q. If you go to -- it's actually page 6, for</p> <p>3 whatever reason, of the article. It's actually the</p> <p>4 second page, but on the top it says 6?</p> <p>5 A. That's because --</p> <p>6 Q. Do you see that?</p> <p>7 A. Yes. That's because this is an editorial</p> <p>8 piece. This is not peer reviewed, and so it's right at</p> <p>9 the very beginning, which is important to note. So this</p> <p>10 has been -- again, it's an opinion piece.</p> <p>11 Q. It is an opinion piece. No one is stating</p> <p>12 otherwise. It's supported by 600 surgeons who take care</p> <p>13 of women with pelvic organ prolapse, true? I mean, 600</p> <p>14 surgeons in the United States signed off on this?</p> <p>15 A. In 2011, I'll take your word for it as far as</p> <p>16 600 surgeons put on there, but I also said the caveat of</p> <p>17 how many were getting paid by industry.</p> <p>18 Q. Well, you don't have to take my word for it.</p> <p>19 It says, on the first page of the article, that the</p> <p>20 manuscript has been endorsed by over 600 members of the</p> <p>21 Pelvic Surgeons Network, and a list of those surgeons</p> <p>22 are included with the article?</p> <p>23 A. Yeah.</p> <p>24 Q. Hopefully, in the copy I gave you.</p> <p>25 A. I don't -- that's fine. I don't need it.</p>	<p style="text-align: right;">Page 265</p> <p>1 of that could be due to the duration of the study. The</p> <p>2 surgeon's role plays a role. The surgeon's training</p> <p>3 does play some role. I cannot say how much of a role.</p> <p>4 Q. The study looked -- well, strike that.</p> <p>5 This paper looks specifically at the incidence</p> <p>6 rate of erosion comparing transvaginal mesh to the ASC</p> <p>7 procedure. Do you see that?</p> <p>8 A. I'd have to -- page 2, I believe you're on?</p> <p>9 Q. Page 3, actually.</p> <p>10 A. Page 3. Okay. So which is page 7?</p> <p>11 Q. Right.</p> <p>12 A. Okay.</p> <p>13 Q. It's a little confusing.</p> <p>14 A. Oh, here we are, erosion.</p> <p>15 Q. Do you see under, Erosion? Do you see the</p> <p>16 author knows --</p> <p>17 A. Yes.</p> <p>18 Q. -- that the results, at least in two large,</p> <p>19 multicenter trials, the results of the abdominal and</p> <p>20 vaginal approach are quite similar in terms of erosion</p> <p>21 rates?</p> <p>22 A. Yes. But they're -- you know, they're cherry</p> <p>23 picking. Let me see what study they're quoting here,</p> <p>24 Study No. 20, Brubaker, Nygaard -- well, see, they're</p> <p>25 not even quoting the Kari study, which is the biggest</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 266</p> <p>1 one out there. So, yeah, the studies that they have</p> <p>2 quoted, I will not argue with the data they have written</p> <p>3 down here.</p> <p>4 Q. Would you agree, at least, Doctor that, while</p> <p>5 they're choosing to discuss certain studies, you're</p> <p>6 discussing certain studies, we've looked at other</p> <p>7 studies, there is varied rates of erosion in all of</p> <p>8 these studies with respect to transvaginal mesh and the</p> <p>9 ASC?</p> <p>10 A. There are varying numbers of extrusion rates</p> <p>11 out there. The ramifications and the frequency and the</p> <p>12 severity and the complications are going to be</p> <p>13 different, which are not discussed here. But I'll agree</p> <p>14 with you, there's varying rates out there.</p> <p>15 Q. And I think we've -- I think we've beat this</p> <p>16 like a -- like a horse, but I think, on the next page,</p> <p>17 you would agree with me and agree with the statement</p> <p>18 that mesh erosion is a risk any time mesh is used in</p> <p>19 reconstructive pelvic surgery and that surgical</p> <p>20 experience and technique play a significant role in the</p> <p>21 risk of erosion?</p> <p>22 A. Yeah. We've beaten this thing. I disagree</p> <p>23 with that.</p> <p>24 Q. Okay. I just wanted to make sure.</p> <p>25 A. For the aforementioned reasons that even, in</p>	<p style="text-align: right;">Page 268</p> <p>1 mean, it's a lot of data to support that opinion.</p> <p>2 Q. Well, I don't mean to oversimplify. But let</p> <p>3 me point you to the request.</p> <p>4 A. And I can just cut to the chase. Yes, you're</p> <p>5 right.</p> <p>6 Q. Well, hold on. All right. Okay. Because on</p> <p>7 the first page it says, what you're asking is to ban the</p> <p>8 marketing of all currently available, nonabsorbable,</p> <p>9 surgical mesh products specifically designed to treat</p> <p>10 POP. So you're asking for a ban of the marketing of all</p> <p>11 products, correct?</p> <p>12 A. That's what the document states, yes.</p> <p>13 Q. And -- well, that's what you wanted, right?</p> <p>14 A. Yeah.</p> <p>15 Q. And the second part, the second request to</p> <p>16 FDA, is an order that all manufacturers of</p> <p>17 nonabsorbable -- nonabsorbable surgical mesh products</p> <p>18 designed for POP, to recall the products. So you wanted</p> <p>19 a recall order immediately of all products?</p> <p>20 A. That's what it states, yes.</p> <p>21 Q. Then there is no caveats in here about, Well,</p> <p>22 let's wait and see. Let's look at studies. This was</p> <p>23 requesting an immediate recall at that moment, urgent</p> <p>24 request, pull all products from the market. That's what</p> <p>25 this was asking for, right?</p>
<p style="text-align: right;">Page 267</p> <p>1 high-volume, very talented surgeons, they're having an</p> <p>2 unacceptably high extrusion rate.</p> <p>3 Q. Let me show you quickly, Doctor, your -- I</p> <p>4 think I'm on Exhibit 14. Okay. We're all in agreement</p> <p>5 on some things, right?</p> <p>6 MR. CARTMELL: Mm-hmm.</p> <p>7 (Elliott Deposition Exhibit No. 14</p> <p>8 was marked for identification.)</p> <p>9 BY MS. GEIST:</p> <p>10 Q. Let me show you Exhibit 14, Doctor, which is a</p> <p>11 copy of the FDA petition that we talked about before.</p> <p>12 And this was the petition to the FDA by Public Citizen</p> <p>13 back in August -- August of 2011?</p> <p>14 A. Correct.</p> <p>15 Q. I assume you reviewed that and signed off on</p> <p>16 it?</p> <p>17 A. Yes.</p> <p>18 Q. You actually are a signatory to the petition;</p> <p>19 is that correct?</p> <p>20 A. That is correct.</p> <p>21 Q. And you, along with Public Citizen, were</p> <p>22 seeking government involvement and an actual, I guess,</p> <p>23 order from the government to order all manufacturers to</p> <p>24 recall their products?</p> <p>25 A. Well, that's an oversimplification of this. I</p>	<p style="text-align: right;">Page 269</p> <p>1 A. Correct. Based upon that on a daily basis I</p> <p>2 see these individuals, and I have seen individuals who</p> <p>3 have been implanted after this document. So when we</p> <p>4 wrote this up with Michael Karram, who is -- who is the,</p> <p>5 Carome, excuse me, who is the deputy officer involved</p> <p>6 with this. He is the one who wrote the document. I</p> <p>7 completely signed off on it. My opinion was -- is that</p> <p>8 extremism in the protection of women and their bodies</p> <p>9 was justified in this situation. Because if one more</p> <p>10 woman is permanently injured by a product that has no</p> <p>11 benefit or minimal benefit, that is unacceptable.</p> <p>12 Q. Did you know Dr. Carome before you</p> <p>13 participated in this FDA petition?</p> <p>14 A. No. He e-mailed me out of the blue.</p> <p>15 Q. How did he find you and why, do you know?</p> <p>16 A. I have no idea. I got an e-mail from him,</p> <p>17 from Public Citizen, or he went through our media</p> <p>18 department. I don't know. I don't recall how that</p> <p>19 actually happened. He contacted me. I did not want to</p> <p>20 get involved at all. I told him I did not want to get</p> <p>21 involved. I had enough headaches.</p> <p>22 And he is the one who convinced me stating</p> <p>23 that he asked me a lot of questions, you know, are you</p> <p>24 seeing these type of people? And, I said, yes. He</p> <p>25 says, you have a moral obligation to be helping out</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 270</p> <p>1 these women, and that's why I signed on.</p> <p>2 (Exit Mr. Jeffrey Kuntz.)</p> <p>3 BY MS. GEIST:</p> <p>4 Q. Do you know who funds the efforts of Public</p> <p>5 Citizen?</p> <p>6 A. No. People. Industry.</p> <p>7 Q. Industry?</p> <p>8 A. No.</p> <p>9 (Enter Mr. Jeffrey Kuntz.)</p> <p>10 BY THE WITNESS:</p> <p>11 A. No, you're right. Not --</p> <p>12 Q. You're saying medical device companies --</p> <p>13 A. No, not medical device.</p> <p>14 Q. -- funds Public Citizen, do you?</p> <p>15 A. As far as -- no. As far as I don't know who</p> <p>16 all gets involved in the funding of it. I know there's</p> <p>17 been -- they deal with it. I don't know where the money</p> <p>18 comes from; but, no, not medical industry.</p> <p>19 Q. Do you know whether the plaintiffs' bar funds</p> <p>20 Public Citizen?</p> <p>21 A. I have no -- I'll be on the record very, very</p> <p>22 clear. I have no idea where one single dollar comes</p> <p>23 from to fund them. I don't know.</p> <p>24 Q. Wouldn't you want to know maybe something</p> <p>25 about the motivation of an organization like Public</p>	<p style="text-align: right;">Page 272</p> <p>1 don't know if that's the right word -- of my own</p> <p>2 profession. Lawyers have led the way in getting this</p> <p>3 problem solved.</p> <p>4 Q. I noticed that, in one of your articles, you</p> <p>5 made that statement after you had already received quite</p> <p>6 a bit of compensation from the plaintiffs' bar, true?</p> <p>7 A. No. I disagree with that. I wrote that</p> <p>8 article in September of '11. Chris Winters, who is the</p> <p>9 chair of SUFU, asked me to write it for Current Opinions</p> <p>10 of Urology. At that point in time, maybe a month or</p> <p>11 two -- I would have to look at the specific dates. So,</p> <p>12 as far as a significant amount of money, I don't know</p> <p>13 what I had made, but it was not a -- I probably couldn't</p> <p>14 buy a car with it.</p> <p>15 Q. Well, you all -- let's not get into the</p> <p>16 details of how much you were being paid by the</p> <p>17 plaintiffs' bar at the time. But you were being</p> <p>18 compensated by the plaintiffs' bar at the time you wrote</p> <p>19 that article and talked about how wonderful it was that</p> <p>20 lawyers are leading the charge --</p> <p>21 A. No.</p> <p>22 MR. CARTMELL: Wait. Hold on.</p> <p>23 BY MS. GEIST:</p> <p>24 Q. -- in the pelvic mesh litigation; isn't that</p> <p>25 true?</p>
<p style="text-align: right;">Page 271</p> <p>1 Citizen? We've been talking a lot about why people are</p> <p>2 putting articles out there and what motivates them.</p> <p>3 A. Sure. No.</p> <p>4 Q. Wouldn't you want to know what motivates</p> <p>5 Public Citizen?</p> <p>6 A. You raise a very good point. I did as much</p> <p>7 looking into it. I never did come out and ask that</p> <p>8 specific question. But that's a good one. I can give</p> <p>9 Michael a call or an e-mail.</p> <p>10 When I looked into where the money is coming</p> <p>11 from, all I could find is that, when Ralph Nader ran for</p> <p>12 president, he was no longer going to be in charge of</p> <p>13 Public Citizen because they thought it introduced bias,</p> <p>14 which I respected that position. But, no, I do not know</p> <p>15 where money came from.</p> <p>16 Q. Would it surprise you to learn that certain</p> <p>17 members of the plaintiffs' bar fund Public Citizen?</p> <p>18 A. I'm not -- after getting involved in this</p> <p>19 whole mesh issue, I'm not surprised at much anymore.</p> <p>20 Individuals I respected have changed their writing</p> <p>21 styles based upon funding, which has come out in trial,</p> <p>22 like Altman in the Gross trial versus Ethicon.</p> <p>23 If lawyers are supporting this, I'm not</p> <p>24 necessarily against it because I have made public</p> <p>25 statements that, unfortunately, to the denigration -- I</p>	<p style="text-align: right;">Page 273</p> <p>1 MR. CARTMELL: Object to the form. You keep saying</p> <p>2 that they're being paid by the plaintiffs' bar. He's</p> <p>3 never been paid by the plaintiffs' bar. He has been</p> <p>4 retained as an expert in litigation by certain</p> <p>5 attorneys. And your continual statements of payments by</p> <p>6 a bar on the plaintiffs' side in inappropriate. It's</p> <p>7 argumentative and it misstates facts.</p> <p>8 BY MS. GEIST:</p> <p>9 Q. Okay. Well, you're paid by plaintiffs'</p> <p>10 counsel or plaintiffs' lawyers in this litigation and in</p> <p>11 the Ethicon litigation; is that accurate?</p> <p>12 A. Correct.</p> <p>13 Q. And when you wrote this article, Doctor, which</p> <p>14 I'll mark as Exhibit 15 -- I hope that's right. And I'm</p> <p>15 not getting any better at using the stamp as we go along</p> <p>16 today.</p> <p>17 MR. CARTMELL: Thank you.</p> <p>18 MS. GEIST: You're welcome.</p> <p>19 (Elliott Deposition Exhibit No. 15</p> <p>20 was marked for identification.)</p> <p>21 BY MS. GEIST:</p> <p>22 Q. Do you have Exhibit 15 in front of you,</p> <p>23 Doctor?</p> <p>24 A. Yes, I do.</p> <p>25 Q. Okay. When -- when you wrote that article,</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 274</p> <p>1 that was published in 2012, correct?</p> <p>2 A. July of 2012 it was published.</p> <p>3 Q. And, at that point in time, you had already</p> <p>4 been retained as an expert for certain plaintiffs by</p> <p>5 plaintiffs' lawyers in the pelvic mesh litigation, true?</p> <p>6 A. Correct.</p> <p>7 Q. And, on page 280 of the article, which is,</p> <p>8 again, sort of misleading, right, because it's six</p> <p>9 pages?</p> <p>10 A. Correct.</p> <p>11 Q. For some reason on the bottom left it says</p> <p>12 280?</p> <p>13 A. That just because Current Opinions of Urology</p> <p>14 continues January 1st with page 1 and then December just</p> <p>15 continues right on through, so that's why.</p> <p>16 Q. Okay. And, in this article, under the</p> <p>17 discussion, this is where you essentially applaud the</p> <p>18 plaintiffs' lawyers for doing something about the pelvic</p> <p>19 mesh problem as you call it, correct?</p> <p>20 A. No. I do not applaud them. I say sadly, for</p> <p>21 whatever reason, it seems to be them, meaning lawyers,</p> <p>22 not us, doctors, looking at the data, recognizing</p> <p>23 something is wrong, and aggressively trying to stop mesh</p> <p>24 use. This is a condemnation of my -- myself and my</p> <p>25 peers. This is not praising lawyers. That's the last</p>	<p style="text-align: right;">Page 276</p> <p>1 attending the meetings, we are hearing of the</p> <p>2 complications, and no physician that I knew of,</p> <p>3 including myself, had really done anything to try and</p> <p>4 stop it.</p> <p>5 Q. Well, how did you know the legal community</p> <p>6 were involved in the issue at this point in time --</p> <p>7 A. Well.</p> <p>8 Q. -- if you hadn't yet been talking to the</p> <p>9 lawyers about it?</p> <p>10 A. No. You know, at this point in time, the FDA</p> <p>11 had already come out with their warnings and things like</p> <p>12 that, and you can't turn on a TV without hearing about</p> <p>13 all of these lawsuits.</p> <p>14 Q. So do you think this paper is the reason why</p> <p>15 you got retained by counsel?</p> <p>16 A. No, absolutely not. This was -- this was</p> <p>17 written after they had contacted me. But in February of</p> <p>18 2011, at our national meeting, I presented an article --</p> <p>19 or, excuse me, I gave a talk and talked with all of</p> <p>20 the -- you know, I just did a Google search and came up</p> <p>21 with all of the various different lawyers searching for</p> <p>22 cases. So that was well-known that was going on. I --</p> <p>23 this, again, is a condemnation of me and my colleagues</p> <p>24 of not doing something to protect women. Okay.</p> <p>25 Q. So this was written after you had been</p>
<p style="text-align: right;">Page 275</p> <p>1 thing I'd ever want to do is praise a lawyer. We're</p> <p>2 told that from day one. This is a condemnation of my</p> <p>3 own profession, and this is something I have stated in</p> <p>4 audiences. This is -- this is not a new thought.</p> <p>5 Q. Okay. And all of that withstanding, at this</p> <p>6 point in time, you had already been providing expert</p> <p>7 opinions against manufacturers when you published this</p> <p>8 for more than a year, right?</p> <p>9 A. No. That's not correct at all. September of</p> <p>10 '11 is when Mr. Anderson first contacted me, or right</p> <p>11 around there, very, very close. That was my first</p> <p>12 interaction. I was asked, perhaps, in October, we had a</p> <p>13 visiting professor, Dr. Christopher Winters, the chair</p> <p>14 of SUFU, a very powerful position, he knew my position</p> <p>15 on meshes. He asked me to write this opinion piece.</p> <p>16 Again, it was in October. I wrote the piece. It just</p> <p>17 took seven months for it to come out.</p> <p>18 Q. So how did you know that the legal community,</p> <p>19 as you write under the discussion section, you write, It</p> <p>20 seems the legal community is significantly ahead of the</p> <p>21 medical community in realizing the magnitude of the</p> <p>22 problem and doing something about it?</p> <p>23 A. Because that's a true statement.</p> <p>24 Q. Well, how did you know?</p> <p>25 A. Because I am in the medical community, I am</p>	<p style="text-align: right;">Page 277</p> <p>1 contacted by plaintiff's lawyers?</p> <p>2 A. As I mentioned, in September or so of 2011,</p> <p>3 Mr. Anderson had contacted me.</p> <p>4 Q. Did -- are you working with Citizens</p> <p>5 Petition -- I'm sorry. Strike that.</p> <p>6 Are you working with Public Citizen on any</p> <p>7 other types of petitions to ban any other types of</p> <p>8 products or any other activity?</p> <p>9 A. No. Every once in a while Michael Carome,</p> <p>10 again, who his title is -- whatever his title is here,</p> <p>11 he is the one in charge of things, will contact me when</p> <p>12 some issue is coming up for the FDA. It's been a long</p> <p>13 time, a year or more on that. Deputy Director of Health</p> <p>14 Research Group, Michael Carome, again, he is responsible</p> <p>15 for getting me involved in stuff.</p> <p>16 Q. Does Mr. Carome --</p> <p>17 A. Dr. Carome.</p> <p>18 Q. I'm sorry. Does Dr. Carome or anybody else at</p> <p>19 Public Citizen compensate you for your consulting work</p> <p>20 with that group?</p> <p>21 A. No. If anything, it is adding work onto my</p> <p>22 schedule without any compensation, but I'm doing that to</p> <p>23 help.</p> <p>24 Q. You do it for free?</p> <p>25 A. I do it for free.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 278</p> <p>1 Q. FDA, of course, denied the relief that you and 2 Public Citizen were seeking, right? 3 MR. CARTMELL: Object to the form. 4 BY MS. GEIST: 5 Q. Well, you wanted -- you wanted an immediate 6 and urgent order to pull all products from the market, 7 and the FDA disagreed with you, correct? 8 A. The FDA made a decision not to the extent that 9 I felt was appropriate. 10 Q. They disagreed with what you wanted? 11 MR. CARTMELL: Object to the form. 12 BY THE WITNESS: 13 A. No. I didn't say that. I said they didn't go 14 to the extent that I wanted them to go. 15 Q. Right. You wanted them to immediately pull 16 all products from the market, and they didn't? They 17 wouldn't do that, correct? 18 A. Yes. And if you look at the people who are on 19 that FDA board, I don't believe a single one of those is 20 the one who is taking care of these mesh complications. 21 That's besides the point. But at least we have -- the 22 fact that it failed to get to the extent that I wanted 23 is not an issue for me. It's we're trying to make a 24 difference in these women's lives. 25 Q. And you wrote separately, in support of that</p>	<p style="text-align: right;">Page 280</p> <p>1 Q. The fourth paragraph, are you with me? 2 A. Yes, I am. 3 Q. And on the fifth line, you state in your 4 letter, I do feel this position is extreme. Do you see 5 that? 6 A. Mm-hmm. Yep. I see it. 7 Q. So, at this point in time, your position and 8 your opinions and thinking in 2011, you admit was 9 extreme? 10 MR. CARTMELL: Well, objection. That misstates it. 11 THE WITNESS: Yeah. 12 MR. CARTMELL: And you add a bunch of additional 13 things. It says what it says, and your question is 14 misstating what the letter says. 15 THE WITNESS: Yeah. That is -- I'm sorry. 16 BY MS. GEIST: 17 Q. Does the letter say -- 18 MR. CARTMELL: Why don't you read it? 19 BY MS. GEIST: 20 Q. And it stands on its own. It says, I do feel 21 this position is extreme? 22 A. Absolutely. It states it. And as it 23 continues, However, extremism in the pursuit of surgical 24 responsibility, patient care, financial responsibility, 25 and medical ethics is the only honorable end point. So,</p>
<p style="text-align: right;">Page 279</p> <p>1 position -- I'm sorry. Strike that. 2 You wrote separately, in support of the 3 request, to remove and immediately ban all products from 4 the market? 5 A. There was a follow-up something. I don't 6 recall the details on that one. 7 Q. All right. Let me -- 8 A. But I would have to look at that document. 9 But, yeah, there was a follow-up petition. 10 (Elliott Deposition Exhibit No. 16 11 was marked for identification.) 12 BY MS. GEIST: 13 Q. Okay. Well, let me show you what I've marked 14 as Exhibit 16. This is a separate letter from you, 15 Dr. Elliott, to the FDA in strong support of the Public 16 Citizen petition, correct? 17 A. Yes, which is very, very, very important. The 18 date on that is prior to me having any interaction with 19 any legal team. Okay, August 19th, 2011. 20 Q. And if you look with me down at the last 21 paragraph, the fourth paragraph in your lower, sort of 22 in the middle -- 23 A. The fourth paragraph, the bottom? 24 Q. Yeah. 25 A. The last? Yes, I'm there.</p>	<p style="text-align: right;">Page 281</p> <p>1 yes, and I stand by that then and I stand by it now. If 2 anything, it's more firm of a conclusion. 3 Q. And that's -- that's fine, Doctor. But I 4 asked you earlier back in 2011 if you thought your 5 position was extreme. Back in 2011 we had a group of 6 pelvic floor reconstructive surgeons writing in response 7 to the FDA petition setting forth their statements that 8 women needed to have transvaginal mesh as an option. We 9 had 600 surgeons sign on to that document. And in 10 contrast, you were working with Public Citizen to get an 11 order immediately banning and recalling all products? 12 MR. CARTMELL: Okay. 13 BY MS. GEIST: 14 Q. Isn't that position extreme at the time you 15 made it? 16 MR. CARTMELL: Okay. Object and move to strike the 17 statement of counsel. I'll also note for the record 18 that your statement that you asked him previously in 19 this deposition, if his position was extreme, related to 20 the FDA actions he wanted. You had never asked him that 21 previously in the deposition. So that was a 22 misstatement of what you asked. 23 BY MS. GEIST: 24 Q. Well, the record is what it is. But can you 25 answer my question, Doctor?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 282</p> <p>1 A. Absolutely, and I can answer that very 2 clearly. 2011 is 365 days. As of August 19th, I make 3 that statement. Prior to that time, a month or two 4 prior, is when Mr. -- or Dr. Carome contacts me and I 5 start looking at the literature and what he had written 6 up. Okay. And so my position evolved. So, in 2011, I 7 can still make a comment that I was not extreme. But, 8 again, extremism in taking care of patients and women 9 and their bodies is not a wrong thing. And I'll stand 10 by that and I'll state that over and over and over. And 11 I'm proud of that. 12 Q. So notwithstanding what you're saying in your 13 letter to a government agency, you're telling me you 14 don't think you were extreme back then? 15 A. You have to look at the entire document, not 16 just one. If all I wrote on here, To whom it may 17 concern. I do feel this position is extreme, period, 18 and signed it, that's a foolish statement. I put 19 qualifiers. I say why and I follow it up saying 20 extremism, in this situation, responsibility, patient 21 care, financial, medical ethics is the honorable thing. 22 That's a good thing, and I'll stand by that. 23 Q. Doctor, let me show you -- I think I'm up to 24 17. 25</p>	<p style="text-align: right;">Page 284</p> <p>1 be about a thousand hits on it. It's been taken. And I 2 don't necessarily appreciate lawyers using it in that 3 fashion, but I have no control over that. 4 Q. Okay. Well, that was my question. Were you 5 aware of this? Were you being compensated -- 6 A. No. 7 Q. -- by Levin Papantonio to use your statements 8 on their Website? 9 A. Absolutely -- I have not received a dollar 10 from anybody as far as posting comments, and we get 11 those things frequently. 12 Q. How about the Mesh News Desk? 13 A. No. 14 Q. Do you remember being interviewed by somebody 15 from the Mesh News Desk? 16 A. Yes. Julie Akre or something like that. 17 Q. Do you know who runs the Mesh News Desk? 18 A. No, I don't. I know they have solicited money 19 from me to support putting my words on her page, which I 20 didn't like. 21 Q. Have they ever provided you with any 22 compensation for your statements that they put on the 23 Mesh News Desk site? 24 A. Zero. And recently, as of, I don't know, a 25 month or two ago, she contacted me asking for money to</p>
<p style="text-align: right;">Page 283</p> <p>1 (Elliott Deposition Exhibit No. 17 2 was marked for identification.) 3 BY MS. GEIST: 4 Q. Doctor, let me show you what I've marked as 5 Exhibit 17 to your deposition. And, for the record, 6 this is a copy of an article that was on the Levin 7 Papantonio Website. Do you see that? 8 A. Yes, I do. 9 Q. And this was published on the Website back on 10 August 19th, 2011? 11 A. I'll trust you on that. I don't know. I 12 don't see a published date. 13 Q. If you look under the title, it says, Mayo 14 Clinic Doctor: Mesh patients have suffered needlessly. 15 And underneath that, it says -- 16 A. Yes. 17 Q. -- August 19th, 2011. Do you see that? 18 A. Yes, I do. 19 Q. Do you know who Levin Papantonio are? 20 A. I don't recognize those names, no. 21 Q. They're a plaintiffs' law firm involved in the 22 mesh litigation. Were you working with them back in 23 August of 2011? 24 A. No. I have no idea who they are. If you 25 search my name and mesh and Publish Citizen, there will</p>	<p style="text-align: right;">Page 285</p> <p>1 support her Web page, and I say, no. So that Website I 2 am not a supporter of. 3 (Elliott Deposition Exhibit No. 18 4 was marked for identification.) 5 BY MS. GEIST: 6 Q. Let me show you Exhibit 18, Doctor. This is 7 the -- this is a copy of one of the articles on the Mesh 8 News Desk site. This appears to be pretty recent, from 9 October 27th, 2014? 10 A. Yeah. It's one that was posted, yes. 11 Q. And that's you. That's your smiling face 12 there on the article, right? 13 A. Yeah. It's an updated photo. 14 Q. I'm sorry? 15 A. It's an updated photo. I don't know where she 16 got it. That's interesting. She must have got it off 17 the Web page, Mayo's Web page. 18 Q. But you provided her with the interview that's 19 set forth here, correct? 20 A. She interviewed me, took lots of notes, sent 21 me a manuscript that was severely false. I then edited 22 it to what it is, and I have not reviewed this final one 23 because it got posted without my permission. So, again, 24 I am not a supporter of the Medical Desk. 25 Q. But, at least, you know, some of the</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 286</p> <p>1 statements in here, Doctor, seem to be consistent with 2 our discussion here today. If you look at page 2, there 3 is a question, Should it be off the market, referring to 4 transvaginal mesh? 5 A. Yeah. If this is quoting me correctly, and I 6 have been consistent with what I've stated. But I'll 7 say it should be off the market. Polypropylene mesh 8 used for transvaginal prolapse should never have been 9 put on the market. I stand by that. For selected 10 individuals who have failed standard treatment -- that's 11 what we've gone through ad nauseam today -- there may be 12 a role. I was abbreviating what we've talked about 13 today. 14 Q. And you stand by that statement with the 15 caveats you made today in your deposition; is that fair? 16 A. That is correct. This here does not go into 17 all of them. I did say in selected individuals. With 18 selected individuals is what we have talked about today. 19 Q. Got it. Now, on the first page of the 20 interview, Doctor, it says that you reported that no one 21 in the urology department at the Mayo Clinic used 22 polypropylene transvaginal mesh for prolapse. Do you 23 see that? 24 A. Yeah. And, actually, that's -- that's 25 correct, but short. No one in the urology or GYN at</p>	<p style="text-align: right;">Page 288</p> <p>1 this document before. 2 Q. Well, I'll just represent to you, as you can 3 tell from the date on the bottom right corner, that we 4 printed this out on November 5th, 2014. And on page 2 5 of the exhibit, it appears to indicate that this is 6 dated August 9th, 2014. Do you see that? 7 A. Yeah. I don't have any reason to doubt its 8 validity. I just wasn't involved in this, the 9 production of this. 10 Q. Okay. It says, pelvic organ prolapse at the 11 top, correct? 12 A. You're on page -- the first page? 13 Q. I'm on the first page, yeah. 14 A. Yes, it does. That's what it says. 15 Q. And, it says, concerned about transvaginal 16 mesh complications associated with treatment for pelvic 17 floor disorders? Here is what you need to know, 18 correct? 19 A. Yes. 20 Q. And this is provided by the Mayo Clinic staff, 21 true? 22 A. Mayo Clinic staff, there is a ghostwriter who 23 interviewed somebody and this was written up. 24 Q. Okay. At least, according to this statement 25 from the Mayo Clinic, surgical mesh, including synthetic</p>
<p style="text-align: right;">Page 287</p> <p>1 Mayo use meshes for prolapse transvaginal. 2 Q. So that was my question to you. Does anyone, 3 in the urogynecology division of the Mayo Clinic, use 4 transvaginal mesh to treat pelvic organ prolapse? 5 A. No. In 2005, when they came out, there were 6 roughly six or seven of us on staff at that point in 7 time. All of us independently, without a discussion, 8 elected not to use it. So that is a correct statement, 9 and they misspelled my name, too. 10 Q. So if we look at -- let me just mark Exhibit 11 19. 12 (Elliott Deposition Exhibit No. 19 13 was marked for identification.) 14 BY MS. GEIST: 15 Q. Doctor, this is a print off from the Mayo 16 Clinic -- I'm sorry. 17 A. That's all right. 18 Q. This is a download or a printed page from the 19 Mayo Clinic site. Do you see that? 20 A. Yeah, I do. I'm trying to figure out, because 21 I was involved with Mayo's policy on meshes and -- but I 22 was not involved with the drafting of this. But I don't 23 know what -- 24 Q. Okay. 25 A. -- I don't know what this -- I have not seen</p>	<p style="text-align: right;">Page 289</p> <p>1 materials, can be used to treat pelvic organ prolapse; 2 do you see that? 3 A. I don't see that document. 4 Q. All right. So go with me to the second -- 5 A. I mean, I don't see -- 6 Q. Sorry. Second paragraph, it says, Surgical 7 mesh is a medical device that is used to provide extra 8 support when repairing weakened or damaged tissue? 9 A. Yep. 10 Q. Most surgical mesh devices are made from 11 synthetic materials or animal tissue? 12 A. Yes. 13 Q. Surgical mesh can be used to treat, and then 14 it says POP, right? 15 A. Yes. 16 Q. And it says surgery can be done through the 17 abdomen or through the vagina, transvaginal, correct? 18 A. That's what it states, yes. 19 Q. And then, on the second page of the statements 20 from Mayo Clinic, it says, if you are considering 21 treatment for a pelvic floor disorder that involves 22 surgical mesh, be sure to have your health care provider 23 explain all of your options, as well as their possible 24 risks and benefits. In particular, be aware of the 25 risks associated with surgical mesh for transvaginal</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 290</p> <p>1 repair of POP, such as the need for additional surgery 2 due to mesh-related complications. Did I read that 3 correctly? 4 A. Yes, you did. 5 Q. But, at least, according to this statement 6 from the Mayo Clinic, as of August 9th, 2014, the 7 surgeons at the Mayo Clinic were still offering 8 transvaginal mesh for the repair of pelvic organ 9 prolapse? 10 A. Absolutely not. No one has. No one at Mayo 11 Clinic Rochester has ever put in, to the best of my 12 knowledge, a transvaginal mesh kit. 13 Q. So where did this statement come from? 14 A. This is a ghostwriter. This was written up 15 for information for patients. So I had nothing to do 16 with this one. But all of those authors on that Blandon 17 article, I know them. I operate with them daily. And 18 so, you know, they're -- they're giving the warnings 19 because we are contacted. We are inundated with 20 patients calling up, and this is a resource for patients 21 to look at this. 22 And then we're not -- we're saying, if you're 23 considering pelvic floor surgery that involves mesh, 24 okay, no one at Mayo does that. But patients come from 25 all over the world to the Website for information. But</p>	<p style="text-align: right;">Page 292</p> <p>1 and let you ask questions -- 2 MS. GEIST: You can ask your own questions if you 3 want. 4 MR. CARTMELL: -- that misstate evidence. 5 MS. GEIST: You can ask your own questions if you 6 want. Be my guest. 7 MR. CARTMELL: I don't get that. 8 BY MS. GEIST: 9 Q. So my question was, Doctor, is that -- is that 10 the accurate site for the Mayo Clinic, mayoclinic.org? 11 A. Yeah. This is for patient access. But 12 myself, Dr. Lithner, in our department of female 13 urology, Dr. Klingele, Dr. Ochino, Dr. Trabuco, and I 14 believe there is another gynecologist who has never 15 implanted it. So this isn't information for patients 16 who contact the Web. It's not. If they come into Mayo, 17 they're not getting the mesh. 18 Q. Well, and there is nowhere in this statement, 19 on behalf of the Mayo Clinic, as it states by the Mayo 20 Clinic staff, there is nowhere in here that says, by the 21 way, we don't agree with the implant of transvaginal 22 mesh, we don't use transvaginal mesh, or we think you, 23 patient accessing our site, should not use transvaginal 24 mesh? There is nowhere in here that states that, is 25 there?</p>
<p style="text-align: right;">Page 291</p> <p>1 we're saying, whoever wrote this, make sure you've got 2 all of your options and risks, and they go on and on and 3 on here about the potential risks. 4 Q. Right. But nowhere in this document, Doctor, 5 does it say, Don't use transvaginal mesh for POP repair, 6 does it? 7 A. Well, that's what the article states, and it 8 states what it states. 9 Q. Right. 10 MR. CARTMELL: Where does it say that you're 11 supposed to -- that they use it like you just said in 12 your question? 13 MS. GEIST: You can't ask me questions. 14 MR. CARTMELL: Well, you just asked him a question 15 that said -- 16 MS. GEIST: I said you can't -- 17 MR. CARTMELL: -- so as of this time -- 18 MS. GEIST: No, no, no. 19 MR. CARTMELL: -- Mayo was using it. 20 MS. GEIST: Stop. 21 MR. CARTMELL: And there is nowhere in this 22 document that says Mayo was using it. 23 MS. GEIST: You can't make speaking objections like 24 you are. 25 MR. CARTMELL: No. I'm just supposed to sit here</p>	<p style="text-align: right;">Page 293</p> <p>1 A. Well, there is no statement of support either. 2 Q. Well, there is a statement that says, Surgical 3 mesh can be used to treat pelvic organ prolapse through 4 the vagina. And if you're considering this transvaginal 5 repair, talk to your doctor about the risks and 6 benefits. That's what it says, correct? 7 A. I -- I can completely support that the 8 document says surgical mesh can be used to treat pelvic 9 organ prolapse. I agree with that. It can be. It's 10 not a statement of support. 11 Q. Well, you have -- I understand your 12 interpretation of that. 13 MR. CARTMELL: I'll object and move to strike the 14 statement of counsel. Ask him questions if you want to. 15 MS. GEIST: I am. And if you would stop 16 interrupting me, we would get along a lot better today. 17 You're making your own statements. 18 BY MS. GEIST: 19 Q. Doctor, I want to move on to some of the 20 specific opinions in your report that we didn't talk 21 about already. Do you need a break before we move on? 22 A. No. Let's keep going. 23 Q. Okay. Okay. Let me start, Doctor, with -- 24 the videographer is signaling us again. 25 MS. GEIST: Are we okay?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 294</p> <p>1 VIDEO TECHNICIAN: (Inaudible.)</p> <p>2 BY MS. GEIST:</p> <p>3 Q. All right. Doctor, let me start with a</p> <p>4 discussion in your report relating to degradation. We</p> <p>5 talked a little bit about that before?</p> <p>6 A. Correct.</p> <p>7 Q. And I think you told me earlier, and correct</p> <p>8 me if I'm misstating it, that, while polypropylene mesh</p> <p>9 is polypropylene -- polypropylene mesh, degradation does</p> <p>10 not occur in all polypropylene mesh?</p> <p>11 A. I never stated that.</p> <p>12 Q. All right. So then here is my question. Do</p> <p>13 you still use polypropylene-made urethral slings to</p> <p>14 treat stress urinary incontinence?</p> <p>15 A. No.</p> <p>16 Q. Have you ever?</p> <p>17 A. Yes.</p> <p>18 Q. And how about your colleagues at Mayo? Do</p> <p>19 they continue to use polypropylene midurethral slings to</p> <p>20 treat stress urinary incontinence?</p> <p>21 A. My colleague in urology used mesh slings for</p> <p>22 about a year or two starting in 2003 or 2004. She felt</p> <p>23 it should never have been done and she stopped using it</p> <p>24 back then. I continued using it longer. But she</p> <p>25 stopped using it. I cannot speak to what my</p>	<p style="text-align: right;">Page 296</p> <p>1 Q. So do you consider yourself to be a</p> <p>2 physiological expert in how the body actually reacts to</p> <p>3 polypropylene?</p> <p>4 A. I would say, yes, based upon my experience, my</p> <p>5 review of the literature, surgical experience, yes, I</p> <p>6 am. I see it on a daily basis.</p> <p>7 Q. Is there any article, Doctor, or anything in</p> <p>8 the literature that has said that polypropylene cannot</p> <p>9 be used in the human body to correct pelvic organ</p> <p>10 prolapse or stress urinary incontinence?</p> <p>11 MR. CARTMELL: Object to the form.</p> <p>12 MS. GEIST: When in doubt.</p> <p>13 MR. CARTMELL: I mean, I don't get it, anything in</p> <p>14 the literature.</p> <p>15 BY MS. GEIST:</p> <p>16 Q. Well, is there any -- anything in the</p> <p>17 literature, any medical article, that has said</p> <p>18 polypropylene cannot be used in the human body to treat</p> <p>19 anything, or pelvic organ prolapse, in particular?</p> <p>20 A. Well, when you state anything, that's very,</p> <p>21 very broad. If we want to just focus on just the</p> <p>22 urinary tract or reproductive tract, for lack of a</p> <p>23 better phrase, there are hundreds of articles that warn</p> <p>24 against its use and the complications and the</p> <p>25 devastating nature of it. Do they come out and use that</p>
<p style="text-align: right;">Page 295</p> <p>1 urogynecology colleagues, what they use.</p> <p>2 Q. So the opinion in your report that</p> <p>3 polypropylene mesh in the Avaulta products degrades and</p> <p>4 is not inert, does that apply to polypropylene used in</p> <p>5 slings?</p> <p>6 A. Well, I think polypropylene has to be looked</p> <p>7 at the specifics of the product. From everything I have</p> <p>8 read and the literature that we have quoted,</p> <p>9 polypropylene, in the human body, degrades. I don't</p> <p>10 think that's even a point of discussion. We can go</p> <p>11 through the articles that talk about that.</p> <p>12 Q. Well, let me ask you a question. I don't mean</p> <p>13 to interrupt you. But let me ask you a question about</p> <p>14 what you just said. You're providing expert opinions in</p> <p>15 three plaintiffs' cases tomorrow, correct?</p> <p>16 A. I believe so, yes.</p> <p>17 Q. Did you see or observe any degradation in the</p> <p>18 polypropylene mesh they had implanted?</p> <p>19 A. Absolutely.</p> <p>20 Q. Okay. So we'll talk about -- we'll talk about</p> <p>21 that more tomorrow. Do you consider yourself to be an</p> <p>22 expert in the human body's response to polypropylene?</p> <p>23 A. As it pertains to implantation in the human</p> <p>24 body relative to female organ prolapse and incontinence,</p> <p>25 yes.</p>	<p style="text-align: right;">Page 297</p> <p>1 specific language? They probably don't use those exact</p> <p>2 words. But they will state over and over, and I can</p> <p>3 find those articles, that there is limited data to</p> <p>4 support their use.</p> <p>5 Q. Even though polypropylene-based products have</p> <p>6 been used for decades and decades in different medical</p> <p>7 device applications?</p> <p>8 A. Well, I'd have to ask, are those the same</p> <p>9 grade that's put through the vagina? Is it in contact</p> <p>10 with the vaginal flora, lacto- -- lactobacillus, does it</p> <p>11 have arms going through the vagina, through the</p> <p>12 obturator foramen, through the buttocks? So we have to</p> <p>13 be very, very specific in our question and the answer.</p> <p>14 Q. Is it your opinion that the specific grade of</p> <p>15 polypropylene in the Avaulta products has resulted in</p> <p>16 pain?</p> <p>17 A. Yes.</p> <p>18 Q. And what do you base that on?</p> <p>19 A. My experience of seeing patients in the</p> <p>20 clinic, my research on the data here of, you know, the</p> <p>21 national meetings, international meetings, talking with</p> <p>22 colleagues. Because it's not just my experience. It's</p> <p>23 also the experience of all of my urogynecology</p> <p>24 colleagues who arguably see more of this than I do. So,</p> <p>25 by all means, we see it, the pain.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 298</p> <p>1 Q. So maybe my question was bad, Doctor, but</p> <p>2 have -- what evidence or article can you point me to</p> <p>3 that specifically links up the use of polypropylene with</p> <p>4 pain? Do you understand my question?</p> <p>5 A. No. No, I do. If we want to go down -- you</p> <p>6 know, let's just say -- just here. I'm just looking at</p> <p>7 this, Clave, et al., polypropylene is not inert. That's</p> <p>8 an abbreviation of the title, okay, but he's going</p> <p>9 through the complications that happen. Complication is</p> <p>10 pain. Pain is a reflection of inflammation.</p> <p>11 Inflammation is a response to degradation. Okay. Mamy,</p> <p>12 et al., correlation between mesh shrinkage and infection</p> <p>13 of implanted synthetic meshes. And this is in the</p> <p>14 animal model. You know, yeah, there is an extensive</p> <p>15 amount.</p> <p>16 Q. All right. Well, let's look at that. You</p> <p>17 want to bring up Clave. Do you have a copy of Clave?</p> <p>18 A. Yes, I do.</p> <p>19 Q. Because when you talk about degrading and not</p> <p>20 being inert, you're citing specifically to Clave,</p> <p>21 correct?</p> <p>22 A. That was one of them. My expert report has,</p> <p>23 when we're talking about degradation of the product,</p> <p>24 Liebert, et al.; Ali, et al.; Zhong, et al.; Castello,</p> <p>25 et al.; Mamy, as I already mentioned; Smith, et al. --</p>	<p style="text-align: right;">Page 300</p> <p>1 fact, inert?</p> <p>2 MR. CARTMELL: Object to the --</p> <p>3 BY MS. GEIST:</p> <p>4 Q. Do you see that?</p> <p>5 MR. CARTMELL: Object to the form.</p> <p>6 BY THE WITNESS:</p> <p>7 A. I don't see. I vaguely remember what you're</p> <p>8 talking about. Yeah. It says, This study, however,</p> <p>9 brings into question the prevailing understanding of</p> <p>10 polypropylene as inert when it comes to transvaginal.</p> <p>11 Q. All right. So up --</p> <p>12 MR. CARTMELL: Are you --</p> <p>13 BY THE WITNESS:</p> <p>14 A. Now, you interrupted me.</p> <p>15 Q. Go ahead. No. I'm sorry. I didn't mean to.</p> <p>16 A. So this study --</p> <p>17 Q. I'm getting tired.</p> <p>18 A. -- is one of the landmark studies of saying,</p> <p>19 Wait a second, people. What we have been told, what is</p> <p>20 in the IFUs, what the industry has told us is actually</p> <p>21 not true. This thing is not inert. It is ert.</p> <p>22 Q. All right. So -- I'm sorry. Go ahead.</p> <p>23 A. It is active.</p> <p>24 Q. Right. So Clave is saying, in 2010, he's</p> <p>25 acknowledging that all of the studies that came before</p>
<p style="text-align: right;">Page 299</p> <p>1 again, we can go on -- white, et al. I have it in here.</p> <p>2 Q. Well, let's talk about Clave, first of all?</p> <p>3 MR. CARTMELL: Clave.</p> <p>4 BY MS. GEIST:</p> <p>5 Q. Clave, is it Clave?</p> <p>6 A. Clave, yeah. He's part of the French group.</p> <p>7 Q. Oh, I see that. It's Clave. Okay. So Clave</p> <p>8 in the article entitled, Polypropylene As a</p> <p>9 Reinforcement in Pelvic Surgery is Not Inert?</p> <p>10 A. Correct.</p> <p>11 Q. Colon, Comparative Analysis of 100 Explants,</p> <p>12 that's what we're talking about, correct?</p> <p>13 A. Correct.</p> <p>14 Q. And Clave notes that this is the first study</p> <p>15 to evaluate synthetic implants used in a vaginal</p> <p>16 approach for pelvic floor reinforcement; that's what it</p> <p>17 says?</p> <p>18 A. That is correct.</p> <p>19 Q. And this was published in 2010?</p> <p>20 A. Well, it was received in '09, published online</p> <p>21 January of '10.</p> <p>22 Q. And he admits, if you look in the conclusions</p> <p>23 part of the study, he admits, in his study, that there</p> <p>24 is quite considerable medical literature that has</p> <p>25 concluded and demonstrated that polypropylene is, in</p>	<p style="text-align: right;">Page 301</p> <p>1 found that polypropylene is inert, right?</p> <p>2 MR. CARTMELL: Object to form.</p> <p>3 BY THE WITNESS:</p> <p>4 A. No. That's not true. And even if that's what</p> <p>5 they state, you have papers in 1976, Liebert, et al.,</p> <p>6 talking about polypropylene degradation in their</p> <p>7 studies, White from 19-, also, the '70s. So they're</p> <p>8 saying this and specifically vaginal floor repair.</p> <p>9 And you have to look at the Ostergard's paper,</p> <p>10 I don't know when Ostergard's paper came out, talking</p> <p>11 about it is not inert, too. I don't know, again, when</p> <p>12 that one came out. That was 2011. Excuse me. So that</p> <p>13 was after that. So I don't think --</p> <p>14 Q. Okay. And you know what? That was my bad</p> <p>15 question.</p> <p>16 MR. CARTMELL: Were you done?</p> <p>17 BY MS. GEIST:</p> <p>18 Q. So let me -- let me state it again.</p> <p>19 His paper in 2010 is the first paper to</p> <p>20 provide contrary evidence that characterized</p> <p>21 polypropylene as inert in the context of its use in the</p> <p>22 vaginal application?</p> <p>23 A. Yeah. What they're stating here -- again, I</p> <p>24 have not gone back and looked at the dates of other</p> <p>25 studies that have come out. And Klosterhalfen and</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 302</p> <p>1 Klingele have studies, but that's in abdominal wall</p> <p>2 hernias. But I'll assume, which is never a good thing</p> <p>3 to do, that they are accurate in saying -- we're saying,</p> <p>4 hey, everybody, there is an issue here that we are</p> <p>5 unaware of. And I will trust that they're accurate, but</p> <p>6 they must have done a literature search.</p> <p>7 Q. Okay. And I should have been more precise.</p> <p>8 We're talking about polypropylene used in -- in the</p> <p>9 vagina as a method for pelvic floor reconstructive</p> <p>10 surgery. So that's what we're talking about?</p> <p>11 A. For transvaginal implantation, correct.</p> <p>12 Q. Yes. Okay. So Clave acknowledges that this</p> <p>13 is contrary to the evidence that has come before looking</p> <p>14 at that specific application, looking at polypropylene</p> <p>15 as being inert in the use of transvaginal mesh. He</p> <p>16 acknowledges that, correct?</p> <p>17 A. I'm sorry. Can you repeat the question or</p> <p>18 read it back?</p> <p>19 Q. Sure.</p> <p>20 A. I'm sorry.</p> <p>21 Q. I'll actually read it. Clave says, The study</p> <p>22 provides evidence contrary to published literature</p> <p>23 characterizing polypropylene as inert in such</p> <p>24 applications, and that's referring to synthetic implants</p> <p>25 used in a vaginal approach for pelvic floor</p>	<p style="text-align: right;">Page 304</p> <p>1 evidence for just the degradation cracking of the</p> <p>2 product, for lack of a better phrase.</p> <p>3 Q. He did a chemical analysis, which he referred</p> <p>4 to as FTIR, correct?</p> <p>5 A. Yeah. And that's a study just looking at --</p> <p>6 and it's oversimplified, but is something being</p> <p>7 released, is there information around it, those types of</p> <p>8 things.</p> <p>9 Q. Okay. And then he also did something he</p> <p>10 called DSC or differential scanning?</p> <p>11 A. Yeah. And, again, that -- that -- he's doing</p> <p>12 some pretty advanced stuff here, but he's just looking</p> <p>13 at the morphology of the polymer, of the polypropylene</p> <p>14 polymer -- sheesh, polypropylene polymer. Again, that's</p> <p>15 involved with degradation breakdown changing of the</p> <p>16 sub- -- of the material.</p> <p>17 Q. It's like a tongue twister today.</p> <p>18 A. I'll give that one. That's a tough one.</p> <p>19 Q. Now, two of his three tests that we just</p> <p>20 discussed did not actually show any degradation in this</p> <p>21 study, true?</p> <p>22 A. Again, I would have to look at the specifics</p> <p>23 of the study. If you support that as being true, I'll</p> <p>24 follow along with that.</p> <p>25 Q. Okay. Well, I'm happy to have you look at it,</p>
<p style="text-align: right;">Page 303</p> <p>1 reinforcement?</p> <p>2 A. Correct. I agree with that statement, yeah.</p> <p>3 Q. Okay. Thank you. I should have just read it</p> <p>4 from the beginning to make things simpler. Now, Clave,</p> <p>5 in this study, performed three types of tests, correct?</p> <p>6 A. I would have to go back and look at the</p> <p>7 specifics. I remember he did fairly exhaustive research</p> <p>8 on it, but I can't say it's three. Scanning, electron</p> <p>9 microscopy, chemical analysis, statistical analysis, and</p> <p>10 then infrared spectroscopy.</p> <p>11 Q. Yeah.</p> <p>12 A. So -- and a histological analysis, so he's</p> <p>13 done a lot more than just that.</p> <p>14 Q. All right. Well --</p> <p>15 A. He's done a lot.</p> <p>16 Q. Okay. He looked at 100 explants; is that</p> <p>17 correct, in this study?</p> <p>18 A. Yeah. Based upon the title, 100 explants.</p> <p>19 Q. Okay. And it's also in the body of the paper,</p> <p>20 right?</p> <p>21 A. Correct.</p> <p>22 Q. And it says -- let's see. I'm trying to use</p> <p>23 the acronyms. He performed the scanning electron</p> <p>24 microscopy, SEM, right?</p> <p>25 A. Correct. Yeah. That's looking for physical</p>	<p style="text-align: right;">Page 305</p> <p>1 but --</p> <p>2 A. I don't think you are, because it will take</p> <p>3 you a long time. This is a detailed paper. This is a</p> <p>4 big paper, so...</p> <p>5 Q. I hear you, but this is one of the main things</p> <p>6 that you cited in your expert report.</p> <p>7 A. Okay.</p> <p>8 Q. So I kind of thought you'd be prepared to talk</p> <p>9 about it?</p> <p>10 A. I am.</p> <p>11 MR. CARTMELL: Object to the form.</p> <p>12 BY THE WITNESS:</p> <p>13 A. I have written -- reviewed 509 papers, so I</p> <p>14 will now read this one then, and that's going to take</p> <p>15 some while, as per your permission.</p> <p>16 MR. CARTMELL: Please do.</p> <p>17 VIDEO TECHNICIAN: Is it okay if I go off real</p> <p>18 quick? I need a file break.</p> <p>19 MS. GEIST: Oh, yeah. Absolutely. That's a good</p> <p>20 idea, and then the doctor can have time to read the</p> <p>21 article.</p> <p>22 THE WITNESS: I'll stop reading. I'll read on</p> <p>23 camera.</p> <p>24 VIDEO TECHNICIAN: We're off the record. The time</p> <p>25 is 4:39 p.m.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 306</p> <p>1 (A recess was had.)</p> <p>2 VIDEO TECHNICIAN: We're back on the record. The</p> <p>3 time is 4:52 p.m.</p> <p>4 BY MS. GEIST:</p> <p>5 Q. Okay. Doctor, we were talking about the Clave</p> <p>6 article before we took a break, and I think you said you</p> <p>7 would need an opportunity to review the article in</p> <p>8 detail and in full before you could answer my question</p> <p>9 about whether two of his three tests did not show</p> <p>10 degradation?</p> <p>11 A. Correct.</p> <p>12 Q. Okay. In the interest of time, I'm going to</p> <p>13 move on and skip to a couple of other things I'd just</p> <p>14 like to point out to you in the article and ask if you</p> <p>15 considered them?</p> <p>16 A. Okay.</p> <p>17 Q. Okay. Did -- did you at all consider whether</p> <p>18 the degradation that was observed in one of the three</p> <p>19 tests that Clave performed was actually grooves in the</p> <p>20 biofilm?</p> <p>21 A. Well, I, by all means, considered the multiple</p> <p>22 different reasons for the possibility of a</p> <p>23 false-positive study. However, when you look at the</p> <p>24 actual photographs on page 265, I mean, it demonstrates</p> <p>25 fractures in it. That is not biofilm. That's a true</p>	<p style="text-align: right;">Page 308</p> <p>1 this. Subsequent there have been other authors talking</p> <p>2 about degradation.</p> <p>3 Q. Okay.</p> <p>4 A. So at that point in time, as being the first</p> <p>5 author, he's going to say there, We're trying to figure</p> <p>6 this thing out.</p> <p>7 Q. Right.</p> <p>8 A. So you have several possible etiologies of</p> <p>9 this.</p> <p>10 Q. Okay. But a hypothesis, Doctor, whether that</p> <p>11 term is used by a medical doctor, a scientist, a</p> <p>12 hypothesis, by definition, means something that is not</p> <p>13 proven, correct? It's an idea? It's a theory, but it's</p> <p>14 not proven; is that correct?</p> <p>15 A. Yeah. I mean, I think that's probably a fair</p> <p>16 assessment at that point in time when this was written.</p> <p>17 Yeah, there are several evolving theories as far as why</p> <p>18 this is occurring.</p> <p>19 Q. All right.</p> <p>20 A. And that's what they wrote in 2010.</p> <p>21 Q. Okay. And that's fair. So the paper is about</p> <p>22 theory. It's nothing that's proven?</p> <p>23 A. I disagree. They're not -- they're saying</p> <p>24 this product degrades, period. Why it degrades is up</p> <p>25 for discussion.</p>
<p style="text-align: right;">Page 307</p> <p>1 fracture.</p> <p>2 Q. Okay. So you considered but disagree with the</p> <p>3 thinking that the cracks or the grooves or the fractures</p> <p>4 could be the biofilm?</p> <p>5 A. Yes.</p> <p>6 Q. Is that fair?</p> <p>7 A. I'm sorry.</p> <p>8 Q. Yes?</p> <p>9 A. No. I agree with that, and I've heard that</p> <p>10 argument multiple different times. I think it's a</p> <p>11 legitimate argument to look at; however, when these are</p> <p>12 washed appropriately, I believe the data shows that that</p> <p>13 is not a result. So that is not causing a</p> <p>14 false-positive study.</p> <p>15 Q. Okay. Fair enough. So if you look at page</p> <p>16 269 of Clave under Conclusion --</p> <p>17 A. Okay.</p> <p>18 Q. -- under the third paragraph there, he notes,</p> <p>19 Several hypotheses persist concerning the nature of</p> <p>20 polypropylene in vivo degradation? Do you see that?</p> <p>21 A. Correct.</p> <p>22 Q. Is he right that there are several hypotheses</p> <p>23 that still persist?</p> <p>24 A. Well, I think in 2010 or whenever he wrote</p> <p>25 this -- remember, he's the first person to come out with</p>	<p style="text-align: right;">Page 309</p> <p>1 Q. But it didn't degrade using two of the three</p> <p>2 tests that Clave put the materials through?</p> <p>3 A. But it degraded in one of them at least.</p> <p>4 Q. On page 266 of his article, does he also</p> <p>5 state, in the second paragraph, several hypotheses</p> <p>6 concerning the degradation of the polypropylene are</p> <p>7 described below. None of these particular direct</p> <p>8 oxidation could be confirmed in this study. Does he</p> <p>9 also state that?</p> <p>10 A. I don't see where you are; however, I listened</p> <p>11 to what you had to say because I didn't know which</p> <p>12 column you were in. But, again, this is a landmark</p> <p>13 paper saying, Everybody, this product is not inert. It</p> <p>14 degrades. We're trying to figure out why.</p> <p>15 Q. Well, the why is sort of important, right,</p> <p>16 because the why would determine whether or not</p> <p>17 degradation would occur in a particular woman, for</p> <p>18 example?</p> <p>19 A. The why is very important. This one paper</p> <p>20 might not be able to answer all of the questions, and</p> <p>21 that's why I have to look at the totality of knowledge</p> <p>22 out there.</p> <p>23 Q. Did --</p> <p>24 VIDEO TECHNICIAN: Counsel, your mic.</p> <p>25 MS. GEIST: Sorry.</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 310</p> <p>1 BY MS. GEIST:</p> <p>2 Q. Did you look at any other articles looking at</p> <p>3 the Clave study, in particular?</p> <p>4 A. I'm sorry. Looking at -- did I look at the</p> <p>5 other articles in reference to the Clave?</p> <p>6 Q. Yeah. So did you look at it with any other --</p> <p>7 strike that.</p> <p>8 Did you look at any other papers that actually</p> <p>9 discussed the Clave article in particular?</p> <p>10 A. Well, I don't know if I could look at ones</p> <p>11 that discussed it. I would have to go back and look at</p> <p>12 each one and reference it. It's a very popular</p> <p>13 manuscript to go to. I mean, but the other ones,</p> <p>14 Ostergard looking at degradation; Coda, C-O-D-A;</p> <p>15 Costello; Cozad; Sternschuss, S-T-E-R-N-S-C-H-U-S-S --</p> <p>16 and the list goes on -- Ali, et al.; Zhong, et al. I</p> <p>17 don't know if I mentioned Costello or Mamy. But, I</p> <p>18 mean, there's like 20 -- if we keep going, 20 articles</p> <p>19 at least that are building upon Clave's original work.</p> <p>20 Q. Did -- did you look at the De Tayrac, and I</p> <p>21 may be pronouncing that wrong, the De Tayrac article</p> <p>22 from 2011 that actually looked at what Clave did?</p> <p>23 A. Yes. I looked at De Tayrac. He's written</p> <p>24 multiple articles.</p> <p>25 Q. I'm talking about the De Tayrac article</p>	<p style="text-align: right;">Page 312</p> <p>1 A. Yes. It should be in my report. I have a</p> <p>2 copy of it here with me. So I would assume so.</p> <p>3 Q. And De Tayrac, if you look at page -- I think</p> <p>4 it's 778. Again, it's one of those weird numbering</p> <p>5 things. 778 is on the fourth page of the De Tayrac</p> <p>6 article?</p> <p>7 A. Yes. I'm there.</p> <p>8 Q. Okay. And he notes, Using the same model of</p> <p>9 mesh infection, we also experimentally tested Clave's</p> <p>10 conclusion regarding a correlation between infection and</p> <p>11 polypropylene degradation. Do you see that?</p> <p>12 A. Yes, I do.</p> <p>13 Q. And then it goes on to describe what they</p> <p>14 actually did. They implanted polypropylene mesh in</p> <p>15 Wistar rats and the mesh were explanted and examined,</p> <p>16 correct?</p> <p>17 A. There we have to be more specific. They</p> <p>18 implanted it in an incisional abdominal hernia in the</p> <p>19 rats.</p> <p>20 Q. Okay. Fair enough. I'm trying to summarize.</p> <p>21 A. And inoculated it with E. coli, which all of</p> <p>22 those are very important factors in this.</p> <p>23 Q. And he concludes, at the end of that</p> <p>24 discussion, that they also observed signs of superficial</p> <p>25 degradation and transverse cracks, but these appeared to</p>
<p style="text-align: right;">Page 311</p> <p>1 entitled, Basic Science and Clinical Aspects of Mesh</p> <p>2 Infection in Pelvic Floor Reconstructive Surgery?</p> <p>3 A. Yes. I've looked at that one. I have that</p> <p>4 one.</p> <p>5 MS. GEIST: Okay. Let me mark it. And I have no</p> <p>6 idea where I am with exhibits, so maybe the court</p> <p>7 reporter can help me out.</p> <p>8 THE REPORTER: I think 20.</p> <p>9 MS. GEIST: I'm sorry?</p> <p>10 THE REPORTER: 20.</p> <p>11 MS. GEIST: 20, thank you.</p> <p>12 (Elliott Deposition Exhibit No. 20</p> <p>13 was marked for identification.)</p> <p>14 BY MS. GEIST:</p> <p>15 Q. Doctor, let me hand you the De Tayrac --</p> <p>16 sorry.</p> <p>17 A. I have a copy.</p> <p>18 Q. Let me toss it to you. Let me give a copy to</p> <p>19 counsel. Thank you. So you've heard of Dr. De Tayrac.</p> <p>20 You've read several of his articles I think you</p> <p>21 indicated?</p> <p>22 A. Yes. I know him by reputation at various</p> <p>23 different meetings.</p> <p>24 Q. And did you consider this particular paper in</p> <p>25 reaching your opinions relating to degradation?</p>	<p style="text-align: right;">Page 313</p> <p>1 concern only the biofilm with no effect on the implant</p> <p>2 thread itself?</p> <p>3 A. Yeah. And that's what the study found, which</p> <p>4 is, to me, completely immaterial, because, number one,</p> <p>5 it's not implanted in the vagina. They inoculated it</p> <p>6 with E. coli, which, to the best of my knowledge, does</p> <p>7 not produce hydrogen peroxide like lactobacillus, which</p> <p>8 is in the Sternschuss article saying that's the most</p> <p>9 common bacteria in women that produces hydrogen</p> <p>10 peroxide. So in this study here with E. coli, which is</p> <p>11 a rare bacteria in adult females' vaginas, that's what</p> <p>12 finding they had at 30 days.</p> <p>13 Q. Doctor, just so I understand your opinions,</p> <p>14 you don't have the same concern with polypropylene</p> <p>15 degradation when polypropylene materials are used in a</p> <p>16 midurethral sling application; is that correct?</p> <p>17 A. No. I don't think that is correct. I do</p> <p>18 have -- I don't use it in my practice anymore because of</p> <p>19 my concerns because of the complications I saw and</p> <p>20 because of the complications that have been referred in</p> <p>21 to me.</p> <p>22 Q. Okay.</p> <p>23 A. So I do have those concerns.</p> <p>24 Q. So you don't agree with the AUGS position</p> <p>25 statement regarding polypropylene midurethral slings and</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 314</p> <p>1 those slings being the gold standard for the treatment 2 of stress urinary incontinence? 3 A. I would have to look at exactly what the AUGS 4 said on that. I'm familiar. We looked at the one for 5 prolapse. I would have to look at the ones -- what they 6 said for stress incontinence. 7 Q. Well, before I show you that, let me just show 8 you what I'll mark as Exhibit 21. 9 (Elliott Deposition Exhibit No. 21 10 was marked for identification.) 11 BY MS. GEIST: 12 Q. A copy for counsel. This is one of your 13 publications, Doctor. This one was published in -- or 14 actually accepted for publication in the last year, 15 September of 2013, entitled Risk of Repeat 16 Anti-Incontinence Surgery Following Sling Release: A 17 Review of 93 Cases. Do you see that? 18 A. Yes, I do. 19 Q. And you note, in your conclusions, that sling 20 release remains an important treatment option in 21 patients with obstruction after anti-incontinence 22 surgery. Did I read that correctly? 23 A. I don't see where you are. It sounds correct. 24 Q. Sorry. I'm in the first page of the 25 conclusion in your report.</p>	<p style="text-align: right;">Page 316</p> <p>1 looked to see whether there were any issues with erosion 2 or adverse events after 17 years, after a woman had a 3 sling in place for 17 years, right? 4 A. For specifically for the TVT. 5 Q. Transvaginal mesh? 6 A. Correct. TVT is the product, transvaginal 7 tension-free mesh for incontinence. 8 Q. And there were no late-onset erosions or 9 adverse events reported in that study even at 17 years, 10 correct? 11 MR. CARTMELL: Objection. Misstates the evidence. 12 There was an erosion. 13 BY THE WITNESS: 14 A. I would -- I would have to look at the 15 manuscripts. I have reviewed them in the past; but as I 16 stated there, I think four Nilsson studies. 17 Q. Well, let's look at it together. 22, I think, 18 is the one I'm referring to. I'm sorry. I'm marking it 19 as Exhibit 22. 20 (Elliott Deposition Exhibit No. 22 21 was marked for identification.) 22 BY MS. GEIST: 23 Q. Just for the record, Exhibit 22 is the Nilsson 24 study published in 2008 entitled, Eleven Years 25 Prospective Follow-Up of the Tension-Free Vaginal Tape</p>
<p style="text-align: right;">Page 315</p> <p>1 A. Yeah. I agree with that. 2 Q. And you also state that only a small 3 percentage of patients require repeat anti-incontinence 4 surgery. Do you see that? 5 A. Yeah. It was 14 percent required a repeat. 6 It's debatable if you call that small or not, but that's 7 what we state there. 8 Q. That's what you state there, though, correct? 9 A. That is correct. 10 Q. And you also conclude, in this article, that 11 the synthetic sling remains a mainstay and an important 12 treatment option for women? 13 A. That's -- that's what we stated there, yes. 14 It is a -- it is still -- I think I can say this with 15 some accuracy. It is still the most common procedure 16 done for incontinence, but not in my practice it's not. 17 Q. Okay. But -- and that's -- we're talking 18 about a polypropylene-based sling, correct? 19 A. That is correct. 20 Q. And I assume you're also familiar with the 21 Nilsson study that looked at whether there were any 22 issues with a polypropylene-based sling after 11 years? 23 A. Oh, the Nilsson, yeah. There's -- he 24 published five, ten, 12, 15, and 17 years of TVT. 25 Q. Right. He actually went all the way out and</p>	<p style="text-align: right;">Page 317</p> <p>1 Procedure For Treatment of Stress Urinary Incontinence? 2 A. Yes. 3 Q. And under -- and the conclusions of this study 4 were that there were no late-onset adverse events found 5 and no case of tape erosion was seen. 6 A. That is -- that is what they state here, yes, 7 except this was -- came out in other depositions from 8 the medical director at Ethicon that they don't even 9 believe this was the TVT product. They can't vouch for 10 that. That's immaterial to what you're saying, but 11 that's an issue with this paper. But that's the 12 conclusion the authors came to. 13 Q. Is there -- and that sling, obviously, is 14 implanted transvaginally, correct? 15 A. Yes. We're talking apples and oranges as far 16 as the angle that's put in, the volume of mesh, the 17 tension that's put on the mesh. It's not going 18 transobturator. It's going suprapubic or retropubic 19 would be more accurate to say. 20 Q. So that's the reason why we can -- so that's 21 the reason why we don't see any degradation of that mesh 22 in your opinion? 23 MR. CARTMELL: Object to the form. 24 THE WITNESS: No. 25 MR. CARTMELL: This study didn't talk about</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 318</p> <p>1 degradation.</p> <p>2 BY MS. GEIST:</p> <p>3 Q. Right. Well, this study actually says there</p> <p>4 were no adverse event whatsoever, and you told me</p> <p>5 earlier that degradation results in all sorts of adverse</p> <p>6 events, including dyspareunia?</p> <p>7 A. Yeah. We have to -- let's go look at this</p> <p>8 study carefully. I never said there were no adverse</p> <p>9 events. There is less mesh put in. So we were not</p> <p>10 comparing apples to apples here. We're comparing a TVT</p> <p>11 procedure that's done transvaginal with a plastic sheath</p> <p>12 over it versus Avaulta. So we can't -- there is no</p> <p>13 correlation to Avaulta with this.</p> <p>14 With this one, as far as complications, I</p> <p>15 would have to look at the study. They talk about cure</p> <p>16 rate, which is one aspect as far as complications.</p> <p>17 Again, I would have to look at all that they state. If</p> <p>18 there is an erosion or an extrusion, that's a</p> <p>19 complication.</p> <p>20 Q. Agreed. And I'm reading from the study at</p> <p>21 page 1046 and it says, It is therefore reassuring that</p> <p>22 we do not find a single case of tape erosion, tissue</p> <p>23 reactions, or other adverse events during, at the most,</p> <p>24 up to 13 years of follow-up.</p> <p>25 A. I don't see exactly where you are, but that's</p>	<p style="text-align: right;">Page 320</p> <p>1 Q. Okay. And the position paper put out by these</p> <p>2 groups states, at the top, the polypropylene mesh</p> <p>3 midurethral sling is the recognized worldwide standard</p> <p>4 of care for the surgical treatment of stress urinary</p> <p>5 incontinence. The procedure is safe, effective, and has</p> <p>6 improved the quality of life for millions of women. Do</p> <p>7 you agree with that?</p> <p>8 A. Well, let's take it sentence by sentence. The</p> <p>9 polypropylene mesh midurethral sling is the recognized</p> <p>10 worldwide standard of care in the surgical treatment of</p> <p>11 stress urinary incontinence. I think that is somewhat</p> <p>12 debatable. It is, I think, no question probably the</p> <p>13 most common implantation done now. Many in the society</p> <p>14 don't use meshes anymore. We are a member of the</p> <p>15 society. So it doesn't mean that everybody is in</p> <p>16 support of it, but I can argue that it is the most</p> <p>17 common procedure done.</p> <p>18 The procedure is safe, effective, and improved</p> <p>19 the quality of life for millions of women. I can't</p> <p>20 necessarily argue with that. However, what it doesn't</p> <p>21 also say is the complications that have been seen.</p> <p>22 Millions of women may have been benefitted, but how many</p> <p>23 have been injured?</p> <p>24 So, you know, the way they state it, that's --</p> <p>25 yeah, I can -- it states what it states. How could they</p>
<p style="text-align: right;">Page 319</p> <p>1 okay. That's the findings of these authors relative to</p> <p>2 a possible TVT with plastic sheaths over the arms in a</p> <p>3 different route that's put in compared to Avaulta, but</p> <p>4 that's what these findings are.</p> <p>5 Q. You said you wanted to see the position</p> <p>6 statement on mesh midurethral -- midurethral slings or</p> <p>7 stress urinary incontinence?</p> <p>8 A. Well, I said, if we're going to talk about it,</p> <p>9 I want to see it.</p> <p>10 Q. Okay. Let me show it to you briefly. I'm</p> <p>11 trying to move along. I think I'm up to 23.</p> <p>12 (Elliott Deposition Exhibit No. 23</p> <p>13 was marked for identification.)</p> <p>14 BY MS. GEIST:</p> <p>15 Q. This statement, Doctor, was put out as a joint</p> <p>16 position statement by both AUGS and SUFU, which you've</p> <p>17 mentioned a few times before. That's the Society of</p> <p>18 Urodynamics Female Pelvic Medicine and Urogenital</p> <p>19 Reconstruction, correct?</p> <p>20 A. Correct, which I'm a member of and sit on the</p> <p>21 education committee.</p> <p>22 Q. And you're a member of both of these</p> <p>23 societies, correct?</p> <p>24 A. Correct. I don't have any leadership role in</p> <p>25 AUGS, though.</p>	<p style="text-align: right;">Page 321</p> <p>1 show me data? Do we have the studies on millions of</p> <p>2 women? No. We have the studies, you know, a hundred</p> <p>3 here and a hundred there. So there is no data to</p> <p>4 support it's helped millions of people. Millions have</p> <p>5 been sold.</p> <p>6 Q. So you think the statement put out by AUGS and</p> <p>7 SUFU is a formal position statement and it's not based</p> <p>8 on data?</p> <p>9 A. Well, show me the data. Show me where a study</p> <p>10 with millions of women.</p> <p>11 Q. Well, we just looked at the Nilsson study,</p> <p>12 which looked at women who had slings implanted and</p> <p>13 looked at women not 17 years later, correct?</p> <p>14 A. Mm-hmm.</p> <p>15 MR. CARTMELL: No. We didn't look at the 17-year</p> <p>16 study.</p> <p>17 MS. GEIST: Oh, we looked at the 11-year study?</p> <p>18 MR. CARTMELL: Right.</p> <p>19 MS. GEIST: Sorry.</p> <p>20 MR. CARTMELL: And the reason I objected is because</p> <p>21 the 17-year shows the erosion. I just didn't want it to</p> <p>22 look like I was trying to jack with you.</p> <p>23 MS. GEIST: That's fine.</p> <p>24 BY THE WITNESS:</p> <p>25 A. Yes. That study, in a very high-volume center</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 322</p> <p>1 of an individual who was involved with the inventor of</p> <p>2 the TVT and arguably one of the best surgeons in the</p> <p>3 world for this, that is the results that they have</p> <p>4 found. But that does not correlate to everybody else's</p> <p>5 results.</p> <p>6 Q. Well, how about the Mayo Clinic? Doesn't the</p> <p>7 Mayo Clinic discuss sling procedures and actually state</p> <p>8 that using surgical mesh is a safe and effective way to</p> <p>9 treat stress urinary incontinence?</p> <p>10 A. I would have to look at -- but, again, I</p> <p>11 didn't write that article. I don't use -- no one in</p> <p>12 urology uses mesh slings.</p> <p>13 Q. Who is Dr. John Ochino, O-C-H-I-N-O?</p> <p>14 A. He is a urogynecologist.</p> <p>15 Q. Is he with Mayo?</p> <p>16 A. Yes.</p> <p>17 Q. And he's a colleague of yours?</p> <p>18 A. Well, he's in urogynecology.</p> <p>19 Q. Has -- have you seen his YouTube video where</p> <p>20 he states that sling procedures to treat stress urinary</p> <p>21 incontinence are safe and effective and have minimal</p> <p>22 risk associated with mesh complications?</p> <p>23 A. I have not seen his video, no.</p> <p>24 Q. At least as of last year, though, Doctor,</p> <p>25 referring back to your own article that we looked at</p>	<p style="text-align: right;">Page 324</p> <p>1 (Elliott Deposition Exhibit No. 24</p> <p>2 was marked for identification.)</p> <p>3 BY MS. GEIST:</p> <p>4 Q. Do you recognize this article,</p> <p>5 Doctor?</p> <p>6 A. Yes.</p> <p>7 Q. I'm trying to give a copy to counsel.</p> <p>8 MR. CARTMELL: Thanks.</p> <p>9 BY MS. GEIST:</p> <p>10 Q. This is one of the articles you mentioned to</p> <p>11 me earlier, Doctor, when we talked about some of your</p> <p>12 review of the different types of meshes available in the</p> <p>13 sling surgery?</p> <p>14 A. Yes. That's correct.</p> <p>15 Q. And this is an animal study, correct?</p> <p>16 A. Yeah. It's a rabbit study we did.</p> <p>17 Q. And this was published back in 2003?</p> <p>18 A. Excuse me, with work starting in 2001 or so,</p> <p>19 yes.</p> <p>20 Q. And you looked at slings of different types of</p> <p>21 materials, including polypropylene slings, correct?</p> <p>22 A. That is correct.</p> <p>23 Q. And each rabbit had different types of slings</p> <p>24 implanted? Some of these were autologous and some were</p> <p>25 synthetic?</p>
<p style="text-align: right;">Page 323</p> <p>1 before, the risk of repeat anti-incontinence surgery --</p> <p>2 A. Yes.</p> <p>3 Q. -- you stated, in that article, that synthetic</p> <p>4 slings remain an important treatment option for women</p> <p>5 experiencing stress urinary incontinence, correct?</p> <p>6 A. Yeah. But that's not -- that's just stating</p> <p>7 that it is used frequently. That's all that is stating.</p> <p>8 Q. Well, it says it remains an important option.</p> <p>9 Do you disagree with that, that it should be offered as</p> <p>10 an option?</p> <p>11 A. It is an option. I don't do it, but it is an</p> <p>12 option out there.</p> <p>13 Q. And certainly you wouldn't say that the</p> <p>14 doctors who offered that option are not performing</p> <p>15 according to the standard of care, would you?</p> <p>16 A. No, I'd say --</p> <p>17 MR. CARTMELL: Object to the form.</p> <p>18 BY THE WITNESS:</p> <p>19 A. I would say that the pendulum is swinging</p> <p>20 anti-mesh. And so right now they're being done. What's</p> <p>21 going to happen a few years from now, I don't know. The</p> <p>22 same thing with pelvic organ prolapse.</p> <p>23 Q. Let me show you, Doctor, one of your other</p> <p>24 articles that I thought was of interest. I think I'm up</p> <p>25 to 24.</p>	<p style="text-align: right;">Page 325</p> <p>1 A. Yes. We put in human, cadaveric, porcine,</p> <p>2 polypropylene, porcine dermis, SIS. We put, as I</p> <p>3 recall, five.</p> <p>4 Q. And you note in this study that the results of</p> <p>5 this study support the use of polypropylene mesh for</p> <p>6 sling surgery relative to other nonautologous materials,</p> <p>7 correct?</p> <p>8 A. Yes. And this is a very good one. I'm glad</p> <p>9 you brought that up because this is a study we did very</p> <p>10 early on looking at the product and issues. And we</p> <p>11 raised issues in the discussion that polypropylene mesh</p> <p>12 gained stiffness with time. At that point in time, we</p> <p>13 thought that was a good thing, and that's what we wrote</p> <p>14 in our conclusion. But this is in 2003.</p> <p>15 Q. Right.</p> <p>16 A. Sine there's been a vast amount of data</p> <p>17 gathered we're actually realizing that's not a good</p> <p>18 thing.</p> <p>19 Q. And, in your own words, as you've just</p> <p>20 indicated, in this study, you say, More important than</p> <p>21 tensile strength is material stiffness. The stretching</p> <p>22 of the suburethral sling with time is a much more likely</p> <p>23 scenario than breakage and it may be partly responsible</p> <p>24 for the reemergence of symptoms following a successful</p> <p>25 anti-incontinence procedure. So, in other words, you</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 326</p> <p>1 conclude from this study that the stiffness seen in 2 polypropylene mesh is a positive or a good thing? 3 A. Yeah. And, at that point in time, I agree. 4 And I stand by the arguments that we proposed here. But 5 what we originally thought, and individuals like Chris 6 Winters, when he came to Mayo, raised this as one of the 7 early papers describing the mesh problems. We had our 8 facts correct. Our interpretation of those facts I 9 would have to say, in the 12-week model, was not 10 correct. 11 Q. Well, what about your investigation in the 12 same study, Doctor, regarding the issue of shrinkage. 13 You looked specifically at the issue of shrinkage with 14 polypropylene mesh in this study, correct? 15 A. That is correct. In the 12-week 16 transabdominal model in a rabbit, we did. 17 Q. And you concluded, from this study, that 18 polypropylene mesh did not demonstrate a significant 19 decrease in surface area compared to the other sling 20 types; in other words, no shrinkage per your own study, 21 correct? 22 A. Yeah. At 12 weeks, in the rat model -- excuse 23 me, in the rabbit model without the contamination in the 24 vagina. I think others have come along and shown that 25 our data does not correlate to other things.</p>	<p style="text-align: right;">Page 328</p> <p>1 it's needed for the body to heal? 2 A. I don't know of any that scarring and 3 contraction is actually a good thing. Heart valves 4 can't do that. I mean -- so, no, I don't know of any. 5 Q. So I just want to make sure I understand. 6 It's part of the body's normal healing process. You 7 disagree that scarring and inflammation is part of the 8 normal process that the body goes through to heal itself 9 after surgery when a device is implanted? 10 MR. CARTMELL: Object to the form. 11 BY THE WITNESS: 12 A. Well, the body's natural response is to heal 13 itself and to decrease inflammation. It is normal with 14 any surgery to have that to a certain extent that then 15 heals up and finishes and that process stops. It is 16 abnormal for that process to continue on. 17 Q. You looked at inflammation specifically with 18 polypropylene mesh in another one of your studies, 19 correct? 20 A. That is correct. 21 Q. And you looked at inflammation and scar 22 formation, true? 23 A. Correct. 24 Q. And didn't you conclude in that study that the 25 inflammation and scar formation seen, after the</p>
<p style="text-align: right;">Page 327</p> <p>1 Q. Well, flipping quickly to that issue, 2 shrinkage or contraction, that's one of the opinions in 3 your report? 4 A. Yes. 5 Q. I assume you would agree with me that there is 6 a normal amount of contraction and shrinkage after a 7 medical device is implanted due to the normal and 8 expected healing process? 9 MR. CARTMELL: Object to the form. 10 BY THE WITNESS: 11 A. Well, you say a medical device. Certain 12 medical devices have no contraction. 13 Q. Well, it's not atypical or abnormal or 14 unexpected to see contraction and scarring after a 15 medical device is implanted; is that true? 16 MR. CARTMELL: Object to the form. 17 BY MS. GEIST: 18 Q. The wound healing process needs scarring and 19 inflammation. It's part of the normal process? 20 MR. CARTMELL: Object to the form. 21 BY THE WITNESS: 22 A. I disagree. Artificial hips don't have any 23 contraction. 24 Q. Are there many medical devices that do have 25 scarring and inflammation after they're implanted and</p>	<p style="text-align: right;">Page 329</p> <p>1 polypropylene mesh was implanted, was actually a good 2 thing and helped the in-tissue growth process? 3 A. Our conclusions that we reached in 2006, on 4 that specific study, we attributed that. We thought 5 that was a good thing. I have subsequently been proven 6 wrong. 7 Q. Well, in your own -- let's just mark it 8 quickly so we know what we're talking about. I think 9 I'm up to 24. 10 MR. CARTMELL: 5. 11 MS. GEIST: 5, but who's counting. 12 (Elliott Deposition Exhibit 25 was 13 marked for identification.) 14 MR. CARTMELL: Man, you've used a lot of exhibits. 15 MS. GEIST: Well, I think it's helpful to look at 16 what you're talking about. 17 BY MS. GEIST: 18 Q. Doctor, here is Exhibit 25. This is another 19 one of your studies that we mentioned earlier entitled, 20 Time-Dependent Variations in Inflammation and Scar 21 Formation of Six Different Pubovaginal Sling Materials 22 in the Rabbit Model. So, again, this is another animal 23 study looking at different types of sling materials, 24 including polypropylene sling after implantation, 25 correct?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 330</p> <p>1 A. Yeah, in a 12-week model. I think we had six 2 weeks and 12 weeks. So, roughly, three months. 3 Q. And you conclude from the study that 4 polypropylene mesh compared to the other types of meshes 5 that you looked at in this study had low inflammation, 6 correct? 7 A. Yeah. The high fibrosis and low inflammation 8 in the rabbit transabdominal model at 12 weeks. 9 Q. And you conclude that not only did 10 polypropylene mesh have lower inflammation than the 11 other materials you've looked at, but that the fibrosis 12 and scarring noted with polypropylene mesh may also 13 contribute to a more lasting repair? 14 A. That was our conclusion. And then I go on and 15 warn, Urologists performing this procedure should be 16 aware of the time-dependent tissue reactions when 17 choosing a sling material. As I mentioned, we had -- we 18 reached certain conclusions, which, now, I think are 19 actually incorrect. And it's been pointed out by other 20 authors that we had our facts right, our interpretation 21 wrong. 22 Q. Well, you said -- you said a couple of times 23 that these studies were done in rabbits, correct? 24 A. Correct. 25 Q. Would you agree with me that it would be more</p>	<p style="text-align: right;">Page 332</p> <p>1 If you look with me at it quickly, Doctor, Dietz 2 actually looked at the issue and phenomenon of mesh 3 contraction or shrinkage by looking at the mesh via 4 ultrasound and concluded that there was no contraction 5 after 18 months? 6 A. That is what this one study states. But if 7 you look at my actual report, I've got a list of 12 or 8 15 articles that state opposite to that. 9 Q. Well, you didn't consider this study in 10 forming your opinions relating to mesh contraction and 11 shrinkage; is that fair to say? 12 A. That is -- 13 MR. CARTMELL: Objection to form. Go ahead. 14 BY THE WITNESS: 15 A. That is -- that is true. 16 Q. Did you look at Bard's soft mesh study in 17 forming your opinions? 18 A. I don't know what study that is. 19 Q. Did you look at the Pierce study? It showed a 20 shrinkage of less than 10 percent? 21 MR. CARTMELL: With Avaulta? 22 MS. GEIST: You're asking me a question? 23 MR. CARTMELL: Yeah. 24 BY THE WITNESS: 25 A. Piece, Biomechanical Properties of Synthetic</p>
<p style="text-align: right;">Page 331</p> <p>1 important to see what's actually going on in the human 2 body? The best way to do this is to look into the body 3 in vivo, see what's going on? 4 A. Well, I mean that would be the ideal is 5 actually what happens when it's implanted in women. 6 Q. Did -- did you consider, in reaching your 7 opinions relating to contraction and shrinkage, the 8 Dietz study? 9 A. The Dietz study? 10 Q. Yeah. 11 A. I don't recall. I'd have to look at that. I 12 do not recall that name. D-I-E? 13 Q. D-I-E-T-Z? 14 A. Mechanical Properties of Urogynecologic 15 Implants. 16 Q. No. Dietz is the European urogynecologist, 17 and he published a study entitled, Mesh Contraction: 18 Myth Or Reality. Did you review that? 19 A. Okay. I do not have that in -- on my list of 20 ones I reviewed. I'd be happy to take a look at it, 21 though. 22 (Elliott Deposition Exhibit No. 26 23 was marked for identification.) 24 BY MS. GEIST: 25 Q. I'll be happy to hand it to you. Here you go.</p>	<p style="text-align: right;">Page 333</p> <p>1 and Biologic Graft Materials. Is that the article 2 you're referring to? 3 Q. No. I'm referring to Piece, 120-day 4 Comparative Analysis -- 5 A. Okay. 6 Q. -- Of Adhesion Grade and Quantity Mesh 7 Contraction and Tissue Response? 8 A. No. I have not seen that article. 9 MS. GEIST: How much time on the video? 10 VIDEO TECHNICIAN: 6 hours, 43. 11 THE WITNESS: Half and half. The half and half, 12 it's right in the cup. Sorry. Sorry. 13 BY MS. GEIST: 14 Q. Doctor, one of the -- one of the opinions you 15 set forth in your report is that the blind passage of 16 the trocar used to implant the Avaulta products is 17 unsafe, correct? 18 A. That is correct. 19 Q. Are there any other procedures that you, as a 20 urologist or a urogynecologist or a gynecologist, 21 perform in women that are considered to be blind, blind 22 passage; in other words, you have to use palpation? 23 A. Not to the extent and the distance of these. 24 Q. But you still use procedures or engage in 25 procedures that would be considered to be blind passage</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 334</p> <p>1 such as a D&C, for example?</p> <p>2 A. I don't do D&Cs.</p> <p>3 Q. All right. So gynecologists do D&Cs, correct?</p> <p>4 A. Some of them do, I suppose.</p> <p>5 Q. Do you understand that they need to use</p> <p>6 palpation in order to apply the correct amount of</p> <p>7 tension or pressure on the needle?</p> <p>8 A. I've never performed one, so I can't speak to</p> <p>9 that.</p> <p>10 Q. Can you give me any other examples or</p> <p>11 procedures that you may have performed that are</p> <p>12 considered to be a blind procedure or, in other words,</p> <p>13 where you need to use palpation?</p> <p>14 A. Not anymore.</p> <p>15 Q. What about the robotic procedures that you</p> <p>16 perform? Are those not considered to be blind</p> <p>17 procedures in some respect?</p> <p>18 A. It's all under direct vision.</p> <p>19 Q. What about the laparoscopic procedures that</p> <p>20 we've talked about?</p> <p>21 A. Again, that's all under direct vision.</p> <p>22 Q. What about the sacrospinous?</p> <p>23 A. Sacrospinous fixation, I don't -- I don't</p> <p>24 perform that procedure.</p> <p>25 Q. Did you ever perform it?</p>	<p style="text-align: right;">Page 336</p> <p>1 needle right onto it, so...</p> <p>2 Q. Well, you've recently done some work in</p> <p>3 developing innovations in autologous sling procedures,</p> <p>4 correct?</p> <p>5 A. Autologous transobturator sling.</p> <p>6 Q. And I'm referring to your case report that was</p> <p>7 published just this year?</p> <p>8 A. Correct.</p> <p>9 Q. And to implant that autologous sling, you used</p> <p>10 a trocar, correct?</p> <p>11 A. And it would be passed 5 millimeters to,</p> <p>12 perhaps, 1 centimeter onto your finger behind the</p> <p>13 obturator bone.</p> <p>14 Q. So that's a good example of a blind passage,</p> <p>15 agree? It's a blind passage procedure using the trocar,</p> <p>16 true?</p> <p>17 A. To a minor degree, yes, that is going to be</p> <p>18 blind because it's going to be passing it 5 millimeters</p> <p>19 to 1 centimeter.</p> <p>20 Q. And you consider that to be an innovation and</p> <p>21 another option that you could offer for women suffering</p> <p>22 from stress urinary incontinence, true?</p> <p>23 A. Yeah. That is -- that is an evolving option.</p> <p>24 We are the world's first to do that. We have to have</p> <p>25 the data pan out to see if it's going to be a viable</p>
<p style="text-align: right;">Page 335</p> <p>1 A. I performed them as a fellow under the staff</p> <p>2 guidance. However, the staff never let me pass the</p> <p>3 needles through the sacrospinous. Even with that it's a</p> <p>4 small degree of passage. But he didn't feel it was safe</p> <p>5 for someone learning to do, so I never did pass it.</p> <p>6 Q. Well, but some doctors do it. It goes through</p> <p>7 the deepest recesses of the vagina; isn't that true?</p> <p>8 A. Yeah. But that's with a Capio needle.</p> <p>9 Q. Right.</p> <p>10 A. And you're passing it, perhaps, 2 centimeters,</p> <p>11 maybe, with your finger back there. That's different</p> <p>12 than passing a trocar through the obturator foramen or</p> <p>13 larger passages of several centimeters. It's over 5, 10</p> <p>14 centimeters. That's different.</p> <p>15 Q. Okay. So you'll agree with me it's considered</p> <p>16 a blind procedure because it's done by palpation, but</p> <p>17 it's less than the amount of -- strike that.</p> <p>18 You'll agree with me it's a blind procedure</p> <p>19 because there is some portion of it where you would need</p> <p>20 to use palpation only?</p> <p>21 A. No. I can't necessarily. I mean, there is a</p> <p>22 minor passage of a minor distance. So very strictly</p> <p>23 defining it as that, yes. But, again, we're not talking</p> <p>24 of 10 centimeters of blind passage. And with a Capio</p> <p>25 needle, your finger is back there and you just pass the</p>	<p style="text-align: right;">Page 337</p> <p>1 option. It appears to be, though.</p> <p>2 Q. Sure. It's a novel technique, as you state in</p> <p>3 your own case report, but it is used with a trocar and a</p> <p>4 blind passage?</p> <p>5 A. With the caveat that it is a 5 millimeter to,</p> <p>6 perhaps, 1 centimeter of passage right down onto your</p> <p>7 finger.</p> <p>8 Q. Okay.</p> <p>9 A. So it is minimal.</p> <p>10 Q. I'm running out of time here, Doctor, so I'm</p> <p>11 going to try and wrap it up as fast as I can.</p> <p>12 Let me ask you some questions about pore size.</p> <p>13 Pore size is one of the opinions in your report that the</p> <p>14 pore size of the Avaulta products was inadequate to</p> <p>15 promote proper tissue ingrowth?</p> <p>16 A. Correct.</p> <p>17 Q. What do you believe or define as optimal pore</p> <p>18 size in a mesh product?</p> <p>19 A. According to my review of the literature, my</p> <p>20 experience of taking care of complications in patients,</p> <p>21 I believe that the pore size ranging between 4</p> <p>22 millimeters or so is going to be a lower chance of</p> <p>23 complications.</p> <p>24 Q. Is there a consensus in the literature as to</p> <p>25 what the optimal pore size should be?</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 338</p> <p>1 A. I believe there is based upon the literature 2 out there, that because the pore size as it's taken out 3 of the box does not correlate to the pore size once it's 4 in the women when there's contraction. 5 Q. You've never designed a mesh product; is that 6 correct, Doctor? 7 A. I've been involved in consulting with 8 Coloplast -- excuse me, AMS on theirs, but I'll leave it 9 at that. 10 Q. Have you ever designed a mesh product? 11 MR. CARTMELL: Object to the form. Asked and 12 answered. 13 BY THE WITNESS: 14 A. Yeah. I've been a consultant on their mesh 15 and their design. 16 Q. On the design specifically? 17 A. The shape, the length of it. 18 Q. How about the pore size? 19 A. Pore size, I was not involved specifically in 20 the pore size of this product, no. 21 Q. Have you ever done a study looking at pore 22 size and its impact on tissue integration? 23 A. I have relied on the work of others as 24 outlined in my expert report. 25 Q. Can you point to me, Doctor, any study that</p>	<p style="text-align: right;">Page 340</p> <p>1 A. Yes, I do. 2 Q. And I think I counted in this these pages that 3 you said Bard failed to do any number of things, but I 4 think you said Bard failed to do something about 36 5 times from pages 35 to 38. Does that seem like a fair 6 estimate? 7 A. Well, without counting it up, just that seems 8 a little bit high, but I wouldn't be surprised. 9 Q. There is no citations anywhere to any 10 authority for your opinions about what Bard did or 11 didn't do or warned or should have warned of in this 12 section of the report, true? 13 A. I guess I don't know what you mean citations. 14 I mean, what I have down here is, in my understanding of 15 labeling and warnings and regulations, that Bard is 16 responsible for warning about complications. And so, 17 you know, we could go through each one of those 18 complications and find a manuscript that discusses it. 19 And so I have depositions here talking about them. So I 20 guess I disagree that there's -- there are references 21 listed. 22 Q. You don't consider yourself to be an expert in 23 terms of what a label should and should not say, do you, 24 Doctor? 25 MR. CARTMELL: Object to the form.</p>
<p style="text-align: right;">Page 339</p> <p>1 has demonstrated that a pore size of greater than 2.0 2 millimeters is superior to a 1.0- or 1.3-millimeter pore 3 size in a mesh? 4 A. I think when you look at Cobb's study, 5 Klinge's study, looking at various different pore 6 sizes, that -- and probably also Klinge and also 7 looking at the internal documents with Bard where they 8 acknowledge that the pore size has to be larger. 9 Q. Are you referring to the Bobbie Orr memo 10 that's cited in your report? 11 A. Yeah. What's cited there, yes, Dr. Ross. 12 Q. Did you read that memo in its entirety? 13 A. Yes. 14 Q. The memo says that the -- what's proposed by 15 Mr. Orr is a hypothesis, does it not? 16 A. I would have to see it, because I don't have 17 that document with me. I've read it, but I don't have 18 the document with me. 19 Q. Let me quickly go to the section of your 20 report, Doctor, if you could, with me. Go to the end. 21 On page 35 of your report, page 35 to 39, Doctor -- 22 A. Yes. 23 Q. -- this section of your report relates to your 24 opinions that Bard failed to disclose pertinent risk 25 information; do you see that?</p>	<p style="text-align: right;">Page 341</p> <p>1 BY THE WITNESS: 2 A. No. I disagree with that. Based upon -- 3 based upon my experience in dealing with patients for 20 4 years, dealing with IFUs, handing out patient brochures, 5 I can count up 20 or so different products that I've 6 used the IFU, being a researcher, talking about 7 complications in my manuscripts which you have listed, 8 being on the SUFU Board of Education where we talk 9 about warnings, asked to be speaking 10 nationally/internationally, no, everything I do is about 11 warnings. What I talk to my patients about, the 12 complications I have to see is all about warnings. 13 Q. Have you ever participated in the drafting of 14 an instruction for use or directions for use for any 15 medical device product? 16 MR. CARTMELL: Okay. Hold on. I think we're at 17 seven hours according to the -- we're not yet? Okay. 18 VIDEO TECHNICIAN: About five and a half minutes 19 left. 20 MR. CARTMELL: Five and a half minutes left. 21 You're in good shape. 22 MS. GEIST: Oh, yeah. I'm in great shape. 23 BY MS. GEIST: 24 Q. Can you answer that question, Doctor? 25 A. And the question -- let me reiterate it to</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 342</p> <p>1 make sure I've got it correct. Have I ever been 2 involved in the drafting of an IFU? I have been 3 involved in the discussions about complications that can 4 go on IFUs. I have not sat down and written an IFU. 5 Q. You've never drafted a label or an IFU for a 6 medical device company, true? 7 A. I have not. In your specific limitations, I 8 have never sat down with a company and written up 9 specifically an IFU. 10 Q. Are you an expert in the regulations relating 11 to what IFUs should contain or not contain? 12 A. Yes. 13 Q. You are? 14 A. Yes. 15 Q. What are those regulations? 16 A. Those regulations are that every -- every 17 known complication, regardless of severity or frequency, 18 need to be reported on an IFU. 19 Q. So you looked at the Bard IFUs, right? 20 A. Yes. 21 Q. And there is, in the adverse event section, a 22 warning relating to erosion, correct? 23 A. Yeah. I would like to see that IFU, because I 24 have to see all of the IFUs, including the original one. 25 So I would have to look at that. I don't have those</p>	<p style="text-align: right;">Page 344</p> <p>1 frequency. Provide frequency data from adequately 2 reported clinical studies. 3 Q. That wouldn't apply to a product that was 4 cleared by FDA through the 510(k) process, would it? 5 MR. CARTMELL: Object to the form and misstates the 6 evidence. 7 BY THE WITNESS: 8 A. Well, absolutely. I mean, the 510(k) is just 9 merely a clearance. It's not an approval of the safety 10 of that product. And so I cannot speak to what 11 information, all the FDA was given and all of the 12 discussions that was going on. But when I read over the 13 IFU, that is what doctors are going to be reviewing, I 14 don't see in there, based upon the FDA Blue Book, 15 adverse reaction, descending order, and provide 16 frequency data. 17 Q. No. But you just referred to clinical 18 studies, and those are not required through the 510(k) 19 clearance process. You understand that, correct? 20 A. However, with the 522 where the FDA came back 21 to all of the manufacturers of kits saying, You need to 22 provide us with adequate data, none of those companies, 23 including Bard, could come up with that data and decided 24 to pull their product off the market. 25 Q. I think what actually the FDA said was, in</p>
<p style="text-align: right;">Page 343</p> <p>1 IFUs with me. 2 Q. You don't remember sitting here now talking 3 about these sorts of issues that we've been talking 4 about all day, whether Bard warned of erosion in the 5 IFUs for the Avaulta products? 6 A. Well, no. That's why we have to go back to my 7 expert report and what I've talked about. The failure 8 to warn to the extent and the severity and the lifelong 9 nature of that, I never saw anything in there to support 10 that. 11 Q. What regulation says you need to do that? 12 A. Well, based upon the FDA regulations as far as 13 everything needs to be warned about and the severity and 14 the frequency of it. 15 Q. What FDA regulation are you referring to? 16 A. Based upon the FDA Blue Book. 17 Q. Can you give me the particular regulation or 18 the cite? 19 A. Yeah. FDA Blue Book started in March of 1991, 20 but updated -- this one is a 3/11/13. It's the guidance 21 for labeling, contraindications of warnings, an adverse 22 reaction is an undesirable effect, all of these have to 23 be reported. Adverse reactions should be listed in 24 descending order according to their clinical 25 significance determined upon their severity and</p>	<p style="text-align: right;">Page 345</p> <p>1 order to continue marketing and selling the products, 2 you need to engage in clinical trials at this time? 3 A. Absolutely, and they did not have it. 4 Q. They did not proceed with the clinical trials, 5 correct? 6 A. Because they did not have that data. 7 Q. No. They didn't do it? 8 A. But I'm correct in that they did not have it. 9 Q. There were 21 articles relating to the Avaulta 10 products from the time of launch through 2013. Do you 11 dispute that? 12 A. I would have to look at it. According to my 13 recollection, I have 17 down. So if you have 21, I 14 would not dispute that. 15 Q. So that's clinical data, correct? That's data 16 from actual product use? 17 A. Absolutely that is data. But for the reasons 18 of the FDA, when they reviewed them, none of that data 19 was sufficient for the FDA to be appeased. 20 Q. In this litigation, you're not holding 21 yourself out as an expert in FDA regulations or whether 22 Bard complied with each and every regulation in terms of 23 the IFUs, are you? 24 A. No. I would disagree. Because, as I 25 mentioned, you know, multiple times to you, all of those</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 346</p> <p>1 various different criteria as far as reviewing the</p> <p>2 manuscripts, reviewing patients, taking care of</p> <p>3 patients, education committee, talking about warnings</p> <p>4 that I have a very good working knowledge of what is</p> <p>5 required of a product to meet the standards.</p> <p>6 Q. So let me just make sure I understand. You</p> <p>7 don't have any formal education, training, or experience</p> <p>8 designing a pelvic mesh product; is that correct?</p> <p>9 A. Well, no. That's also incorrect.</p> <p>10 Q. When have you designed a pelvic mesh product?</p> <p>11 MR. CARTMELL: We're at seven hours.</p> <p>12 MS. GEIST: Okay. Well, counsel is telling me I</p> <p>13 need to stop, so...</p> <p>14 MR. CARTMELL: I think you asked that last</p> <p>15 question. If you want him to answer, I think it's</p> <p>16 already been asked and he told you he consulted on it.</p> <p>17 But I'll let him answer that last question.</p> <p>18 BY THE WITNESS:</p> <p>19 A. Yeah. I've been involved as far as with the</p> <p>20 Interpro as far as the measurements, the design of the</p> <p>21 product, and that's a pelvic organ prolapse mesh.</p> <p>22 MS. GEIST: All right. If you're telling me my</p> <p>23 time is up, my time is up.</p> <p>24 CROSS-EXAMINATION</p> <p>25</p>	<p style="text-align: right;">Page 348</p> <p>1 A. Correct.</p> <p>2 Q. Now, at that time, I think you were asked</p> <p>3 questions and asked if you were an extremist in your</p> <p>4 position about pelvic organ prolapse that are</p> <p>5 transvaginal mesh products like the Avaulta products; do</p> <p>6 you remember that?</p> <p>7 A. Yes.</p> <p>8 MS. GEIST: Objection to form.</p> <p>9 BY THE WITNESS:</p> <p>10 A. Yes, I do.</p> <p>11 Q. And, in fact, in your submission to the FDA</p> <p>12 that you signed off in 2011, I believe it was August; is</p> <p>13 that correct?</p> <p>14 A. August 19th, 2011, something like that.</p> <p>15 Q. In your Public Citizen submission that you</p> <p>16 signed off on in your letter, you admittedly</p> <p>17 acknowledged that what you were asking the FDA to do, as</p> <p>18 far as banning the products, was admittedly an extreme</p> <p>19 position; is that right?</p> <p>20 A. Yeah. It was extreme. The extreme word</p> <p>21 everyone is getting hooked up on. I took it as an</p> <p>22 aggressive measure to protect women and their bodies.</p> <p>23 And everyone is getting hooked up on extremism. But as</p> <p>24 it pans out, I was absolutely right. Jump forward three</p> <p>25 years.</p>
<p style="text-align: right;">Page 347</p> <p>1 BY MR. CARTMELL:</p> <p>2 Q. And, Doctor, I'm going to ask you a few</p> <p>3 follow-up questions. But let me start by asking you,</p> <p>4 have all of your opinions that you've offered today been</p> <p>5 within a reasonable degree of medical certainty?</p> <p>6 A. Yes.</p> <p>7 Q. Okay. And you've talked ad nauseam about all</p> <p>8 of the materials that you've reviewed, including</p> <p>9 literature, Bard documents, you've talked about your</p> <p>10 experience and training. Do you feel like you have all</p> <p>11 of the information you need as of this time to offer the</p> <p>12 opinions that you have offered throughout today's</p> <p>13 deposition?</p> <p>14 A. Yes.</p> <p>15 Q. Okay. Now, you were asked, at some length,</p> <p>16 about 2011 when you sent a letter, I believe, to the FDA</p> <p>17 supporting a petition by Public Citizen for the Avaulta</p> <p>18 products that we're talking about here today, among</p> <p>19 other pelvic organ prolapse, being banned or removed</p> <p>20 from the market. Is that true?</p> <p>21 A. That is correct.</p> <p>22 Q. Okay. And, again, that was in 2011. So the</p> <p>23 Avaulta products that we're talking about today had been</p> <p>24 on the market for approximately three years, maybe a</p> <p>25 little longer than that; is that true?</p>	<p style="text-align: right;">Page 349</p> <p>1 Q. Let me ask you about that. So in 2011,</p> <p>2 August, you asked the FDA -- and feel free to review</p> <p>3 Exhibit 14, which was talked about earlier. You asked</p> <p>4 the FDA, as a urologist practicing at the Mayo Clinic,</p> <p>5 to ban the product and to require that medical device</p> <p>6 manufacturers like Bard, who was selling the Avaulta</p> <p>7 products, you asked the FDA to make them do actually</p> <p>8 controlled, randomized studies to demonstrate safety,</p> <p>9 didn't you?</p> <p>10 A. That is correct.</p> <p>11 Q. And I think you testified that you did that</p> <p>12 because you didn't believe, at that time, that there had</p> <p>13 been adequate data to suggest or support that the</p> <p>14 Avaulta products were safe for women, correct?</p> <p>15 A. There was not data to support the use of any,</p> <p>16 including Avaulta, mesh kits in women.</p> <p>17 Q. Now, I will represent to you that only four</p> <p>18 months later the FDA sent what's called a 522 letter or</p> <p>19 order to Bard as a manufacturer of the Avaulta products;</p> <p>20 did you know that?</p> <p>21 A. I know a 522 was sent out. I don't know the</p> <p>22 date on that.</p> <p>23 Q. Well, I'll represent to you that it was in</p> <p>24 January of 2012, just four months after you asked the</p> <p>25 FDA to ban these products and require the manufacturers</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 350</p> <p>1 to do well-controlled studies to demonstrate safety.</p> <p>2 Will you assume that for purposes of my questions?</p> <p>3 MS. GEIST: I'll just object to the form.</p> <p>4 BY THE WITNESS:</p> <p>5 A. Yeah. I have no reason to doubt that's</p> <p>6 accurate.</p> <p>7 Q. And just four months later, when the FDA sent</p> <p>8 a letter to Bard, did you know that the FDA told Bard,</p> <p>9 like you had said and recommended, that they needed to</p> <p>10 do well-controlled, randomized studies in order to</p> <p>11 continue marketing the Avaulta products?</p> <p>12 A. I'm --</p> <p>13 MS. GEIST: Objection to form.</p> <p>14 BY THE WITNESS:</p> <p>15 A. I'm aware of that, yes.</p> <p>16 Q. And that was exactly what you had asked for,</p> <p>17 as a part of your submission, just four months before</p> <p>18 that; isn't that right?</p> <p>19 A. That is correct. I feel that my statement</p> <p>20 there was taking an educated moral stand on the product</p> <p>21 trying to protect women. So I'm very proud of that</p> <p>22 document because I think it possibly may have led to</p> <p>23 some good.</p> <p>24 Q. And what is your understanding based on your</p> <p>25 review of Bard's documents that they produced in this</p>	<p style="text-align: right;">Page 352</p> <p>1 success, but it's also a failure.</p> <p>2 Q. And not only did Bard take these products,</p> <p>3 these pelvic organ -- strike that.</p> <p>4 Not only did Bard take these pelvic organ</p> <p>5 prolapse mesh products off the market, but other</p> <p>6 manufacturers of those products also took their products</p> <p>7 off the market; isn't that fair?</p> <p>8 MS. GEIST: Objection to form.</p> <p>9 BY THE WITNESS:</p> <p>10 A. My understanding is that all manufacturers of</p> <p>11 mesh kits have been pulled off the market because they</p> <p>12 could not meet the criteria of the 522 as requested by</p> <p>13 the FDA.</p> <p>14 Q. And so now going on several years, these</p> <p>15 products are not being marketed and sold by Bard,</p> <p>16 correct?</p> <p>17 A. That is my understanding, but I'm continuing</p> <p>18 to see the complications and will for years.</p> <p>19 Q. Now, you were asked several questions about</p> <p>20 the AUGS, or the American Urogynecologic Society</p> <p>21 position statement related to pelvic floor disorders; do</p> <p>22 you remember that?</p> <p>23 A. Yes.</p> <p>24 Q. Okay. And that's a 2011 document, correct?</p> <p>25 A. That was right around the time of the first</p>
<p style="text-align: right;">Page 351</p> <p>1 litigation? In other words, when the FDA asked Bard to</p> <p>2 do controlled studies to try to demonstrate that the</p> <p>3 Avaulta products were safe, what was Bard's response?</p> <p>4 MS. GEIST: Objection to form. Misstates facts.</p> <p>5 BY THE WITNESS:</p> <p>6 A. My understanding of the situation is just as</p> <p>7 you mentioned. The FDA asked for certain documentation,</p> <p>8 certain studies. Bard came forward with incomplete data</p> <p>9 and then elected not to pursue the studies that would</p> <p>10 allow the product to be continued to be sold.</p> <p>11 Q. And then Bard actually took the products off</p> <p>12 the market, didn't they?</p> <p>13 A. That is correct.</p> <p>14 Q. In other words, since, approximately, 2012,</p> <p>15 shortly after you asked the FDA to make them no longer</p> <p>16 sell these products and look into safety studies, Bard</p> <p>17 decided, themselves, not to do a safety study and</p> <p>18 took the product off the market. Is that your</p> <p>19 understanding?</p> <p>20 MS. GEIST: Objection to form.</p> <p>21 BY THE WITNESS:</p> <p>22 A. That is absolutely correct. However, from my</p> <p>23 angle on it, it is that there were four or five months</p> <p>24 there that this was continued to be implanted in women</p> <p>25 and continued to have damage for women. So to me it's a</p>	<p style="text-align: right;">Page 353</p> <p>1 FDA warning in, what, August of '11.</p> <p>2 Q. And that was before the time that the FDA had</p> <p>3 told the manufacturers that they needed to do safety</p> <p>4 studies in order to keep marketing their products,</p> <p>5 correct?</p> <p>6 A. Correct.</p> <p>7 Q. So this 2011 statement by AUGS, since this</p> <p>8 statement, there virtually -- there are no pelvic organ</p> <p>9 prolapse kits still being sold in the United States,</p> <p>10 correct?</p> <p>11 A. That is my understanding. To the best of my</p> <p>12 knowledge, there are none available.</p> <p>13 Q. So this AUGS position statement that you were</p> <p>14 asked questions about is referring to products, POP kits</p> <p>15 like the Avaulta products, that aren't even being sold</p> <p>16 anymore, right?</p> <p>17 A. Correct.</p> <p>18 Q. And this position statement that you were</p> <p>19 asked about, this was written by a select small group of</p> <p>20 authors from AUGS; is that right?</p> <p>21 MS. GEIST: Objection to form.</p> <p>22 BY THE WITNESS:</p> <p>23</p> <p>24</p> <p>25</p>

In Re: CR Bard 200

Daniel Elliott, M.D.


11/15/2014

<p style="text-align: right;">Page 354</p> <p>1 A. I have no idea who wrote it. Usually this is 2 coming from the board, but I don't know who wrote that. 3 I know for SUFU, members of the board wrote it. 4 Q. Okay. But you can't tell from this position 5 statement if any of the authors of this document 6 even used the Avaulta products on their patients, can 7 you? 8 MS. GEIST: Objection to form. 9 BY THE WITNESS: 10 A. No, I can't. I can't state that, no. 11 Q. This position statement certainly 12 doesn't endorse the Avaulta products specifically, does 13 it? 14 MS. GEIST: Objection to form. 15 BY THE WITNESS: 16 A. Avaulta is never mentioned in that one. 17 Q. And then you were asked also several questions 18 about midurethral slings that are transvaginally placed. 19 Do you recall that? 20 A. Correct. 21 Q. Now, your opinions in this case, in your 22 report and during your testimony today, relate to 23 the Avaulta pelvic organ prolapse products, 24 correct? 25 A. Correct.</p>	<p style="text-align: right;">Page 356</p> <p>1 support it. 2 Q. And you were asked a question about this 3 statement in here that says, at this time, AUGS was 4 saying the procedure is safe, effective, and has 5 improved the quality of life for millions of women 6 talking about slings, not pelvic organ prolapse, 7 correct? 8 A. That document is very clearly, as it mentions, 9 mesh midurethral slings for stress urinary incontinence, 10 has nothing to do with prolapse. 11 Q. In fact, you were asked if you agreed with 12 this statement. But in your personal practice, you have 13 now concluded that the risks even of these transvaginal 14 mesh slings outweigh the benefits in your patients, 15 correct? 16 MS. GEIST: Objection to form. 17 BY THE WITNESS: 18 A. Correct. And that is based upon my review of 19 the literature, my interactions with patients who are 20 coming in refusing to have slings put in because of fear 21 of complications, and dealing with the complications of 22 these. 23 Q. And have you found in your practice, based on 24 your interactions with doctors all around the world in 25 your professional meetings, in your publications, and in</p>
<p style="text-align: right;">Page 355</p> <p>1 Q. Okay. This case is not about a midurethral 2 sling, correct? 3 A. No. 4 MS. GEIST: Objection to form. 5 THE WITNESS: It's about Avaulta. 6 BY MR. CARTMELL: 7 Q. Okay. And is a pelvic organ prolapse mesh kit 8 very, very different than a midurethral sling? 9 A. There are many, many factors in there, which 10 we could kind of go down and dissect it out, that it is 11 a different device for a different problem, different 12 locations the mesh is going, different volume of meshes, 13 arms, et cetera. 14 Q. And you were asked specifically about AUGS 15 again, the position statement, related to the slings. 16 But this position statement doesn't specifically endorse 17 any of Bard's products, does it? 18 A. No. 19 MS. GEIST: Objection to form. 20 BY THE WITNESS: 21 A. No products are mentioned. And now SUFU is on 22 that one, which I'm a member of the education 23 committee. But many of us -- and there are strong 24 anti-mesh people. So just because the foundation came 25 out with that document, doesn't mean all of its members</p>	<p style="text-align: right;">Page 357</p> <p>1 your practice, that more and more doctors are like you 2 and now finding that they should not implant even 3 transvaginal mesh slings? Are you finding that that 4 tide is turning? 5 MS. GEIST: Objection to form. 6 BY THE WITNESS: 7 A. There's no question the pendulum is swinging 8 back towards native tissue types of repairs because at 9 least then we don't deal with the long-term 10 complications. 11 MR. CARTMELL: That's all I have. Thank 12 you. 13 MS. GEIST: You're not letting me go past seven 14 hours. 15 MR. CARTMELL: Well, I think the Federal Rules are 16 pretty clear, and I did tell you beforehand that, if you 17 were going to do an examination, again, that you should 18 save some time. 19 MS. GEIST: I'm just making sure I understand your 20 position. 21 MR. CARTMELL: Okay. And if we need to take it up 22 later, we can. 23 MS. GEIST: No. That's fine. I just wanted to 24 understand your position. All right. 25 VIDEO TECHNICIAN: This concludes today's</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 358</p> <p>1 deposition of Dr. Daniel Elliot. We're off the record.</p> <p>2 The time 5:58 p.m.</p> <p>3 (Elliott Deposition Exhibit Nos. 27 &</p> <p>4 28 were marked for identification.)</p> <p>5 (Whereupon, the deposition was</p> <p>6 continued to November 14, 2014 at</p> <p>7 8:53 a.m.)</p> <p>8</p> <p>9</p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>	<p style="text-align: right;">Page 360</p> <p>1 In witness whereof, I have hereunto set my</p> <p>2 hand and affixed my seal of office at Chicago, Illinois,</p> <p>3 this 5th day of November, A.D., 2014.</p> <p>4</p> <p>5</p> <p>6</p> <p>7</p> <p>8</p> <p>9</p> <p style="text-align: center;">  JENNIFER L. BERNIER, CSR, RPR, CLR CSR No. 084-004190 </p> <p>10</p> <p>11</p> <p>12</p> <p>13</p> <p>14</p> <p>15</p> <p>16</p> <p>17</p> <p>18</p> <p>19</p> <p>20</p> <p>21</p> <p>22</p> <p>23</p> <p>24</p> <p>25</p>
<p style="text-align: right;">Page 359</p> <p>1 UNITED STATES OF AMERICA)</p> <p>2 NORTHERN DISTRICT OF ILLINOIS)</p> <p>3 EASTERN DIVISION) SS.</p> <p>4 STATE OF ILLINOIS)</p> <p>5 COUNTY OF COOK)</p> <p>6</p> <p>7 I, Jennifer L. Bernier, Certified Shorthand</p> <p>8 Reporter, Registered Professional Reporter, and Notary</p> <p>9 Public, do hereby certify that DANIEL S. ELLIOTT, was</p> <p>10 first duly sworn by me to testify to the whole truth and</p> <p>11 that the above deposition was reported stenographically</p> <p>12 by me and reduced to typewriting under my personal</p> <p>13 direction.</p> <p>14 I further certify that the said deposition was</p> <p>15 taken at the time and place specified and that the</p> <p>16 taking of said deposition commenced on November 3, 2014,</p> <p>17 at 9:23 a.m.</p> <p>18 I further certify that I am not a relative or</p> <p>19 employee or attorney or counsel of any of the parties,</p> <p>20 nor a relative or employee of such attorney or counsel,</p> <p>21 nor financially interested directly or indirectly in</p> <p>22 this action.</p> <p>23</p> <p>24</p> <p>25</p>	<p style="text-align: right;">Page 361</p> <p>1 TO: Daniel Elliott, M.D.</p> <p>2 Re: Reading and Signing Your Deposition Transcript</p> <p>3 Date Errata due back at our offices: 12/20/2014</p> <p>4</p> <p>5 Greetings:</p> <p>6 You have reserved the right to read and sign your</p> <p>7 deposition transcript. Please review the attached</p> <p>8 PDF transcript, noting any changes or corrections</p> <p>9 on the attached PDF Errata. You may fill out the</p> <p>10 Errata electronically or print and fill out manually.</p> <p>11</p> <p>12 The PDF files open with Adobe Reader. If you need help</p> <p>13 opening these files, please see the instructions in the</p> <p>14 cover letter of this email.</p> <p>15</p> <p>16 Once you have completed your Errata, please print it, sign</p> <p>17 it, and have the document notarized in the place provided.</p> <p>18</p> <p>19 When the signed Errata is returned to us, we will seal</p> <p>20 and forward to the taking attorney to file with the</p> <p>21 original transcript. We will also send copies of the</p> <p>22 Errata to all ordering parties.</p> <p>23</p> <p>24 If the signed Errata is not returned within the time</p> <p>25 below, the original transcript may be filed with the</p> <p>26 court without your signature.</p> <p>27</p> <p>28 Please send completed Errata to:</p> <p>29 Tiffany Alley Global Reporting & Video</p> <p>30 730 Peachtree St. NE, Ste 470</p> <p>31 Atlanta, GA 30308</p> <p>32 (770) 343-9696</p> <p>33</p> <p>34</p> <p>35</p>

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p style="text-align: right;">Page 362</p> <p>1 ERRATA</p> <p>2 I, the undersigned, do hereby certify that I have read the transcript of my testimony, and that</p> <p>3</p> <p>4 ___ There are no changes noted.</p> <p>5 ___ The following changes are noted:</p> <p>6</p> <p>7 Pursuant to Rule 30(7)(e) of the Federal Rules of Civil Procedure and/or OCGA 9-11-30(e), any changes in form or substance which you desire to make to your testimony shall</p> <p>8 be entered upon the deposition with a statement of the reasons given for making them. To assist you in making any</p> <p>9 such corrections, please use the form below. If additional pages are necessary, please furnish same and attach.</p> <p>10</p> <p>11 Page ____ Line ____ Change _____</p> <p>12 _____</p> <p>13 Reason for change _____</p> <p>14 Page ____ Line ____ Change _____</p> <p>15 _____</p> <p>16 Reason for change _____</p> <p>17 Page ____ Line ____ Change _____</p> <p>18 _____</p> <p>19 Reason for change _____</p> <p>20 Page ____ Line ____ Change _____</p> <p>21 _____</p> <p>22 Reason for change _____</p> <p>23 Page ____ Line ____ Change _____</p> <p>24 _____</p> <p>25 Reason for change _____</p>	
<p style="text-align: right;">Page 363</p> <p>1 Page ____ Line ____ Change _____</p> <p>2 _____</p> <p>3 Reason for change _____</p> <p>4 Page ____ Line ____ Change _____</p> <p>5 _____</p> <p>6 Reason for change _____</p> <p>7 Page ____ Line ____ Change _____</p> <p>8 _____</p> <p>9 Reason for change _____</p> <p>10 Page ____ Line ____ Change _____</p> <p>11 _____</p> <p>12 Reason for change _____</p> <p>13 Page ____ Line ____ Change _____</p> <p>14 _____</p> <p>15 Reason for change _____</p> <p>16 Page ____ Line ____ Change _____</p> <p>17 _____</p> <p>18 Reason for change _____</p> <p>19 _____</p> <p>20 _____</p> <p style="text-align: center;">DEPONENT'S SIGNATURE</p> <p>21</p> <p>22 Sworn to and subscribed before me this ____ day of _____, ____.</p> <p>23 _____</p> <p>24 NOTARY PUBLIC</p> <p>25 My Commission Expires: _____</p>	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

	18	120-day 333:3	332:5
<hr/>			
\$	1046 318:21	120-or-so 7:20	18-point 250:9
	105 238:13	9:14	19 226:1 242:7,
\$100,000 83:18	10:51 78:15	12:20 138:18,19	20 243:14,20
\$700 84:21,22	11 75:22 115:5	12:58 139:3	244:7 250:12,14
85:3	230:21 231:1	13 159:4 162:21	251:6 252:18
<hr/>	237:11,14,15	214:2 224:19	287:11,12
0	238:11 272:8	241:22 253:7,8,	19- 301:7
	275:10 315:22	12 318:24	1950 199:13
0 164:22 166:19,	353:1	13th 91:13	200:10 201:18
20,22 167:3	11-year 321:17	14 246:6 267:4,7,	1976 301:5
247:4	11.7 235:1	10 315:5 349:3	1990s 156:22
0.7 203:1	11:06 78:18	15 9:3 29:6 49:13	1991 343:19
08 229:19	11:10 82:5	72:6,9,10 95:24,	1996 262:14
09 299:20	11:11 82:8	25 96:10 101:18	1997 228:24
<hr/>	12 74:20 75:22	148:21 149:10	229:5
1	123:7 133:20	208:13 209:2	1999 152:5,17
	159:4 205:2	213:3 214:1	154:6
1 4:3 5:16,19	206:17,18	264:24 273:14,	19th 279:19
62:2 74:8	208:9,11,15,16,	19,22 315:24	282:2 283:10,17
228:19 229:3	25 209:16,19,21	332:8	348:14
242:18 274:14	214:1 217:11	15.2 218:22	1st 274:14
336:12,19 337:6	218:9,12	150 125:10	
1.0- 339:2	219:10,20	15th 8:23	<hr/>
1.3-millimeter	221:21 223:15	16 124:18,23	2
339:2	232:7,9 245:24	125:3,8 279:10,	2 5:16,23 22:12
10 61:16 123:8	246:9 248:2	14	23:4,5,6 128:20
209:3,8 222:20,	249:9,11 315:24	16.7 218:22	144:11 238:18,
21 223:1,5	326:22 330:2,8	16.9 246:9	242:19 258:21,
237:12,13,15,16	332:7	17 54:7 282:24	22 265:8 286:2
238:7 299:21	12-month 208:5	283:1,5 315:24	288:4 335:10
332:20 335:13,	217:13 218:8	316:2,3,9	2.0 339:1
24	219:3 232:5	345:13	20 14:14 61:16
100 80:25 81:3,	241:12	17-year 321:15,	72:6,9,10,16
14 105:4 133:22	12-week 326:9,	21	95:24,25 96:10
136:7 158:20	15 330:1	18 246:2 285:3,6	101:18 108:16
159:1,24 247:6	120 9:1,11,25		115:5 265:24
299:11 303:16,			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

310:18 311:8, 10,11,12 341:3, 5 200 80:21 81:2,3, 14 125:10 238:17 2000 136:2 152:17 2001 324:18 2002 154:14 2003 120:1,13 121:19 122:10, 14 128:5 132:15 179:1,5,21 226:17 294:22 324:17 325:14 2004 248:8 294:22 2005 88:1 109:10 121:22 132:2 176:6 186:17 200:11 229:17 287:5 2006 10:3 37:19 183:10 251:12 252:1 329:3 2007 103:6 104:23 105:7,10 109:4,10 120:1, 14 121:19,25 122:11,14 128:6 132:17 179:1,6, 22 229:18 2008 10:3 109:8 121:25 176:6 185:19 231:23 236:24 240:22 316:24	2009 109:8 118:11 133:1 179:20 2010 105:18 170:5 183:10 199:13,25 201:19 222:18 223:7 227:13 235:15 236:24 242:14 248:1 250:19,23 299:19 300:24 301:19 307:24 308:20 2011 74:20 76:5, 14 87:2,25 105:14 106:17, 22 111:7 185:20,22 186:19,22 189:17,19 198:24 203:17 204:9 212:18 246:19 260:16 262:14 263:15 267:13 276:18 277:2 279:19 280:8 281:4,5 282:2,6 283:10, 17,23 301:12 310:22 347:16, 22 348:12,14 349:1 352:24 353:7 2012 274:1,2 349:24 351:14 2013 100:3,7 170:2,4 182:12, 16 314:15	345:10 2014 74:20 77:7 80:2 91:13 105:7 285:9 288:4, 290:6 202 238:8,20 241:16 204 27:4 205 27:4 21 31:2 121:3,9 122:5 123:3 129:2 132:17 221:6 314:8, 345:9,13 215 248:25 22 128:16 316:17,19,20,23 23 31:9 35:14 319:11,12 235.e.3 227:8 24 10:11 12:1 38:11 66:14 232:9,11 233:15,16 234:13 323:25 324:1 329:9 25 65:23 66:5,12, 16,17 87:2 109:14 112:4,5, 16 123:21 195:2 262:19,21 329:12,18 26 66:5,13,16,17 331:22 265 306:24 266 309:4	269 307:16 27 66:8,13,16 27th 285:9 28 66:17 229:9, 21 280 274:7,12 29 209:3 2:49 230:16 <hr/> 3 <hr/> 3 118:1,4,9 163:21 248:20 250:15 265:9,10 3.3 235:1 3.4 248:16,18 250:1 252:9 3/11/13 343:20 30 14:14 56:13 66:22 80:6 104:20 109:12 111:19,22 112:1, 115:5 136:25 137:16 166:18 313:12 300 80:24,25 300,000 137:20 310 110:11 312 110:18 347 184:2 35 108:25 339:21 340:5 36 223:19,21 246:1 340:4 365 282:2
--	---	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

37 64:21 209:4	233:12	60s 156:24	90 161:14 163:22
38 340:5	50-year-old	65 217:12	164:4,21
39 339:21	233:12		165:23,25
3:03 230:20	500-or-more	<hr/> 7 <hr/>	166:18 202:12
<hr/> 4 <hr/>	13:23		244:11
	500-plus 81:6	7 198:10,14,16	93 67:23 208:10
4 144:10 171:1,3,	506 61:3,15	200:20 265:10	249:3 314:17
10 337:21	509 9:13 28:18	70 200:20,21	95 220:12 229:7,
40 103:19 105:3	262:20 305:13	201:5,8	19
109:1 151:18	50s 156:24	700 84:1,11,13,	97 208:9 238:11,
224:8 233:12	51 208:9	19 85:3 130:8	13
40- 233:12	510(k) 21:20	700-dollar-an-	9:23 4:2
40-year-old	60:23 61:4,9	hour 84:4	9th 290:6
224:7	344:4,8,18	70s 12:17 301:7	<hr/> A <hr/>
41 224:18 241:23	522 117:7 261:8,	75 73:6	
42 108:14	11 344:20	778 312:4,5	A-b-d-u-c-t-o-r
43 65:4 333:10	349:18,21	<hr/> 8 <hr/>	194:3
45 110:15 220:14	352:12		A-d-d-u-c-t-o-r
229:9,20	524 126:20 127:1	8 203:9,10 209:4,	194:4
45.2 206:16	527 125:25	7 234:9 242:19	a.m. 4:2 78:15,
4:39 305:25	53 208:9,10	244:7 250:8	18 82:5,8
4:52 306:3	530 129:8	251:7 252:17	Abbott 180:3
<hr/> 5 <hr/>	54 67:21	8.9 201:23	abbreviating
	55 199:16,18,21	80 207:9	286:12
	57 208:10	800 130:8	abbreviation
5 133:20 180:14,	5th 288:4	81 217:10	298:8
15,17 247:25	<hr/> 6 <hr/>	8th 8:19,22	abdomen 213:24
250:20 329:10,		16:19	289:17
11 335:13	6 187:17,21	<hr/> 9 <hr/>	abdominal 37:12
336:11,18 337:5	263:2,4 333:10		151:21,24
5,000 154:3	6-by-11 227:4	9 216:17,18	152:1,7 153:14
5.4 252:1,9	60 103:17 199:21	222:19	155:5 158:16,
5.6 244:24 245:7,	600 258:6	9.1 201:9	17,18 168:23,25
22 247:25	263:12,13,16,20	9.6 201:25	169:7 170:10
50 136:25 137:16	264:3,7 281:9	206:17	214:19,21
			245:18 248:12

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

251:10,17 264:14 265:19 302:1 312:18 abdominally 154:9 264:13 abductor 194:3 Abed 228:24 229:6 ability 195:8,20 able 25:4 38:13 71:20 117:2 140:15,19 141:1 149:13 153:7 156:20 161:22 173:5 180:1 195:9,23 237:15 244:21 247:22 261:10 309:20 abnormal 327:13 328:16 about 9:3,5,11, 12 11:18 13:11 14:9,15 15:8 19:5 20:22 26:6 28:13 29:15,18 31:3,15,16 33:19 34:3 35:13 39:5,6 40:10,14,22 43:8 44:13,14, 16,19 46:1,9 47:8 49:4,15 50:19 51:11,20 52:13 53:4,10, 16 54:13,24 56:13,25 57:6, 20,23 60:17,18 66:16 67:6	68:21 72:6, 74:18 76:24 77:4 78:10 80:2, 16 81:23 84:18, 20 86:6,19,20 91:16 92:25 95:10 97:9,13 98:18,19,23 101:13,24 102:11 105:7,25 106:1,22 108:16 110:6 115:23 117:15 120:18 121:9 122:3,12 123:16 129:25 130:16,20 133:16,23 134:6,8,24 139:11,15,21,25 140:12 145:14, 19 148:11 149:6 151:12 152:17 157:25 160:21 162:9 163:19 165:1,12,20, 166:21,23 167:2,5,17,20, 23 168:3,21,23 169:2 170:7,23 171:2 173:20,24 177:16,22 178:15 181:17 183:8,19 184:14,20,23 185:7,24 186:15 187:6 193:18, 21,25 194:16 195:10 197:23 198:9 201:19 202:7 204:20,	22,23 205:8,9, 15,16,19 206:5, 9 207:16,19,20 210:11,12,17, 19,21 211:7 214:8 216:16 218:11 220:17 221:8 223:12 225:18 226:7,17 227:5 228:2 229:14 232:23 235:2 237:1 238:8,11 241:4, 6,7 242:13 243:8,20 245:4, 5,10,16 249:10 251:12 256:8,16 257:2,8,19,21 259:3,12,13,15, 18 261:3,25 267:11 268:21 270:25 271:1 272:19 274:18 275:22 276:9,12 284:1, 286:12, 18 288:15 291:3 293:5,21 294:5, 18,22 295:11, 13,20 298:19,23 299:2,12 300:8 301:6,11 302:8, 10 305:9 306:5, 9 308:2,21 310:25 315:18 317:25 318:15 319:8 322:6 326:11 329:8,16 334:15,19,20,22 337:12 338:18 340:4,10,16,19	341:6,9,10,11, 12,18 343:3,4,7, 13 346:3 347:7, 9,16,18,23 348:4 349:1,3 352:19 353:14, 19 354:18 355:1,5,14 356:2,6 above 201:4 absence 260:23 absolute 248:22 absolutely 10:11 18:25 53:22 65:10 117:18 185:17 210:1 233:7 252:13 264:6 276:16 280:22 282:1 284:9 290:10 305:19 344:8 345:3,17 348:24 351:22 abstract 52:8 53:24 54:12 123:25 124:20, 21,22 126:2 199:8 201:1 accept 205:17 acceptable 116:18 178:16 215:15 251:19 262:8 accepted 95:15 170:19 182:15, 16,21 314:14 access 18:10 54:11,12 154:18
---	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

162:8 292:11 accessible 78:4 255:9 accessing 259:7 292:23 according 56:23 242:5 259:14 288:24 290:5 323:15 337:19 341:17 343:24 345:12 accounts 8:3 accuracy 105:17 131:8 137:24 172:23 315:15 accurate 7:12 27:19,22 62:21 63:12 83:22 110:19 112:18 113:3 273:11 292:10 302:3,5 317:19 350:6 accurately 7:5 16:21 125:24 234:12 achieve 144:3 achieved 143:16 217:11 acknowledge 238:25 339:8 acknowledged 348:17 acknowledges 302:12,16 acknowledging 122:13 300:25	acronyms 303:23 across 9:17 119:15 across-the-board 260:1 acting 173:3 256:22 actions 281:20 active 208:10 242:8 300:23 activities 82:14 activity 277:8 actual 50:2 53:16 125:7 128:11 234:4 267:22 306:24 332:7 345:16 actually 14:17 15:24 20:23 50:9,16 51:8 72:22 75:24 76:4 96:19 108:11 112:2 113:17 118:15 123:2,4 140:1,6, 8,20 147:7 163:18 171:5 178:2 182:1,14 184:13 191:15 192:18 218:14 222:4 226:21 232:3 234:8 237:25 238:2 242:9 246:10,14 247:4 263:2,3 265:9 267:18 269:19 286:24	296:2 300:20 302:21 304:20 306:19 310:8,22 314:14 315:25 318:3 322:7 325:17 328:3 329:1 330:19 331:1,5 332:2 344:25 349:7 351:11 ad 286:11 347:7 adamant 185:2 add 62:22 72:15 280:12 added 11:10 16:8,10 62:25 addendum 62:23 adding 13:5 277:21 Addison 156:23 addition 21:11 151:23 220:15 additional 9:1 12:19 13:7 18:24 19:20 20:21 22:3 24:18 280:12 290:1 address 71:8 145:4 226:5 addressed 6:21 156:9 addressing 145:8 adductor 194:3 214:17	adequate 344:22 349:13 adequately 344:1 Adhesion 333:6 adipose 150:19 admit 280:8 admits 299:22, 23 admittedly 348:16,18 admitting 91:1 adult 313:11 advanced 49:9 92:20 101:3 175:12 194:10, 11 195:5 262:4 304:12 adverse 40:16 44:14,19 45:2, 17,19 46:2 146:25 148:7,25 160:15 163:6 196:13 199:11, 17,24 316:2,9 318:4,5,8,23 343:21,23 344:15 advertisements 106:5 advertising 106:18 affect 136:12 affected 137:1 aforementioned 175:9 177:10 266:25
--	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

after 18:22 19:6 24:23 45:3,8,9 47:10 56:11 80:5 81:22 83:3 105:14 109:1 113:23 120:14 121:5 128:6 141:11 142:4 147:8,23,25 148:22 149:7, 13,25 150:13 151:1,15 159:3 164:14 182:10, 25 189:19 195:22,25 205:3 206:17,18 207:3 217:11 219:3 223:8,15,18 224:11,18 234:7 235:13 241:21 242:3 251:2 269:3 271:18 272:5 276:17,25 301:13 314:21 315:22 316:2 327:6,14,25 328:9,25 329:24 332:5 349:24 351:15 afterwards 15:20 149:13 again 6:20 9:12 12:25 13:5 16:18 18:21 19:10 20:24 21:9 24:5 25:15 26:18 30:5 32:3 36:9 38:3 42:23 43:12 45:18 48:7 53:8 55:4	56:9 71:25 72:15 78:20 79:5 80:22 83:16,19,21 85:14 87:3 89:25 91:10 93:23 95:22 98:6 99:2, 100:4 109:11,14,16 115:9 122:19 124:10,20 125:10 131:7 133:1 135:18 137:6 140:3 151:20 162:6,7, 21 164:2 166:14 170:7,11 174:7, 18 175:10,12 176:11 177:13, 17 184:16 186:17 198:14 203:24 209:21 210:2 212:25 219:2 224:24 225:11 226:17, 18 231:3,5 232:19 234:9 242:17 248:2 249:6 252:13 262:3,4 263:10 274:8 275:16 276:23 277:10, 14 282:8 285:23 293:24 299:1 301:11,18,23 304:11,14,22 309:12 312:4 318:17 322:10 329:22 334:21 335:23 347:22	355:15 357:17 against 35:17 57:1 75:16,19 76:7,15 85:6 88:5,10 89:1 91:12 173:8 185:3 256:7 261:13 271:24 275:7 296:24 age 134:14 135:2 agency 282:13 aggressive 348:22 aggressively 274:23 ago 11:1 12:16 51:12 75:23 77:9 91:13 161:8 170:14 172:18 284:25 agree 9:24 50:14 52:2 60:8 68:20 91:24 113:4 129:16,18 130:1 131:2 136:11 137:19 144:22 148:9 149:21 150:24 151:13, 22 154:25 155:17 156:7,12 157:3 168:7 174:8 185:12 186:4,18 190:8 191:12,15,17 192:2 196:3,4 208:14 209:20 213:4 215:7 219:12 227:9	231:14 246:15 248:17 259:19, 22,25 260:7 261:17 262:23 264:12,17,24 266:4,13,17 292:21 293:9 303:2 307:9 313:24 315:1 320:7 326:3 327:5 330:25 335:15,18 336:15 agreed 10:25 73:2 216:17 318:20 356:11 agreeing 202:25 agreement 267:4 ahead 33:6 34:7 36:15 43:5 54:3 55:15,25 72:12 121:17 124:14 137:9 162:16 191:5,10 192:20 200:9,15 206:24 239:10 248:20 256:4 275:20 300:15,22 332:13 AJOG 239:15 Akre 284:16 al 235:12 298:24, 25 310:16 Ali 298:24 310:16 Align 109:5 all 6:7,16,22 7:2, 8,10 8:4,16 9:8
---	--	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

10:14 11:10,11	177:10,18 178:5	298:16 299:2	261:4 272:5
12:10 13:12	180:2 184:14,20	300:11,22,25	274:3 275:6
15:9,16,22,23	185:17,23,24	303:14 306:17,	276:11 293:21
16:2,12 18:6,17	186:20,21	21 308:19	298:25 346:16
19:11,14,17,18,	187:10,23 188:3	309:20 312:21	also 5:23 6:24
20,22 20:8,10,	190:13,18	315:25 318:5,17	7:21 11:17
11,12,14,17,18,	192:24 193:17	323:7 334:3,18,	13:16,23 21:3,6
25 21:3,5,8,10,	194:12,18	21 341:12	24:17 34:13
13,18,22,24	195:4,24 196:3	342:24 343:4,22	37:10 47:2
22:6 24:3,12	197:17,19,23	344:11,21	49:23 50:11,18
28:4,16,20,21,	200:13 203:4	345:25 346:22	65:8 68:14,17
24 29:9,10,12	204:24 205:21	347:4,7, 352:10	73:20 74:10
34:2 39:20 42:5,	210:3,6 213:4	355:25 356:24	93:5 94:11
19 45:1 46:19,	217:6,24 218:6	357:11,24	98:22 101:4
22 52:2,9,12,17	220:16,17	allow 255:12	103:23 104:4,23
53:15,22 54:8	224:24 226:9,24	351:10	107:18 111:21
56:1 59:16 61:3	235:7 239:3	allowing 255:8	112:14 113:1
65:17 66:13	240:11 245:19	almost 29:9,12	117:6,20 128:10
67:3, 70:4 74:10	246:17 247:16	61:17 137:11	135:14 140:10,
75:13,16 78:1	249:17,25	148:2 153:10	15 141:5,9,11
79:4 80:25 81:5	253:23 255:1,18	158:20 159:24	148:9 149:7
85:16 89:14,16	256:17,24	188:13 190:18	151:24 153:20
94:14 96:9,11	257:12,17,21	alone 35:16	155:24 158:2
100:6 103:8	258:1,9,11	36:19,20,21	159:20 165:7,13
104:13 106:2	259:23 260:17	46:11 106:2	176:9 184:10
107:22 108:1,4	261:9,20,23	along 11:18	197:23 200:10
109:16 111:4,23	262:5 264:4	111:6 124:4	204:14 206:12
112:1 114:11	266:7 267:4,23	182:23 198:6	208:8,16 217:4
115:4 119:15,	268:6,8,10,16,	267:21 273:15	225:19 236:25
16,18 120:10	19,24 269:20	304:24 319:11	240:6 246:5
121:23 122:19	270:16 271:11	326:24	257:6 263:16
123:18 127:13	272:15 275:5,9	already 22:5	281:17 297:23
128:4 133:12	276:13,19,21	24:12 27:17	301:7 303:19
134:15 135:2	278:6,16 279:3,	28:16 35:11	304:9 309:4,
136:25 150:20	7 281:11 282:16	45:25 47:7	312:9,24 315:2,
156:11 161:20	286:17 287:7,17	77:20 88:4	10,20 320:21
165:2 166:13	289:4,23	96:24 102:11	330:12 339:6
167:22 172:23	290:16,25 291:2	106:9 178:3	346:9 352:1,6
173:4,14 175:1,	294:3,10,12	237:12 255:14	354:17
5,9 176:20	297:23,25		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

alter 88:3	amend 12:20	14,23 206:16	251:16 292:14
altered 164:4	American 49:12	207:2,16 217:3,	329:18,22
alternative	68:17 182:16	10,11,13,22	336:21
191:22	188:9 189:25	225:10 237:5,7,	answer 7:16
Although 126:7,	352:20	19,20	14:7 16:20
12	among 149:23	anatomical	29:13 42:8 43:4,
Altman 271:22	168:11 174:10	241:12	12,14,22 47:24
always 13:9,10	175:18 178:13,	anatomically	48:7 54:22 55:4
20:12 85:3	14 196:21	143:20 224:25	56:5,8,10,15,16,
105:7 113:16	211:14 347:18	225:9	18 57:6,23,25
135:25 136:6	amount 85:10	anatomy 145:1	61:19 74:5 85:8
141:7 142:6,10	92:23 135:11	206:21 225:13	97:23 103:24
145:24 148:2	160:4 173:13	and/or 183:1	106:12 107:10
am 7:24 33:4	215:23 272:12	Anderson 76:18,	113:20 123:1,12
39:2 41:25	298:15 325:16	20 77:2,12	137:17 161:14
48:21 53:13	334:6 335:17	275:10 277:3	173:5 176:4
59:22 65:14	AMS 31:19,23	Anderson's	179:13 182:2
66:8 68:7 70:9	32:13 34:12,23	81:21	193:19 243:14
79:15 90:18	36:1,19 38:8	anger 186:16	256:24 281:25
93:23,24 100:19	45:22 51:9	angle 317:16	282:1 297:13
101:1 103:9	103:18,19	351:23	306:8 309:20
108:22 109:2	105:1,4 127:24	animal 66:13	341:24 346:15,
127:12 128:22	338:8	90:14,15	17
136:7 166:12	Analog 210:16	233:14,24	answered 9:7
185:25 186:1	211:22	289:11 298:14	34:18,19,25
188:7,11,13,15	analysis 37:3	324:15 329:22	35:11 41:3 42:5,
194:14 213:20	38:10 39:8	Ann 217:15	16 43:11 44:4
229:24 236:17,	96:14 104:19	220:19	47:7 48:4 55:2
23 256:17,19	183:5 299:11	annual 85:22	56:6,8,19 57:16
261:2,12 275:25	303:9,12 304:3	another 7:20	58:1,15 59:3
285:2,24 293:15	333:4	20:23 30:21	61:11 91:21,22
296:6 305:10	analyzing 214:1	32:6 33:3 37:16	106:10 164:2,8
311:6	anatomic 137:5,	40:23 64:12	177:7 338:12
ambiguous	13 143:23	118:7 151:25	answering 41:12
53:19	144:1,2,3,5,15,	164:16 198:3	42:2 94:5
amenable	19,20 145:8	217:2 222:11	174:16
154:10	147:13 157:1	225:20 231:1	answers 56:4
	158:14 204:10,		59:10

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

anterior 21:23 146:8,13,20 147:2,3,8,25 148:4 158:6,7 195:22 223:8 251:2 Anterior/ posterior 31:21 anti- incontinence 67:22 314:16,21 315:3 323:1 325:25 anti-mesh 88:10, 11,20 89:8 184:24 323:20 355:24 any 6:10 11:22 12:21 13:7 18:23 20:20 23:22 24:2,24 26:18 27:16 29:21,23 30:6,8, 19 34:10 35:22 37:14 38:7,13, 16 39:2,5,6,7,25 41:1 45:6,19 46:2, 47:13,16 48:10,11,22 51:3,4,25 53:21 62:22 63:14 67:7,18 73:22 76:21 77:16 79:10,11,18 83:22 85:16 87:6,15,17,19, 20 89:11,18 92:17,21 93:7 94:15 95:1 96:6,	14,19 97:2,9,12 98:11,24,25 105:17 108:20 110:5 111:10 115:25 129:20 131:7,9 132:15 143:7 146:19 148:10,15,17 149:1 150:7,13, 15 163:23 165:2 168:12 172:25 173:21 181:2,10 184:4 189:2 190:1 202:14 209:16,25 212:1,19 214:22 222:4 233:18 236:17 241:4,6 242:24 243:3, 11,15,23 252:22 255:15,20 256:15 261:7 262:17 266:18 273:15 277:6,7, 8,22 279:18,19 284:21 288:7 295:17 296:7, 16,17 304:20 310:2,6,8 315:21 316:1 317:21 319:24 327:22 328:2,4, 14 333:19 334:10 338:25 340:3,9 341:14 346:7 349:15 354:5 355:17 anybody 130:23 230:2,5 236:3 254:11 277:18	284:10 anymore 31:19 152:10 153:22 176:23 271:19 313:18 334:14 353:16 anyone 130:24 287:2 anything 13:3,4, 11 26:19 40:11 61:25 62:22,25 63:10 65:3 84:4, 16 104:17 134:20 150:4 168:12 182:22 183:19 184:10 227:5 241:8 251:9 276:3 277:21 281:2 296:7,13,16,19, 20 343:9 anyway 249:18 anywhere 30:16 85:11 340:9 apart 71:13 72:2 apical 146:8 Apogee 127:24 Apogee/perigee 31:19 105:2 130:20 apologize 32:25 33:4 76:12 118:7 161:9 222:23 appearance 84:15 appeared 312:25	appears 23:25 24:16 62:20 63:12 264:18 285:8 288:5 337:1 appeased 345:19 applaud 274:17, 20 apples 200:14 249:6,7 317:15 318:10 applicable 13:22 application 92:8 301:22 302:14 313:16 applications 297:7 302:24 apply 295:4 334:6 344:3 appointment 171:17 172:4 appreciate 54:22 59:24 60:14 182:3 193:19 284:2 approach 141:23 154:4,5 155:4,5 157:17 158:16 162:2,10 168:23 170:11 248:12, 13 265:20 299:16 302:25 approached 77:10 154:15 approaches 155:16, 169:20 appropriate
--	---	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

177:5 190:13 192:9 259:25 278:9 appropriately 49:22 142:25 190:5,10,11,12 192:5 307:12 approval 101:12 344:9 approved 49:12 95:15 100:13 approximate 121:2 approximately 4:2 80:8 122:6, 14 133:20 347:24 351:14 approximation 80:16 April 226:17 archaic 229:1 area 11:23 13:8 63:14 64:9 93:8 155:2 172:6 175:3,18 186:7, 23,25 326:19 areas 64:6 68:24 134:4 175:16 aren't 165:17 190:11 202:18 353:15 arguably 187:8 197:6 251:21 264:22 297:24 322:2 argue 68:21 101:24 243:8	266:2 320:16,20 arguing 168:21 argument 176:15 178:18 243:13 307:10, 11 argumentative 40:3 43:25 67:9, 12 273:7 arguments 326:4 arm 221:25 228:13 229:15 235:18 236:15, 16 arms 31:3,5 32:2,5,6 112:9 161:22 173:16 174:25 175:11 177:13 205:10 213:21 214:15 215:18, 219:19 220:11,22 222:5 226:20 227:5,6, 7 228:16,17 229:16 234:2 249:3 297:11 319:2 355:13 arms' 221:3 around 12:10 13:3 25:16 100:10 144:17 156:14 168:20 178:3 216:7 220:14 257:24 275:11 304:7 352:25 356:24 arsenal 168:9	article 9:20,22 11:7,8, 28:17,23 39:25 48:14 65:12 68:1 69:3 70:22,25 118:9 119:4 120:12 124:5 127:1 129:8 169:21 171:11 178:7,10 179:16,18,24 180:5 182:18,20 229:17 231:11, 17 239:5 262:12,25 263:3,19,22 264:11 272:8,19 273:13,25 274:7,16 276:18 283:6 285:12 290:17 296:7,17 298:2 299:8 305:21 306:6,7, 14 309:4 310:9, 21,25 312:6 313:8 315:10 322:11,25 323:3 324:4 333:1,8 articles 7:21 9:2, 8,11,13,14,17, 25 10:12,15,25 11:6,8,10,20 12:2,4,11,16 13:12 28:7,25 29:3,10,13 38:12 41:6,21 53:25 54:7 65:17 66:5 67:3, 7,19 81:6 181:8 199:24 230:7 241:9,11 262:19	271:2 272:4 285:7 295:11 296:23 297:3 310:2,5,18,24 311:20 323:24 324:10 332:8 345:9 Artificial 327:22 as 4:16,17,24 5:4,14,19,23,25 6:9,12,15,17 7:1,3,15,16 8:21 10:18 11:14,18 12:15 14:13 15:6,20 16:16, 23 20:24 21:6,7 22:4,12 25:3 29:6,22 39:2 42:19 50:9,12, 16 52:7,10 59:22 60:10 61:14 62:2,15, 24 63:7,18 64:16 70:19 71:21 73:24 74:11,14,24 75:10 76:1,11 77:6,15,17,24 81:16 83:2 85:1, 6,18,23 86:6,15, 21 87:14 88:4 92:8 93:1,20 94:3,7,10,11 96:21 97:17 98:4 100:9 105:3,12 109:18 110:17,18 111:2,3 116:11, 17 118:4, 126:8, 19 130:15
---	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

132:16 134:18	279:14 280:22	aside 133:14	164:8 177:7
135:4,15,16	281:8 282:2	160:3 184:21	200:3 235:2
139:6,7 140:2,	283:4 284:10,24	203:4 220:16	269:23 272:9
12,16 143:2	288:2 289:23	240:2 241:3	275:12,15
144:15 145:4	290:1,6 291:17	ask 6:20 17:3	281:4,18,20,22
149:6 151:4,	292:19 295:23	18:23 19:8,19	291:14 338:11
152:13,15,21	298:25 299:8	20:12 23:18	341:9 346:14,16
154:9 155:25	300:10 301:21	24:2,10,22,24	347:15 348:2,3
156:17 158:25	302:9,15,23	25:2,16,17 26:4,	349:2,3,7,24
159:9,13,14,	304:4,23 305:15	8 29:17 30:5	350:16 351:1,7,
160:25 161:3,10	308:4,17 314:8	39:20 42:6	15 352:19
162:18 163:5,15	316:15,19	45:18 56:4,14	353:14,19
169:2,5,14	317:15,16	57:2 58:6,23	354:17 355:14
171:10 172:18	318:14,16	59:9,13 63:20	356:2,11
174:17 176:6,21	319:15 322:24	76:12 82:16	asking 32:23
177:2 179:18	323:9 325:2,19	106:15 113:25	45:14 46:1,22
180:12 182:23	326:6 330:17	124:16 171:1	51:5 52:7,9
183:15 185:6	333:19 335:1,23	172:21 173:5	67:13 114:8
187:20 188:16	337:2,11,17,24	181:23 182:1	116:22 133:16
189:12,16	338:2,23 343:12	184:20 231:2	237:22 268:7,
190:20 191:13	345:21,24	235:9,21 244:18	10, 284:25
193:4 195:12	346:1,19,20	259:3 271:7	332:22 347:3
196:23 198:14	347:11 348:17,	291:13 292:1,2,	348:17
199:8 202:25	18,21,23 349:4,	5 293:14	asks 62:7 74:10
203:8 209:7,20	19 350:17 351:6	295:12,13 297:8	79:7
215:16 216:7,17	352:12 356:8	306:14 337:12	aspect 153:25
223:5,6 225:19	ASC 153:13	347:2 349:1	318:16
228:14,19 229:3	154:1, 155:4	asked 18:16,21	aspects 12:25
231:1 233:14	156:2,17,25	19:2,12,20,22	13:22 311:1
237:10,11,12	157:5,6,13,17	20:17,18,21,25	assessment
239:4 240:5,23	158:12,13,24	21:10 22:4	308:16
242:6 244:10	159:5,12,19	25:20,23 26:5	associate 86:6,15
249:8,19,20	160:5 169:14	34:17,18,25	associated 47:14
253:7,11 254:14	194:20 195:16	35:2,3,4 40:14	48:3 65:9 141:8
255:7,25 256:24	196:6,15 243:11	41:2,13 42:2,16	158:1,15,23
257:2 261:9	244:13 247:24	43:11 44:3	159:12,21
270:15 271:6	248:12 252:2	46:19 48:4 55:1	160:16,20
272:12 273:4,	265:6 266:9	57:9,19 61:11	161:12 163:6
14,15 274:4,	ASCS 243:10	91:16,21 117:7	
275:19 277:2		158:12 161:9	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

167:3 231:12,20 243:11 253:15 288:16 289:25 322:22 Association 68:18 assume 68:21 73:17 79:14 113:4 136:10 146:4 148:8 159:23 163:2 168:7,16 175:2, 5 190:13 212:7, 8 215:7 233:4 264:12 267:15 312:2 315:20 327:5 350:2 assuming 175:10 assumption 116:3,4 assumptions 87:21 115:23 at 6:15 7:14 8:18 9:1,11,23 11:9 14:21 15:22 17:14,15 18:18 19:1,9 21:18 22:11 23:20 24:3,16, 27:18 30:13,25 31:12 33:20 34:3,9 35:24 37:25 38:4,16 39:15, 22 40:15 42:12 45:7,19 46:2,11, 47:13,25 49:7, 13,20 50:5 52:9, 23 57:11,15 61:6 63:1 64:18	68:15 72:20,25 74:24 76:7 79:23 80:7 83:23 84:15 85:16 86:8,10 89:5,6,7,21,23 91:12 94:3, 103:12,13,14,15 108:25 109:11, 17 117:21 119:5,20,25 120:11 122:15, 17 123:23 126:17,23,25 128:8,20 131:18,19,22 132:5,10,12,20 136:13 137:14, 138:19 144:14 148:3,21 149:10 150:21 154:7,8 155:1 156:16, 23,24 163:9,22 164:20 165:2 166:17 168:3 170:11,12,17 171:15,16 172:5,18 173:4, 8,20,21 177:1 178:5,9,11,25 179:19 180:4,7 182:21 183:9 185:12,17,23 186:3,13,20 187:21,22 188:11 190:25 191:2,19,22 192:8 195:4 197:6,13 198:15 199:24 200:10,	25 201:20 202:7 203:14 204:13, 14,17 205:1,2 206:9,12 207:24 208:5,8,11,15, 16,25 209:14, 15,16,19,20 210:2,15 211:8 212:16 214:11 216:14 217:4, 13,20 218:7,11 219:2,10,12,20 220:12 222:4,5, 8,11,12,18,20, 21 223:13,14, 17,19 224:2,6, 25 225:6,8,15, 16,17,19 226:16 227:13,15,17, 19,24 229:6,9, 11 230:6 231:5, 24 232:1,3,4,5, 8,13,14,22 233:6,15,16 234:4,13,24 235:1,3,15,19 236:7,10,11,14, 24,25 237:5,7,9, 16,18,22 238:7, 10 241:12,21 242:18,19 243:9,22 244:7 245:17,24 246:1,5,9,12 248:2,8,10,11, 22 250:1,8,19 251:6,7,13,16, 22,25 252:1,9, 10,12,13,15,17, 18,19 255:6	257:3,20 258:21, 260:22, 24 262:8,19 263:8 265:5,18 266:4,6 268:22, 23 269:20 271:19 272:10, 11,17,18 273:15 274:3,22 275:5, 9 276:6,10, 278:18,21 279:8,20 280:7 281:14 282:5,15 285:25 286:2, 21,25 287:6, 288:10,24 290:5,7,10,21, 24 294:18 295:7 298:6,16 301:9, 24 302:14 303:6,16 304:5, 13,22,25 306:17,23 307:11,15 308:4,16 309:3, 21 310:2,4,6,8, 10,11,14,19,20, 22,23 311:3,22 312:3,23 313:12 314:3,4,5 315:21 316:9, 14,17 317:8 318:7,15,17,20, 23 320:2 321:11,12,13, 15,17 322:10, 24,25 324:20 325:10,12 326:3,13,22 328:17,21
---	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

329:15,23 330:5,8, 331:11, 20 332:1,2,3,7, 16,19 338:9,21 339:4,5,7 341:16 342:19, 25 345:2,12 346:11 347:15 348:2 349:4,12 356:3 357:8 attached 7:11 attend 10:19 attended 9:5 attending 276:1 attest 172:13 attorneys 273:5 attributable 213:10 attributed 329:4 atypical 327:13 AUA 257:3 audiences 275:4 AUG 188:14 augment 153:2 Augmentation 37:19 AUGS 188:1,8, 14, 189:16 255:6 258:16 259:4 261:17 313:24 314:3 319:16,25 321:6 352:20 353:7, 13,20 355:14 356:3 August 80:9	267:13 279:19 282:2 283:10, 17,23 290:6 348:12,14 349:2 353:1 Australia 247:14 author 65:5,14 70:8,9,11,15,16, 18,19 178:21 233:9 265:16 308:5 authority 340:10 authors 70:17 119:4,24 125:19 126:5 128:3,10 129:11 131:3 133:4 179:25 206:15 212:3,16 213:4 225:22 226:7 239:2,16, 23 242:11 253:22 262:13 264:3 290:16 308:1 317:12 319:1 353:20 354:5 authors' 128:15 autologous 66:1 324:24 336:3,5, 9 AVA 18:1 available 6:14 19:22 31:5,13, 15,19 37:6,10 42:19 43:17 46:20,23 47:4, 23 52:18 53:7, 22 115:12,16	131:20 132:15, 16,19,25 179:9, 11,15,16 190:4 229:12 258:13 259:7 260:19,24 261:5,12 268:8 353:12 Avaulta 18:19 21:2,23,24 30:7, 20 31:3,22 32:12 34:11,22 35:14,17,18 36:17,25 37:4,9, 15 38:2,8,12,22, 25 39:14,15,19 40:10,17,18,23 41:8 42:12,14 43:18 45:9,15, 16 47:15,16 48:25 50:15,16 53:11,13,24 54:1 61:9 94:16, 18,20 95:1,2,4, 5,7,9,19,25 96:3,12,13,15, 20,25 101:14 102:3,12,16,24 109:5 110:6,17, 25 111:17,20,23 113:6,11,14,24 114:10,21 117:3 126:19,21 128:1 129:4 130:19 132:1,3,11,18, 23 133:2 178:1 179:3,8, 183:14, 18,22 184:5,8,9 205:10,17,18,24 206:6 210:11 211:20 217:8	219:22,25 220:11,22 228:7, 229:18 233:6 234:18,25 235:5,13,23 236:13,14,15 295:3 297:15 318:12,13 319:3 332:21 333:16 337:14 343:5 345:9 347:17,23 348:5 349:6,14, 16,19 350:11 351:3 353:15 354:6,12,16,23 355:5 Avaulta-specific 234:16 Avaultas 179:14 average 9:6 92:10 avoid 157:12 aware 7:23 49:18 107:14,16 130:10,24 172:14,18 174:19 176:18 189:2 227:21 284:5 289:24 330:16 350:15 awareness 125:17 away 180:24 181:21 195:24 awful 228:2
--	---	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

B	357:8	24 19:7 21:5,19	59:11 87:20
B-o-n-d-i-l-i	background	24:25 31:22	97:24 102:16
235:11	92:1,4	32:2 34:11,22	105:4 110:12,23
baby's 140:9	bacteria 213:22	38:17 39:8,9,22	112:21 115:15
back 10:3,20,25	313:9,11	45:21 46:5,7,14,	116:4,8 131:18
11:9 12:16,17	bacterial 215:25	17 47:3,25 48:3,	136:10 146:12
13:6 16:18 25:5	bad 166:24	15 50:24 51:1,2	186:2 204:8
33:7 37:25 38:4	167:22 203:1,2	53:11 74:15	206:25 210:6
45:16,24 53:1,9	206:8 298:1	77:4,5 85:9 93:5	212:12 217:18
57:8,11 72:22	301:14	102:3 103:20	218:1 220:4
73:7,10 74:7	bag 259:13	104:21 109:5,7,	234:12 244:17
75:21 76:14	balance 187:13	13,23 110:5,25	247:16 255:5
78:17 82:7,10	Bales 187:9	111:17 114:21	261:13 264:10
87:1,25 88:1	ball 193:15	115:12,24	269:1 271:21
90:15 99:25	212:11	116:5,18,23,24	296:4 303:18
104:23 105:11,	ballpark 83:1,8	117:14 123:16	321:7 338:1
17 110:21,23	85:17 87:3	126:22 128:1	341:2,3 343:12,
111:14 117:24	ban 190:3	129:4 229:3,11,	16 344:14
131:25 132:20	191:22 192:8	24 236:2 261:10	350:24 356:18,
139:2 143:12,19	259:5,21,22,25	339:7,24 340:3,	23
144:2,11 147:20	260:1,6,17,23	4,10,15 342:19	basic 90:16 93:3
154:14 156:13,	268:7,10 277:7	343:4 344:23	94:22 96:23
24 176:12	279:3 349:5,25	345:22 347:9	311:1
182:14 186:22	band 257:23	349:6,19 350:8	basis 32:1 46:21
195:3,4 197:12	bank 86:9	351:1,8,11,16	52:25 102:15,23
202:9 212:25	banned 261:5,16	352:2,4,15	115:25 116:22
215:16,19	347:19	Bard's 29:22	141:24 196:25
216:11 230:19	banning 281:11	30:7,20 32:12	197:21 210:6
243:13 250:25	348:18	35:25 37:4	256:20 257:13
257:13 260:15	bar 254:17,23	48:25 114:13	269:1 296:6
261:8 262:6,11	256:12 270:19	126:19,22	Bates 17:8,25
267:13 281:4,5	271:17 272:6,	332:16 350:25	18:9 23:15
282:14 283:9,22	17,18 273:2,3,6	351:3 355:17	Baylor 154:7
301:24 302:18	barbed 226:3	barely 78:22	beast 247:1
303:6 306:2	Bard 4:10 5:1,2	barriers 141:4,5	beat 266:15
310:11 322:25	17:22,24 18:14,	base 117:19	beaten 266:22
324:17 335:11,		297:18	became 156:17
25 343:6 344:20		based 19:3 21:1	
		30:14,25 47:22	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

because 8:12	213:1 215:24	15:19 16:14	63:25 79:13,16
9:22 10:17	219:2 220:22,25	21:12 33:14	83:2 91:16 93:6
16:11,23 20:10	224:11 225:7	45:12 58:4 62:3	97:16 107:18
21:8 25:3,15	226:2 229:14	96:24 97:20	113:23 140:15,
32:20 37:7	232:9 233:5	98:4 104:6,15,	19 141:1 148:19
41:25 46:17,19	235:4 238:7	17 107:20	153:16 190:24
53:10 54:12	240:5,6,21	110:22 111:10,	192:5 201:19
56:5 57:14	244:2,15 245:10	12 122:23	206:2 209:13
59:16 67:1,3	246:19 247:1	124:16 126:8	220:2 248:11
72:15 73:22	250:15 251:20	132:15 135:16	272:16,17 273:2
82:24 85:9 87:3	252:13 256:4,10	141:10 147:22	284:5,14 298:20
96:6 101:2	257:17 259:12,	180:9 193:4	302:15 304:6,23
103:9 104:2,11,	13 260:15	205:8,15 232:5	308:4 314:1
23 105:4,21,25	263:5,7 264:4	237:1 242:7	323:20 341:6,8
106:4 108:3,7,	268:6 269:9	246:5 255:6	347:19 352:15
19 109:8 111:5	271:13,24	261:20 267:11	353:9,15
112:20,22	274:8,13	269:12 288:1	beings 50:21
113:18 117:20	275:23,25	293:21 294:5	belabor 144:8
118:6 120:19	285:23 287:20	300:25 302:13	211:25
123:14,15,19,	290:19 297:22	306:6,8 314:7	believe 16:23
20,22 124:10,17	298:19 305:2	319:17 323:1	38:12 53:11
126:22 130:5	309:11,16	350:17 353:2	73:16 75:9 76:4
132:1,4,25	313:4,18,19,	beforehand	98:5 120:23
137:4,12 138:13	321:20 325:9	357:16	159:2 161:23
140:16 147:11,	335:16,19	beginning 4:2	165:6 166:23
19 148:13	336:18 338:2	15:6 89:8 100:3	188:11 213:9
149:11 150:19	339:16 342:23	127:9 191:18	220:13 237:8,9
153:1,4 156:3	345:6,24 349:12	229:19 263:9	250:5 255:11
158:16 160:13	350:22 352:11	303:4	262:17 265:8
161:18,21	355:24 356:20	behalf 29:17	278:19 292:14
162:15,18 163:9	357:8	75:13,19 83:14	295:16 307:12
166:13 167:5,	become 6:13	85:18 86:22	317:9 337:17,21
11,12,20 173:19	49:15 50:1 53:6	89:13,19 98:3	338:1 347:16
174:17 175:25	54:15,24 60:18	257:16 292:19	349:12
178:20 179:5,14	108:17 179:8	behind 157:15	below 23:24
180:5 181:21	185:19	336:12	309:7
183:23 184:6	becoming 49:4,	behoove 131:15	Ben 76:18
193:8 195:1,18	10 107:14,15	being 29:22 47:4	171:19
197:2 204:17	before 4:22 7:18	49:23 59:19	
207:19 209:2,11			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

benefit 193:11, 13 260:21 269:11 benefits 86:11 192:10,11,14 261:7 289:24 293:6 356:14 benefitted 320:22 besides 105:22 278:21 best 29:7 31:18 33:6 63:21 96:22 110:2,4 112:16 124:24 169:20 189:3 191:25 251:21 256:23 290:11 313:6 331:2 353:11 bet 230:8 237:24 238:1 242:8 better 10:23 38:15 41:5 52:18 92:9 129:23 157:5 168:12 187:8 225:1 237:20 241:12 251:21 273:15 293:16 296:23 304:2 betterment 190:23 between 8:18,22 9:5 38:17 40:16 79:8 80:21,25 81:3 100:23 114:20 117:11	136:25 220:4 234:18 235:22 236:7,15 247:24 264:19 298:12 312:10 337:21 bewildered 67:2 beyond 140:7 241:14 bias 131:24 255:17,20,25 257:14 271:13 biased 256:10,13 257:17 258:9 264:4 bibliography 8:5 17:6 23:13 28:7, 10,15 62:19 77:21,23 78:3 81:6 262:19 big 111:9 126:11 135:14 155:6 176:8 224:15 228:14 305:4 bigger 158:17 187:8 biggest 221:7 265:25 bio 61:25 78:10 Biochemical 65:24 biocompatibility 21:4,17,19 biofilm 306:20, 25 307:4 313:1 biologic 152:7 201:12,25 202:14,21 333:1	biological 201:16 biologicals 201:19 biologics 152:10, 12,15,18 202:16 203:2,3 biomaterials 90:4,7,19,21 91:2,16,20 92:18,22 93:9, 17,20 94:4,8,9, 14 97:17,22 98:5,9,13 biomaterials- designated 98:3 Biomechanical 332:25 biopsy 74:4 bit 28:21,24 53:6 61:22 132:8 146:17 157:8 169:3 184:22 193:18,20 197:24 272:6 294:5 340:8 bladder 69:25 72:17,20,24 73:12,24 74:4 134:9 140:20 146:4 147:12,13 160:22 Blaivas 187:9 blanche 165:15 Blandon 118:9, 18,25 178:9 290:16	blanket 191:13 blanking 171:19 bleeding 147:4 160:23 blind 333:15,21, 25 334:12, 335:16,18,24 336:14,15,18 337:4 bloody 71:11 blue 269:14 343:16,19 344:14 board 49:12 99:13 100:1,9, 13 278:19 341:8 354:2,3 board-certified 99:7,15,19 100:10,11,15,17 boards 101:7,9, 10 boards' 101:9 Bobbie 339:9 bodies 269:8 282:9 348:22 body 13:5 39:15 94:1 125:7 126:2 140:1 194:6 214:25 215:9 221:16,22 229:16 295:9,24 296:2,9,18 303:19 328:1,8 331:2 body's 295:22 328:6,12
---	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

Bondili 235:11	230:12,14	buy 272:14	126:10 132:1,18
bone 336:13	293:21 305:18	buying 117:21	183:25 189:19
Book 343:16,19	306:6	buys 117:23	229:5,6,18
344:14	breakage 325:23	bypasses 154:13	257:19,20 261:8
borderline	breakdown 82:1		271:15 276:20
239:16	304:15	<hr/>	287:5 300:25
borne 152:24	brief 78:8 82:13	C	301:10,12
boss 70:18	briefly 145:20	C-o-d-a 310:14	317:7,12 326:6
Boston 31:20,24	319:10	C.R. 4:9 5:1,2	344:20 351:8
32:14 34:12,24	bring 23:15,16	cadaveric 50:11	355:24
36:1,20 38:9	53:9 62:7 77:15,	65:24 202:17	camera 305:23
45:10, 103:22	19 79:7,9 181:2	325:1	can 14:5 17:14
130:21	206:1,2 298:17	cadaverics 50:18	19:16 20:21,23
both 21:22 75:23	brings 300:9	Cadillac 115:21	21:25 26:22
93:2,5 101:2	broad 215:12	calculations	27:20 33:7
144:14,22	296:21	110:10,12	37:14 39:6,10,
168:25 201:10,	brochures 51:24	California 89:7	12 40:9 41:5
11 207:10,25	341:4	192:25	42:18 43:5,7,10,
209:17 217:3	broken 81:22	call 17:25 28:5	12,17,20 44:2
219:12,13 221:1	112:24 235:4	74:2 99:17,18	47:18 48:7
236:25 237:18,	brought 8:4	100:15 135:9	53:21 54:5 55:4
19 240:24	22:23 205:24	146:7 228:13	56:14 59:11
241:9,10,	206:8 325:9	230:2 271:9	60:4,6 64:11
319:16,22	Brubaker	274:19 315:6	69:21 72:2,14
bothersome	152:16 248:23	called 4:16 6:17	73:2,25 74:18
126:15	265:24	28:7,15 33:13	76:25 78:10,22
bottom 274:11	building 310:19	139:6 141:12	80:13 82:3 85:5,
279:23 288:3	bulge 225:19	147:9 229:21	22 100:15
bowel 158:19	242:12	304:10 349:18	106:12 107:9,10
box 338:3	bulging 237:2	calling 100:9	109:20,22
brand-new	bunch 138:14	290:20	110:9,24 112:13
11:12 208:19	178:3 280:12	calls 229:7,8,22,	113:3,25 115:5,
Brandon 230:18	buttock 194:1	25 230:1	9 116:17,23
break 61:22,25	214:16	came 16:11	124:13 133:6,14
71:13 78:11	buttocks 297:12	22:15 54:7	136:12,13,21
81:18 138:4		71:15 119:16	138:13 140:6,8
139:10 193:17		121:21 123:18	141:10,23
			142:9,20,21
			143:5 147:21
			148:2,5,6 149:3,

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

7 169:22 171:1 172:3,23 174:20 181:13,14 182:22 186:12 193:9 199:8 200:15 201:23 202:6,7 203:4, 23 213:14 217:24 226:1 227:9 230:11,25 231:19 243:7 244:10 247:16 262:3 268:4 271:8 281:24 282:1,7 288:2 289:1,13,16 292:2,5 293:3,7, 8,9 295:10 298:2 299:1 302:17 305:20 311:7 315:14 317:20 320:16, 25 334:10 337:11 338:25 341:5,24 342:3 343:17 354:6 357:22 can't 7:13 11:16 13:24 15:20,22 16:4,7,12, 18:20 19:11,17 24:4 25:2,15 29:10 33:2 38:5 40:19 42:10 44:2,8 47:21 56:6 69:17 73:10 80:23 82:25 83:10,12, 89:16 91:8 103:7 105:17 106:13	107:25 108:4,5 113:2,21 114:8 119:16 122:25 123:22 124:11 130:22 131:6,7 135:19 151:9 154:24 157:2 158:11 171:20 172:13,21 175:25 176:20, 24 177:23,25 189:1 191:12 193:8,9 196:1, 25 212:6 216:8 222:7 228:8 248:18 249:6,7 251:8 252:24 255:19 256:24 258:2 262:21 276:12 291:13, 16,23 303:8 317:9 318:12 320:19 328:4 334:8 335:21 354:4,10 candida 213:23 215:18 candidates 108:17 177:5 cannot 38:6 172:24 183:23 184:6,8 191:11 250:15 265:3 294:25 296:8,18 344:10 Capio 335:8,24 car 272:14 card 230:13	care 10:18 46:21 49:14,23,24 52:23, 142:24 146:11 149:10 154:8 173:3 175:8,12 177:18 183:7 187:14 188:21 190:2,21 195:5 197:6 207:15,16 210:20 257:13 258:6 263:12 278:20 280:24 282:8,21 289:22 320:4,10 323:15 337:20 346:2 career 51:8 71:9 careful 109:2 carefully 123:1 166:14 318:8 Carey 216:14 218:10 223:13 244:18,21 245:6,21 247:14,25 Carome 269:5, 12 277:9,14,16, 17,18 282:4 carry 93:24 cars 115:21 carte 165:15 Cartmell 4:7 16:22 23:3, 24:5 27:14,19 29:25 30:10,17 32:18 33:24 34:6,15, 17,25 35:4,9 36:4,12,15 40:2,	7,21 41:2,16,19, 22,25 42:16,24 43:3,11,24 44:3, 10 45:11 48:4,7 49:5 52:4,14 53:18 54:3,17 55:1,4,7,10,13, 15,20,24 57:3, 13,17 58:6,9,13, 18,20,23 59:2,5 60:4,6,9,12,21 61:11 78:9,12 81:8 82:19 85:12 86:23 87:9,22 88:7,12, 21 89:3 90:8 91:4,21 92:14 96:17 97:18,21 106:6,9,21,24 107:2 109:24 110:3,5 113:8, 25 114:4,22 116:1 121:16 122:8 123:11 124:7,14 126:21 130:13 133:6, 10,12 137:9 156:5 164:8,18 165:3 166:5,8 168:14 171:7,23 174:4,14 175:19,23 177:7 181:23 185:10 186:9 188:23 189:6,10 191:7, 19 194:13,24 203:6 206:5 211:1 212:22 215:10 219:16 221:17 222:20,
---	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

22 228:4,21 230:9 233:21 234:20 238:14, 16,18 239:10 240:13,16 243:17,20 244:3 249:21,23 250:12 254:19 259:9 261:25 267:6 272:22 273:1,17 278:3, 11 280:10,12,18 281:12,16 291:10,14,17, 19,21,25 292:4, 7 293:13 296:11,13 299:3 300:2,5,12 301:2,16 305:11,16 316:11 317:23, 25 321:15,18,20 323:17 324:8 327:9,16,20 329:10,14 332:13,21,23 338:11 340:25 341:16,20 344:5 346:11,14 347:1 355:6 357:11, 15,21 cascade 221:21 cascades 213:15 case 24:11 33:21 61:2 71:23 75:4 97:10,13 171:20,23 317:5 318:22 336:6 337:3 354:21	355:1 case-specific 5:12 6:5 77:23 81:16 cases 5:13 74:10 76:7,14 81:19 140:8 146:3 276:22 295:15 314:17 Castello 298:24 caught 111:4 239:2 cause 74:1 140:22,23 158:3 213:15 caused 35:15 151:7 causes 35:18 36:17 causing 32:6 147:15 220:25 307:13 caveat 163:17 263:16 337:5 caveats 149:20 168:5 177:3 190:9 268:21 286:15 cavity 215:3 center 49:14 52:24 148:21 149:11 175:13 190:17 195:5 197:6,16 246:11 247:15 321:25 centers 183:7,9, 13 247:3,5	centimeter 336:12,19 337:6 centimeters 335:10,13,14,24 Central 10:21 certain 5:5 13:22 14:9,13,19 33:18 117:23 155:10 170:9 172:20 174:12 177:4 184:6 186:12 192:3 214:24 261:18 262:7 264:16 266:5,6 271:16 274:4 327:11 328:14 330:18 351:7,8 certainly 7:19 217:20,21 323:13 354:11 certainty 347:5 certificate 101:6 certification 99:20 100:1,9, 13 certified 49:10 cetera 19:15 48:12 117:4 133:24 135:2,21 215:18 261:15 355:13 chair 119:1,5,7 178:10,20 197:2 272:9 275:13 challenges 149:24 150:13 151:1,14	challenging 154:13 chance 163:21, 164:22,25 165:20,22 166:2,7,20,22 167:4 168:19 202:10 247:19 337:22 chances 165:18 change 12:20 107:3 212:19 changed 142:23 176:24 271:20 changing 12:4 304:15 characterized 301:20 characterizing 302:23 charge 119:1 271:12 272:20 277:11 charged 84:25 chase 268:4 chemical 303:9 304:3 chemistry 92:3 cherry 265:22 Chevron 25:6 Chicago 171:22 187:9 childbirth 134:13,14,16 135:1,11,12,17 children 193:7
--	--	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

choice 50:23	Citizens 256:16	357:16	closely 149:12
choose 142:2	277:4	clearance 49:19	163:10 195:21
chooses 142:19	claim 63:21	54:14 344:9,19	239:6
147:1 159:5	claiming 53:16	cleared 60:20	closer 87:2
choosing 266:5	57:21 58:11	344:4	143:19
330:17	240:10	clearly 97:21	clotting 221:21
Chris 119:3	clarification	207:15 225:1	Cobb 221:8
272:8 326:5	24:6 25:17	261:13 282:2	229:7,23
Christopher	40:22 51:24	356:8	Cobb's 229:16,
275:13	98:10 114:1	Cleveland 76:20	17 339:4
chronic 134:14,	clarifiers 173:10	77:2 171:15,16,	Coda 310:14
17 149:23	clarify 94:24	19,24 172:4	coincidence
194:5,6,7,8	173:10	clicking 180:23	241:16
chronology	class 130:6	clinic 86:15	coli 312:21
160:9	classic 221:8	104:4,8 107:21	313:6,10
circle 187:5	classification	108:10 114:17	collagen 31:6,10
circumstance	229:2	118:16 119:15,	32:7 35:14 37:1,
107:5 149:19	classified 228:19	17 120:1,8	5,11,15,20,24
circumstances	Clave 298:7,17,	121:11 131:3,19	40:11 94:19
74:19 147:24	20 299:2,3,5,6,	136:8 171:16	135:20 205:10
260:2 262:7	7,14 300:24	179:2 192:12	214:13 219:20,
citations 340:9,	302:12,21 303:4	197:13 261:15	23 220:15,16,18
13	306:5,19 307:16	283:14 286:21	colleague 71:12
cite 343:18	309:2 310:3,5,9,	287:3,16,19	154:15 294:21
cited 28:17	22	288:20,22,25	322:17
66:12 305:6	Clave's 310:19	289:20 290:6,7,	colleagues 8:14
339:10,11	312:9	11 292:10,19,	94:7 108:21
citing 298:20	cleaned 142:23	297:20 322:6,7	146:10 150:8
Citizen 267:12,	clear 18:17	349:4	178:14 276:23
21 269:17	40:24 44:8 52:7	clinical 136:4,8	294:18 295:1
270:5,14,20	56:14 59:20	192:1 261:18	297:22,24
271:1,5,13,17	105:21 131:16	311:1 343:24	College 154:7
277:6,19 278:2	162:23 166:12	344:2,17 345:2,	Colon 299:11
279:16 281:10	168:11 169:19	4,15	Coloplast 75:5
283:25 347:17	198:9 246:25	close 57:16,	338:8
348:15	257:8 259:24	181:18 275:11	colporrhaphy
	261:3 270:22	closed 13:11	195:23 216:21

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

244:22	319:21 346:3	250:16 251:9,24	complete 6:7
column 127:5,7	355:23	compared 16:18	7:16 44:18
309:12	common 105:23	37:15 38:8,24	260:17
come 9:17,18	140:3 142:21	42:13 45:22	completed 17:7
10:19 11:7 17:4	147:6 170:10	46:5,15 47:16	completely 17:7
22:2 32:9 60:4	313:9 315:15	48:1,11,16,20,	40:3,9 65:21
73:7 104:13	320:13,17	23 158:14	67:14 123:20
117:15 119:18	communication	203:15,18	153:8 214:19
131:24 155:13	189:17 253:14	206:17 220:13	293:7 313:4
178:2 184:17	258:8	241:23 319:3	complicated
202:3 221:1	community	326:19 330:4	12:24,25 43:15
262:10 271:7,21	168:11 169:20	compares 169:9	160:13 173:20
275:17 276:11	174:10 184:25	comparing 39:4,	222:2
290:13,24	185:6 275:18,	13 41:7 45:15	complication
292:16 301:25	20,21,25 276:5	47:20 200:14	44:15 46:3 47:9
302:13 307:25	comorbidities	202:18,19,20	115:4 130:9
326:24 344:23	149:24	206:10 217:2	163:6,15 165:18
comes 9:19,20	companies	244:25 265:6	166:16 196:5,13
13:10 104:5	157:20 190:3,22	318:10	298:9 318:19
110:18 114:17	258:14 261:9	comparison	342:17
144:11 170:15,	270:12 344:22	39:13 47:22	complications
23 257:10	companies'	48:11 101:1,2	11:25 30:14
270:18,22	113:16	235:17,22	31:13 35:18
300:10	company 27:10	236:19	44:22,23 45:2
comfortable	115:17,20	compartment	46:8 49:23
174:16	116:9,12,25	146:21 158:5	63:24 64:10,15,
coming 85:11	117:22 131:15	compensate	20,21,24 65:9
106:4, 107:19,	255:18 342:6,8	277:19	66:7,19,20 67:6,
21 111:6 176:7,	comparative	compensated	8,15,17,19 68:8,
15 197:4 243:13	32:22 37:3	79:13 83:14	16 69:4 75:8
271:10 277:12	38:10,17 39:8	85:5 256:12	90:12,13 92:9
354:2 356:20	40:16 219:4	272:18 284:5	93:2 94:10,13,
comment 44:25	236:15 299:11	compensation	14 98:19 103:5
105:23 282:7	333:4	77:17 79:9,12	106:20 107:14
comments 25:7,	compare 37:6,10	272:6 284:22	114:20 119:9
59:24 181:7,10	39:17 41:5	compilation	120:14 121:5,
256:15 284:10	195:24 217:7	104:20	11,25 122:6,16
committee 63:4	247:23 249:6		123:7 125:20
			126:6,12,13

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

128:6,18,24 130:4 131:21 132:6,9,11 148:8 149:6,17 150:6 158:16 173:15 174:19, 20 178:2,25 180:7 182:9,25 183:13,21,25 184:4,13,17 194:10 246:20 253:14 266:12 276:2 278:20 288:16 290:2 296:24 298:9 313:19,20 318:14,16 320:21 322:22 337:20,23 340:16,18 341:7,12 342:3 352:18 356:21 357:10 complied 345:22 component 229:14 components 52:10 computer 14:18 15:1 112:24 con 18:18 concentrate 63:15 concern 254:6 282:17 313:1,14 concerned 288:15	concerning 18:18 19:13,15 307:19 309:6 concerns 313:19, 23 conclude 125:20 126:5 315:10 326:1 328:24 330:3,9 concluded 39:9 40:18 42:14 45:20 46:4 47:15 48:14 169:18 200:17 208:3 225:22 237:19 241:11 299:25 326:17 332:4 356:13 concludes 204:5 312:23 357:25 conclusion 131:2 242:11 281:2 307:16 312:10 314:25 317:12 330:14 conclusions 71:7 98:25 201:3,4 232:14 264:2 299:22 314:19 329:3 330:18 concurrent 146:10 148:3 condemnation 274:24 275:2 276:23 condition 133:20 134:2 136:16,24 139:17 141:16	conducted 94:15 96:19 confines 187:2 confirmed 309:8 confluence 214:12 confusing 265:13 confusion 246:23 cons 166:13 consensus 168:11,18 337:24 consent 71:18 164:25 167:9 consents 163:2 conservative 108:18 115:8 142:15 consider 48:24 90:19 92:6 175:13 295:21 296:1 306:17 311:24 331:6 332:9 336:20 340:22 considerable 299:24 considered 6:23 7:9 156:25 199:18 229:13 231:2 306:15,21 307:2 333:21,25 334:12,16 335:15	considering 170:6 289:20 290:23 293:4 consistent 89:22 112:11 139:19 169:16 175:11 186:22 187:10 206:3 286:1,6 constant 8:14 constantly 8:12, 13,20 10:17,22 12:13 constipation 134:18 140:22, 23 consultant 116:10,13,15,17 338:14 consultation 142:4 159:6 consulted 346:16 consulting 277:19 338:7 contact 77:3 277:11 292:16 297:9 contacted 76:9 269:19 275:10 276:17 277:1,3 284:25 290:19 contacts 282:4 contain 6:7 34:2 342:11 contained 6:18, 24 13:13 81:15 containing 7:20 40:11
---	---	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

contaminated 213:22 214:13 215:17 234:2	contribute 330:13	267:11 283:6 285:7 311:17,18 312:2 314:12 324:7	14,16,17 119:6, 11,12,15,19,21, 22,23 120:2,16 121:6,12 125:9, 21 126:6,19 127:20,23,25 128:1,2,8,13,14, 18,19 129:7,24 132:13,17,24 133:22 134:7, 13,20 136:17,23 138:12 139:18, 25 140:2,7,8 141:4,19,20 142:2,12 143:23 145:5,6,9,11,15, 16,21 146:2, 151:24 152:8,9, 23 153:3,21 156:7 157:18 159:22 161:5,7 163:1,4 167:10 169:11 175:7 180:6,8 182:6,7, 12,13 183:2,3, 10,11 185:18 188:6,10,22 189:5,17,18,23 196:10 197:13 198:21 199:2,3, 4,17,23,25 200:6,18,19,22 201:9,12 202:23 203:16 204:3,16 205:5 206:13 207:3,13,22 208:2,5,18,21 209:19 216:23 217:14,23 218:8,9,15,
contamination 215:25 326:23	contribution 233:10	corner 288:3	
context 301:21	control 46:11 284:3	correct 4:22,23 5:5,6,9 6:5,6,20 8:9 10:2,5,8 11:2 13:17 16:1, 9,10 18:2,5,8 20:2,3,15,19 21:14,20 22:13, 14,17,19 23:21, 23 25:14 27:8 28:9,12,14,19 29:14,24 32:17 33:14 36:3 37:1, 2 40:1,6 44:20 47:1,6,11,12,25 48:6 50:25 53:12 62:11,16 64:5,25 65:19 66:13 68:3,6 69:11,15 72:11 74:13 75:15 76:16 77:14 78:6 80:7,10,19 81:4,17 83:25 84:3,8,14,24 85:3 86:7,9 88:10 90:5,6,7, 10 94:21 95:14, 16,17,21 96:11, 20 97:1,17,19 98:4 99:8,9,17, 100:18,19,22 102:13,14,25 103:1 110:14 111:25 113:7,13 115:11 118:12,	
Continence 235:15	controlled 38:21 39:3 41:1,9 48:12,22 223:9 238:8,12 260:2, 4 349:8 351:2		
continual 273:5	controversy 174:9 185:7		
continuation 239:1,13 241:1, 17	conventional 203:15,18 208:9 209:3		
continue 59:17, 22 60:2 72:15 153:12 230:24 234:3 294:19 328:16 345:1 350:11	conversations 7:3 8:14		
continued 72:13 73:12 139:8 233:14 294:24 351:10,24,25	convinced 188:13 269:22		
continues 208:13 274:14,15 280:23	Cook 103:23		
continuing 255:12 352:17	cookie 175:22, 24,25 176:3		
contraction 327:2,6,12,14, 23 328:3 331:7, 17 332:3,4,10 333:7 338:4	COPD 150:8 151:6,7,8		
contraindication s 343:21	copies 77:22,24 78:3 80:11		
contrary 301:20 302:13,22	copy 5:23 8:8 14:25 17:17 22:21 28:11 62:12 90:2 118:7 169:24,25 170:2 171:5,10 180:21,22 181:3 182:15 223:5 251:15 252:3 255:19 263:24		
contrast 281:10			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

219:23,24,25	10 337:16 338:6	149:20 158:3,8,	29:17 91:13
224:20 225:21	342:1,22 344:19	18,22 159:7,10,	161:8 179:9
227:11, 228:12	345:5,8,15	23 163:25 164:6	197:11 245:17
231:15,25	346:8 347:21	165:11,21	306:13 330:22
232:17 234:7	348:1,13	181:17 202:10	course 20:16
236:9,16 237:3,	349:10,14	220:14 257:9	122:24 278:1
21 241:13,24	350:19 351:13,	260:5 265:1	court 4:11 75:9
242:4,6 243:25	22 352:16,24	271:11 306:8	168:2 180:15
244:24 245:8	353:5,6,10,17	307:4 309:8	311:6
246:12 248:16	354:20,24,25	310:10 320:25	cover 84:6
253:17 254:24	355:2 356:7,15,	336:21 339:20	239:18,19
255:21 259:22	18	340:17 344:23	covered 193:4
260:18 267:14,	corrected 141:11	352:12 355:10	covering 32:6
19,20 268:11	correction 63:25	couldn't 272:13	Cozad 310:15
269:1 273:12	178:24 203:21	counsel 4:5 7:21	cracking 304:1
274:1,6,10,19	234:23	17:1 18:8,23	cracks 307:3
275:9 278:7,17	correctly 120:15	20:5 27:17 34:7	312:25
279:16 285:19	124:1 131:11	42:1 44:10	crazy 71:18
286:16,25 287:8	173:6 236:23	45:12 76:6,14	216:8
288:11,18	250:5 253:18	78:22 82:11,16	create 114:5
289:17 294:6,7	286:5 290:3	85:1 87:7,16,21	158:3
295:15 296:9	314:22	97:8 223:6	credentialed
298:21 299:10,	correlate 144:4	273:10 276:15	190:5,14
12,13,18	205:18 322:4	281:17 293:14	criteria 108:19
302:11,16	326:25 338:3	309:24 311:19	134:21 175:1,5,
303:2,5,17,21,	correlation	314:12 324:7	10 177:3,11
25 304:4 306:11	298:12 312:10	346:12	261:21 346:1
307:21 308:13,	318:13	counseling	352:12
14 313:16,17	correspondence	143:16	critical 130:2
314:23 315:8,9,	26:17 79:8	count 9:1,9	226:12,13
18,19 316:6,10	Costello 310:15,	254:14 341:5	232:22
317:14 319:19,	17	counted 340:2	critically 129:20
20,23,24 321:13	cotton 200:12	counting 109:16	criticism 210:23
323:5 324:14,	cough 134:14	112:14 329:11	252:11
15,21,22 325:7	could 39:16	340:7	criticisms
326:8,10,14,15,	112:10,11	country 119:15,	205:23 223:11
21 328:19,20,23	134:18 141:4	18	
329:25 330:6,	142:25 147:3,7	couple 7:19 8:10	
23,24 333:17,18			
334:3,6 336:4,8,			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

236:12		240:24 244:14	312:3,5
criticize 175:14	D	260:19,23	deal 49:24 67:4,
CROSS-		261:5,8,10,12	7,19 71:17
EXAMINATIO	D&c 334:1	262:5 266:2	72:21 90:11,12
N 346:24	D&cs 334:2,3	268:1 274:22	141:23 150:22
cross-examining	D-i-e 331:12	297:3,20 307:12	174:20 192:22
240:13	D-i-e-t-z 331:13	321:1,3,8,9	228:14 255:1
crowning 140:9	daily 46:21	325:16 336:25	270:17 357:9
crumbs 176:3	49:23 52:24	344:1,16,22,23	dealing 37:11
Culligan 234:22	53:3 82:1 86:12	345:6,15,17,18	53:2 63:23,24
Cundiff 248:24	141:24 196:25	349:13,15 351:8	67:16 68:11
cup 333:12	210:21 256:20	database 128:15	70:6 71:25 73:1,
cure 318:15	257:13 269:1	date 10:25	3 90:16 92:4
current 66:17	290:17 296:6	12:16,17 21:10	93:1,11,12,13,
105:16 166:3	damage 134:12	26:19 27:3	25 94:14 121:22
272:9 274:13	135:18 193:10	133:6 157:2	240:5 261:14
currently	351:25	169:22 170:1	341:3,4 356:21
127:15,20	damaged 135:21	279:18 283:12	dealt 72:23
132:22 179:19	192:6 289:8	288:3 349:22	debatable 315:6
190:3 192:11	dangerous	dated 288:6	320:12
246:18,24 268:8	155:11 258:3	dates 272:11	debate 175:17
curriculum	Daniel 4:3,15	301:24	debated 129:14
62:19	139:5	day 10:18 82:2	257:1
curve 166:25	data 6:22 13:10	86:4,5 136:8,9	debilitating
252:18	37:9 39:16	140:2 192:12	194:7,8
curved 252:17	46:12,13,17,22,	197:9 255:1	decades 297:6
cut 71:21 195:23	24,25 47:1,4,5,6	275:2 343:4	December
221:20 268:4	61:19 70:20	day-to-day	183:10 274:14
cutting-edge	71:5 72:14	261:14	decide 142:10
68:24	86:18 87:7,12	days 7:19 8:11	191:25
CV 7:5 62:12,23	115:21 117:14	80:6 282:2	decided 71:18
64:14 65:21	129:23 151:3	313:12	344:23 351:17
68:20 188:11	163:10 176:6,23	de 147:7,9,24	decides 145:25
cystocele 146:5,7	181:22 205:17	149:12 208:17,	decision 278:8
	208:13 210:14	18,20,22 209:8,	decline 182:3
	212:4,5,15	9 218:7 310:20,	decrease 326:19
	226:10,12	21,23,25	328:13
	233:14 235:16	311:15,19	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

decreases 221:25	216:11 221:10,	denied 278:1	25:20 26:7,11
deep 131:12	11,23 233:14,25	denigration	27:3,5,15,24
deepen 12:23	234:1 294:4,9	271:25	28:3 56:22,23
deepening 13:1	295:17 298:11,	denominator	62:1,3, 74:8
deepest 335:7	23 301:6 304:1,	103:15 113:5,21	75:10,22,23
defecate 140:16	15,20 306:10,18	114:6 115:10	77:15 78:21
Defecation	307:20 308:2	116:23 117:15	79:6 82:2,14,18
140:21	309:6,17 310:14	123:10,16,18	84:16 91:1,11,
defect 143:24	311:25 312:11,	125:11 178:4	14 111:15
145:8 147:2	25 313:15	183:24	118:1,5 171:3
225:3	317:21 318:1,5	dense 31:4, 32:5	180:16,17 181:3
defective 242:21,	degrade 216:4	density 205:10,	182:1 187:17,21
25 243:5,16	309:1	11 220:5,9,23	198:10 203:9,10
244:2,17 255:2	degraded 309:3	221:3,6,9 222:5	216:18 223:1,5
defendant 4:9	degrades 216:5	deny 176:8	230:21 249:11
deficiencies	295:3,9 308:24	185:3	253:8 267:7
211:11	309:14	denying 89:8	273:19 279:10
deficiency	degrading	department	281:19,21
134:22 135:5,8	298:19	119:5,7 120:9,	283:1,5 285:3
211:10	degree 92:20	18,20 121:1,11	286:15 311:12
deficient 211:9	129:12 137:1	122:15 128:17	314:9 316:20
define 92:13,16	246:7 247:11	154:7 269:18	319:12 324:1
159:14 337:17	335:4 336:17	286:21 292:12	329:12 331:22
defining 70:12,	347:5	depending	347:13
13 89:20 244:16	degrees 92:17	155:21 174:3	depositions
335:23	delayed 39:18	246:11	13:16,20 14:14
definitely 143:5	43:19 121:24	depends 70:11	15:8,9,21 16:3,
213:14 261:13	174:22 195:19	89:20 137:4	17 22:10 23:16,
definition	Delivery 234:23	141:16 155:7	20,23 24:3,13,
308:12	demand 104:6	159:14 216:15	15,23,25 25:3,4
degrade	demonstrate	247:10	47:3 75:18
214:23	326:18 349:8	deposed 90:23	117:6 236:3
degradation	350:1 351:2	deposit 86:10	317:7 340:19
208:12 213:2,8,	demonstrated	deposition 4:3,	Depositions-
9,12 214:4,9,	299:25 339:1	22 5:8,19,20	testimony 22:8
215:22,23,24	demonstrates	14:3 15:2,11,15	depth 262:1
	126:14 306:24	23:25 24:21	deputy 269:5
			277:13

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

derived 85:23	detail 15:18	24	difference 70:10
dermatology 100:12	19:13 81:23 237:9 306:8	devoted 136:4	100:23 117:11 196:21 198:5,6 208:3 209:25 212:20 217:19 220:4,10 225:23 234:17 278:24
dermis 65:24 202:17 325:2	detailed 305:3	diabetes 149:22 150:4 151:9,19	different 12:4,9 14:13 24:15 31:7 39:20 41:13 42:3 59:2 66:10 70:3, 72:4 84:9 90:22 119:21 123:20 124:6,23 125:6 133:19 136:21 138:5 141:17 145:14,17 150:1,16,18 151:21 153:8,9, 18 155:16,20 157:19 179:17 183:9 193:15 194:18 196:10, 21 197:10 205:7,8,9,10 209:14 211:19 212:1 214:12,18 215:1,6 219:10 220:22 221:21 222:5 226:18 237:23 239:4 240:10,11 241:5,7 247:1 256:3,5,6,20 261:21 266:13 276:21 297:6 306:22 307:10 311:23 319:3 324:12,20,23
descend 135:3	details 272:16 279:6	diabetic 150:25	
descending 343:24 344:15	determine 104:9,11,20 110:24 111:15 113:21 232:18 309:16	diabetics 150:12 151:14	
describe 182:24 199:10 232:12 312:13	determined 343:25	didn't 14:2,17 15:13 16:15 26:8 35:20 55:3, 6 58:5,6 59:4,16 61:21 87:17 88:3 98:7 100:1 109:8,9 111:3,6 122:12 128:11 135:12 172:21 179:8 181:2,4 191:9 192:17 205:15 206:1 211:17 217:25 220:6 226:13 233:6 239:19 243:23 246:20 247:16 252:12 262:17 278:13, 16 293:20 300:15 309:1,11 317:25 321:15, 21 322:11 328:24 332:9 335:4 340:11 345:7 349:9, 351:12	
described 194:18,19 200:20,21 201:5,8 261:1 309:7	determining 130:3		
describes 183:24	devastating 108:4 296:25		
describing 115:4 326:7	develop 147:7 148:22 149:7		
description 82:13	developed 155:24 156:2		
design 30:14 31:1,6 338:15, 16 346:20	developing 336:3		
designated 5:3	development 99:21 147:4 157:15		
designed 115:18 157:11 268:9,18 338:5, 346:10	device 49:4 50:9 54:14,16,25 60:19 116:9,12 157:20 224:14 255:2 270:12,13 327:7,11,15 328:9 341:15 342:6 349:5 355:11		
designing 346:8		die 193:15	
Desk 284:12,15, 17,23 285:8,24		Dietz 331:8,9,16 332:1	
desktop 14:11	devices 75:4 289:10 327:12,	differ 12:7	
destroyed 187:14 193:8			
destroying 196:18			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

329:21,23 335:11,14 341:5 346:1 355:8,11, 12 differential 304:10 differently 12:11 24:23 175:15 differs 182:22 difficult 42:20 71:17 100:7,14 108:15 137:3 154:12 251:1 dime 256:18 direct 4:18 139:8 309:7 334:18,21 directions 341:14 directly 30:23 213:10 director 277:13 317:8 dirty 124:1 disability 193:12 disagree 36:6,7 40:9 44:25 67:8, 13,14 98:25 130:5 151:17 153:4 175:21 177:12 185:1 190:20 191:12 192:7 195:1,14, 18 196:23 224:7 255:13 262:24 266:22 272:7 307:2 308:23 323:9 327:22	328:7 340:20 341:2 345:24 disagreed 278:7, 10 disagreeing 148:24 149:2,15 disagreement 223:22 Disc 4:3 discharge 194:6 disclose 239:19 339:24 disclosed 258:14 disclosure 165:6 166:23 258:5 discomfort 143:1 210:4 211:23 discount 257:15 discourse 186:15 191:2 discovered 147:14 discuss 15:12 163:8,17 173:8 266:5 322:7 discussed 177:2 237:3 255:7 258:17 266:13 304:20 310:9,11 discusses 340:18 discussing 207:21 266:6 discussion 95:18 125:19,25 133:17 142:4	150:7 152:12 174:10 176:14 178:8 230:24 235:7 274:17 275:19 286:2 287:7 294:4 295:10 308:25 312:24 325:11 discussions 185:6 342:3 344:12 disease 149:23 242:20 dismissing 264:1,2 disorder 289:21 disorders 188:18 190:6 288:17 352:21 dispute 194:17 345:11,14 dissect 131:12 355:10 dissecting 161:16 162:18 distance 333:23 335:22 distracting 138:14 District 75:9 divide 73:2 division 120:22 128:5 287:3 doctor 5:10,20 6:3 7:7 9:10,24 12:14 13:17 17:3,12,20	21:21 22:7,11 23:20 26:24 28:5 29:15 32:10 33:3, 34:10,21 35:23 37:4 38:7,23 40:13 41:12 42:10,22 43:7, 23 47:1,5 48:13, 25 49:2,3,15 53:9 54:22 56:7 57:5 58:25 60:14 61:5,20 62:2,13 63:21 67:3 68:8,20 74:7 77:19 78:20 79:2,5 82:10,23 88:5 91:8 99:7 106:12 108:10 110:9 113:5 115:24 116:21 117:10 118:8,15 123:4,23 125:18 126:25 127:16 128:21 129:9,18 131:3 132:10,19 133:5,14,15,18 140:24 141:7 142:23 143:6,23 146:4,13,19 149:15,21 155:1 159:6 160:8 161:1,9 165:20 169:2 171:6,9 174:1,8 175:16 176:17 177:21 179:23 180:20 181:25 182:23 184:21,22
--	---	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

187:20,25	doctors 89:12	108:22 110:10,	down 14:17,25
191:9, 194:17	107:15,16	22 111:7 145:10	21:6 23:24
197:11,25	131:18 155:20,	148:3 153:23	81:22 82:19
198:22 203:8,14	25 156:3,12	154:10 157:19	108:5 112:24
204:5,13 206:9,	157:3 188:21	158:5,7 160:14	127:3 132:5
22 207:1 209:24	189:3 190:18	161:6 170:5,8	134:3 138:4
212:7 213:17	274:22 323:14	175:13 198:8	147:12,19
216:10 217:2,9	335:6 344:13	199:7 206:14	193:9,17 197:1
218:4 219:11	356:24 357:1	208:23 226:8	209:2 213:25
222:15 223:11	document 7:13	274:18 275:22	216:6 233:16
225:14 226:22	8:4 15:11 25:18,	276:24 277:22	235:4 249:17
230:24 231:5,11	25 26:1,4,8	304:11	252:24 258:1,24
232:21 235:2	61:14 259:11,18	dollar 270:22	266:3 279:20
237:18 238:6,22	268:12 269:3,6	284:9	298:5 337:6
239:17 240:19	279:8 281:9	dollars 85:11	340:14 342:4,8
242:22 244:18,	282:15 288:1	done 37:4 38:13,	345:13 355:10
23 246:15 247:9	289:3 291:4,22	14 56:13 64:15	download
250:24 252:8	293:8 339:17,18	68:23 90:12	287:18
253:11 254:18	350:22 352:24	94:19,25 95:5,8	Dr 4:3,20 11:7
255:4,15 256:25	354:5 355:25	96:14,23 109:3	23:25 24:17
262:12 266:4	356:8	111:16 133:11	98:5,15 99:4
267:3,10	documentation	145:22,25	114:3,8 118:5,
273:13,23	21:1 351:7	147:8,25 153:16	18 139:10
281:3,25 282:23	documents 7:2,	158:10 172:24	152:16 168:2,8
283:4,14 285:6	8,9 8:4 13:21,23	191:7,14 194:13	172:25 175:2,5,
286:1,20 287:15	14:6 16:16 17:7,	196:1 233:9	6,12 198:13,16,
291:4 292:9	8,22,24 18:6,14,	236:20 239:13	204:24 223:4
293:5,19,23	22,24 19:2,7,14	240:1 258:19	269:12 275:13
294:3 296:7	20:1,8,10,11,14,	276:3 289:16	277:17,18
298:1 305:20	25 21:13 53:22	294:23 301:16	279:15 282:4
306:5 308:10,11	81:13 87:14,18	302:6 303:13,15	292:12,13
311:15 314:13	93:4, 339:7	315:16 318:11	311:19 322:13
319:15 322:24	347:9 350:25	320:13,17	339:11
323:23 324:5,11	doing 8:12,	323:20 330:23	drafted 342:5
326:12 329:18	32:21,22 50:10	335:16 336:2	drafting 287:22
332:1 333:14	55:21 57:2	338:21	341:13 342:2
337:10 338:6,25	71:10 72:1	doubt 53:21	drew 242:11
339:20,21	73:20 74:4	137:24 288:7	drop 134:3
341:24 347:2	81:10 107:12	296:12 350:5	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

Dropbox 8:3 78:7	198:2,18 199:11 200:17,21	184:3,22 191:10 204:9 206:1,21	effort 134:21
DSC 304:10	201:4,10,15,24	223:12 241:20	efforts 270:4
dual 171:17 172:3	202:13 204:17 207:20,24	242:13 258:17 281:4 294:7	eight 99:22
due 37:21 102:24 134:13 204:6 265:1 290:2 327:7	208:4,17,18,19, 20 209:8,10,17 210:8,25 211:14 212:20 213:10, 13,15 216:13 218:3,6,7 219:5, 13 221:4,15 222:6,11 225:17,23 226:2 227:14 231:3, 13,21,22,24 232:15 234:6, 14,17 235:2, 236:7,15 242:3 318:6	318:5 324:11 329:19 349:3	either 15:10 39:13 47:4 92:17 143:16 158:12 160:16 183:24 186:19 194:22 196:6 199:8 205:3 224:10 226:3,20 238:9 239:18 293:1
Duke 156:23	dyspareunias 208:11	early 71:9 166:25 223:17 246:18,21 325:10 326:7	elected 287:8 351:9
duly 4:16 139:6	<hr/> E <hr/>	earned 82:25	electron 303:8, 23
duplicates 61:18		easiest 162:8	electronic 77:24 181:4
duration 265:1		eat 175:25	elevating 143:18
during 10:6 11:3,13 12:6 56:22 74:11 80:3 113:11 122:7,20 123:18 128:17 160:22, 23 166:25 179:15 184:12 200:17 242:8 318:23 354:22		edited 285:21	Eleven 316:24
Dutch 203:20	e-mail 15:18,19, 20 269:16 271:9	editorial 263:7	eliminate 252:24
dynamic 153:8	e-mailed 269:14	educated 110:19 350:20	eliminated 190:18
dysfunction 49:9	e-mails 19:14,21 79:8,11	education 63:4 92:21,23 93:8 319:21 341:8 346:3,7 355:22	Elliot 4:4,15 139:5 204:24
dyspareunia 38:25 44:17 45:7,20,21 46:1, 5,11,13 47:19 123:8 149:7,12, 14,16 159:12, 17,21 160:6 167:5,8 193:21 195:11,13,22 196:12,14,16 197:23,25	each 11:25 12:2 28:17 82:2 207:11 310:12 324:23 340:17 345:22	effect 121:24 158:2 163:6,15 194:22 195:15 196:6 228:25 313:1 343:22	elliott 4:20 5:16 24:17 87:5 114:3,8 118:1,5 139:10 168:2,8 171:3 187:17 198:10,13,16 203:10 216:18 223:1,4 230:21 249:11 253:8 267:7 273:19 279:10,15 283:1
	earlier 10:3 12:18 80:1 101:11 119:18 169:2,6 177:4	effective 320:5, 18 322:8,21 356:4	
		effectiveness 259:14	
		effects 44:24 142:19 158:1 196:20	
		efficient 124:3	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

285:3 311:12 314:9 316:20 319:12 324:1 329:12 331:22 else 19:8 20:11 53:5 57:24 63:10 65:1,3,11 70:24 78:4 81:11 107:4 138:12 156:21 168:12 173:13 230:2,5 254:11 277:18 else's 322:4 elsewhere 166:16 247:8 embarrassment 141:6 employee 25:7 116:11 employee's 25:9 encourage 157:23 end 15:7 79:23 80:7 123:21 229:18 280:25 312:23 339:20 endorse 354:12 355:16 endorsed 263:20 264:3 engage 333:24 345:2 engaged 93:6 engine 10:13 engineer 90:19	engineers 93:14 enough 117:9 211:19 212:3 217:25 252:12 269:21 307:15 312:20 enter 60:5 216:25 220:19 270:9 entire 13:21 22:2 25:17,22,24 26:1,4,8 27:24 124:2 282:15 entirety 13:19 14:2 15:4 16:13 29:4 61:10 339:12 entitled 5:2 22:8 33:19 59:7 182:9 203:17 223:7 250:2 253:12 299:8 311:1 314:15 316:24 329:19 331:17 entrance 140:7 equal 207:10 208:11 218:2 equals 238:15 era 181:4 204:11,12 erosion 38:25 39:17 44:16 48:13,16,19 68:12 69:19,23 72:19 73:8,11, 23 142:25 158:23 159:7	162:12,25 163:5,13,25 165:20 166:3 167:12,14,19 193:1,22 194:5 197:24 198:18 199:10 242:7 244:17 245:5,8, 17 246:5,7,10, 14,16,25 247:4, 10 248:11,16 250:1,6,19 251:16 252:2, 12,23 253:3 264:19 265:6, 14,15,20 266:7, 18,21 316:1,12 317:5 318:18,22 321:21 342:22 343:4 erosions 69:24 71:9 123:7 316:8 ert 300:21 especially 234:1 essential 52:10, 12 essentially 72:17 74:12 104:5 154:19 179:14 205:2 256:9 274:17 established 224:17 256:14 estimate 9:10 85:17 101:15 104:23 105:1,11 108:16 110:4,11	112:18 115:9 340:6 estimation 83:12 estrogen 142:14 et 19:15 48:12 117:3 133:24 135:2,20 215:18 235:11 261:15 298:24,25 310:16 355:13 et al 37:17 180:3 221:8 234:22 298:7,12,24,25 299:1 301:5 310:16 Ethicon 31:24 34:13,24 36:1, 20 38:9 45:10, 23 74:21 75:17, 19,24 76:7,15 85:2,6 90:23 91:12 93:5 103:20 261:9 271:22 273:11 317:8 Ethicon's 31:20 32:14 ethics 239:22 280:25 282:21 etiologies 308:8 etiology 133:23 European 331:16 evaluate 299:15 evaluated 232:7 evaluation 182:9,24 234:22
---	---	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

evasive 74:5 even 12:18 35:15 36:17, 44:22 56:19 57:15,18 83:1,9,10,12 85:16 86:3,10 97:14 117:15 121:19 132:15 161:9 177:2 179:15 195:16 196:1,25 213:17 218:13 226:19 242:22 243:2 247:5 266:25 295:10 297:5 301:4 316:9 317:8 335:3 353:15 354:6 356:13 357:2 event 45:20 46:3 148:25 163:6 196:13 318:4 342:21 events 40:16 44:14,19 45:2, 17 147:1 148:7 160:15 199:11, 17,24 316:2,9 317:4 318:6,9, 23 ever 74:24 93:20 94:2 110:21,23 111:14 116:8, 11,15 151:18 165:21 275:1 284:21 290:11 294:16 334:25 338:10,21 341:13 342:1	every 11:17 13:24 14:5,6,16 15:1, 16:2,5,12 28:17,21,23,24 61:17 80:6 104:5,8 112:23, 24,25 113:1 116:24 122:25 136:8 181:14 192:12 255:1 277:9 342:16 345:22 everybody 176:24 257:22 260:7 302:4 309:13 320:15 322:4 everyone 348:21,23 everything 20:5 21:16 29:9,12 77:24 78:4,7 108:6 137:15 165:7 166:23 173:13 258:4 259:17 295:7 341:10 343:13 everywhere 250:22 evidence 292:4 298:2 301:20 302:13,22 304:1 316:11 344:6 Evidence-based 253:13 evolved 282:6 evolving 308:17 336:23	exacerbating 147:16 exact 15:10 35:12,20 37:25 55:2 59:13 80:15,23 110:19 113:2 218:7 297:1 exactly 8:5 35:23 56:9 69:18 79:24 80:4 83:17 91:24 114:14 158:20 159:24 163:9 164:2 171:18 200:13 225:15 233:19 250:10 314:3 318:25 350:16 exam 100:4,7 108:5 197:1 examination 4:18 133:9 139:8 357:17 examined 4:17 139:7 312:15 example 6:18 9:21 25:5,14 38:24 113:22 150:25 151:15 309:18 334:1 336:14 examples 334:10 exceedingly 136:18 148:20 excellent 264:15 except 317:7	excerpts 13:20 26:2,3,20,21 exchanged 19:15 excise 73:5 excising 113:12 excision 107:22 108:12 109:4 111:16,24 112:2,6 113:23 exclude 41:10 164:6,15 excluding 163:23 excuse 64:16 67:22 90:15 103:19,20 213:24 214:2 220:8 232:9 259:20 269:5 276:19 301:12 324:18 326:22 338:8 exercises 142:14 exhaustive 303:7 exhibit 5:16,19, 23 6:12 15:14 16:2 22:12 23:3, 4,6 62:2,10 74:8 118:1,4,8 171:1, 3,10 180:13, 187:17,21 198:9,10,14,16 203:9,10 216:17,18 222:19 223:1,5 230:21 231:1 237:11,12 238:7,11 249:9,
--	---	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

11 253:7,8,12 267:4,7,10 273:14,19,22 279:10,14 283:1,5 285:3,6 287:10,12 288:5 311:12 314:8,9 316:19,20,23 319:12 324:1 329:12,18 331:22 349:3 exhibits 15:8,9, 25 16:9,17 23:16,23,24 24:1,2,7,13 311:6 329:14 exist 177:15 208:19 exists 236:5 exit 55:17 208:6 217:15 230:18 270:2 expected 327:8 experience 7:3,4 37:11 44:23 45:3 47:10 51:2 52:11 76:21 96:13 102:1,17, 19,24 103:2 116:4,8 117:20 119:13 129:19 135:23 136:4,10 138:2 139:12 140:11 141:1,2 149:9 151:17 155:21 159:7,9 160:3 163:25 177:23 195:3 197:12,15 198:2	210:20 212:12 253:2 261:13 262:8 264:7 266:20 296:4,5 297:19,22,23 337:20 341:3 346:7 347:10 experienced 72:18 128:24 135:16 162:12, 24 167:13,21 184:13 194:19 245:8 experiences 143:22 experiencing 45:8 133:20 165:24 166:3 176:18 189:4 236:8 323:5 experimentally 312:9 expert 5:4,24 6:2,3,11 10:10 16:15 19:12 22:2,12 23:7 24:12,19 26:21 30:16,19 31:1 33:12,13,14,20 34:3 48:24 49:4, 16 53:11,13,17 54:15,24 57:21 58:12 60:18 62:15 74:12,15, 21,24 75:11 76:2 77:6,17,22 79:14 83:24 84:5 85:1,6,18, 23 86:21 89:11,	15 90:4,7,18,21 91:2,17,20 92:6, 12,16 93:21,24 94:3,8,10,11 97:17,22 98:3,5, 8,9,14 102:16, 23 133:15 214:11 221:5 235:8 240:3,5 274:4 275:6 295:14,22 296:2 298:22 305:6 338:24 340:22 342:10 343:7 345:21 expert's 89:24 expertise 49:25 73:3 93:16 129:22 155:8 experts 89:19 97:2,4,7,13,15 99:1 256:11 explain 181:25 214:8 289:23 explant 93:6 95:19 101:13 107:23 108:11 109:3 110:25 111:16,23 112:2,6 113:23 explanted 96:1 109:22 312:15 explanting 96:4 102:2,17,24 explants 299:11 303:16,18 explore 59:8 157:4, 197:21	exploring 216:12 exposure 167:15,23 168:3 234:9 242:18,19 243:2,16,18 244:2,12,24 245:23 246:14, 16,24 247:4,10 252:24 253:2,5 264:25 exposures 242:23 243:11, 23 extended 238:1 extensive 150:19 160:4 298:14 extensively 169:1 extent 97:18 107:17 109:19 192:3 214:24 278:8,14,22 328:14 333:23 343:8 extra 117:9 289:7 extracting 113:12 extraction 73:15 extrapolate 83:11 115:6 124:11 extrapolating 104:25 extreme 135:11 185:14,22 193:10 280:4,9,
---	--	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

21 281:5,14,19 282:7,14,17 348:18,20 extremism 269:8 280:23 282:8,20 348:23 extremist 348:3 extruding 140:7 extrusion 48:19, 20 167:15,16 194:4 226:2 235:1 245:12 246:17 252:23 264:24 266:10 267:2 318:18 extrusions 112:14,15 244:10 eye 215:3 eyes 101:7	355:9 facts 6:22 273:7 326:8 330:20 351:4 failed 173:12 174:23,24 278:22 286:10 339:24 340:3,4 failure 37:20 152:18 157:10 204:6,23 206:16,18 207:3,12 237:5 343:7 352:1 failures 177:19 fair 6:18 7:7 18:13 20:6 44:17 59:19 64:7 68:25 72:5 76:15 81:1 88:6, 23 101:1,23 105:1 115:24 134:1 135:6 137:1 146:16,20 152:25 154:5 155:23 156:25 157:6,8 163:25 172:3 178:24 184:5 188:19 189:22 198:4 224:6 253:25 256:1 286:15 307:6, 308:15, 21 312:20 332:11 340:5 352:7 fairly 7:12 62:21 112:18 140:21 148:19 216:16	303:7 fairness 56:17 fall 142:21 falling 138:6 139:22 140:1,4 147:12 193:3 falling-out 139:23,24 false 242:9 285:21 false-positive 306:23 307:14 fame 63:22 familiar 33:16 50:1,4,6 57:24 130:15 188:3 208:22 253:19, 21 314:4 315:20 family 193:6 far 7:1,3,15 10:18 11:14 15:6 21:7 42:19 43:14 50:12 52:7 63:18 64:16 65:20 70:19 76:11 77:24 79:18 80:14 82:22 83:6 87:14 93:1 96:21 100:9 109:18 110:17 130:15 132:16 151:4 159:14 176:21 183:15 189:12 190:20 192:11 196:23 223:20 240:5 249:19 261:9	270:15 272:12 284:10 308:17 317:15 318:14, 16 343:12 346:1,19,20 348:18 Fascia 66:1 fashion 42:20 48:9 284:3 fast 33:3 222:24 337:11 fat 150:19,22 fault 24:7 236:18 faults 227:22 favor 264:4 favorable 255:17 fax 104:17 FDA 49:18 54:24 60:20 105:14 106:1,22 189:17,19 253:13 258:8 260:16 261:8,11 262:15 267:11, 12 268:16 269:13 276:10 277:12 278:1,7, 8,19 279:15 281:7,20 343:12,15,16,19 344:4,11,14,20, 25 345:18,19,21 347:16 348:11, 17 349:2,4,7,18, 25 350:7,8 351:1,7,15 352:13 353:1,2
<hr/> F <hr/>			
face 176:4 285:11 facing 149:24 fact 97:24 102:11 103:8 135:7 137:13 167:6 242:17 255:5 278:22 300:1 356:11 factor 154:24 factors 134:15, 18 135:2 141:18 150:1 174:3 214:12 215:1 232:2 312:22			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

FDA- ACCEPTABLE 191:24	females' 313:11	234:12,24	162:11,19,23,24
fear 356:20	few 18:4 41:8 75:23 120:9	238:3,4 241:18 242:9,10 319:1, 4	163:11,14 164:3,13 166:17 204:23 207:6 217:9 263:19 268:7 275:10,11 286:19 288:12, 13 299:2,14 301:19 307:25 308:4 336:24 352:25
February 68:15 176:13 276:17	145:18 155:19 162:5 176:21 319:17 323:21 347:2	fine 47:8 56:15, 16 63:8 80:5 101:24 102:22 178:24 182:4 204:25 205:22 213:7 240:2 263:25 281:3 357:23	fistula 74:1
federal 56:23 117:8 357:15	fibrosis 330:7,11	finger 335:11,25 336:12 337:7	five 8:25 19:11 77:9 99:22 101:16,19,20, 21,22 103:4,15, 16 105:9,16 108:14 109:12 110:14,15 117:23 121:10 122:6,14 197:9 207:2,6,12 212:13,17 221:15 243:22 250:14,17 251:8 253:22 257:25 315:24 325:3 341:18,20 351:23
fee 83:23 84:1,4, 11,15,19	field 99:22 202:9	finish 33:5 36:12,15 42:24 55:23 121:16 174:4 178:14 216:11	five- 250:6 252:15
feel 13:2,6 108:17 112:7, 11,13 133:9 174:16 280:4,20 282:17 335:4 347:10 349:2 350:19	fifth 258:24 280:3	finishes 328:15	five-minute 78:10
feeling 139:21 140:12 225:19	fight 254:25	finished 36:11, 134:23 191:6 200:5	fix 107:25 108:3, 7 123:22 156:15 194:11 195:9,20 196:1 207:6
feels 139:25	figure 83:1 87:3 287:20 308:5 309:14	Finland 227:2	fixation 155:11 158:10 334:23
fellow 118:25 119:2 154:9 335:1	figures 254:6,8	firm 4:25 76:19, 20,22 281:2 283:21	
fellowship 99:23 154:16	file 117:1,7 305:18	first 4:16 11:13, 17 13:3 24:7 56:1 59:3 60:1 62:12 63:25 65:12 69:1 70:15,19 118:6 123:5 125:13,17 127:7 133:2 142:20 153:22 154:17 159:3 161:15,25	
felt 154:10 278:9 294:22	final 182:18,20, 23 285:22		
female 29:8 49:10 63:5 66:18 94:1,12 99:10,12,15,20 100:2,16 101:1, 3,5 120:25 124:24 155:3 175:4 186:7,25 187:2,7 292:12 295:24 319:18	financial 280:24 282:21		
	find 13:25 26:24 35:6 37:25 38:13 91:8 106:3 202:11 204:20 219:3 224:22 232:8 235:10 250:21 255:19 269:15 271:11 297:3 318:22 340:18		
	finding 211:13 214:2 247:13 313:12 357:2,3		
	findings 208:15 218:11 227:17		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

fixed 73:9,10	347:3	114:22 116:1	8:17 215:19
flat 84:11,15,19	followed 232:23	122:8 130:13	281:7 285:19
161:22 213:24	240:22 246:2	156:5 164:18	333:15
214:1	following 67:23	165:3 174:14	forum 186:2
flip 253:6	115:20 131:11	175:19 185:10	forward 12:13
flipped 14:9	198:18 199:12	186:9 188:23	97:17 251:19
flipping 22:7	231:20 314:16	189:6,10 194:24	348:24 351:8
327:1	325:24	212:22 215:10	fought 257:25
floor 49:9	follows 4:17	219:16 221:17	found 11:13 70:6
130:11 134:3,4,	139:7	228:4, 233:21	71:14 133:4
12 142:13 153:3	foolish 282:18	234:20 243:17	206:15,19
168:9 172:7,25	foramen 194:2	244:3 254:19	234:13,16
188:18 190:6	214:15 216:7	259:9 264:14	241:21,24
253:24 281:6	335:12	273:1 278:3,	247:17 301:1
288:17 289:21	forced 158:8	296:11 300:5	313:3 322:4
290:23 299:16	forces 93:12	301:2 305:11	356:23
301:8 302:9,25	forefront 107:19	317:23 323:17	foundation
311:2 352:21	foreign 194:6	327:9,16,20	355:24
flora 297:10	forget 151:5	328:10 332:13	four 8:25 9:15
focus 5:11,12	forgot 78:24	338:11 340:25	19:10 32:2
11:22 63:19	79:4 259:3	344:5 348:8	74:11,14 79:25
64:8 65:17	form 14:22	350:3,13 351:4,	103:4,15 105:8,
193:20 296:21	29:25 30:17	20 352:8 353:21	15,16 121:2,4,9
focused 66:19	32:18 33:24	354:8,14 355:4,	126:17 127:14,
fold 213:21	34:6 35:9 36:4	19 356:16 357:5	19 132:5,22
follow 117:3	40:2,21 43:24	formal 346:7	183:6,9 184:1,
163:10 166:14	44:3 49:5 52:4,	format 46:19	17 227:7 253:21
227:23 235:12	14 53:18,24	64:17	254:22 316:16
255:23 282:19	54:3,17 55:1	formation 66:10	349:17,24
304:24	56:24 57:4	328:22,25	350:7,17 351:23
follow-up 159:4,	60:21 81:8,15	329:21	four-and-a-half
25 162:22	85:12 86:23	formed 7:21	121:3
211:19 223:10,	87:9,22 88:7,12,	24:11 222:14	four-and-a-half-
24 224:2,16	21 89:3 90:8	former 119:2	year 122:4,13
232:4 249:5	91:4 92:14	forming 332:10,	four-armed
250:7,8 252:15,	106:6,9,21	17	214:5 226:21
16 279:5,9	107:7 113:8,25	forms 54:12	227:10 228:2,6,
316:25 318:24		forth 6:11 7:10	10,13

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

fourth 70:16 279:21,23 280:1 312:5	69:4 76:10 80:8 83:11 85:23,25 86:4,14,21 89:8, 12 90:20 98:13, 21 102:2,4,6 105:7 109:22,23 114:5,11 119:9, 15,16,18 120:1, 13 122:10 127:21,24 128:1,5,12 131:3,18,20 132:14 134:3 140:14 148:8 149:17 151:25 152:16,17 154:1,3 155:4 163:2 166:3 170:22 171:13 176:12 179:1 182:10,22 183:9,15 184:2, 4 190:19 197:17 199:13 200:10 201:18 208:12 209:23 210:15 211:25 212:13, 24 213:23 219:14 226:16 228:24 234:25 240:2 244:7 247:25 250:1 251:12 252:17, 25 253:13,25 254:6,8,17,22 256:6,8 258:3,7, 10,13 259:6,18 262:14 267:23 268:24 269:16, 17 270:18,23	271:11,15 272:6 275:2 278:6,16 279:3,14 284:10,15,19 285:8 287:15,18 288:3,25 289:10,20 290:6,13,24 301:7 303:4 310:22 317:7 318:20 323:21 326:1,17 330:3 336:22 340:5 344:1 345:10,16 347:20 351:22 353:20 354:2,4	235:5 functions 167:7 fund 43:15 270:23 271:17 funding 270:16 271:21 funds 270:4,14, 19 further 12:22,23 30:13 99:25 260:19 261:5 future 166:24
<hr/> G <hr/>			
free 133:9 216:3 277:24,25 349:2		front 6:2 8:7 17:11,19 22:18 28:11 59:17 78:2,6 182:5 187:25 237:13 244:19 258:17 262:12 273:22	gain 154:18 162:8 gained 325:12 gaining 52:11 153:18 game 34:4 193:15 212:11 gather 72:14 gathered 41:10 71:5 325:17 gathering 70:20 gave 57:23 75:18 193:19 197:22 213:3 263:24 276:19
French 130:7 299:6		FTIR 304:4 full 27:10 165:6 166:23 258:5 259:7 260:6,17 306:8 fullness 138:6,12 139:23 140:13 193:3 fully 166:13 173:11 174:19, 21 191:12 260:3 262:6 fun 222:10 Function 235:12 Functional	Gayle 217:15 220:19 Gebhart 118:18, 25 Geist 4:9,19,24 5:18 17:1,2 23:6
frequency 183:20,23 194:1 198:7 266:11 342:17 343:14 344:1,16			
frequent 44:19			
frequently 146:14 284:11 323:7			
friend 108:24			
fringe 186:5			
from 10:20 12:7, 10 19:1,12 23:24 24:16,18 26:6,10 27:6 37:19 41:10 44:8,14,15 46:3 51:4 53:1 54:10 67:20 68:9,13			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

24:9 27:16 28:1 30:18 34:1,8,16, 20 40:5,24 41:17,20,23 42:9,25 43:6 44:1,6,12 48:5 52:15 55:3,6,9, 11,18,22 56:1, 21 57:4,9,12,19 58:5,8,10,17,19, 21 59:1,4,24 60:8,11,13 61:12 78:10,13, 19,24 79:1 82:3, 9,16,20,21 86:24 88:22 96:18 97:20 98:1 106:7,11, 23 107:1,6 110:1,4,6,8 113:9 114:2,7, 23 116:2 118:3 124:8,15 126:24 133:8,11,13 138:15 139:9 164:10 166:6,9 168:1 171:5,8 174:5 175:25 180:12,15,19 181:24 185:11 187:19,24 189:7 191:8,21 194:15 198:8,12 203:7, 12 206:7 211:3 217:1 220:20 222:21,23 223:3 228:5,22 230:12,14,23 238:21 240:15, 18 243:19,21	248:4,7 249:22, 24 253:10 254:20 267:9 270:3 272:23 273:8,18,21 278:4 279:12 280:16,19 281:13,23 283:3 285:5 287:14 291:13,16,18, 20,23 292:2,5,8 293:15,18,25 294:2 296:12,15 299:4 300:3 301:17 305:19 306:4 309:25 310:1 311:5,9, 11,14 314:11 316:22 318:2 319:14 321:17, 19,23 324:3,9 327:17 329:11, 15,17 331:24 332:22 333:9,13 341:22,23 346:12,22 348:8 350:3,13 351:4, 20 352:8 353:21 354:8,14 355:4, 19 356:16 357:5,13,19,23 general 5:5,11, 24 54:11 63:17 151:12,13 generally 19:5 32:4 44:15 133:16,18 134:13 150:12 231:13	generic 22:12 68:5,7 75:4 81:15,20 Geoff 248:24 German 230:10 Gerry 187:9 get 11:17 26:1,2 27:9 59:18 65:12,13 71:10 73:9,10,12,25 86:3,14 99:25 105:5,23,24 106:8 112:24 113:1 168:3 173:21 175:22, 23 182:1,2 193:4 196:9 206:22 216:8 221:15 235:19 239:2,22 241:14 251:8 269:20 272:15 278:22 284:10 292:7 296:13 get along 293:16 gets 11:20 81:22 170:19,20 216:8 240:16 250:17 270:16 getting 20:11 34:9 76:1 104:7 105:20 106:13, 14 144:2 190:22 197:17 249:25 263:17 271:18 272:2 277:15 300:17 348:21, 23	ghostwriter 288:22 290:14 give 6:17 20:5 27:2 33:12,20 45:4 83:12 85:17 103:7 113:2,3,16 115:9 116:23 157:2 165:13 169:24 209:12 210:13,22 211:21 221:14 258:2 271:8 311:18 324:7 334:10 343:17 given 15:4 27:23 63:1 75:10 103:4 115:12 125:9 168:12 344:11 gives 32:4 56:9, 15 giving 34:22 50:25 51:21 56:18 91:11,14 97:22 163:17 290:18 glad 325:8 go 10:3 11:9,18 13:6 14:11,14 15:2 17:17,18 21:6 22:1 33:6 34:7 36:15 37:24 38:3 43:5 45:17 47:22 49:4 54:3 55:15, 24 56:1,2 57:8, 10,11 61:21 64:17 65:14
--	--	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

66:25 71:21	357:13	22 146:6 151:3	255:14 286:11
72:12 74:22	goal 143:7,10,11,	155:6 156:23	301:24
82:3 83:2 88:16	25 144:6,8,25	165:1,19,25	good 4:20, 9:21
99:25 100:9	157:18	168:3 170:5	46:18 51:22
110:23 111:14,	goals 144:22	185:3 190:16	52:2,18,20,22
23 112:13 115:5	goes 18:3 50:4	193:15 194:16	53:7,14 54:15,
117:9 119:25	140:3 143:22	195:3,14 196:2	19,23 58:8
121:16 124:14	156:13 159:15	203:6 205:17	60:19 68:23
125:19 127:3	170:18 198:6	209:5 210:17	89:25 108:20,24
129:8 131:12	216:7 310:16	212:7,8,13,25	125:13 157:20
132:20 137:9	312:13 328:8	215:16 216:11	166:24 172:8,
138:15 145:14	335:6	221:5 222:24	10,11 176:5,16
146:18 149:13	going 7:4 8:13	223:14,18	179:5 187:15
150:2,3 162:16	11:19 13:11	224:8,12 226:4	192:18 203:25
175:10 180:4	19:10,17 26:8	227:1 233:4,16,	205:21 211:8
181:14 182:23	27:16 29:18	23 234:3 241:14	213:1 233:9,15
190:15 191:5,10	33:20 34:3 42:7	242:17 249:2,17	236:4 240:25
192:19 200:9,15	43:22 44:7	252:19,25	243:6 251:11
201:6 202:10,24	45:15,17,24	259:17,18 262:5	256:25 257:3,8,
206:23 210:18	52:22 53:6	264:25 271:12	9 271:6,8
214:14 216:11	55:18,20,25	293:22 297:11	282:22 302:2
221:5 224:14	56:3,8,10,12,25	298:8 305:14	305:19 325:8,
227:4,6 235:10	59:21, 61:22,	306:12 308:5	13,17 326:2
237:8 239:10	62:24 67:1	310:18 317:17,	328:3 329:1,5
247:13 248:20	68:21 74:7	18 319:8 323:21	336:14 341:21
252:23,25 256:4	75:21 82:10	331:1,3 336:17,	346:4 350:23
257:13 258:1,24	85:20 87:1,2	18,25 337:11,22	Google 12:3
262:3,5,11	95:3 97:23	344:12,13 347:2	276:20
263:2 273:15	103:9,13,17,18	352:14 355:12	Gortex 200:12
278:13,14	104:22,23	357:17	got 10:20 26:3,
286:16 289:4	105:1,2,17	gold 156:17,20,	10 53:1 79:2
291:2 295:10	107:5 108:14	22 314:1	103:3 106:23
298:5 299:1	109:11,13	Goldman	107:6 111:9
300:15,22 303:6	111:11 114:15	171:13,14	132:3 154:14
305:17 310:11,	115:19 117:4	172:25 175:2,5,	170:9 171:17
13 318:7 330:14	123:14,22	6,12 254:16	175:23 176:11,
331:25 332:13	131:11,14,23	256:25	15 177:17,18
339:19,20	133:24 137:3	gone 16:11,18	180:24 207:12
340:17 342:4	138:13 140:21,	110:21 178:3	221:14 236:1
343:6 355:10			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

257:21 269:16 276:15 285:16, 23 286:19 291:1 332:7 342:1 government 117:8 267:22,23 282:13 grade 144:10,11 297:9,14 333:6 graft 37:19,20, 24 198:17,19 199:10 201:16, 25 202:23 333:1 grafts 202:14 grams-per- meter-squared 220:12 229:10, 20 grams-per- perimeter- squared 229:8 grandchildren 193:7 granulation 194:5 198:18 199:11 grasp 52:18,20, 22 53:2,7 great 17:23 61:25 341:22 greater 31:10 35:15 36:17,22 47:16 48:2 80:17,18, 149:24 198:2 201:15 212:9 216:1,2, 221:3 247:5 339:1	greatly 264:19 green 70:4 181:6 Greg 187:9 grooves 306:19 Gross 271:22 group 88:10,11, 20 130:7 166:18 189:21 190:19 198:25 206:17, 18 207:7,11 208:10 209:8,9 210:7,9 212:1,2, 9,10,21 217:11, 13 218:15,22,23 219:14,15 224:19,20 225:24 227:11, 14,15 231:25 232:16 234:6, 15,18,19 235:23,24 238:2,3 241:13, 22,23 242:2,14 244:24 245:7,23 246:6 256:16 257:19 264:22 277:14,20 281:5 299:6 353:19 groups 208:4, 209:18 239:4 320:2 groves 307:3 growth 329:2 guarantee 206:23 guess 56:25 75:6 79:12 93:22 94:23 101:16	209:24 212:7,8 233:20 252:8 267:22 340:13, 20 guessing 212:11 guesstimate 112:17 guesswork 233:19 guest 292:6 guidance 335:2 343:20 guy 77:13 guys 58:21 GYN 49:12 99:13,19 100:12,15 101:10 108:21 146:10 154:7 286:25 Gynecare 127:18,21 131:20 Gynecologic 66:2 199:1 gynecologist 292:14 333:20 gynecologists 72:20,25 334:3 gynecology 66:18 100:21 182:17 GYNS 155:12 <hr/> H <hr/> H-o-l-i-u-m	69:22 half 121:2, 249:4,5 333:11 341:18,20 hand 18:19 180:16 187:20 203:13 221:20 231:4 311:15 331:25 handed 171:9 180:21 handing 341:4 handle 10:23 hands 115:7 161:14 164:21 165:24 166:17, 19 happen 107:14 143:5 147:22 148:2,5,6,21 149:3 158:8,22 159:10 164:7,16 165:1,21 186:2 211:6 233:16 242:18 298:9 323:21 happened 155:13 157:2 166:24 212:17 226:6 269:19 happening 107:16,17 happens 70:5 166:15 216:6 233:13 243:4 331:5 happy 125:12 144:4,18 145:1
---	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

207:10 304:25 331:20,25 harass 56:18 harassing 42:5 harassment 56:7 hard 28:11 41:14 68:22 180:21 181:3 216:8 has 6:21 8:3 9:20 18:9 19:10,17 38:24 43:19,21 46:8 47:13 48:19,22 64:13, 24 65:8,20 68:17 71:4 73:11,12,22 86:21 89:2 90:4 102:1 105:7 106:17 108:3 115:12 117:14 129:23 135:21, 25 138:2 140:19 142:22,23 144:11 145:24 149:22 151:8 158:25 159:19 160:6 168:9,18 172:3 174:18,22 175:11 176:10 185:5 194:19 196:5,13 209:21 210:14 219:23 222:16 225:9 226:20 231:22 233:12 235:10 236:14 253:4 257:25 260:20 263:10,20	269:10 271:21 273:3 290:10,11 292:14 295:6 296:8,17 297:15 298:22 299:24 300:20 302:13 320:5 322:19 339:1,8 356:4, 10 hasn't 7:13 58:1 95:15 having 4:16 41:14 45:3,8,9 47:10 107:13 139:6,12 164:22 173:13 178:8 197:19 201:24, 25 205:3 214:16 219:5 220:15,24 221:9 222:10 267:1 279:18 he's 27:17,20 34:18 42:2,5 44:4 56:19 59:15,21 60:1 89:7 97:21 106:9 119:1 154:15 171:17, 18,21 172:4,6, 17,24 203:20 211:1 216:16 230:10 257:3 273:2 298:8 299:6 300:24 303:12,15 304:11,12 307:25 308:5 310:23 322:17, 18	head 19:16 22:1 31:11 32:8 39:4 64:12 140:9 151:10 222:8 head-to-head 39:13,21 47:22 48:11 headaches 269:21 heal 150:20 328:1,8,12 healing 37:21 39:18 40:12 43:19 149:25 150:13,23 151:1,4,12,15 214:14 327:8,18 328:6 heals 328:15 health 141:17 188:20 190:2,21 227:3 277:13 289:22 healthy 191:2 hear 27:13 78:23 140:3 225:14 305:5 heard 105:25 137:23,24 140:11 150:7 220:1 247:7 251:5 307:9 311:19 hearing 276:1,12 heart 193:14 328:3 heaviness 140:12	heavy 228:16,18 234:2 heavyweight 220:12 229:7, 22,25 230:1, 234:2 Heinonen 233:8 help 133:3 208:14 277:23 311:7 helped 7:22 16:23 321:4 329:2 helpful 41:9 113:18 329:15 helping 269:25 here 5:7 6:16 7:15 8:5 11:11 17:17 18:7 19:6 24:13,14 26:13, 22 28:17 29:4 38:5,6 39:2 41:25 43:18 48:21 58:22 61:16 62:8,23, 24 63:2,6 65:14 67:1,6 74:15 79:10 82:18 84:12,13 89:18 91:12,19 97:17 109:21 110:22 111:9,13 112:17 129:6 131:24 166:1 171:6,20 179:14 180:1 184:7 190:9 201:6 203:23 210:10 211:17
---	---	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

213:5 227:4, 233:5, 234:9 235:3,11 236:1 239:12,14 241:17 245:11 248:19,25 249:16 250:22 251:1,2 258:20 259:14 264:3 265:14,23 266:3,13 268:21 277:10 282:16 285:19 286:1,2, 16 288:17 291:3,25 292:20,24 294:12 297:20 298:6 299:1 301:23 302:4 304:12 312:2 313:10 317:6 318:10 321:3 326:4 329:18 331:25 337:10 340:14,19 343:2 347:18 356:3 herein 4:16 139:6 hernia 215:2 312:18 hernias 215:13, 14 302:2 hesitant 74:2 137:15 hey 302:4 high 66:3 114:19 130:9 131:12 137:17 168:19 177:1 193:23	202:13 204:6 205:10 267:2 330:7 340:8 high-density 219:19 High-grade 66:24 high-profile 186:13 187:7 high-volume 49:14 52:23 130:6 173:7 174:18 176:22 186:13 190:16 195:5 267:1 321:25 higher 30:13,25 31:12 35:18 40:12 43:19 45:21 46:4,8,14 47:20 48:19,23 49:13 138:8 157:10 173:22 201:20 202:14 210:15 218:14, 17,19 221:9 231:12,13 242:3 249:5 252:22 highest 157:1 168:19 173:21 264:22 highlight 181:13 highlighted 203:24 204:4 highlights 181:7, 9,14 182:6 218:4	highly 115:7 129:13 130:11 159:10 173:11 174:18 175:12 262:4 him 27:19 34:17 35:4 36:12,15 42:7,24 56:14, 18 57:9,19 58:6, 23 59:5,17,18 97:6,23 114:4 121:16 123:11 124:7 133:6 172:12,16,21 175:14 211:6 240:13 257:1 269:16,20 281:18,20 293:14 311:22 346:15,17 hips 327:22 his 25:7 40:3 56:5 58:13 60:7 89:24 97:5,21 98:16 99:5 110:2,4 114:5 166:8, 168:9 172:20 175:7,22 277:10 281:19 299:23 304:19 306:9 309:4 311:20 322:19, 23 histological 303:12 hit 14:20 hits 284:1 hold 6:8 33:2	34:10 55:11,22 58:9 94:7,10,11 107:2 152:19 153:7 168:2 170:9 174:6 178:13 194:12 200:2 205:23 243:1,15 268:6 272:22 341:16 holding 153:5,10 345:20 holium 70:1 holmium 69:18, 22 70:2 71:12 72:9 73:5 honorable 280:25 282:21 hooked 348:21, 23 hope 116:5 253:18 273:14 hopefully 157:12 263:24 hopes 56:9 hops 221:15 horrible 200:11 horse 266:16 hospital 117:23 hot 176:5 hour 56:10,11, 12,25 84:1,13, 21,22 85:4 hourly 84:9 hours 80:18,20, 21 81:1,2,3,14, 21,24,25 82:24
--	---	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

83:10,20 85:3,8 333:10 341:17 346:11 357:14 Houston 154:8 how 9:17 15:8 17:3,9 39:5,6 44:13 47:8 49:2, 3,15,22 50:1,4, 15,19 51:20 53:25 54:13 60:3 64:9 70:11, 13 75:10 76:24 77:4 78:10 79:21 80:13,16 82:22,25 83:5, 12,13,21 84:18, 20 85:5,17 86:3, 88:14 89:20 95:22,25 96:3 102:5,9 103:3,7, 25 106:8 107:20 108:9,10 109:3, 21 110:16,24 111:15 113:10 114:14 115:16, 18,21 116:6,19, 24,25 117:1 120:6 125:1 131:12,13 137:4 149:6 151:12 164:4,12 169:9 171:18 176:10 178:4 181:17,25 183:12 184:11 223:19,23 224:22 226:1 232:8,10 237:24 246:20,22 251:5,12 252:4 254:12,15,16	256:3,5,11 258:2,5,13,14 263:17 264:8 265:3 269:15,18 272:16,19 275:18,24 276:5 284:12 294:18 296:2 320:22,25 322:6 333:9 338:18 Howard 171:13, 14 172:1 256:25 however 7:2 51:1 70:16 74:22,23 84:12 163:21 208:11, 14 210:13 215:1 236:2 242:6 262:8 280:23 300:8 306:23 307:11 309:10 320:20 335:2 344:20 351:22 huge 106:19 215:23 human 12:24 50:21 66:14,15, 90:17 93:3 295:9,22,23 296:9,18 331:1 humans 234:1 hundred 80:17, 18,21,24 83:20 321:2,3 hundreds 25:15 41:6 103:24 262:20 296:23 hurt 135:12	190:24 hurts 108:6 135:12 216:8 hybrid 229:15 hydrogen 313:7, 9 hypotheses 307:19,22 309:5 hypothesis 308:10,12 339:15 hypothetical 165:10 <hr/> I <hr/> I've 5:19,23 7:2, 14 10:11 11:6 16:11 31:25 35:11 41:13 47:7 50:11 63:1 65:20 72:5 82:25 83:10,20 88:15,18 89:8, 15,23 90:12 92:3 93:10 94:19 96:16 98:11 116:10,13 118:4,9 122:24 136:19 144:25 148:13,21 149:5,11 150:6, 10 164:2 168:5 169:3 171:9 172:12 175:23 177:17 180:22 187:13,20 192:24 195:21 197:15 198:13	200:14 203:24 208:25 233:9 236:1 249:8 250:21 251:5 252:15 253:11 279:13 283:4 286:6 307:9 311:3 332:7 334:8 338:7,14 339:17 341:5 342:1 343:7 346:19 ICS 235:15 idea 51:22 52:2 53:14 54:15,23 58:8 60:19 269:16 270:22 283:24 305:20 308:13 311:6 354:1 ideal 331:4 ideas 9:22 identical 101:7 209:5,6 217:19 218:21 identification 5:17 118:2 171:4 187:18 203:11 216:19 223:2 230:22 249:12 253:9 267:8 273:20 279:11 283:2 285:4 311:13 314:10 316:21 319:13 324:2 329:13 331:23 identified 120:12
---	---	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

121:4 128:16	357:2	implied 256:9	incidence 47:19
identify 4:5	implantation	importance	113:22 114:5,
IFU 131:11	30:15 50:8,12,	255:8	16,18,24 125:20
341:6 342:2,4,5,	21 65:9 96:7	important 63:3	126:6,13 138:9
9,18,23 344:13	160:23 222:9	123:2,15 129:20	183:20 184:11,
IFUS 21:7,8,9,	243:12 255:2	136:14 137:12	18 198:17
10,21,22 190:11	295:23 302:11	144:5 177:11	199:10 218:14
300:20 342:4,	320:13 329:24	202:4 219:8	231:13,24 232:4
11,19,24 343:1,	implanted 31:7	226:25 236:19	242:3 244:12
5 345:23	45:3,9 50:22,24	248:22 250:6	245:5 247:24
ignore 202:6,7	51:1,3,8 68:2	263:9 279:17	265:5
241:19	96:25 101:14	309:15,19	incident 38:10,
imagine 218:10	102:2,12	312:22 314:20	17,24 40:16
immaterial	104:10,21	315:11 323:4,8	45:7,21 46:4,
202:18 313:4	113:6,11,24	325:20 331:1	47:14,15 48:2,
317:10	114:10 116:20	importantly	15 212:20 219:5
immediate	117:12 128:24	107:15 194:10	incidents 163:14
268:23 278:5	129:4 130:8	improve 144:25	incision 151:21
immediately	132:3 178:1,5	145:3,4 149:17	157:7 158:18
268:19 278:15	183:14,21	improved 145:1	incisional 312:18
279:3 281:11	184:12 214:21	320:6,18 356:5	include 16:16
immensely 257:1	235:23 248:12	improvement	81:14 107:3
impact 136:21	269:3 292:15	144:14,15,17	150:15 163:5,14
151:4 221:3	295:18 298:13	163:13 167:7	164:24 169:13
338:22	312:14,18 313:5	224:14 225:11	179:10,21
impaired 37:21	317:14 321:12	improving	included 7:15
40:12 136:13	324:24 327:7,	145:12,15	9:8 12:15 82:17
impairs 214:14	15,25 328:9	in- 211:18	123:7 132:22
impetus 72:4	329:1 331:5	in-tissue 329:2	167:9,12 200:22
implant 46:4	351:24	inaccurate 122:3	234:11 263:22
47:10 49:22	implanters	210:14	includes 69:23
50:2,15 67:20	131:5 186:13	inadequate	78:7
68:9 115:19	implanting	337:14	including 24:6
126:18 162:11	50:16	inappropriate	37:18 49:10
201:16 213:18	implants 175:6	273:6	126:19 276:3
292:21 313:1	180:7 299:15	Inaudible 248:6	288:25 318:6
333:16 336:9	302:24 331:15	294:1	324:21 342:24
	implement 222:9		344:23 347:8

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

349:16	216:5 221:11	industry-	19:21, 20:22
income 85:23	255:16	sponsored 40:15	22:3,6 27:12
86:20 254:22	increases 126:10	42:11 48:12	46:20 87:15
incomplete	150:11 222:1	255:16	190:14 290:15,
190:11 351:8	incredible	inert 295:4	25 292:15 304:7
inconsistency	221:19 252:16	298:7,20 299:9	339:25 347:11
131:4	incredibly	300:1,10,21	informed 21:12
inconsistent	12:24,25 177:11	301:1,11,21	163:2 164:25
89:22 186:6	independently	302:15,23	167:9 173:11
incontinence	287:7	309:13	174:21 190:5,
63:19,25 64:23	indicate 219:13	infection 39:17	10,11,12 260:3
68:2,13 141:8,	247:9 262:13	148:10,12,15,	262:6
10,12 147:5,8,	288:5	19,22,25	infrared 303:10
10,11,14,25	indicated 17:24	150:11,21	infringement
173:22 183:1	31:25 145:4	151:11 159:12,	75:4,7,8
192:22 294:14,	188:16 311:21	15 193:1 298:12	ingrowth 337:15
20 295:24	325:20	311:2 312:9,10	inguinal 215:2,
296:10 314:2,6	indicates 138:11	infections 150:9	12
315:16 316:7	indicative	158:18 160:22	initial 19:7 72:4
317:1 319:7	139:17	inflammation	initially 20:2
320:5,11 322:9,	Indirectly 30:23	66:9 93:13	109:9 111:3,6
21 323:5 336:22	individual 53:4	98:20 112:12	injured 269:10
356:9	108:3 193:13	215:25 216:2,6	320:23
incontinent 72:3	322:1	221:11 222:1	injuries 72:17
incorporation	individuals	298:10,11	injury 160:22
221:12	103:11 104:24	327:19,25	innovation
incorrect 18:16	108:16 112:12	328:7,13,17,21,	157:23,24
40:9 44:21	117:7 132:17	25 329:20	336:20
48:20 51:6	160:21 190:17	330:5,7,10	innovations
66:14 120:3,5,6	260:5 269:2	inflammatory	336:3
122:10 179:20	271:20 286:10,	31:10 36:18,22	innovative
330:19 346:9	17,18 326:5	43:19 44:16	131:16 235:13
increase 88:2	industry 254:6,9	66:7 194:6	inoculated
105:15 126:11	256:10 258:3,10	216:1 221:9,10	312:21 313:5
252:17	263:17 264:5	inform 18:15	inserted 207:25
increased 37:20	270:6,7,18	163:16	inserting 256:18
103:7 150:5,8,	300:20	information	
21 151:8,10		6:13 18:18	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

insignificant 218:16,18 219:1 225:7	interest 256:23 306:12 323:24	42:23 57:12,19 58:21 293:16	inundated 290:19
instance 207:6	interested 251:20	interruption 78:8	invasive 73:18, 19,20 74:3, 157:5
institution 52:23 72:21,25 117:21,22 120:13,17 172:5 186:2 262:9	interesting 243:1 251:23 258:12 285:16	intervention 243:4,24	inventor 322:1
institutions 128:12 184:1,18	interestingly 238:19	interventions 126:15	investigation 326:11
instruct 97:23	interferes 191:23	interview 285:18 286:20	invited 68:14
instructing 50:15	internal 7:1 8:4 17:8 19:14,21 21:1 26:16 81:12 87:14 93:4 339:7	interviewed 284:14 285:20 288:23	inviting 94:11
instruction 341:14	international 9:19 11:16,19 52:25 69:8 118:10 173:22 176:12 188:14 199:4 235:15 261:14 297:21	Intestine 65:25	invoice 80:5 81:24 83:4
insufficiencies 213:6	interpretation 293:12 326:8 330:20	intestines 134:11,12	invoices 77:16 79:18,21,25 80:8 81:18,19, 20 82:10 83:2, 16
insufficiency 213:6	interplay 98:20	intimacy 140:25	involve 64:21
insufficient 209:1 210:3 211:18 224:9,11	Interpro 51:9 346:20	into 11:19 56:18 69:24 72:20 73:11,23,25 114:17 120:8,20 134:3 138:4 147:13 167:19 183:25 184:17 221:1 224:14 234:11 239:22 256:18 271:7,10 272:15 292:16 300:9 331:2 351:16	involved 37:22 38:1 49:18,19, 21 50:11 53:7 70:24 76:1 93:12 95:8,22 96:4 101:17 109:4 110:25 111:17 117:20 165:25 173:5 190:22 192:4 201:11 255:22, 24 256:17 269:5,20,21 270:16 271:18 276:6 277:15 287:21,22 288:8 304:15 322:1 338:7,19 342:2, 3 346:19
insurance 190:3, 22	interrupt 58:20 72:8 161:18 191:9 295:13	introduce 157:11	
integration 250:3 338:22	interrupted 32:24 36:9 239:8,21 300:14	introduced 204:6 255:17 271:13	
intend 6:10,16	interrupting 41:23,24,25	introduction 199:9	
interaction 53:3 275:12 279:18			
interactions 356:19,24			
interchangeably 246:17			
intercourse 141:1,2 200:18			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

involvement 189:12 199:19 267:22	issues 7:6 20:1 21:4 31:12 33:19 92:24 134:17 140:15, 25 150:13 157:16 204:15 206:13 217:5 225:16,17 226:14,25 237:1 315:22 316:1 325:10,11 343:3	journals 9:4,18 12:10 29:6 70:21 124:23	110:13,22 111:13,18 112:8,15 114:16 115:8,14 116:17,23 118:8 119:18 120:8,19 122:4,20 123:2, 15,19 124:7,11, 14 131:24 133:4,16 134:21,23 135:20 137:12 144:3 145:4 147:15,18 149:1 151:12 153:17, 24 154:2 155:13,15 158:5 161:3,11 162:7, 9,23 163:9 164:13 165:15 166:1 168:25 169:7,22 170:1, 2,13,25 171:9 173:25 174:17 175:2 176:11 177:2 178:17 180:12,20 182:11 184:16 185:6 186:1 192:22 193:6,18 194:17,18 196:2 197:21,22 202:6,10 203:2, 16 204:4,13 207:10 209:7 211:6,12 212:8 215:21 220:17 221:14,23 231:17 232:2,21 237:11 241:1,
involves 152:6 289:21 290:23	25 150:13 157:16 204:15 206:13 217:5 225:16,17 226:14,25 237:1 315:22 316:1 325:10,11 343:3	judge 94:2	
involving 68:13 72:16 73:1 199:22	itself 15:14 160:24 179:17 313:2 328:8,13	judgments 241:2	
irreversibility 195:8	IVS 121:22	Julie 284:16	
isn't 40:20 42:15 106:8 122:16 171:22 207:7 228:18 256:1 272:24 281:14 292:15 335:7 350:18 352:7	<hr/> J <hr/>	July 80:9 274:2	
isolate 41:8	jack 321:22	jump 230:11 348:24	
isolated 112:8,9 158:5	January 120:1, 13 128:5 132:14 179:5,21 183:10 274:14 299:21 349:24	June 77:9 80:2	
isolation 221:23	Jeff 4:8	jury 208:24	
issue 7:12 19:21 20:5,7,14,25 21:12,14,15 25:6,21 27:11 123:15,16 136:15 144:8 161:16 162:17 185:13 190:23 191:10,17 192:23 193:12 226:5 231:3 271:19 276:6 277:12 278:23 302:4 317:11 326:12,13 327:1 332:2	Jeffrey 208:6 216:25 270:2,9	just 4:22 8:21 9:7 10:20,25 12:3 16:22 17:18,24 19:25 21:8,11,15 24:10 25:14 26:2 27:14,23 28:15 30:5 32:10,22 33:8, 24 35:4,20 36:12,15 39:14, 24 40:21 41:8 43:9 44:4 51:24 52:6 53:1 55:2 57:5 59:19 60:2 61:13,20 63:7 65:13 66:12 68:13 70:2 72:17 73:10 74:6 76:12 77:2 81:24 82:10,16 83:23 84:1 86:25 91:22,24 95:7 100:5,14 102:7 103:12, 14,16 106:17,21 107:3 109:17,24	
	jive 226:10		
	job 86:4,5,6		
	John 118:25 322:13		
	joined 260:16		
	joint 319:15		
	journal 9:19 12:11 29:7 70:21,23 118:10 182:16 199:5 239:14 240:6		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

19,20 243:15,22 244:1 245:4,10, 246:25 247:19 249:9,17 259:12 260:6 264:1,8 266:24 268:4 274:13,14 275:16 276:20 282:16 287:10 288:2,8 291:11, 14,25 295:14 296:21 297:22 298:6 303:3,13 304:1,5,12,19 313:13 314:7 316:23 321:11, 21 323:6 325:19 328:5 329:7 335:25 340:7 344:8,17 346:6 349:24 350:3,7, 17 351:6 355:24 357:19,23 justified 269:9 justify 88:14	17,21 85:15,21 87:4 104:2,3 111:2,3,6 112:20 132:19 203:6 212:25 215:16 228:17 251:3 273:1 293:22 310:18 353:4 keeping 104:24 keeps 67:1 keywords 13:25 14:10,12 kill 192:23 kind 30:2 73:1 154:18 172:4 198:15 210:11 257:6 305:8 355:10 kindly 257:1 kit 51:4,7 176:22 290:12 355:7 kits 130:16,17,18 157:11 172:10, 24 176:9,10 199:19,22 344:21 349:16 352:11 353:9,14 Klinge 230:9,10 Klinge 118:23 119:3,8 230:6 292:13 302:1 339:6 Klinge's 339:5 Klosterhalfen 208:12 212:25 230:3,4 301:25	knew 275:14 276:2 knot 112:11 know 7:4 9:10 14:13 15:6,20, 21 16:10,20,22 19:1,18,19 20:10,11,14,16 21:3,9 22:25 25:15,23 26:7, 10,19 27:12,14 28:25 29:3 39:21 41:13,15, 18 48:10 50:4 53:23 54:1 56:6 59:9,10 63:20 64:11 70:13 74:18 76:4,8,9, 11,19 80:23 81:22 82:24 83:5,9,19,21 85:8,10 86:3,10, 11,12,14 87:1 88:14 89:7 90:1 91:8 94:5,23 96:3 97:2,4,6,14 98:6,11,15,22 100:5 103:25 107:10,16 112:20 113:10, 19,21 114:16, 18,24 115:15, 16,18 116:6,19 117:1,2,4,9,14, 17 122:18 123:12,17 124:9,12 125:11,15,22,24 130:8,20,22 132:25 137:7	150:4 156:23 160:8 163:21 165:7,17 166:15 171:18,20 172:1,17,22 174:6 175:2 176:21,25 177:22 178:4,5 182:14,22 183:16,24 184:2,10,11, 186:16 187:11 188:12 200:8 201:20 202:17 204:9 207:19 208:12,16 209:23 210:22 211:6,24,25 212:4,14,19,24 223:19,23 226:19,20,25 228:8,13 230:3, 4 233:13 234:5, 10,11 236:12 237:24 241:3 246:2,20,22 247:14,25 248:24 249:4 251:5 252:3,4, 20 254:12,13, 15,16 256:9,25 257:6,7 259:2, 12 261:8,9 265:22 269:12, 15,18,23 270:4, 15,16,17,19,23, 24 271:4,14 272:1,12 275:18,24 276:5,10,20
--	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

283:11,19 284:17,18,24 285:15,25 287:23,25 290:17,18 297:20 298:6,14 301:10,11,14 309:11 310:10, 17 311:22 320:24 321:2 323:21 328:2,4 329:8 332:18 340:13,17 345:25 349:20, 21 350:8 354:2, 3 knowing 123:16 242:22 knowledge 8:15 12:12,15,23 13:1,5 31:18 39:16 41:10 42:19 43:16,17 53:7 54:20 58:14 59:7 88:2 92:9 105:22,24 106:8 107:19 133:23 210:18 290:12 309:21 313:6 346:4 353:12 known 21:3 47:9 63:21 140:14 149:16 184:7 194:21 195:14 232:25 342:17 knows 115:21, 116:24,25 173:14 227:2	265:16 Kohli 257:6 Kuntz 57:8,10, 14,18 58:3 208:6 216:25 270:2,9 <hr/> L <hr/> label 340:23 342:5 labeling 340:15 343:21 labels 49:20 54:21 labor 134:17 laboratory 94:16 labs 50:12 lack 153:2 296:22 304:2 lacto- 297:10 lactobacillus 215:17 297:10 313:7 landmark 300:18 309:12 language 178:19 297:1 laparoscopic 64:3 65:6,15,19 66:2,23 67:4 68:25 154:4,21 160:10,11,16 162:2,7 169:14 334:19 laparoscopic- assisted 153:24	154:17 laparoscopically 153:21 154:12 195:16 laparoscopy 64:22 154:17 laptop 8:2,3 26:13,15 78:5 180:24 203:22 large 68:6 132:16 137:25 142:3 157:7 176:9 247:10,15 251:22 265:18 larger 125:16 335:13 339:8 largest 262:9 laser 68:12,16 69:18,20,22 70:1,2,3,4,6 71:21 72:10 73:5,17 95:3,10, 20 96:5 101:12 lasers 70:4,5 71:13 last 7:19 8:10,25 9:15 21:7 51:11 57:6 60:7 73:10 86:21 105:20 161:7,14 163:22 164:21 165:23, 25 170:2,13 182:11 251:6 252:5 254:22 257:2 274:25 279:20,25 314:14 322:24 346:14,17	lasting 330:13 late-onset 316:8 317:4 later 117:24 144:10 170:20 321:13 349:18 350:7 357:22 laudable 157:18 launch 345:10 law 4:25 76:20, 21 77:2 283:21 lawsuit 256:15 lawsuits 276:13 lawyer 33:17 106:5 189:12,13 275:1 lawyers 16:23 18:12,13,17,20 19:8 26:17 33:18 79:9 107:12 188:21 271:23 272:2,20 273:10 274:5, 18,21,25 276:9, 21 277:1 284:2 lawyers' 24:7 lay 161:22 208:24 lays 214:1 lead 70:8,11,17, 18 119:4 221:22 leader 88:15 leaders 88:11 leadership 319:24 leading 186:23
--	--	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

272:20	347:15	262:11, 265:23	letting 357:13
leads 221:10,11, 12,13	lengths 228:14	267:3,10 268:2	level 49:14
leak 147:20,21	less 29:22 30:7, 21 31:23 32:13	279:7,13 282:23	173:21 177:1
learn 10:22	34:12,23 35:25	283:4 285:6	194:10,11 195:5
271:16	38:19 39:9,23	287:10 292:1	Levin 283:6,19
learning 11:18	40:19 42:15	293:23 294:3	284:7
166:25 176:9	43:21 73:20	295:12,13	liability 5:2,5,11, 24
335:5	80:3,24 143:9	301:18 311:5, 15,18 314:7	lie 108:5 193:9
least 6:15 9:1,11	157:4 203:1,2	319:10 323:23	Liebert 298:24
131:18,22	237:21 249:5	335:2 337:12	301:5
132:10 137:19	318:9 332:20	339:19 341:25	life 72:3 136:12, 13,15 141:24
172:18 185:12	335:17	346:6,17 347:3	144:25 145:3
190:25 227:13	let 9:10 10:24	349:1	193:2,16 206:13
234:24 265:18	17:3 23:18	let's 17:14,18	217:4 225:16
266:4 278:21	24:10,22 29:17	19:23 57:8,10	233:13 235:6,13
285:25 288:24	33:5,10 36:12,	103:16,17	236:25 237:9
290:5 309:3	15 39:20 41:14	108:13 126:7	320:6,19 356:5
310:19 322:24	42:6,7,24 45:17,	138:15 145:19	life-changing
357:9	18 53:9 55:22	150:3 159:16	44:24 126:16
leave 106:24	58:17 62:1	174:7 175:1,5	life-threatening
107:2 116:17	64:16 72:8	178:7 180:4	136:16,19
142:10 338:8	74:18 76:12	181:18,19,22	lifelong 194:9
led 272:2 350:22	83:23 107:1,5	182:5 204:22	343:8
left 61:21 233:13	110:24 118:4,5	210:18 220:16,	lifetime 233:2
274:11 341:19, 20	121:16 123:12	17 222:10,11	lift 143:12
left-hand 127:8	124:9,16 133:15	230:14,24	lifting 140:2
250:2	156:11 170:25	232:13 239:7	ligature 153:3
legal 34:7 76:8	174:4,7 178:8,	244:15 248:10	light 70:4 228:13
275:18,20 276:5	23 180:16,	257:23 259:2	229:9
279:19	181:23,25	268:22 272:15	lightweight
legitimate	182:22 187:20	293:22 298:6,16	228:19 229:3, 13,21
307:11	193:17 196:3	299:2 303:22	like 10:24 11:7
legitimately	197:25 198:13	316:17 318:7	12:3 20:20
192:19	203:4,8,13	320:8 329:7	
length 338:17	205:15 231:1	letter 279:14	
	244:18 245:13	280:4,14,17	
	249:8 251:15	282:13 348:16	
	253:6 259:24	349:18 350:8	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

25:11 26:22	limitations 342:7	129:2,6 179:18	24 87:6,20
27:13 41:21	limited 69:11	340:21 341:7	89:17 90:5
43:1,7 44:5,16	120:21 297:3	343:23	91:12 97:3 98:4
47:8 49:2,3	limiting 42:19	Listen 41:22	111:10 240:3
51:12,23 55:20	46:10 48:9 95:7	listened 309:10	256:15 257:12,
56:5,7, 58:22	218:9	lists 127:18	21 272:24
71:5,18 79:7	limits 129:22	128:23	273:4,10,11
83:17 84:16	219:8	literally 41:6	274:5 283:22
85:15 91:7	line 67:5 117:3	153:10	345:20 351:1
96:23 108:25	124:11 125:8,23	literature 7:8,14,	little 37:9 53:6
112:8 113:17	244:16 258:24	17 11:9 13:13	56:7 90:22
114:13 115:20	259:3,4 280:3	37:6,8,10 39:25	132:8 146:16
125:3,15,23	links 298:3	40:4 51:20,23,	184:22 193:18,
128:7 131:16	lion's 160:14	25 52:3,8,13	20 197:24
132:7 139:21,25	list 7:11,16,20,25	53:15,23 84:7	265:13 294:5
140:9,18 141:6	8:17 9:9 10:16	93:2 137:20	340:8 347:25
147:14,19,20	11:11 13:14,17	146:13 148:15	live 50:19 141:23
149:1 154:22	14:4 16:3,9,15	150:5 152:24	224:8
156:2 158:9	17:4,16,21,23,	160:2,5 194:22	lives 187:14
159:10 193:20	24 18:3,7 19:1	212:24 231:16,	193:5,8 196:19
209:13 216:8	21:6 22:8,16,19	18 233:10	278:24
219:11 221:15,	23:5,8,10,14,15,	245:21 246:16,	living 29:9 50:21
21 224:10	19,22 24:17,24	23 262:14 282:5	124:25 186:21
225:15 226:2	25:13 28:6 54:9	295:8 296:5,8,	210:3
236:4 259:8	61:5,6 66:25	14,17 299:24	local 190:2,21
261:20 266:16	68:20 74:10	302:6,22	location 194:1
270:25 271:22	77:25 78:4	337:19,24 338:1	195:7 196:11
276:11 284:16,	89:14 118:13	347:9 356:19	198:6
20 291:11,23	122:22 129:4	Lithner 292:12	locations 153:9
304:17 306:14	179:11 204:2	litigation 5:3,4,	355:12
310:18 313:7	241:6 251:25	8,24 6:4,8, 7:23	logical 222:3
321:22 340:5	258:1 263:21	12:21 25:1	long 10:25 13:24
342:23 347:10	310:16 331:19	29:16 33:12	19:18 25:16
348:5,14 349:6	332:7	34:22 74:16	59:22 63:7
350:9 353:15	listed 13:16 16:3	75:14 76:2,14	84:12 170:14
357:1	21:25 23:24	77:4,6,11,17	193:19 198:15
likely 207:2,7	24:1,13,14,24	80:2,14 82:23	232:10 252:12
325:22	29:4 54:8 62:10	83:15 85:2,7,19,	261:6 277:12
limit 42:18 43:15			
44:22 50:20			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

305:3	246:13,18	236:14,24,25	332:3 338:21
long-term 65:5	248:8,10,22	237:7,18 241:20	339:5,7
149:22 163:11	251:10,13,19,25	243:22 245:17	looks 79:7
357:9	252:9,12,13	246:5 248:11	204:13,14,
longer 85:10	257:20 268:22	250:19 252:1,	223:17 231:23
224:5 229:4	272:11 278:18	10,15 255:6	265:5
232:5 240:22	279:8,20 282:15	262:19 265:4	lot 29:15 71:10
271:12 294:24	283:13 286:2	266:6 271:10	85:9 105:5
347:25 351:15	287:10 290:21	295:6 301:24	106:18 108:23
longevity 174:21	298:16 299:22	303:16 310:22,	132:2 138:5
look 11:9 17:14,	301:9 303:6	23 311:3 314:4	169:4 173:17,18
15 19:9 21:18	304:22,25	315:21 316:1	175:17 185:2
37:25 38:4	306:23 307:11,	321:11,12,13,17	186:11 190:9
39:15 49:7	15 309:21	322:25 324:20	200:11 224:5
57:11,15 61:6	310:2,4,6,8,10,	326:13 328:17,	240:7 248:24
62:1 83:23	11,20 314:3,5	21 330:5,11	257:10,11 268:1
86:10 89:14	316:14,17	332:2 342:19	269:23 271:1
91:10 98:16	318:7,15,17	looking 9:23	293:16 303:13,
103:12,13,14	321:15,22	19:1 22:11	15 329:14
109:11 110:24	322:10 329:15	23:20 24:16	lots 185:5 210:17
119:25 120:11	331:2,11,20	38:7 46:11	285:20
122:18 123:5,23	332:1,7,16,19	49:20 64:18	louder 89:1,2
126:25 128:20	339:4 342:25	89:21 103:14	Louis 89:6
131:25 132:5,20	345:12 351:16	105:11 127:17	low 114:19
137:14 140:9	looked 9:20	144:14 156:24	330:5,7
143:14 163:9,22	14:9,21 15:22	164:20 182:21	lower 138:8
166:17 169:23	24:17 27:18	183:8 189:3	232:16 234:6,15
170:11 180:4,5,	38:16 39:22	191:2 200:10	242:14 279:21
20 188:11	40:15 42:12	203:22 206:9,12	330:10 337:22
189:24 190:25	45:7,19 46:2,	212:16 214:11	Lucente 254:10,
191:19 202:7	47:13,25 89:23	217:4,20 222:8,	14 257:5
204:19 210:2,15	119:20 128:7,8	18 232:1 234:4	lunch 138:20
211:8 216:14	178:9 199:24	236:7,10,11	lying 213:24
219:12 222:11,	203:14 205:1	237:5,9 251:16,	
12 225:8 230:6	207:23 219:2	22 260:23 271:7	
232:8,13 233:6	222:4,5 223:13,	274:22 282:5	
235:3,19	14 224:6,25	298:6 302:13,14	
237:16,22	225:6,14,15,16,	303:25 304:5,12	
238:7,10 242:18	19 231:2,5	310:2,4,14	
	232:3,5,22	325:10 329:23	

M

M.D. 4:15 139:5

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

macroporous 228:20 229:4	make 9:7 10:24 20:8 21:12 25:3 33:11 52:6 56:13 57:4 59:20 63:5 107:6 108:8 115:18 117:4 131:15 147:22 156:11 165:2 221:14 239:17, 19 254:17,21,24 255:1 256:18 257:23 258:2,5, 10,13,15 260:8 266:24 278:23 282:2,7 291:1, 23 303:4 328:5 342:1 346:6 349:7 351:15	125:4,8 management 11:24,25 66:19 68:16 69:18,20, 22 70:1 94:13 182:9,24 198:17 maneuvers 155:11 manifest 111:4 manifested 147:12 Manny 119:1 manufactured 51:17 226:23 manufacturer 42:13 51:4 75:17 116:16 349:19 manufacturer's 29:23 30:8,21 104:9 manufacturers 75:16 131:21 267:23 268:16 275:7 344:21 349:6,25 352:6, 10 353:3 manufacturers' 40:17 46:6,15 47:17 48:1,16 manuscript 15:17 73:14 82:2,14 182:15, 21 263:20 285:21 310:13 340:18 manuscripts	17:6 52:8 68:11 69:8 77:25 78:1 258:4 316:15 341:7 346:2 many 16:4 40:10 47:18 53:25 64:9 70:17 75:10 79:21 95:22,25 102:5, 9 103:3,7,23 108:9,11 109:3, 21 110:16,24 111:16 112:15 113:10 114:14 115:19,21 116:6,19 125:1 136:21 168:20 178:4 183:12 184:11 185:20, 25 210:19 223:20,23 224:22 232:8 258:2,13,14 259:6 263:17 264:8 320:13,22 327:24 355:9,23 March 343:19 mark 170:25 203:8 211:5 231:1 241:12,13 253:7 273:14 287:10 311:5 314:8 329:7 marked 5:17,19, 23 6:11 22:12 24:3 118:2, 171:4,10 180:12, 187:18, 20 198:11,13
made 25:6,24 56:25 82:22 83:5,13 85:18 88:15,18 116:24,25 117:2 157:7 185:18 189:19 200:14 220:9 223:20,24 232:8,11 241:2 256:6,15 271:24 272:5,13 278:8 286:15 289:10	made-up 257:18 264:10		
magnitude 275:21	makes 31:7,8 165:5 228:14 244:16 251:10 254:15,16 257:10		
main 10:13 193:22 225:17 305:5	making 59:25 115:23 117:8 241:4 246:25 254:5,8 257:11 293:17 357:19		
mainly 72:16,24 103:10 171:18 172:4			
mainstay 315:11			
maintenance 142:22	male 63:25 101:4		
major 71:10,20 74:1 150:17 226:5 227:22 236:18	Mamy 298:11,25 310:17 Man 329:14		
majority 67:24 145:23,24 146:3 153:16 154:23 193:2 207:15	manage 175:14 177:20 246:21, 22 managed 124:19		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

203:11 216:19	90:3,18 98:21	347:24	16 53:9,10 54:6
223:2,5 230:22	126:9 198:19	Mayo 86:8,15	55:22 57:12,19,
237:11,12	227:1 255:9,10	104:8 107:21	23 58:20,21
244:20 249:8,12	259:6 289:1,11	108:10 118:16	62:1 64:16
253:9,11 267:8	309:2 313:15	119:2,5,14,17,	66:12,25 67:22
273:20 279:11,	324:21 325:6	25 120:7 121:10	68:20 69:13,21
13 283:2, 285:4	329:21,23	122:5,15 131:3,	72:8 74:18
311:13 314:10	330:11 333:1	19,22 132:12	76:12 77:18
316:21 319:13	347:8	178:11,25	79:6 80:1,13
324:2 329:13	math 108:15	283:13 286:21	83:12,23 85:5,
331:23	109:12,15	287:1,3,15,19	17,22 86:25
marker 198:9	110:10,12,22	288:20,22,25	87:13,17,18
market 54:14	111:8,13 121:15	289:20 290:6,7,	88:1 90:15
121:20,21,22	matter 17:15	10,24 291:19,22	92:25 94:11
126:23 130:19,	37:12 214:25	292:10,16,19	96:6 97:20 98:4,
131:20 132:1	240:21	294:18 322:6,7,	7 101:11
229:12,18	may 12:9 27:24	15 326:6 349:4	103:19,20
268:24 278:6,16	45:3 47:10	Mayo's 285:17	105:8,21 107:20
279:4 286:3,7,9	61:15 67:5	287:21	109:5,21,22
344:24 347:20,	68:18 71:19	mayoclinic.org	110:24 111:14,
24 351:12,18	88:14 98:9 99:4	292:10	21 113:4,18,19
352:5,7,11	123:2 126:15,16	MDL 5:1	114:8 115:17
marketed	130:3 138:2	me 6:14 10:24	116:20 118:4,5
126:18 127:15,	143:16,25	12:14 13:22	119:18 122:21
20 132:22	149:24 158:13	15:13 17:3,9,15,	123:5 124:9,16
179:19 229:12	164:16 174:1,10	16 18:20 19:24	126:25 127:11
352:15	177:11 191:25	20:5 22:7,20,23	128:21 129:8
marketing	194:19 241:10	23:18 24:10,16,	133:1,3,15
268:8,10 345:1	257:2 282:16	22 28:16 29:17	136:6,11 137:19
350:11 353:4	286:11 310:21	32:24 33:10	138:14 139:15
marking 216:17	320:22 325:23	35:8,20 36:8,9	142:16 144:8,22
316:18	330:12 334:11	37:14 38:5,18	148:9,24
material 215:8	350:22	39:7,10,20	149:15,21
304:16 325:21	maybe 30:2	40:14,19 41:14,	150:24 151:13
330:17	67:18 86:1	23,24 42:10,18,	155:1 156:11,12
materials 6:24	121:10 137:20	23 43:8,9 44:2,8	157:3 161:7,11
8:16 23:19	251:3 270:24	45:17,18 46:12,	168:7 169:22,23
66:10 89:23	272:10 298:1	18,24 49:23	170:25 174:7,8
	311:6 335:11	50:14,20 52:2,	177:23,25
			178:8,13

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

180:16,23	300:14 301:12,	14 344:8 355:25	275:21, 280:25
181:25 182:22	18 311:5,7,15,	meaning 70:14	282:21 285:24
185:12 186:4	18 312:2 313:4,	86:2 187:22	289:7 296:17
187:20 189:24	21 314:7 318:4	219:9 274:21	297:6 299:24
193:17,19	319:10 321:1,9	meaningless	308:11 317:8
195:14 196:3,22	323:23 324:11,	233:5	327:7,11,12,15,
197:4,8,18,25	18 326:23 327:5	means 15:23	24 341:15 342:6
198:13 200:3,21	330:25 332:1,22	52:10 70:18	349:5
203:5,8,13	334:10 335:2,	117:25 134:21,	medicine 49:11
205:15 211:21	15,18 337:12	25 147:10	99:10,16 100:2
213:9,24 214:2,	338:8,25	150:20 190:15	154:7 175:17
6, 215:8 219:12	339:17,18,19,20	200:6 204:9	319:18
220:8 221:15	341:25 343:1,17	208:19,21,22	medium 229:9
223:12 231:1	346:6,12,22	243:4,16 297:25	Medline 199:24
232:9 233:5	347:3 349:1	306:21 308:12	meet 97:12
236:17 237:22	351:25 357:13	meant 71:8	108:18 112:7
239:8 240:21	mean 24:4,20,21	102:20	346:5 352:12
244:1,18 245:14	27:17,21 32:25	measure 348:22	meeting 9:5
246:15 249:8	33:4 51:23,25	measurements	10:20 53:1
251:15 252:3	52:21 63:18	346:20	68:15,18
253:6 254:7	76:8 87:12	Mechanical	176:12,13 211:7
259:20,24	94:23,24 97:19	331:14	257:3 276:18
260:12 262:11,	100:8 109:24	media 269:17	meetings 8:13
265:23 266:17	110:5 120:8	Median 252:16	10:20 46:22
267:3,10 268:3	131:23 137:13	medical 7:14,17,	50:6 52:9 53:1
269:5,14,19,22,	143:18 149:9	21 39:25 49:4	54:10 69:8
23 272:9	156:20 178:19	50:9 52:7,8	150:7 173:8,20,
275:10,15	189:3 192:17	53:23 54:14,25	21 176:11
276:17,19,23	211:10 212:6	60:19 75:4 84:6,	185:24 186:14,
277:3,11,15	214:11 223:24	23 93:2 104:12,	20 226:16 276:1
278:23 279:7,	227:20 233:7,24	13 112:22	297:21 311:23
13,18,20 280:1	240:16 243:18	116:9,12 139:17	356:25
282:4,13,23	256:24 262:20	157:20 168:11	Melissa 4:9,24
283:4 284:19,25	263:13 268:1,2	169:19 174:10	16:22 41:19
285:6,20,21	289:5 295:12	184:25 185:6	59:8
286:5 287:10	296:13 300:15	186:24 190:2,21	member 11:19
289:4 291:13	306:24 308:15	192:4 195:2,3	188:8,13
293:16,23	310:13,18	270:12,13,18	319:20,22
294:3,7,8	320:15 331:4		
295:12,13 298:2	335:21 340:13,		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

320:14 355:22	48:1,16,23 51:1,	189:20 193:24	272:24 274:5,
members 263:20	2,18 53:2 63:3,	194:4,5 195:25	19,23 278:20
271:17 354:3	23 64:10,15,20,	196:7,8,16	281:8 283:14,
355:25	21,24 65:9,25	198:2 199:19,22	22,25 284:12,
memo 339:9,12,	66:6,7,21,22	201:12 203:15,	15,17,23 285:7
14	67:6,7,14,19,20,	17 204:6 205:4,	286:4,7,22
memory 181:19,	24 68:1,8,9	13,20 206:11,	287:4 288:16,25
20	69:4,5,19,23	12,18 207:25	289:7,10,13,22,
mention 168:5	70:7 71:8,11,16,	208:12 209:7,19	25 290:8,12,23
mentioned 38:18	21 73:5,14	210:7,19 212:1,	291:5 292:17,
65:20 96:21,23	74:15 75:3,5,6,	8,21 213:2,9,18,	22,24 293:3,
105:3 111:2	16,19 76:2 85:7,	21 214:4,13,15,	294:8,9,10,21
133:24 135:3	19,24 87:25	21 216:2,4,5,21	295:3,18 298:12
150:1 154:22	88:5 90:11 94:9,	217:3,7,11,20,	302:15 311:1
159:1,9 162:19	13,17 99:12,20	21 218:22	312:9,14,15
168:6 177:3	100:16 101:5,13	219:6,14 223:8	316:5,7 317:16,
178:7 179:23	102:2 103:5	224:20,25	17,21 318:9
180:9 184:3	104:9 109:22	225:24 226:1,21	319:6 320:2,9
195:20 228:14	112:3,9 113:12	227:10,11,14	322:8,12,22
232:2 233:15	116:16 119:10	228:6,20 229:4	325:5,11 326:2,
238:3 242:7	120:15 121:5,11	231:6,24 232:16	7,14, 328:18
244:10 277:2	122:6,16 128:7,	234:6,9,15,18,	329:1 330:4,10,
298:25 319:17	23 129:25	23 236:9 237:20	12 331:17
324:10 329:19	130:12,16	238:10 241:13,	332:2,3,10,16
330:17 345:25	132:15 152:7,	22 242:2,7,14,	333:6 337:18
351:7 354:16	13,22 153:12	23 243:2,10,12,	338:5,10,14
355:21	155:24 157:11	15,18,23	339:3 346:8,10,
mentions 356:8	158:23 159:7,8	244:12,22,23,24	21 348:5 349:16
merely 344:9	160:25 161:2,3,	245:6,7,12,17,	352:5,11 355:7,
mesh 11:25	10,12,21 162:1,	21,23 246:6	12 356:9,14
18:19 21:2 30:8	11,12,24 163:5,	247:24 248:11	357:3
31:6 35:16	25 166:3	250:1,5 252:2,	mesh-implanted
36:19,20,21	172:15,19,24	11 253:15 255:9	211:14
37:16 39:1	173:1,7,15,16	257:21,22	mesh-related
40:17 42:13	174:2,12 175:6,	259:5,14,15,17,	106:20 182:25
43:20 44:15	11 176:9,10,19,	19 260:17	290:2
45:3,16 46:3,6,	22 177:6,13,20	261:4,19	meshes 35:19
15 47:10,17	178:1 180:7	264:13,19 265:6	50:12,13,23
	182:10 183:13	266:8,18 268:9,	68:13 88:10
	184:8,12 185:8	17 271:19	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

89:1 90:11,12, 16 93:1,11 98:19 109:2 176:16 184:14 185:3 275:15 287:1,21 298:13 320:14 324:12 330:4 355:12 met 4:22 175:1,6 233:9 261:10 metaanalysis 211:9 method 302:9 methodically 17:19 methods 145:14 227:1 mic 309:24 Michael 269:4 277:9,14 Mickey 132:7 microphone 78:25 79:2 microscopy 303:9,24 mid-1990s 156:16 middle 36:14 53:5 127:3,13, 14 154:21 279:22 midurethral 294:19 313:16, 25 319:6 320:3, 9 354:18 355:1, 8 356:9	might 25:17,18 90:2 139:11 169:16 220:3 262:7 309:20 mild 149:19 miles 105:4 millimeter 337:5 millimeters 336:11,18 337:22 339:2 million 10:12 12:2 85:11 millions 320:6, 19,22 321:1,4, 10 356:5 mind 13:11 32:9 89:21 262:3 mine 71:12 72:24 108:25 120:24 241:6 262:21 minimal 269:11 322:21 337:9 minimally 73:18,19 74:3 141:25 minimizing 264:6 minimum 192:8 Minnesota's 63:1 minor 160:12 178:23 335:22 336:17 minority 103:9, 11 153:15 160:6	minorly 160:12 minus 61:15 214:13 minute 63:13 91:9 138:16 232:13 minutes 341:18, 20 minutia 177:16 mischaracterizat ion 256:2 mislead 241:8 misleading 121:14 242:10 274:8 miss 11:3 missed 11:6 13:2,4 222:24 misspelled 287:9 misspoke 102:22 misstate 241:8 292:4 misstatement 281:22 misstates 40:3 166:8 211:16,17 243:18 273:7 280:10 316:11 344:5 351:4 misstating 280:14 294:8 mistake 238:23 misunderstood 23:11 mix 146:6	mixed 259:13 Mm-hmm 117:13 236:22 280:6 321:14 model 66:1,11 93:12 233:24 298:14 312:8 326:9,16,22,23 329:22 330:1,8 moderate 186:14 moment 268:23 Monday 153:15 money 82:22 83:13 85:17 86:14 115:18 116:24,25 117:2,5,9 254:17,21,24,25 255:1,22,23,24 257:10,12 258:3,5,9,13,15 270:17 271:10, 15 272:12 284:18,25 monofilament 227:10 228:19 229:3 month 62:20 79:23,24 80:7 83:3 272:10 282:3 284:25 monthly 86:12 months 19:11 77:9 83:3 91:13 117:24 144:10 170:20 179:9,10 205:3 206:17,18 208:9,11,15,16,
---	---	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

25 209:14,15, 16,19,21 217:11 218:9,12 219:10,20 223:15,19,21 232:7,9,11 233:15,16 234:13 245:24 246:1,9 248:2 275:17 330:2 332:5 349:18,24 350:7,17 351:23 moot 210:12 moral 269:25 350:20 morbid 71:11 morbidities 157:16 morbidity 157:12 morbidly 150:17 more 9:22 11:20 12:16 20:9 22:2 27:12 29:22 30:7,20 31:5,23 32:4,5,13 34:11, 23 36:1 38:19 39:10,23 40:19 42:6, 43:15 44:4,19 48:15 49:22 53:6 73:2 80:3 83:18,20 85:9 104:7 105:5,13,14,20 106:3 107:15 108:18,22 109:7 117:24 121:9 125:12 129:22	131:21 132:2,8 140:5 146:14, 17,18,21,22 147:13 150:12 151:1,14 158:13,15 180:5 184:23 185:2,13 186:1 196:8,16 207:2,7,12 210:8 216:5 221:9 229:6 231:20 269:9 275:8 277:13 281:2 295:21 297:24 302:7 303:13 312:17 317:19 325:20, 22 330:13,25 357:1 morning 4:20,21 morphology 304:13 Morris 230:18 most 17:25 19:12 28:21,24 37:8 49:25 63:3 70:19 77:25 78:1 88:19,24 105:23 120:24 121:20 140:3 142:21 147:6 152:9 155:3 156:12 170:10 192:9 210:1,2 211:9 264:21 289:10 313:8 315:15 318:23 320:13,16	motivated 258:9 motivates 271:2, 4 motivation 270:25 mouse 180:24 mouth 110:12 move 34:6 41:21 43:1,5,10 44:7, 45:11 56:16 115:14,21 124:4 133:15 230:25 281:16 293:13, 19,21 306:13 319:11 moved 116:7,19 117:25 154:1,3 155:4 movement 160:9 moving 42:7 MSDS 19:13,21 20:1,20 21:11 25:21 27:6 much 80:13 82:22,25 83:5, 13,21 85:5,17 86:3,14 88:25 89:2 108:15,21 116:24,25 117:1 120:23 124:17 131:13 241:15 245:24 254:12, 15,16 258:5 265:3 271:6,19 272:16 325:22 333:9 multicenter 182:11 183:4	251:22 265:19 multiple 42:3,6 56:25 71:4 73:8 122:24 126:14 134:15 141:17 150:1 170:19 173:12 174:23 177:8,19 214:12 215:1 222:2,16 306:21 307:10 310:24 345:25 Murphy 254:12, 15 257:5 muscles 135:13, 14,15,20 214:16,17 musculature 134:25 must 285:16 302:6 myriad 44:22 Myth 331:18 <hr/> N <hr/> N-i-e-m-i-n-e-n 223:7 Nader 271:11 Nader's 256:16 name 4:24 25:9 89:24 97:6 248:9 251:1,6, 14 252:5 283:25 287:9 331:12 names 89:25 186:12 283:20 narrative 82:11
--	--	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

narrowing 158:4 national 11:16 52:25 69:7 94:12 185:23 276:18 297:21 national/ international 9:4 50:6 nationally/ internationally 341:10 nationwide 114:5 native 39:14 45:15 46:8,9 48:21 145:20 147:2,16 148:8 149:1,8,17,25 150:10 151:4, 15,23 156:4,8, 13,14 158:1,2, 15 194:20 195:4,9,15 196:6,14 197:3, 8,18 202:19 203:15 204:7 205:3 206:16 207:1,7,13 208:1 209:9,18 210:9 211:15 212:2,9,21 217:3,12,23 218:14,22 219:5,14 224:19 225:1,24 227:15 231:8,25 234:18 235:25 236:8,16 238:9 241:23 357:8	natively 147:8 148:1 natives 202:19 natural 328:12 nature 109:19 296:25 307:19 343:9 nauseam 286:11 347:7 near 85:11 nearly 162:21 202:12 necessarily 7:4 15:13 140:18 144:3,21 146:7 147:9 225:13 246:21,22 271:24 284:2 320:20 335:21 need 50:3 56:15 58:13 61:23 62:22 63:5 104:17 115:10 124:12 145:7 153:1,6 165:7 191:20 212:4 223:23 230:12, 13 255:10 263:25 288:17 290:1 293:21 305:18 306:7 334:5,13 335:19 342:18 343:11 344:21 345:2 346:13 347:11 357:21 needed 13:6 262:10 281:8	328:1 350:9 353:3 needle 334:7 335:8,25 336:1 needles 335:3 needlessly 283:14 needs 43:4 62:25 153:4 165:7 327:18 343:13 negatively 136:12 neither 15:2 nerve 221:12 network 257:16, 18 263:21 264:9 neurologic 12:24 never 20:10 47:1,6 50:21,24 51:1,3 52:17 72:14 94:20 95:5 96:25 102:12 148:13, 21 149:5 150:6, 7,10 154:21 165:11 167:6,21 172:12 192:24 195:6 197:2 220:1 236:3 258:11 262:10 271:7 273:3 281:20 286:8 292:14 294:11, 23 302:2 334:8 335:2, 342:5,8 343:9 354:16 new 6:13 8:16 9:1,11,14,17,25	10:14,19 11:6, 13:10 33:8 99:21 246:20 253:2 275:4 News 284:12,15, 17,23 285:8 next 136:9 212:17 266:16 nice 38:14 46:23 90:2 123:6 152:16 Nieminen 222:12,14 223:6 231:2,23 232:19 233:8 236:21 237:12 245:25 250:8,18,22 251:3,4 Nieminen's 248:1 Nilsson 315:21, 23 316:16,23 321:11 nine 123:8 209:15 noise 138:14 nomenclature 76:8 non-avaulta 238:5 241:25 242:6 244:8 non-industry 260:4,20 non-industry- sponsored 39:3 non-peer- reviewed 264:11
---	---	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

nonabsorbable 268:8,17	299:14 307:18 312:8	168:6 170:9,20 172:17,24	218:7,13 219:9 250:11 258:2
nonautologous 325:6	nothing 75:7 122:3 141:25	176:11,14 186:18 203:13	264:8 313:4 340:3
nonavaulta 234:14	184:9 190:15 210:5 290:15	205:17,21 206:8 207:19 212:13	numbering 312:4
nonbard 227:24	308:22 356:10	225:8 243:7 244:1 250:7	numbers 17:8 19:3 23:15
none 31:18 76:23 159:3 179:2 309:7 344:22 345:18 353:12	notice 5:20 33:19 62:1 74:8 77:16, 78:20 79:5,7 82:18	255:19 258:4,20 261:7 264:12 281:1 286:19 300:14 303:4 304:19 305:14	72:14 80:23 101:25 103:8 109:15,18 113:3,17 114:13 115:8 122:11 125:16 126:11 163:18 220:14 248:22 249:3 266:10
nonentity 154:19	noticed 272:4	320:13 323:20, 21 330:18 343:2	numerator 103:14 123:17
nonfactor 151:7	notwithstanding 163:13 174:9 282:12	347:15 348:2 349:17 352:14, 19 355:21	nutshell 71:6
nonmesh 235:17	novel 337:2	356:13 357:2	Nygaard 248:8, 23 249:9 251:20 265:24
nonprofit 188:17	November 8:23 75:22 199:25 288:4	nowhere 32:11, 17 35:24 36:2 47:3 291:4,21 292:18,20,24	
nonsurgical 141:19,20,21 142:11	novo 147:7,9,25 149:12 208:17, 18,20,22 209:8, 9 218:7	number 18:1,9 22:10 31:6 32:24 44:23 62:7 65:14,23 66:1,8,22,25 67:21 72:6 80:15 82:24 83:10 85:8 103:13 104:24 105:8 113:15 117:23 119:20 134:16 137:15, 25 142:3 145:17 155:15,16 169:13 177:3 183:16 184:6 190:9 192:17	
normal 8:21 143:19 144:2 327:6,7,19 328:6,8,13	now 4:1 6:9 8:19,22 19:11 22:7 35:6,8 38:5,6 39:2 41:13 48:10,21 51:5 55:21,24 56:12 59:7,15 62:23,24 73:11 74:8 105:15 110:13,22 119:8 125:14 153:16, 25 154:22 158:20 159:2,4, 24,25 160:13 163:9 164:3		<hr/> O <hr/>
north 105:4			O-c-c-u-l-t 147:10
Nos 5:16			O-c-h-i-n-o 322:13
nose 181:18,19			OB/GYN 195:3
note 129:11 247:2 250:6 263:9 281:17 314:19 325:4			obese 150:17 151:19
noted 126:19 330:12			obesity 134:14
notes 104:4 128:10 132:21 181:7,10 204:3 231:11 285:20			object 14:22 27:16 29:25 30:17 32:18 33:24 34:6 35:9

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

36:4 40:2,21 43:24 44:3,10 45:11 49:5 52:4, 14 53:18 54:3, 17 55:1 60:21 61:11 67:9 81:8 85:12 86:23 87:9,22 88:7,12, 21 89:3 90:8 91:4 92:14 97:18 106:6,9, 21 113:8,25 114:22 116:1 122:8 130:13 156:5 164:18 165:3 166:5,8 174:14 175:19 185:10 186:9 188:23 189:6,10 194:24 212:22 215:10 219:16 221:17 228:4, 233:21 234:20 243:17 244:3 254:19 259:9 273:1 278:3,11 281:16 293:13 296:11 300:2,5 301:2 305:11 317:23 323:17 327:9,16,20 328:10 338:11 340:25 344:5 350:3 objected 321:20 objection 30:10 34:18,25 40:7, 25 42:16 43:11 48:4 91:21 99:5 107:6 164:8	177:7 280:10 316:11 332:13 348:8 350:13 351:4,20 352:8 353:21 354:8,14 355:4,19 356:16 357:5 objections 55:19 56:21,24 57:1,4 59:21,25 291:23 objective 182:24 217:6 234:24 obligation 269:25 observation 141:21,22 142:1 observe 295:17 observed 306:18 312:24 obstetrics 100:20 182:17 obstruction 314:21 obstructions 67:24 obstructive 149:23 obtain 163:2 obturator 194:2 214:15 216:7 335:12 336:13 obviously 16:23 29:15 173:9 247:1 317:13 occasionally 126:16	occult 141:12 147:10 occur 126:14 149:20 165:11 214:5 294:10 309:17 occurred 183:21 occurring 105:22 167:4 308:18 occurs 134:13 214:18 215:24 Ochino 322:13 October 8:19,22 16:19 80:9 182:16 275:12, 16 285:9 odds 165:16,24 off 15:7 17:17 19:16 22:1 31:11 32:8 61:15,20,21 64:11 71:21 78:14 82:3,4 103:6 105:10 115:5,22 130:19,20 138:15,17 151:9 166:15 220:14 222:7 230:11,15 256:18 263:14 267:15 269:7 285:16 286:3,7 287:15 305:17, 344:24 348:12, 16 351:11,18 352:5,7,11	offended 59:12 offer 6:10 30:12 100:1 168:10 182:3 336:21 347:11 offered 142:6 323:9,14 347:4, 12 offering 29:21 30:6 240:3 290:7 office 81:21 91:13 officer 269:5 often 141:7 oh 10:11 21:6 22:22 24:4 26:21 65:4 93:10 102:8 107:9 115:12 118:21 187:9 201:6 206:23 227:5 239:9 245:15 259:20 265:14 299:7 305:19 315:23 321:17 341:22 okay 8:7 11:20 12:2 15:22 17:11,18,23 18:11,13 19:5, 25 20:20 22:11 23:2,11,18 24:10 25:9 27:2 29:19,20 30:12 33:11 34:4,15, 17 35:6,17 40:2, 21 41:2 42:1
---	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

43:5 47:8,24	214:10 215:23	331:19 333:5	145:20 146:21
48:9 52:22 53:2,	216:10,24	335:15 337:8	148:22 149:11
9,14 55:21 57:3	217:20 218:17	341:16,17	150:2,3,10
58:13 60:4,9	220:18 221:5	346:12 347:7,	151:6,25
61:14,22,25	223:4,21 224:1,	15,22 352:24	153:15,23
63:7 65:1,22,23	10 225:7 226:23	354:4 355:1,7	154:17 155:1,
66:17 68:7	227:9,19 228:1,	357:21	13,25 158:21
69:10 72:12	10 231:23	old 70:14	160:1 161:7
74:7 76:12 78:2	232:13 233:3	204:11,12	163:24 165:19
80:5 81:3,18	236:6 237:4,11,	omission 16:24	166:2 168:11
82:16,19 93:1	16,17 239:16	once 50:22,24	170:8 174:24
95:2 96:24	241:3,19 242:2	101:5 195:6	175:7,16
101:1,16 102:21	244:15 245:20	197:3 252:24	176:15,17
108:4 119:20	246:4 247:9,20	277:9 338:3	179:18,25
123:9,25 124:3,	248:8,10,15	one 12:1 15:17	184:23 185:3,
20 126:1,4,8	250:25 253:20,	16:6,12,19 17:7,	13,20,21,25
127:10,11,19	23 256:15	14,15 19:16,18	187:8 190:10
129:10 132:8	257:2,14 258:21	20:23 21:7,15	191:13,15
133:10,14	259:16 260:6,	22:21 23:16	192:7,17,25
135:4,12,15	10,14 262:25	24:1,18 25:5	194:22 195:21
149:4 150:3	264:1 265:10,12	31:4 32:1,7,24	197:7,8 199:7
154:25 159:18	266:24 267:4	33:2 39:10 41:8	203:4,25 205:23
162:10,14 168:7	268:6 273:9,25	42:4,6 44:13,22	207:20 211:5
169:18 170:4,25	274:16 275:5	46:10 49:8	213:1,3,14
171:5 172:2	276:24 279:13,	51:11 52:10	216:15 221:8
174:16 175:4	19 281:12,16	63:3 64:6,11,12,	222:11,18
177:10 178:7,	282:6 284:4	14 65:13 66:11,	225:6,17 227:22
17,22 180:12	287:24 288:10,	14 70:5,18,19	228:1 230:7
181:16 182:21	290:24 293:23,	72:5,22,24 73:7,	231:3 233:8
183:8 188:16	25 295:20	10 75:1 79:4	234:24 235:6,11
190:15 191:5,	298:8,11 299:7	88:9,11,16,19,	236:4,25 237:4,
192:15,21,24	301:14 302:7,12	24 89:9 95:12	11,13 238:1,7
195:18 196:2,4,	303:3,16,19	103:1 104:21	241:17,20
12,20 197:5,25	304:9,25 305:7,	109:23 117:6,7	244:7, 247:14,
200:2,8,10,16,	17 306:5,12,16,	119:4 120:8,23	17 248:10,25
20 202:9,22	17 307:2,15,17	124:11,16	250:17,22,23
203:25 204:22,	308:3,10,21	125:8,13,16	251:7,13 252:7,
23 205:1,21	311:5 312:8,20	126:22 134:16	15,17 253:21
206:4 208:16	313:22 315:17	136:19 138:10	260:10 262:8
209:15,17 212:6	319:1,10 320:1		263:11 266:1

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

269:6,9, 270:22 271:8 272:4 275:2 277:11 278:19,20 279:6 282:16 285:7, 10,22 286:20,25 290:10,16,24 298:22 300:18 301:12 304:18 305:5,14 306:18 309:3,19 310:12 311:3, 314:4,12, 13 316:18 318:14,16 322:2,11 323:23 324:10 325:8 326:6 327:2 328:18 329:19 332:6 333:14 334:8 337:13 340:17 342:24 343:20 354:16 355:22 one-patient 71:23 one-year 208:13 250:8 ones 12:9 16:10, 20 21:25 31:8 32:9 73:1,7 89:16 93:18 109:17 122:20 123:19,22 125:13,17 132:8,16 147:6 176:21,25 187:8 189:13 197:9,15 247:13,15 249:2 250:16 257:5	310:10,13 314:5 331:20 online 299:20 only 6:3,13 24:1 28:2 36:25 50:21 52:6 59:20 73:13 79:4 89:9 99:2 102:18 103:11 121:9, 123:21 125:9 136:19 146:9 154:18 176:9 177:23 179:10 181:6 219:2 223:14 237:17 239:23 241:22 252:25 262:21 280:25 313:1 315:2 330:9 335:20 349:17 352:2,4 onset 174:22 195:19 196:10 onto 132:1 277:21 336:1,12 337:6 Ooh 257:22 open 13:9,10 74:3 89:21 151:20 166:13 operate 109:17 172:12,13 290:17 operating 103:10 109:14 136:9 operative 104:4	opine 29:18 opinion 30:13,24 31:22 32:1,12, 20 34:21 35:3, 17 39:24 50:25 51:22 76:9 101:8, 131:9,10 171:12 173:9,25 185:22 196:7,15 198:1 213:17 221:2 244:1,5,6 255:4,5 256:4 263:10,11 268:1 269:7 275:15 295:2 297:14 317:22 opinions 5:5,12 6:8,10,16,23 7:10,22 10:10 12:20 18:15 21:13 24:11 29:16,21 30:6 33:20 34:3,11 81:15,20 87:5, 19,24 89:18,23 90:4 97:9,13,22 185:5,13,22 186:6, 197:22 222:14 240:3 256:10,14 272:9 274:13 275:7 280:8 293:20 295:14 311:25 313:13 327:2 331:7 332:10,17 333:14 337:13 339:24 340:10 347:4,12 354:21 opportunity	47:2 306:7 opposes 190:1 opposite 138:8 155:13 332:8 optimal 337:17, 25 option 142:11 152:2 168:12 192:1 215:13,14 255:12 281:8 314:20 315:12 323:4,8,10,11, 12,14 336:21,23 337:1 options 127:9 133:19 141:14, 19 142:15 143:6 145:17,18,19,20 155:25 157:4,21 168:8 169:13 174:23 190:4 191:24 259:7 289:23 291:2 oranges 317:15 order 54:15,24 60:18 84:5 124:1 143:21 145:7 157:16 267:23 268:16, 19 278:6 281:11 334:6 343:24 344:15 345:1 349:19 350:10 353:4 organ 29:24 30:9,21 32:14 34:13 45:4 48:17 50:13,22
--	---	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

51:4,7 63:19,23 68:10,12,14 69:5,24 119:22 133:17,18,23 134:1 135:23 136:11 137:21 138:2,9 139:12, 20 140:17 141:8,14 143:7, 11 144:6,23 146:1 149:18 155:17 156:18 157:22 159:20 172:15,20 174:2,12 175:7 176:19 183:1 189:4 192:21,22 194:21 201:11 202:15 231:7 234:23 235:14 253:16,25 255:10 256:8 258:7 260:17 263:13 287:4 288:10 289:1 290:8 293:3,9 295:24 296:9,19 323:22 346:21 347:19 348:4 352:3,4 353:8 354:23 355:7 356:6 organic 92:3 organization 188:17,20,22 189:8 257:19 270:25 organizations 186:24 190:2,	21,25 192:4 organized 17:9 organs 73:1 134:2,8,23 135:5 143:8,12, 18 145:13,15 167:20 original 10:15 11:3 12:7 13:13 22:15 23:7,19 240:22 310:19 342:24 originally 8:20 16:14 23:7 24:11 71:15 143:13 152:4 153:22 156:12 170:8 236:7 246:19 326:5 Orr 339:9,15 Ostergard 89:6 310:14 Ostergard's 301:9,10 other 6:4 7:9,13 11:8 20:20,25 24:3,25 25:4 29:23 30:8 31:5, 8,13,15 32:21 35:19 37:5 38:18,21,23 39:1,8,18,23 40:17 41:7,10 42:13 43:20 45:16 46:6,15 47:17,21 48:1, 16,23 56:22 60:17 68:4 73:1	74:15 84:5 89:12,18,19 93:6 94:16 96:13,21 97:5,7, 8,9,12,14 98:8 99:1 103:21, 105:22 113:10, 15 120:25 121:20 123:22 131:19,20 136:8 138:11 144:17 146:19 148:7 149:1,23 151:6 154:11 155:12 157:4,21 165:9 167:2,20 169:9 172:5,25 174:23 178:14 186:6 191:13,17 195:25 197:9 200:11,12 207:5 208:18 210:15 211:1 212:16,24 215:13,21 216:12 217:18 219:25 221:22 223:12 225:15 233:8 237:13 238:11,20 243:11 245:25 247:13,15 248:21 249:2 250:16,17 252:10 256:11 257:5 266:6 277:7,8 301:24 306:13 308:1 310:2,5,6,8,13 317:7 323:23 325:6,25	326:19,20,25 330:4,11, 333:19,22 334:10,12 347:19 351:1,14 352:5 others 19:17 88:25 96:16 98:12 99:3 108:23 118:9 125:14 130:7 185:2,25 197:4 198:25 208:12 213:1 326:24 338:23 otherwise 18:10 40:15 42:12 107:7 108:19 263:12 our 50:5 72:24 95:3 112:22 120:13 121:1 126:13 149:11 158:20,25 159:2,9,24 161:14 163:10, 20 164:21 165:24 166:16, 19 167:6 178:19 185:23 230:24 249:18 269:17 276:18 286:2 292:12,23 297:13 325:14 326:7,8,25 329:3 330:14,20 out 9:18,19,20 10:18 11:7 13:10 14:19
--	---	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

15:1 20:12 21:9	287:5,20 288:4	214:1 220:25	305:25 306:3
26:24 37:6,9,25	296:25 301:10,	233:15 237:23	page 14:5 15:3
39:16,24 41:6	12,25 306:14	239:15 242:18	22:9 27:4 28:23
43:16 47:13	307:25 308:6	254:22 255:14	31:2,9 32:8,9
48:14,18 51:2	309:14,22 311:7	259:24 260:12	35:14 61:17,18
52:3 53:4 55:13,	315:25 317:7	262:3 263:20	123:6 125:25
14,15,16 59:15,	319:15 320:1	282:10 284:3	126:20 127:1
18,21 60:2	321:6 323:12	290:25 297:2	129:8 132:20,21
71:11,17 81:18	330:19 336:25	318:12 319:2	133:20 191:18
83:17 88:4,9,25	337:10 338:2	335:13 344:12	221:6 227:7
89:9 94:7,10,11	341:4 345:21	overall 184:18	258:21,22
106:1,3,24	348:24 349:21	249:25	263:2,4,19
107:2 110:18	355:10,25	oversimplificatio	265:8,9,10
113:17 121:21	outcome 73:4	n 221:20 267:25	266:16 274:7,14
125:14 126:10	129:20 220:21	oversimplified	284:19 285:1,17
133:3 137:7	outcomes 65:6	304:6	286:2,19 287:18
138:6,13 139:22	157:5 223:8	oversimplify	288:4,12,13
140:1,4 142:21	251:1	268:2	289:19 306:24
143:14 152:24	outlined 214:10	overwhelming	307:15 309:4
160:5 162:13,	338:24	154:22	312:3,5 314:24
20,23,24 168:18	outside 96:7	own 10:7 114:5	339:21
170:15,23	128:12	133:8 136:10	pages 13:24
176:7,21,24	outspoken 88:19	140:11 145:22	14:14,20 15:21
177:14 183:17	184:24 186:1	155:21 160:3	18:4 25:16
185:2,25 186:5,	outweigh	167:13 169:18	26:10 27:5,18
11 189:16,19,21	192:10,11 261:7	197:3,12 272:1	28:2 41:6 61:3,
192:13 193:4	356:14	275:3 280:20	15 133:24 274:9
202:11 205:24	outweighs	292:2,5 293:17	340:2,5
206:1,2,8	193:13	322:25 325:19	paid 79:16 83:2,
208:14 209:3,4	over 13:21 14:5	326:20 329:7	3 255:24 256:10
210:18 212:24	32:6 33:2 45:25	337:3	263:17 272:16
216:9 224:22	61:16 62:24	oxidation 216:4	273:2,3,9
229:5,6 232:8,	71:4 86:20	309:8	pain 11:18,20,24
25 235:10 238:1	108:4 114:11		38:25 39:18
240:16 244:14	119:18 121:2	P	44:17 47:9,14,
251:8 257:10	122:4,18 137:11		19 48:3 103:10
264:8,22 266:1,	175:10 185:7	p.m. 138:18,19	108:4 109:1
11, 269:14,25	186:21 212:17	139:3 230:16,20	112:7,9,10,13
271:2,7,21			138:7,8,9,11
275:17 276:11			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

139:16,19 143:2,3 149:7, 16 159:11,16,21 160:6 193:21 194:1,2,4,7,8, 16,17,18 195:7, 24,25 196:6,7 197:2,22 200:17 209:12,13 210:16,20 211:21 212:1,8, 9 216:6 221:13 231:20 235:1 297:16,25 298:4,10 painful 71:12 palpation 333:22 334:6,13 335:16,20 pan 336:25 pans 348:24 Papantonio 283:7,19 284:7 paper 8:8 14:25 22:18 64:24 65:5,8 68:16 70:8 71:7 72:13 77:22 78:3 95:1, 3,11,19,23 96:2 119:9,20,24 122:16,19,21 123:14 124:1,2, 10 125:7,12,13, 18,19 126:3,5, 20 127:13 128:3,7,10,11 132:7,8,10 133:5 151:10 152:16 170:15,	17 181:18 182:5,8,23 183:15 184:21 188:16 189:15 191:18 199:6, 21,23 202:11 203:22 205:25 206:15 207:23 208:3 211:11,13 212:18 213:6 238:20 239:18 240:6 242:15, 18,19 243:22 249:4 251:21 253:19 254:9 256:21 261:18 265:5 276:14 301:9,10, 303:19 305:3,4 308:21 309:13, 19 311:24 317:11 320:1 papers 63:11,13 64:20 93:10,15 107:18 115:3 181:2 205:16 210:18,19 222:16 241:8 250:21 301:5 305:13 310:8 326:7 paragraph 127:4,8,14 258:25 259:1,4 279:21,23 280:1 289:6 307:18 309:5 Paraiso 37:17 parameters	173:4 pardon 109:5 142:16 200:20 parents 193:7 part 8:21 16:16 18:7 23:14 28:6 62:15 81:10 83:24 102:15, 18,22 125:8 135:14, 166:25 268:15 299:6,23 327:19 328:6,7 350:17 part- 59:10 partially 20:7 102:18 156:7 participated 341:13 particular 11:22 13:7 46:2 52:1,3 60:18 63:14 89:17 92:21 93:8 120:18 130:1 152:12 163:24 174:3 175:18 192:1,14 195:11,13 199:6 204:17 216:13 225:17 231:21 233:6 244:8 289:24 296:19 309:7,17 310:3, 9 311:24 343:17 particularly 59:11 partly 325:23 partner 193:6 194:9	partners 141:2 pass 335:2,5,25 passage 333:15, 22,25 335:4,22, 24 336:14,15 337:4,6 passages 335:13 passed 100:8 101:5 336:11 passing 335:10, 12 336:18 past 62:20 74:11, 14 99:22 105:16 108:21 116:14 166:24 172:23 173:6 176:22 244:11 316:15 357:13 patch 227:5 patent 75:4,7,8 pathologists 93:14 patient 45:3 50:19 51:23 71:24 72:5 81:12 82:15 96:6 104:5,8 109:4,22 112:23,25 120:24 129:3 141:17 142:7 143:15 144:4, 18,21 145:1 148:22 149:11 150:18 164:13, 16,23 165:6 168:10,13 173:5,14 174:3,
---	---	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

20 175:14 183:6 192:25 195:22 197:8 226:3 240:20 241:10 246:12 252:24 253:4 280:24 282:20 292:11, 23 341:4 patient/physician 191:23 patients 10:19 44:21,23 45:8 46:21 52:24 67:23 72:10 101:18 103:5, 15,16 104:20 105:5,9,12,21 106:19 107:14 108:9 109:12 111:19,22 113:1 114:11 120:10, 13 121:3,10 122:5,14,19 123:18,21 124:18 125:3 148:13 149:12 151:18 153:13, 16 157:22 159:1,3,24 160:7 161:25 162:12,24 163:3,10,16,24 164:3,4 165:1, 17,19 166:3,12, 14,18,21 167:2, 13 172:20 173:2,11,12 174:13 175:7 177:4,14 179:1 183:17 184:2,7,	11 190:5,10 192:24 195:25 197:13,17 210:20 211:15 213:18 214:1 217:25 219:10 223:20,24 226:6 227:23 237:25 238:2,3,12 241:15,16 244:11 246:2,6 249:4 253:2 256:23 257:13 260:3 261:14 264:16 282:8 283:14 290:15, 20,24 292:15 297:19 314:21 315:3 337:20 341:3,11 346:2, 3 354:6 356:14, 19 payments 273:5 peace 200:14 peer 263:8 peers 274:25 pelvic 11:19,24, 25 29:23 30:9, 21 32:14 34:13 45:4 47:9,14,19 48:17 49:8,9,11 50:13,22 51:3,7 63:19 68:10,12, 14 69:5,24 74:15 85:7,19, 24 99:10,12,15, 20 100:2,16 101:5 103:10 108:4 109:1	116:16 119:10, 21 126:9 130:11 133:17,18,23 134:1,2,4,12 135:19,23 136:11 137:21 138:2,9 139:12, 20 140:16 141:8,14 142:13 143:7,11 144:6, 23 148:25 149:6,16,18 153:3 155:2,3, 17 156:18 157:22 159:11, 16,20 168:8 172:6,15,20,25 174:2,12 175:4, 7 176:18 182:10 183:1 186:7,25 188:18 189:4 190:6 192:21,22 193:21 194:8,20 195:25 201:10 202:15 231:7 234:23 235:14 253:13,16,24,25 255:10 256:8 257:16,18 258:7 260:17 263:13, 21 264:9 266:19 272:24 274:5,18 281:6 287:4 288:10,16 289:1,21 290:8, 23 293:3,8 296:9,19 299:9, 16 302:9,25 311:2 319:18 323:22 346:8,	10,21 347:19 348:4 352:3,4, 21 353:8 354:23 355:7 356:6 pelvis 12:24 63:16,17 101:3, 4 pending 73:13 76:7,15 101:12 pendulum 176:10 323:19 357:7 people 11:15 105:22 106:3 131:24 154:11 155:8 157:9 177:18 208:24 234:13 238:20, 24 241:1 248:25 258:1 269:24 270:6 271:1 278:18 300:19 321:4 355:24 per 105:8,9,16 110:14,15 121:10 122:6,14 179:16 182:23 305:15 326:20 perceived 156:8 157:9, 204:10 percent 56:13 73:6 87:2 103:18,19 104:20 105:3 108:16 109:1, 12,14 111:19,22 112:2,4,5,16 115:5 123:21
--	---	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

136:7,25 137:16 151:18 163:21, 164:22 166:18, 19,20,22 167:3 201:9,23 202:12 203:1 206:16,17 208:9,10 209:3, 4,7,8 217:10,12 224:18,19 226:1 234:10 235:1 241:22,23 242:7,19,20 243:9,14,20 244:7,8,24 245:7,22 246:9 247:4,6,25 248:16 250:1,8, 9,14,15,20 251:7 252:2,9, 10,18 264:24 315:5 332:20 percentage 29:3 85:22 108:13 112:1 114:9 136:3 177:22, 23, 260:25 315:3 percentages 103:21 165:8 218:20 225:10 perfect 143:20 165:5 perfectly 251:18 perforation 72:23 perforations 72:21 perform 64:1	104:19 128:11 333:21 334:16, 24,25 performed 72:9 160:12 163:3 190:4 195:16 247:3 262:13 303:5,23 306:19 334:8,11 335:1 performing 129:13 323:14 330:15 perhaps 173:12 260:1 275:12 335:10 336:12 337:6 period 39:15 113:12 121:3 122:5,7,13 123:19 128:17 179:1 184:12 199:14 208:5 217:13 218:8 219:3 224:11 227:16 250:20 282:17 308:24 periods 237:23 periphery 33:17 permanence 174:22 permanent 168:19 193:12 224:14 permanently 192:6 269:10 permission 285:23 305:15	permit 255:12 peroxide 313:7, 10 peroxides 216:3 persist 126:16 307:19,23 persistent 109:1 person 172:9,10 175:13 257:4 307:25 personal 7:3 22:21 142:9 149:10 160:3 210:20 356:12 personally 96:22 perspective 90:20 pertaining 19:14 20:24 21:4 25:18 63:3 83:22 92:24 pertains 92:8 295:23 pertinent 339:24 Pessaries 142:13 pessary 142:12, 19,20,21 petition 260:16 267:11,12,18 269:13 277:5 279:9,16 281:7 347:17 petitions 277:7 Ph.d. 90:18 93:23 phenomenon	332:2 Philippe 89:5 108:24 132:7 187:11,12 Phillips 25:7,21 26:25 27:6 photo 285:13,15 photographs 306:24 phrase 74:22,23 232:10 296:23 304:2 phrases 14:13 physical 134:17 141:4 303:25 physically 192:6 physician 142:5 189:16 191:25 276:2 physicians 88:19 97:9 119:14 175:18 184:24 186:6,23,24 188:17 189:21 192:3 255:11 physics 92:4 physiological 296:2 pick 15:20 picked 14:19 picking 192:7 265:23 picture 27:10 piece 46:23 171:12 175:23 263:8,10,11
---	--	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

<p>275:15,16 332:25 333:3 pieces 192:7 Pierce 332:19 pile 249:18,21,22 Pinnacle 31:20 pinpoint 112:10 place 75:9 153:12 171:19 214:16 316:3 placed 37:11 119:10 264:13 354:18 placement 120:15 121:5 152:6 253:15 plaintiff's 76:6, 13 85:23 277:1 plaintiffs 4:7,8 5:4 29:17 75:13, 19 76:2 77:5 83:14 85:18 86:22 87:8 89:13,19 98:3 106:19 274:4 plaintiffs' 79:8 82:11 85:1 97:2, 4,8,12,14 254:17,23 256:12 270:19 271:17 272:6, 17,18 273:2,3,6, 9,10 274:5,18 283:21 295:15 plan 34:22 plastic 32:6 220:24 318:11</p>	<p>319:2 play 134:15 221:1 264:18 265:3 266:20 playing 202:9 plays 265:2 please 4:5,11 30:5 43:9 44:5 74:19 305:16 pleasing 144:20 plenty 48:18 59:25 plus 21:2 31:3 35:14,18 36:17, 25 37:4,15 38:22 39:14,15, 19 40:10,17,23 41:8 42:13 43:19 61:15 115:3 214:13 219:22 220:15 235:5 point 6:9, 7:15 8:18 37:14 39:7, 40:10,19 42:10 43:8,17,20 44:2, 8 123:2 126:17 131:7,19 132:12 154:8,21 155:1 156:16 176:14 179:5,23 200:8 203:14 206:9 208:8 210:12 211:25 217:5 229:11 240:16, 19 241:9 243:2 259:18 268:3 271:6 272:10</p>	<p>274:3 276:6,10 278:21 280:7,25 287:6 295:10 298:2 306:14 308:4,16 325:12 326:3 338:25 pointed 330:19 points 213:5 policing 192:5 policy 287:21 politics 257:20 polymer 92:1,6, 12,17,20,22 93:9,16,21 94:3, 8 304:13,14 polypropylene 35:16, 36:19 37:1,15 43:20 50:12 51:18 65:25 66:11 67:20 71:14 93:11 94:17,18, 19 152:13,22 153:12 161:2,3, 10 162:1, 174:11 213:12, 18 214:4,9,24, 25 215:2,7 227:10 228:6,11 229:4,19 286:7, 22 294:8,9,10, 19 295:3,4,6,9, 18,22 296:3,8, 18 297:15 298:3,7 299:8, 25 300:10 301:1,6,21 302:8,14,23</p>	<p>304:13,14 307:20 309:6 312:11, 313:14, 15,25 320:2,9 324:21 325:2,5, 11 326:2,14, 328:18 329:1,24 330:4,10,12 polypropylene- based 297:5 315:18,22 polypropylene- made 294:13 poor 150:23 pop 12:4 179:19 189:21 226:15 259:12,14,15, 17,19 261:4 264:15 268:10, 18 289:14 290:1 291:5 353:14 popping 12:11 popular 310:12 population 240:20,21 241:10 260:25 porcine 31:9 32:7 35:14 36:17 37:4,11 65:24,25 202:17 325:1,2 pore 20:24 21:1, 13 98:20 222:1 226:23 337:12, 13,14,17,21,25 338:2,3,18,19, 20,21 339:1,2,5, 8</p>
---	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

portion 335:19	posting 284:10	257:24	prevailing 300:9
portions 26:25	postoperative	preference	prevalence
ports 161:23	147:4	155:22	138:8
position 143:19	potential 45:2	preferred	prevalent 136:24
144:2 147:14	46:3 142:18	261:19	137:18 146:14
189:21,25 190:8	146:25 148:7,25	pregnant 209:14	previous 239:1
255:6,7 259:4	149:16 158:2	preparation	262:6
261:2 275:14	160:19,21,23	111:14	previously 139:6
279:1 280:4,7,	163:5,15 165:8,	prepare 17:4	244:19 281:18,
21 281:5,14,19	10,12 173:14	84:5	21
282:6,17 313:24	196:5,13 258:12	prepared 17:4	primarily 65:17
319:5,16 320:1	291:3	87:16 305:8	67:5
321:7 348:4,19	potentially 259:6	presence 215:24	prime 64:6
352:21 353:13,	powerful 275:14	present 16:19	print 15:1
18 354:4,11	practice 53:5	47:4 141:10	170:23 287:15
355:15,16	114:6,12,15	240:23	printed 287:18
357:20,24	120:20,25	presentations	288:4
positions 134:3	123:21 135:22	10:21 52:8	printout 112:25
213:25 257:15	136:1,3 140:11,	presented	prior 10:9 16:19
positive 326:2	15,25 142:9	235:14 240:9	40:3 75:18
possibility 147:4	145:22 149:10	276:18	76:21 77:3
148:17 149:9	152:3 164:15	presenting	87:25 96:6
163:23 164:6,16	175:18 177:17	131:21 176:23	99:23 105:18
177:12 257:14	178:6 186:25	239:1,4 240:9	111:7 147:11
306:22	313:18 315:16	presents 141:13	170:18 179:9
possible 159:23	356:12,23 357:1	president 271:12	208:20 256:14,
177:12 289:23	practicing 49:3,	pressure 138:6	17 279:18
308:8 319:2	13 155:2 186:7,	139:23 140:13	282:3,4
possibly 149:20	23 349:4	193:3 334:7	private 53:5
173:15 174:25	praise 275:1	pretty 44:8	190:18
209:11 254:12	praising 274:25	68:19,23 77:8	pro 18:18
260:5 262:7	preceded 17:25	93:19 120:23	pro-mesh 172:9
350:22	precise 59:10,12	137:16 169:1	probably 12:18,
posted 285:10,23	67:18 302:7	172:6 231:17	22 22:2 26:16
posterior 21:23	predominant	285:8 304:12	42:20 46:16
146:8 158:6,7	105:2	357:16	63:23 81:2
231:12,19	preexisting		85:25 87:2

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

125:10 139:16 142:20 146:16 147:6 155:7 170:6 214:23 226:18 230:6 235:9 241:17 261:23 272:13 297:1 308:15 320:12 339:6 problem 10:23 42:1 45:8 59:9, 14 71:8 73:12 106:3 109:19 111:9 125:17 135:8 137:14,18 139:17 140:22 141:15 144:24 145:8 187:13 193:14 197:9,10 214:3 225:12 244:7,9 272:3 274:19 275:22 355:11 problematic 146:21 problems 10:19 53:2 70:7 111:3 142:18 143:22 151:1,15 156:3, 8 158:19,21 161:24 173:14 197:18,19 202:13 207:21 240:17 326:7 procedure 51:13,15 68:4 71:12 72:10 73:17,18 107:23 108:12 109:4	111:16,24 112:6 113:23 129:21 144:23 152:6 153:5,13,17,20 154:19 156:2,17 157:1 158:13,24 159:5,7,13,19, 21 160:5,12,24 161:13 163:7,25 166:4 167:3,10 168:24 169:8 193:5 198:4 206:11,12 231:6 235:13,25 238:10 264:15 265:7 315:15 317:1 318:11 320:5,17,18 325:25 330:15 334:12,24 335:16,18 336:15 356:4 procedures 66:6 68:13 71:10 93:7 95:20 110:25 128:6,11 129:13 158:9 160:14,18,20,25 161:11 163:3 194:23 196:9,22 243:8 252:2 322:7,20 333:19,24,25 334:11,15,17,19 336:3 proceed 55:18, 20,25 56:3 345:4 proceeded 207:1	proceeding 5:1 75:20 90:23 proceeds 182:1 process 33:11,16 66:7 85:10 98:12 111:10 194:6 213:15 214:17 216:1,4 221:24 242:21 258:3 327:8,18, 19 328:6,8,15, 16 329:2 344:4, 19 produce 261:10 313:7 produced 229:17 350:25 produces 313:9 product 18:19 29:23 30:8,14, 22 31:1,7 37:1, 5,7,15,16 38:2, 8,9,15 39:8 40:23 45:10 46:7 47:25 48:1 49:4,16,19,21 50:2,4,15, 51:17,21 52:1,3, 11,13,19 53:11, 13,16 57:21,23 58:1,7,11,15,24 60:20 70:3 95:2, 4 96:25 102:12, 16,17,24,25 103:23 104:10 105:2 109:6,13 110:5 111:17,23 113:7,11,24 114:10 116:16	117:22,25 126:19,23 127:18,21,24 128:1 129:4 131:16 132:12, 18,23 178:2 179:3,10 183:14 184:5 187:15 190:24 205:7,9, 24 210:10 211:20 214:5 219:18,22,23 220:4,23 226:18,19 227:24 228:6,7, 18,19 229:3,24 232:18 233:1,6 235:24 236:18 238:5 240:25 242:21,25 243:5,6,16 244:2,8,16 269:10 295:7 298:23 304:2 308:24 309:13 316:6 317:9 325:10 337:18 338:5,10,20 341:15 344:3, 10,24 345:16 346:5,8,10,21 349:5 350:20 351:10,18 production 288:9 products 5:2 21:5,19,23,24 29:22 30:7,20 31:5,14,16,23, 24 32:2,12,13,
---	--	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

15,21 34:11,13, 23,24 35:25 36:2 37:5,22 38:17,18,21,25 39:1,4,9,18,22, 23 40:17,18 41:7 42:13,14 45:16,22,23 46:5,6, 47:15, 16,17,21 48:3, 15,16,23,25 53:24 54:1 61:9 63:3 92:5 94:17, 20 95:1,6,7,9,19 96:1,4,12,14,15, 20 101:14 102:3 103:18,19,22 104:21 109:23 110:7,17 111:1 114:21 115:19 116:7,19 117:4, 11,21,23,24 119:21 128:23 130:25 131:20 132:16 179:19 183:22 184:12 200:11 206:6 219:25 220:11 222:5 226:21 228:2 229:11 260:18, 267:24 268:9,11,17,18, 19,24 277:8 278:6,16 279:3 281:11 295:3 297:5,15 333:16 337:14 343:5 345:1,10 347:18,23 348:5,18 349:7,	14,19,25 350:11 351:3,11,16 352:2,5,6,15 353:4,14,15 354:6,12,23 355:17,21 profession 272:2 275:3 professional 356:25 professor 86:6, 15 275:13 progressed 105:13 progressing 107:13 progression 8:15 progressive 196:18 213:2 242:20 244:7 prohibit 259:6 project 16:13 170:22 prolapse 29:24 30:9,22 34:14 45:4 48:17 50:13,22 51:4,7 63:19 64:22 65:16 66:4,24 67:15 68:10,14 69:5,24 119:22 130:8,18 133:17,18,23 134:2,9,19 135:23 136:11 137:1,5,6,13,22 138:3,9 139:12, 20 140:6,17,23	141:5,9,14 143:7,11 144:1, 6,10,11,23 146:1,3,4,8,9, 10,13,14,19,22 147:5 148:4 149:18 150:9 151:8 155:7,17 156:15,18 157:22 159:20 168:17 169:9 172:15,20 173:3 174:2,12 175:7 176:16,19 183:2 189:4 192:21,23 194:21 196:15 198:3,19 201:11 202:15 203:19 207:5 216:22 217:8 224:18, 225:20 231:7,8 234:24 235:14, 24 237:21 241:22 253:16, 25 255:11 256:8 258:7 260:17 263:13 286:8,22 287:1,4 288:10 289:1 290:9 293:3,9 295:24 296:10,19 314:5 323:22 346:21 347:19 348:4 352:5 353:9 354:23 355:7 356:6,10 Prolene 229:20 prolific 216:16 Prolift 31:20	37:7 74:21 109:9 127:21 130:18 132:2 205:6,7 208:15 210:10 211:20 218:10,11 219:18 220:13 229:8 232:20 promote 337:15 prompted 71:24 pronounce 252:4 pronounces 251:6 pronouncing 310:21 proper 337:15 Properties 65:24 331:14 332:25 proposed 326:4 339:14 pros 166:13 Prospective 316:25 protect 254:25 256:19 276:24 348:22 350:21 protection 269:8 proud 282:11 350:21 proven 308:13, 14,22 329:5 provide 26:22 32:12 62:22 87:17 115:10 125:2 143:8 212:3 289:7 301:20 344:1,
---	--	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

15,22 provided 6:4 16:14 17:9 18:8, 12,17,20,21 19:7,24 20:2,9 21:7,16 22:3,20, 25 23:1,7 24:12, 18 27:14,20,22 46:18,19,24 54:6 82:17 87:7, 13,16,18,21 88:1 89:12,19 90:4 284:21 285:18 288:20 provider 289:22 providers 188:21 provides 49:25 123:6 302:22 providing 32:20 275:6 295:14 psychological 141:5 pub- 178:12 public 51:20,23 52:12 54:11 88:18 186:2 256:16 267:12, 21 269:17 270:4,14,20,25 271:5,13,17,24 277:6,19 278:2 279:15 281:10 347:17 348:15 publication 64:14 68:19 73:13,14 95:13, 16 314:14	publications 10:1 11:12 12:19 69:12 169:4,12,19 314:13 356:25 publish 69:2 283:25 published 52:1 53:15,23,25 64:9,13 68:8 69:4 95:1 118:10 169:1,3, 8 170:20,22 171:11 178:10, 20 182:11 198:24 223:7 274:1,2 275:7 283:9,12 299:19,20 302:22 314:13 316:24 331:17 336:7 Pubmed 9:18 10:7,9,11 11:3, 23 12:7,10 38:11 46:20 pubovaginal 66:10 329:21 pull 57:14 91:10 244:14 250:25 268:24 278:6,15 344:24 pulled 352:11 pulmonary 149:23 pure 80:22 153:25 154:19 162:9	purpose 68:10 157:15 189:8 199:9 purposefully 72:8 purposes 208:23 350:2 pursue 351:9 pursuit 280:23 put 16:24 19:23 78:24 97:16 114:14 131:13, 14 132:4 133:14 143:12 147:13, 20 161:7 173:10 184:21 189:15, 21 195:1,18 200:1,11 203:4 214:25 215:2,3, 4 224:7 226:19 244:18 249:17 260:7 262:12 263:16 282:18 284:22 286:9 290:11 297:9 309:2 317:16,17 318:9 319:3,15 320:1 321:6 325:1,2 356:20 puts 257:22 putting 130:21 132:14 177:13, 20 186:11 213:21,23 215:16 233:11 271:2 284:19	<hr/> Q <hr/> qualified 93:20 94:2 190:4,14, 15,16 qualifier 209:21 210:5 qualifiers 91:25 92:19 132:14 173:17,18 174:17 186:11 195:2,19 209:12,16 210:13,22,24 282:19 qualitative 198:5 quality 47:22 136:13,15 144:25 145:3 168:19 193:2,16 206:12 217:4 225:16 235:6,13 236:25 237:9 320:6,19 356:5 quality-of-life 144:24 192:23 193:11 204:14 211:22 225:12 quantify 88:15 Quantity 333:6 question 6:21 7:7,16 9:8 15:24 16:21 20:13 26:6 30:3 33:9 34:15,18 35:2,3 40:13,24 41:12 42:2,5,10 43:4,
--	--	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

22 45:6,12, 47:24 53:14 54:23 55:2 56:4, 6,8,14 57:6,7 58:2,16 59:3,11, 13 60:7,15 61:19 67:18 87:10 91:18,22 92:11 93:22 97:23 104:7 106:10,12 107:3,9,10 110:21 111:12 113:20 123:1 124:16 125:18 137:17 164:5 174:7,17 176:4, 5,7 179:13 181:7 192:15,18 200:4 235:9 236:6 239:23 246:1 247:17,18 252:8 264:13 271:8 280:13 281:25 284:4 286:3 287:2 291:12,14 292:9 295:12, 297:13 298:1,4 300:9 301:15 302:17 306:8 320:12 332:22 341:24, 25 346:15,17 356:2 357:7 questionable 241:2 questionnaires 210:1 questions 29:18	42:3 44:4 58:3 59:9 129:11 171:1 181:23 182:2 226:9,11, 15 237:17 269:23 291:13 292:1,2,5 293:14 309:20 337:12 348:3 350:2 352:19 353:14 354:17 quick 15:16 110:22 111:13 123:25 230:11 236:1 305:18 quick-and-dirty 124:5 quickly 62:24 267:3 327:1 329:8 332:1 339:19 quite 30:3 64:8 70:6 107:11 145:18 155:19 160:13 169:3 265:20 272:5 299:24 quote 15:19 39:12 69:18 124:11 quoted 266:2 295:8 quoting 201:18 221:7 250:4 265:23,25 286:5	<hr/> R <hr/> Raalte 257:6 rabbit 66:1,11 93:12 324:16,23 326:16,23 329:22 330:8 rabbits 330:23 radicals 216:3 raise 125:17 236:3 271:6 raised 123:15 325:11 326:6 Ralph 256:16 271:11 ramifications 93:25 266:11 ran 271:11 random 260:6 randomized 37:18 38:21 39:3,5 41:1,9 46:11 48:12,22 223:9 232:1 238:8,12 249:2 260:4 349:8 350:10 range 259:7 ranging 337:21 rare 136:18 140:19 148:20 158:19 313:11 rarely 138:7 149:3 244:10 rat 326:22	rate 37:20 39:17, 18 40:12 45:21 46:5,14 48:2,19, 20,23 84:9,25 113:22 114:5, 19,24 115:4 125:20 130:9 152:18 157:1,10 168:17 201:9, 14,20 206:16,18 207:12 218:14 232:4 234:6,9 237:20 241:22 242:3,7,19,20 244:12,17,24 246:5,14 247:4, 5 248:11,16,18 249:6,25 250:19 251:16 252:2,23 264:18,19,25 265:6 267:2 318:16 rates 38:10,17, 24 40:16 45:7 47:14,15 48:13, 15 156:4 183:20 184:11 204:7,23 211:14 212:20 219:5 221:4 222:6 236:7,15 237:5,19 241:12 245:5,17 246:10 247:24 252:12 264:24 265:21 266:7,10,14 rather 127:14 rating 228:24 ratio 215:16
--	--	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

rats 312:15,19	17 344:12	reassuring 318:21	recollection 179:8 345:13
Raz 89:5 187:8	reading 11:21	recall 16:4,7	recommend 108:6
RCT 40:22	13:7 123:25	25:2 26:5,9 28:4	recommended 350:9
re-asking 56:17	124:17 305:22	29:2,10 38:20	Reconstruction 319:19
reached 7:22	318:20	61:14 80:4,15,	reconstructive 49:11 99:10,13,
87:20 98:25	real 230:11	23 89:16,24	16,21 100:2,16
264:2 329:3	305:17	90:25 91:11,18	101:6 119:10
330:18	Reality 331:18	99:2,3 158:11	126:9 130:11
reaching 6:23	realizing 107:17	171:20 183:15	155:2,3 168:9
7:9 87:5 216:13	111:8 275:21	199:7 251:14	173:1 175:4
311:25 331:6	325:17	267:24 268:18,	182:10 186:7,25
reaction 43:19,	really 7:8 86:17	19,23 269:18	266:19 281:6
21 194:7 221:9	88:1 99:17,18	279:6 325:3	302:9 311:2
343:22 344:15	105:15 116:5	331:11,12	record 4:1,6
reactions 318:23	162:8 187:22	354:19	44:8 55:12
330:16 343:23	198:14 210:11	recalling 281:11	56:14,20,21
reacts 296:2	211:8 251:19	recap 21:11	57:5,6 59:20
read 7:2,14 8:16	276:3	received 7:19	60:6,10 61:21
9:14 13:24 14:2,	reanalysis	190:13 272:5	78:14,17 82:3,4,
6,16,18 16:2,5	212:15 227:20	284:9 299:20	7,15 83:7 113:1
25:3 28:20,21	reason 59:20	recent 12:7 63:1	118:8 138:15,17
29:9 33:7 52:12	105:19 118:6	77:8 180:5	139:2 198:9,16
53:15,22 54:23	137:23 146:18,	285:8	202:2,3,25
57:8 60:6,10	23 157:14	recently 16:11	203:16 206:5
61:16 67:3	220:21 233:25	264:9 284:24	225:25 230:15,
105:25 117:6	255:23 262:17,	336:2	19 239:25
120:15 122:21,	18,22 263:3	recess 78:16	253:11 261:3
23,24,25 123:11	274:11,21	82:6 138:19	270:21 281:17,
124:1,2,7,10,14	276:14 288:7	230:17 306:1	24 283:5 305:24
125:12,23 126:7	317:20,21	recesses 335:7	306:2 316:23
180:22 203:24,	321:20 350:5	recognize 248:9	recorded 184:19
25 239:5,	reasonable	283:20 324:4	241:18
253:18 259:11	347:5	recognized	records 22:23
280:18 290:2	reasons 211:12	320:3,9	
295:8 302:18,21	266:25 306:22	recognizing	
303:3 305:14,	345:17	274:22	
20,22 311:20	reassurance		
314:22 339:12,	143:17		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

77:16 81:12	referred 15:24	326:12	65:18 69:4
83:17,22 84:6,	104:8 108:9	regardless 21:10	73:14 77:16
23 85:15,21	119:14,25	202:12 342:17	95:1 101:12
86:9 96:7,8	120:7,13,20	region 112:10	114:21 150:13
104:2,12,14,18,	121:10 122:5,15	regions 170:9	180:7 183:13
25 112:22	128:4,12,17	regulation	184:4 185:7
113:14,16	129:2 131:22	343:11,15,17	189:20 197:22
recovery 157:8	179:2 183:12	345:22	294:4 311:25
rectal 72:23	197:4 258:16	regulations	331:7 342:10,22
Rectocele 37:17	304:3 313:20	49:18, 54:20	345:9
rectum 134:10	344:17	60:16 340:15	relationship
recurrence	referring 60:24	342:10,15,16	191:24
73:11 147:5	63:13 78:20	343:12 345:21	relative 52:22
150:9 151:8	79:5 148:12	regulatory	53:8 73:19 74:2,
156:4,10 204:7	168:16 197:12,	54:13,23 57:22,	3,4 150:5
207:5 224:18,19	15 250:23 286:3	24,25 58:7,10,	156:21 170:12
241:21	302:24 316:18	14,24 60:15	211:23 295:24
recurrent 123:8	322:25 333:2,3	61:19	319:1 325:6
203:18	336:6 339:9	reinforce 12:22	relatively 16:11
reduce 156:9	343:15 353:14	reinforcement	160:12
157:12,16	refers 119:13	299:9,16 303:1	release 67:23
Reed 4:25	reflect 114:15	reiterate 209:1	105:14 216:3
reemergence	120:25 122:11	341:25	314:16,20
325:24	123:3	reiterated 209:1	released 132:4
refer 156:17	reflected 7:5	relate 79:9 95:19	133:2, 304:7
reference 15:16	18:7	169:4 354:22	relenting 196:18
25:4, 26:6 180:1	reflecting	related 21:20	relevant 240:17
245:11 310:5,12	120:10,19	40:4 75:3 79:11	reliable 211:13
referenced 11:12	122:2,19	281:19 352:21	219:4
15:11,14 225:10	reflection 298:10	355:15	reliance 7:6,10,
255:18	reflective 132:9	relates 28:6	20 8:17 9:9
references 9:21,	reflects 114:16	36:25 68:1	10:15 13:14,17
23 11:8 25:16	135:8 170:4	339:23	16:3,9,15 17:4,
340:20	247:12	relating 21:18	16,21,23 18:7
referral 197:16	refused 113:16	29:21 50:8	22:8,16,19,24
referrals 105:8,	refusing 356:20	51:20 52:1	23:5,8,10,14
20 119:17 183:9	regarding 87:24	53:25 64:15	24:17,24 25:13
	312:10 313:25		28:6 54:8 61:5,6

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

77:25 78:4	render 35:2	repairs 39:14	333:15 336:6
89:14,25 118:13	rendered 5:13	108:22 148:23	337:3,13 338:24
122:22 204:2	10:10 29:16	155:10 156:9,14	339:10,20,21,23
251:25	87:6	202:19 204:7	340:12 343:7
relied 6:24 16:16	rendering 89:12	215:2 217:7	354:22
23:19 338:23	reoperations	231:19 357:8	reported 140:19
relief 143:10,15	177:19	repeat 67:21,22	150:7 158:25
144:9 278:1	repair 5:2 34:13	76:25 107:9	160:6 184:9
relieve 143:21,	37:17 112:13	253:5 302:17	199:24 201:10,
25	137:21 143:7,20	314:15 315:3,5	24 208:4 209:8,
relieved 144:12	144:6,19,	323:1	9 218:7 231:22
207:17	145:20 146:1	rephrase 30:2	242:23 248:3
rely 87:6,15	147:2,3,8,17,25	replacement	286:20 316:9
89:18,20 93:16,	148:8 149:1,8,	142:14	342:18 343:23
18 221:2	17,25 151:5,16,	report 5:11,24	344:2
remain 129:13	23 154:2, 156:4,	6:2,3,11,18,24,	reporter 4:11
323:4	13 158:3,6,7	25 7:11 10:10	167:24 168:2
remains 246:22	169:9 172:7,15,	16:15 19:13	180:14,16
314:20 315:11	19 174:2,12	22:2,13,15 23:7	222:24 311:7,8,
323:8	194:20 195:15	24:12,19 30:16,	10
remember 12:1	196:14,15	20 31:1,25 32:4,	reporting 264:23
15:23 16:5 19:6	197:3,9,18	10,11,17 33:13,	reports 6:5
27:24 72:14	198:19 199:12	23 34:2 35:7,8,	77:23 78:3
76:3 90:24 91:1,	201:11,17	25 36:2,8 62:16	81:16 89:11,13,
14,15 121:24	203:16,18	74:21 77:22	15,18 98:8,24
122:25 123:20	205:3,4,5 207:2	81:16 83:24	201:15 207:24
124:23 132:2,25	208:1 211:15	84:5 89:24,25	209:17 227:14
139:13 179:3	216:21 217:4	97:22 98:8,11,	234:18 237:3
195:20 197:16	219:6 223:8	13,17,18 99:2	represent 4:6,25
250:10 261:20,	231:6,8,12	111:15 121:8	288:2 349:17,23
23 284:14 303:7	236:8, 238:9	133:16,21 188:1	representations
307:25 343:2	244:22 255:10	214:11 221:5	241:4
348:6 352:22	290:1,8 293:5	232:17 234:9	representative
remotely 196:1	301:8 330:13	235:8 247:16	25:21 27:6,10
removal 109:1	repaired 198:3	248:19 293:20	representing
remove 279:3	235:24	294:4 295:2	184:17 186:24
removed 347:19	repairing 68:10	298:22 305:6	represents 114:9
	144:1 156:18	312:1 314:25	
	225:3 289:8	327:3 332:7	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

reproductive 296:22	researcher 341:6	rest 72:3	review 11:4
reputable 130:11 172:6 175:3 253:23 254:2 256:7	resect 73:24	restate 245:14	12:19 13:12,19, 20 14:17 15:9, 14,17,19 18:23 19:13 20:6 25:22,24 52:2 54:15 57:20,22, 25 58:10,24 60:15,19 67:23 82:2,14,15 84:6 89:11 98:13 104:11 113:14, 15 124:13,23 128:15,16 131:18 146:12 182:8 198:20,25 199:6,14 200:22 226:8 236:1 241:6 262:13 296:5 306:7 314:17 324:12 331:18 337:19 349:2 350:25 356:18
reputation 311:22	resection 68:12 95:3,10	restrictions 190:1	reviewed 9:1 15:10 17:6 18:22 19:6 20:7 24:23 27:1,5,21 29:1,4 58:6 61:8 89:15, 96:16 98:7,8,10,11,17, 24 178:25 180:22 184:3 189:13,14 212:4 245:25 263:8 267:15 285:22 305:13 316:15 331:20 345:18 347:8
request 268:3, 15,24 279:3	residency 99:23	result 307:13	
requested 25:8 60:10 77:15 352:12	resident 71:1,2,3 136:6	resulted 297:15	
requesting 268:23	residents 49:21 71:4	resulting 44:14 46:3 67:19 68:9 69:4 222:6	
require 107:22, 24 122:21 242:24 243:3,23 315:3 349:5,25	resin 19:15	results 66:22 123:5,23,24 124:18,21,22 129:23 134:22 144:12 200:16 201:18 213:12 227:25 232:12 235:5 250:3 251:23 265:18, 19 318:5 322:3, 5 325:4	
required 59:6 104:13 126:15 315:5 344:18 346:5	resolve 141:15	retain 187:13	
requirements 54:20 58:15 261:11	resolved 226:14	retained 76:6,11 274:4 276:15	
requires 73:8	resource 290:20	Rethink 262:12, 25	
requiring 113:23 194:10	respect 5:5 193:23 210:24 257:1 264:21 266:8 334:17	retirement 86:11	
research 7:14 8:12,21 13:7 46:20 63:14,18 64:7 65:18 70:24 71:13 84:7 90:12,17 93:3 94:23 170:6 277:14 297:20 303:7	respected 271:14,20	retrievable 86:18	
	respond 200:7,9	retropublic 317:18	
	response 20:4 31:10 35:15 36:18,22 44:17 58:13 60:7 77:20 79:3 145:25 189:16, 22 221:10 253:13 258:8 281:6 295:22 298:11 328:12 333:7 351:3	retrospective 128:4,16 131:25 183:4	
	responsibility 116:6 280:24 282:20	retrospectively 120:12	
	responsible 116:6 277:14 325:23 340:16	returns 117:1	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

reviewer 9:3 29:6,7 124:24 199:5	121:7,25 126:10 127:13,22 129:5 133:12,21 134:6,24 146:15 152:14,21 156:11 159:2,25 161:1,4,20 166:7 167:12,22 168:4 169:2,6, 15,25 170:14,16 179:3,7,12,17, 18 180:2,5,10, 25 184:15 187:4,6,23 188:3 189:2 191:16 193:17 194:12 196:3,9 197:23 203:4,23 204:2,18,24 205:4,14,20,21 207:14,18,21 208:1 209:25 210:6 212:7 217:5 218:6,19 220:3,13,16,17 222:8 223:15, 17,18 224:24 225:3 226:9,12 227:9 228:3,11 230:8 231:17,21 232:3,24 233:20 235:21 238:6,22 240:4 245:19 248:13 249:17, 25 255:19 259:23 261:7, 22,24 263:8 265:11 268:5,6, 13,25 270:11 272:1 273:14	274:8,15 275:8, 10 278:2,15 279:7 285:12 287:17 288:3 289:4,14 291:4, 9 294:3,12 298:16 300:11, 22,24 301:1 303:14,20,24 307:22 308:7,19 309:15 315:25 318:3 321:18 323:20 325:15 330:20 333:12 334:3 335:9 336:1 337:6 342:19 346:22 348:19,24 350:18 352:25 353:16,20 357:24 rights 190:23 191:17 risk 30:13,25 31:13 67:21,22 134:18 148:9,15 150:8,11,21 151:8, 156:10 158:23 159:11, 20 161:12 165:8,10,12,16, 20 193:12 194:9 196:13 214:22 231:12 233:1 247:10 255:17, 20,25 266:18,21 314:15 322:22 323:1 339:24	risk-versus- benefit 215:15 risks 73:21 147:1 150:6 157:25 160:15, 18,19 163:18 166:21 167:2,4 174:21 192:10, 11,13,14 193:10,18,22 261:7 289:24,25 291:2,3 293:5 356:13 risky 29:22 30:7, 20 31:23 32:13 34:11,23 36:1 38:19 39:10,23 40:19 42:15 road 132:6 209:2 233:17 robot 154:13 robotic 51:16 64:1 153:25 154:4,20,23 160:13,17 162:2,3,4,9,10 169:5,7, 334:15 robotic-assisted 64:3 65:6,15,18 66:2,23 67:4 68:24 162:6 168:24 robotically 153:16 154:11, 24 robotics 64:22 66:18 154:15,16 170:7,8
---	--	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

Rochester 105:5 290:11	rude 33:4	34:12,23 35:25	salary 86:4,12, 13
rock 216:8	ruins 255:2	38:19 39:10,23	
role 98:15,16 130:2 173:15 174:1,11 264:18 265:2,3 266:20 286:12 319:24	rules 33:19 34:4 56:23 57:1,24 357:15	40:19 42:15 157:23 192:10 215:8 261:6 320:5,18 322:8, 21 335:4 349:14 351:3 356:4	same 20:24 21:17,21 28:13, 14 30:10 33:9 34:25 40:7 42:4 45:24 48:13 50:9,16 77:13 84:25 85:8 91:22 98:23 105:8 106:3 109:9 148:3 167:17 196:12, 20,24 209:19 218:6,13 219:15,21 227:15 237:25 238:2,3,16,20 239:16 240:20, 21 241:1,6,10, 15 251:7 312:8 313:14 323:22 326:12
rolling 214:15 215:18 216:2 221:25 234:2	run 137:4	safety 189:17 253:14 258:8 344:9 349:8 350:1 351:16,17 353:3	
room 55:13 59:15,16,18,22 60:1,2 61:21 136:9	running 337:10	said 10:6 14:24 20:4 22:22 23:11 25:19 27:17 28:24 29:6 32:10 36:9 46:14 48:2,19 50:2,18 58:3,8 72:9 90:23 91:6, 24 111:19 112:4 117:8 120:7 135:4 138:12 139:16 151:6,9 161:4 191:16 197:11 200:6 209:7 211:17,18 212:17 215:21 220:9 225:25 243:15, 251:18 254:14 257:22 263:16 264:7 269:24 278:13 291:11,15,16 295:14 296:8,17 306:6 314:4,6 318:8 319:5,8 330:22 340:3,4 344:25 350:9	
Ross 23:25 339:11	runs 284:17		
Ross's 23:25	<hr/> S <hr/>		
rough 87:1 101:15 104:22 105:1 108:15	S-t-e-r-n-s-c-h-u- s-s 310:15		
roughly 72:15 73:6 96:2,12 103:5,17,18,20 105:3,10 109:12 110:14,15,16, 17,18 111:19 163:21 170:5 287:6 330:2	sacro- 155:10		
round 24:7 103:16	sacrocolpopexies 156:24 215:4 244:9 245:1,12		
rounded 105:9	sacrocolpopexy 51:16 64:1,4 65:7,15,19 66:3, 23 67:5 68:25 151:24 152:18 153:14 154:23 160:10,11,16,17 168:18,22 169:5,14,15 195:17 245:11, 18 251:10,17 264:14		sarcastic 192:18
route 152:1,7 153:14 168:25 214:19,21 319:3	sacrospinous 155:11 158:9 334:22,23 335:3		sat 14:24 111:13 342:4,8
routine 261:4,15	sacrum 153:6, 11,19		save 71:20 357:18
row 29:7 124:24	sadly 274:20		saw 19:25 73:10 97:5 105:15 109:10 112:8 122:20 160:9 213:22 220:25 236:3 313:19 343:9
	safe 29:22 30:7, 21 31:23 32:13		sawing 32:6 215:19,20
			say 6:19 7:12

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

11:5 12:15 13:4, 9,24 14:5,8 18:13,20 20:6 25:18 27:11 28:10 31:12 38:19 39:23 46:16 50:3 52:17,20 59:5 63:22 67:7 68:25 69:21 86:5 88:6,23,24 89:22 90:10 93:4 99:6 102:20 107:24 108:13 110:24 113:19 115:24 122:12 135:7 137:3,15 146:20 152:15 154:3 155:12 156:25 157:6 164:1,13 165:15,16 166:19 168:17, 22 169:17 170:1 172:3,21,23,24 178:15,19 184:5,8 188:15, 19 192:13 193:23 204:12 210:7,14 211:17 212:4 214:9,23 215:15 217:24 220:6,7,8 224:2 226:5,13,15 227:19 228:8 230:4 233:23 240:19 242:22 246:24 248:18 252:21 255:25 258:11 261:6	265:3 274:20 278:13 280:17 282:19 285:1 286:7,17 291:5, 10 296:4 298:6 303:8 308:5 309:11 315:14 317:19 320:21 323:13,16,19 325:20 326:9 332:11 340:23 saying 11:14 14:11 33:10 35:13 36:21 42:3 89:9 98:22 100:10 101:19 102:23 114:4 115:25 120:17 123:9 132:19 149:2,3 150:11 166:16 176:15, 25 192:18 202:5,6 207:10 210:3 214:18 224:13 226:4,14 228:17 233:11 236:23 240:11, 25 246:24 251:3 254:4 257:7 260:1 264:10 270:12 273:1 282:12,19 290:22 291:1 300:18,24 301:8 302:3 308:23 309:13 313:8 317:10 344:21 356:4 says 22:10 35:25 36:2 81:24 84:1	123:6 124:5,18 127:14 189:25 201:4 259:5 263:4,19 268:7 269:25 274:11 280:13,14,20 283:13,15 286:20 288:10, 14,15 289:6,14, 16,20 291:22 292:20 293:2,6, 8 299:17 300:8 302:21 303:22 318:3,21 323:8 339:14 343:11 356:3 Scale 210:16 211:22 scan 13:21,25 14:8 scanned 14:5 61:17 scanning 303:8, 23 304:10 scar 66:9 214:16 328:21,25 329:20 scarred 71:17 scarring 112:12 213:16 221:12 327:14,18,25 328:2,7 330:12 scenario 325:23 schedule 83:23 84:1 104:4 277:22 scholarly 186:15	school 195:3 schools 155:6 science 90:16 92:2,7,12,18,20, 22 93:3,9,16,21 94:3,8, 96:23 311:1 scientific 31:20, 24 32:14 34:12, 24 36:1,20 38:9 45:10, 103:22 130:21 262:14 scientist 308:11 score 232:15 234:14 screening 12:10 177:11 SDMS 25:5 search 10:7,9, 11:13,17,23 12:1,3,6,7,8 14:12,19,20 54:5,6 276:20 283:25 302:6 searched 38:11, 12 searches 9:18 12:1 searching 14:1 157:19 276:21 second 62:2 65:13 70:16 79:6 82:3 126:25 127:7,8 132:20 166:18 178:9 194:12 220:17 225:6
--	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

243:1 253:6 263:4 268:15 289:4,6, 300:19 309:5 secondly 144:19 section 6:25 10:21 22:7,9 29:8 31:4 123:5, 23,24 124:4,5, 18,21,22 125:19 250:1 339:19,23 340:12 342:21 see 5:20,25 15:6 18:3 21:22 24:24 25:7 26:4 38:14 55:7 60:2 62:8,13 91:6,7 98:16 103:4,17, 21,22,23 104:6, 9 105:3 106:4 108:13,17 109:8,9,17 110:9,24 111:20,22 112:5,14,15,23 113:17,18 114:11,13 118:11 122:1 123:21 125:22 126:7 127:15,16 128:25 129:14 132:1,3,23 140:6 143:23 151:13 169:21 175:17 176:3 178:5,17 181:25 192:12,13 196:3,25 197:9 198:22 199:8,12	200:23 201:7,23 202:1,2 204:19 205:5 224:12 227:5,7, 231:8 232:14 233:25 236:2,4 237:15 241:17 242:14 244:15 245:9, 11,20 246:7 247:6,7 248:15, 17 250:5,20 251:15 252:1 256:19 257:9,14 258:21 259:8 262:15,23 263:6 265:7,15,23,24 268:22 269:2 280:4,6 283:7, 12,17 286:23 287:19 288:6 289:2,3,5 295:17 296:6 297:24,25 299:7 300:4,7 303:22 307:20 309:10 312:11 314:17, 23 315:4 316:1 317:21 318:25 319:5,9 327:14 331:1,3 336:25 339:16,25 341:12 342:23, 24 344:14 352:18 seeing 89:21 96:6 103:9 104:3 105:12,13 107:12 110:16 114:9 132:6 151:18 156:3	161:24 167:6 197:19,20 244:6,9 251:19 252:17 269:24 297:19 seeking 267:22 278:2 seem 286:1 340:5 seems 131:4,15 146:12,22 236:17 274:21 275:20 340:7 seen 47:1,6 62:3 72:5 107:21 113:15 125:2 132:12 136:19 140:24 146:4,14 148:13 149:5 150:6,10 151:19 157:17 159:25 160:2 167:6,11, 21 172:12 195:6 197:3,8,16 204:7 246:23 269:2 287:25 317:5 320:21 322:19,23 326:1 328:25 333:8 segment 103:1 select 109:2 173:11 184:1 353:19 selected 18:14, 23 132:17 286:9,17,18 selection 131:23	self-tailored 227:6 228:12 sell 115:19 117:24 351:16 selling 117:21 345:1 349:6 sells 117:22 SEM 303:24 seminars 50:5 send 59:18 senior 65:5,14 66:8 70:9,14,17, 18 178:21 233:8 sensation 139:23,24 237:1 sense 85:16 165:2,5 193:3 260:8 sent 120:10 197:8,17 285:20 347:16 349:18, 21 350:7 sentence 36:14 320:8 separate 90:3 98:2 214:19 240:10,23,24 241:7 279:14 separately 81:19 278:25 279:2 September 76:5, 14 80:9 91:13 120:1,14 128:5 179:6,22 272:8 275:9 277:2 314:15
--	---	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

series 126:13 158:20,25 159:2,24 163:20 167:6 195:21 Serious 253:14 served 74:11,14 sessions 186:14 set 6:11 7:10 8:17 19:7 220:16 285:19 333:15 sets 240:24 setting 160:3 281:7 seven 101:20,21, 22 250:14,17 251:8 252:16,19 254:5,8 275:17 287:6 341:17 346:11 357:13 seven-year 250:7 252:15 several 168:6 307:19,22 308:8,17 309:5 311:20 335:13 352:14,19 354:17 severe 48:9 140:5,8 193:10 194:7,8 195:6, 22 196:8,18 severely 174:24 285:21 severity 141:16 193:25 195:7,19 196:21 197:2	198:7 209:12, 22,25 210:5,16, 19,21,22,25 211:21 243:7 266:12 342:17 343:8,13,25 sewing 153:6 sexual 140:25 141:1,2 167:7 194:9 210:4 211:23 235:12 sexually 192:6 208:10 242:8 shadow 53:21 shall 17:19 shape 338:17 341:21,22 share 160:14 she's 139:12 144:11,12 174:23 196:14 sheath 220:24 318:11 sheaths 319:2 sheesh 304:14 shift 178:9 Shimko 65:4 Shlomo 89:5 187:8 short 211:19 232:24 249:5 286:25 short-term 115:6,8 223:16 224:4 shortchanges	43:17 shortcutting 154:2 shorten 158:12 shortened 158:11 shortening 158:3,8 shorthand 188:9 shortly 213:8 230:25 351:15 should 49:3,16 50:1 57:20,22, 23 60:15 129:12 142:6 170:21 209:1 235:9 236:19 239:24 240:11 261:5,15 286:3,7,8 294:23 302:7 303:3 312:1 323:9 330:15 337:25 340:11, 23 342:11 343:23 357:2,17 shouldn't 230:4 show 36:8 104:16 118:4,5 192:9 203:5,8 245:16 249:8 253:6 267:3,10 279:13 282:23 283:4 285:6 304:20 306:9 314:7 319:10 321:1,9 323:23 showed 332:19	showing 40:11 48:18 108:25 202:12 225:9 233:14 241:5 shown 129:23 152:10 326:24 showroom 115:22 shows 151:10 307:12 321:21 shredded 72:1 shrinkage 326:12,13,20 327:2,6 331:7 332:3,11,20 sic 25:6 56:9 57:25 69:22 70:1 108:24 160:12 214:24 side 127:8 137:17 142:19 158:1,2 160:20 163:6,15 194:22 195:15 196:5,20 250:2 273:6 sign 15:7 281:9 signaling 293:24 signatory 267:18 signed 258:7 263:14 267:15 269:7 270:1 282:18 348:12, 16 significance 202:4,8 217:21 343:25 significant 51:2
---	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

62:25 73:21 92:23 151:4 158:15 173:13 183:16 196:8,17 201:21,22 202:11 208:4 210:8 217:17 234:6,17 247:18 250:15 264:18 266:20 272:12 326:18 significantly 74:4 232:16 242:13 246:11 275:20 signs 138:1 139:11,16 141:14 312:24 similar 228:7 245:24 248:15, 18 262:14 265:20 similarly 159:11 256:12 simpler 303:4 since 39:21 72:5 106:17 109:4 136:2 156:15 162:20 163:12, 14 222:10 351:14 353:7 Sine 325:16 sing 313:16 single 11:17 13:24 14:5,6 15:1,3 16:2,5,12 39:10,25 40:14, 20 42:11,12	44:2,9 61:17,18 69:3 104:5 112:23,25 129:3 158:21 176:17 181:15 183:17 270:22 278:19 318:22 SIS 202:16 325:2 sit 14:17 39:2 62:24 108:4 193:8 291:25 319:20 site 284:23 285:8 287:19 292:10, 23 sitting 6:16 19:6 38:5,6 48:21 62:23 84:12 106:1 109:21 110:9 112:17 166:1 343:2 situation 18:18 19:23 107:18 193:1 269:9 282:20 351:6 situations 59:18 260:3 261:18 six 49:8 66:10 101:16,19,21,22 103:4 105:9,16 110:15 144:10 170:20 274:8 287:6 329:21 330:1 size 20:24 21:1, 14 222:1 226:24 337:12,13,14, 18,21,25 338:2,	3,18,19,20,22 339:1,3,8 sizes 98:20 339:6 skill 130:2 155:21 247:11 skilled 130:10 175:3 256:7 skimmed 28:25 skimming 29:5 skin 160:22 skip 306:13 slightly 201:20 sling 66:10 67:23 68:4, 75:5,6 148:3 314:16,19 315:11,18,22 316:3 317:13 320:3,9 322:7, 20 324:13 325:6,22 326:19 329:21,23,24 330:17 336:3,5, 9 355:2,8 slings 294:13,19, 21 295:5 313:25 314:1 319:6 322:12 323:4 324:20,21,23 354:18 355:15 356:6,9,14,20 357:3 slow 103:6 105:10 slowly 135:3 170:9 small 65:25 224:16 260:25	315:2,6 335:4 353:19 smaller 103:13 104:24 249:3 251:24 smattering 103:21 smiling 285:11 Smith 298:25 smoker 149:22 150:25 smokers 150:12 151:14 smokes 150:18 smoking 150:10 151:5,7 soapboxing 186:16 societies 319:23 society 11:20 63:2,4 173:22 188:9,14 190:1 198:25 235:15 319:17 320:13, 15 352:20 Sofradim's 126:21 soft 229:20 332:16 sold 117:11 133:2 321:5 351:10 352:15 353:9,15 solicited 284:18 solitary 39:11 40:14,20 176:17
---	--	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

Solo 21:2 110:3 220:2,4,17	202:24 225:6 226:11 238:22 239:9,20 248:4, 20 256:4 258:19 277:5,18 279:1 280:15 285:14 287:16 289:6 300:15,22 302:17,20 307:7 309:25 310:4 311:9,16 314:24 316:18 321:19 333:12	189:1 251:5 294:25 334:8 344:10 speaking 19:5 44:15 55:19 56:24 57:1 59:17,21,25 64:20 68:15 88:5,9 89:1 134:6,13 164:20 187:2 231:13 291:23 341:9	130:7 132:21 139:24 168:17 169:9 172:22 183:17 207:24 209:6 214:10 231:24 248:11 259:17 265:5 268:9 298:3,20 301:8 316:4 326:13 328:17 338:16,19 342:9 354:12 355:14, 16
solved 272:3			
somebody 33:12 57:20 150:24,25 156:21 172:13 187:12 193:11 257:10 284:14 288:23			
someone 63:20 335:5			
someplace 114:20		specialize 188:18	
sometimes 22:5 33:3 175:17 193:9 246:16	sort 17:18 33:16 34:4 37:3 78:2 82:11 88:4 104:19 107:22 112:6 135:5 141:8,22 142:16 143:8 147:16 148:14 160:9 233:5 240:2 243:23 274:8 279:21 309:15	specializing 253:24	specifics 26:18 29:11 303:7 304:22
somewhat 121:13 130:5 162:20 204:11 211:16 242:9 320:11		species 213:23	spectroscopy 303:10
somewhere 53:5 80:21,25 81:3 89:7 136:25 239:12		specific 15:19 21:8,15 25:5,18, 23 26:6 38:20 64:16 70:3,5 81:19 94:18 108:19 113:15 126:12 132:11 137:24 163:18 174:21 236:13 248:25 249:1 258:2 271:8 272:11 293:20 297:1,13, 302:14 312:17 329:4 342:7	spectrum 224:15
sorry 23:13 45:14 65:8 66:16 69:20 72:8,12,22 76:25 78:22,24 88:16 96:17 102:4 107:9 118:21 120:4 161:18 162:16 167:24 175:23 178:22 187:21 191:6 198:14 199:20 200:5	sorts 318:5 343:3		speculation 80:22 252:21
	sounds 9:3,12 115:20 125:23 169:16 314:23		speculative 233:20,24
	South 10:20		spell 83:16 251:1
	Southwestern 89:6 108:25		spent 80:13 81:5, 22,24 82:12 83:10,20
	speak 16:12 19:11 20:1 68:15 94:12 105:17 106:13 119:16 130:22 131:6,7 135:1 142:9 176:20,24	specifically 19:11,12 26:7 31:2,17 32:5 35:14 37:7 38:8 46:1 51:21 54:1 57:20 60:23 93:11 95:2 107:22 125:3	spoken 69:7 172:16
			sponsored 39:6
			spouse 226:3
			spurs 9:22
			St 89:6
			staff 49:21 119:3 120:9 154:14 287:6 288:20,22 292:20 335:1,2

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

stagnant 10:22 12:12	99:24 105:10 107:18 109:7,8	102:15 104:1 116:22 151:14	289:18 291:7,8 292:19,24
stamp 18:1 273:15	122:1 152:5 185:19 217:9	152:25 154:5 155:23 189:16,	320:2,25 322:20 332:6 353:9
stance 185:13	294:22 324:18	20,22,25 191:13	stating 46:7 48:22 202:3
stand 193:9 281:1 282:9,22 286:9,14 326:4 350:20	starts 17:23 176:7 216:4	202:7 211:16 213:20 239:18 255:7 256:6 257:11,23 258:16 259:5,19	209:13 239:25 263:11 269:22 301:23 323:6,7
standard 154:8 156:18,22 173:3 175:8 286:10 314:1 320:3,10 323:15	state 4:6 53:21 54:5 128:9 132:24 183:23 190:2, 209:20 217:6 218:24 224:21,23 239:5,12,20 241:18,25 242:5,16 255:15 259:18 262:21 280:3 282:10 296:20 297:2 301:5,18 309:5, 9 315:2,7,8 317:6 318:17 320:24 322:7 332:8 337:2 354:10	261:17 264:12 266:17 272:5 275:23 281:17, 18 282:3,18 286:14 287:8 288:24 290:5,13 292:18 293:1,2, 10,14 303:2 313:25 319:6, 15,16 321:6,7 350:19 352:21 353:7,8,13,18 354:5,11 355:15,16 356:3,12	statistic 258:13 statistical 202:4, 8 203:1 217:21 303:9 statistically 164:20 201:21, 22 202:11 209:5,6,19 217:17 218:1, 16,18,21 219:1, 10,20 225:7 232:15 234:5,17 242:13 247:18
standards 156:21 346:5		statements 30:19 34:7 35:8 42:1 88:18 106:23 191:18 262:6,24 271:25 273:5 284:7,22 286:1 289:19 293:17	statistics 165:13 217:18 253:1
standing 140:2	stated 7:21 35:12,19 37:2 206:20,21 207:14 209:16 213:5 223:6, 234:12 261:3,20 262:16 264:11 275:3 286:6 294:11 315:13 316:16 323:3	status 66:18 183:16	status 66:18 183:16
standpoint 98:21		states 115:18 117:1 120:12 136:18,25 170:10 173:23 197:7,17 201:13 246:3 262:9 263:14 268:12, 20 280:22	step 33:6 55:13, 14,15,16 steps 221:22 222:2
stands 280:20			sterile 161:23 213:25 sterilely 213:24
start 11:18 33:8 76:1,17 77:5 105:10 124:17 132:6 133:16 137:11 170:17 174:7 197:25 210:17 259:2,24 260:12 282:5 293:23 347:3	statement 6:7 11:5 36:21 44:10 45:12 53:8 56:7 97:19		Sternschuss 310:15 313:8
started 76:13 79:22 80:1 103:5,6 105:12, 13,20 111:4,7,8 132:4 139:15 153:23 163:14 170:5,22 216:12 249:9 343:19			stick 159:16 241:20
starting 17:22 31:2 87:25			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

sticking 133:4	strengthening 142:13	90:14,15,16	16 128:4,20
stiffness 325:12, 21 326:1	stress 68:2 136:14 183:1	95:8 115:6,9	131:3 132:5
still 33:1 119:7 122:10 130:9, 12,21,24 153:14	stretch 67:7	143:14 192:9	179:4 182:11
159:7 161:6,12	192:21 294:14, 20 296:10	200:21 201:5,8	183:19 184:3,19
163:14, 169:19	314:2,6 317:1	210:2,15 211:8, 9 219:12,13	199:9 200:16
172:14,19	319:7 320:4,11	221:2,7 222:11	203:13,17
174:1,9,10	322:9,20 323:5	223:13 224:5	204:5,12,13
176:19 177:4	336:22 356:9	225:15 227:23	205:1 206:19,25
202:12,13 203:2	stretching 325:21	232:5,8,22,24	207:8, 209:23
205:13 213:18	stricken 240:12	235:3,8 236:12, 23,24 237:5,8,	210:7,12,21
218:17,19 224:4	strictly 335:22	18,19,23 238:2	211:25 216:14
228:25 246:21	strike 34:7 43:5	240:10,24	217:2,8,9,22,25
250:5 290:7	45:11 115:14	241:4,5 245:17	218:4,24 219:2, 4,8,11 220:21
294:13 307:23	142:16 174:7	248:2,21 251:9,	222:4, 223:7,13,
315:14,15	177:24 233:3	22 252:10,11	17 224:10,17,25
333:24 353:9	265:4 277:5	256:21 264:20	225:8,14,16,18,
Stockholm 53:1	279:1 281:16	266:1,5,6,7,8	19,22 226:12,22
176:13	293:13 310:7	268:22 300:18,	227:13,17,20,24
stones 71:13	335:17 352:3	25 301:7,25	229:7 231:1,5,
stop 57:2 106:23	strong 87:24	302:1 316:16	23 232:3,14,18,
137:7 138:13	135:16 152:19,	321:1,2 328:18	25 233:4,18
274:23 276:4	21 256:6 279:15	329:19 330:23	234:5,13,14,16,
291:20 293:15	355:23	344:2,18 349:8	25 235:10,16, 18,19,22
305:22 346:13	strongly 190:1	350:1,10 351:2, 8,9,16 353:4	236:13,14,16,19
stopped 258:22	structure 135:19	study 37:14,23, 25 38:4,7,13,14,	237:12 238:1,7, 11 239:1,4
294:23,25	144:15	16,23 39:7,11,	240:17,22
stops 257:12	structures 135:3	22,24 40:15,20	241:7,17 242:1, 6,12,24 244:18,
328:15	studied 232:11	41:1 42:11,12	23,25 245:6,21,
story 150:16	studies 21:4,18	43:2,8,9,10	25 246:4,6,10
151:21	39:12 40:10	44:2,9 45:6,14,	247:2,12,17
straight 153:10	41:11 43:18,20	19 46:2 47:13,	248:1,8,14,15,
straining 134:18,21	46:7 47:18,23	25 48:10,14	23,25 249:9
strength 153:1,2, 4,7 325:21	48:18 66:12,13	71:23 95:5	250:2,16,19,25
		96:22,23	251:7,12,16,21,
		101:11,17	24 252:1,14
		102:6,7 118:15,	255:16,20

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

265:1,4,23,24, 25 299:14,23 300:8,16 302:21 303:5,17 304:5, 21, 306:23 307:14 309:8 313:3,10 315:21 316:9,24 317:3, 25 318:3,8,15, 20 321:9,11,16, 17,25 324:15,16 325:4,5,9,20 326:1,12,14,17, 20 328:24 329:4,23 330:3, 5 331:8,9,17 332:6,9,16,18, 19 338:21,25 339:4,5 351:17 stuff 14:15 59:17 200:13 208:24 277:15 304:12 styles 271:21 sub- 304:16 subject 12:23 13:8 93:23,24 137:14 251:20 257:2 subjective 74:6 137:5 144:4,9 225:12 234:24 subjects 76:10 submission 21:20 49:19 54:24 58:1,7,10, 24 60:16,20,23 61:4,9 69:14 204:9 348:11,15	350:17 submissions 54:13 57:22 submit 72:13 79:23 81:21 170:18 submitted 64:12 68:11,17 69:9 70:22 73:14 79:18,24 83:4 95:12 170:21 179:20 239:14, 15 subsections 117:3 subsequent 125:14 308:1 subsequently 190:17 216:6 329:5 Subspecialized 99:12 subspecialty 99:20,24 100:12,20 suburethral 325:22 success 73:6 108:23 144:3,5, 13 157:1 158:14 168:19 204:14, 23 206:10 207:16 217:3, 10,11,13,22 237:19,20 352:1 successful 145:2 158:14 325:24	successfully 177:20 such 43:9,10 129:18 149:6 169:14 222:10 290:1 302:23 334:1 sudden 106:2 suddenly 106:17 suffered 283:14 suffering 253:24 256:8 258:7 336:21 sufficient 129:12 345:19 SUFU 68:15 173:23 176:13 188:14 189:13 257:3 272:9 275:14 319:16 321:7 341:8 354:3 355:21 suggest 349:13 suggestion 184:23 Sumika 25:21 26:25 27:6 summaries 87:15,17 summarize 45:1 312:20 summary 32:3 44:17,18 45:5 71:6 76:15 81:1 123:6 125:2 134:1 135:6 137:2 155:15	189:22 198:4 summer 77:7 79:22 80:3 superficial 312:24 superior 339:2 support 134:23 135:1,5,14,19 143:8,9 145:12, 15 210:14 240:24 257:11 260:20 262:18 268:1 278:25 279:2,15 284:19 285:1 289:8 293:1,7,10 297:4 304:23 320:16 321:4 325:5 343:9 349:13,15 356:1 supported 134:3 260:4,20 263:12 supporter 285:2, 24 supporting 271:23 347:17 suppose 334:4 supposed 34:2 44:18 104:15 200:7 291:11,25 suprapubic 317:18 sure 9:7, 10:24 20:8 21:12 30:4, 6 33:11 52:6 61:7 63:5 78:12 102:10 125:25 131:16 140:10,
--	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

14,24 147:22	71:20 74:3	268:9,17 280:23	126:16 138:1,5
156:11 165:5	99:11,13,16,21	288:25 289:6,	139:11,16
188:4 189:14	100:2,16 103:9	10,13,22,25	140:18 141:13
195:13 208:25	108:2,7,17	293:2,8 296:5	143:16,21,25
209:24 211:3	113:1 119:10	320:4,10 322:8	145:5 206:21
230:14 239:17,	122:21 126:9	surgically	207:17 235:12
19 246:25	137:21 141:11	124:19 125:4,9	237:21 325:24
247:21 266:24	143:10,17,18	surprise 271:16	synopsis 133:22
271:3 289:22	144:6,7,9 145:2,	surprised 271:19	synthetic 35:15
291:1 302:19	10 146:1	340:8	36:18,19,20,21
328:5 337:2	147:11,22,23	survey 211:22	126:9 152:7,13,
342:1 346:6	148:10,16,17,18	susceptible	21 182:10,25
357:19	149:1,13 150:5,	146:22	201:12,17,25
surface 326:19	14,15,17,19,22	suspect 15:1	202:21,25
surgeon 129:19	151:2 155:3	204:20	235:14 255:9
144:21 168:9	156:19 157:7	suture 149:14	259:5 288:25
171:15 172:9,11	158:17 175:4	195:23	289:11 298:13
173:1 174:19	182:10,25 186:8	suturing 153:9	299:15 302:24
175:3 247:11	187:1 195:4	213:25	315:11 323:3
257:9	207:3 208:20	swear 4:12	332:25
surgeon's 265:2	224:12 231:20	swinging 323:19	synthetics
surgeons 130:6,	246:12 247:3	357:7	202:13
11 155:1,3	249:1 266:19	switch 230:13	system 5:2 227:3
156:15 157:21	289:16 290:1,23	sworn 4:13,17	228:24 234:23
173:7 176:8,20,	299:9 302:10	139:7	systematic
23 190:5 194:11	311:2 314:16,22	swung 176:10	198:20 200:22
199:1 253:13,24	315:4 323:1	symptom 143:10	262:13
256:7 257:8,16,	324:13 325:6	225:20 242:12	systems 126:18
18 258:6 260:2	328:9,14	symptomatic	127:15,20
262:4 263:12,	surgical 7:3	137:5 141:25	132:22 190:3,21
14,16,21 264:3,	37:18 49:9 50:5	146:17 174:24	
7,21,23 267:1	63:24 103:12	198:25 224:22	<hr/>
281:6,9 290:7	129:18,20 130:1	symptomatology	T
322:2	141:21 143:6,7	136:22 144:16,	<hr/>
surgeries 110:18	144:23 155:16	18	T-r-a-b-u-
201:11 214:20	162:17 169:13	symptoms	118:19
219:3	188:1 190:4		T-r-a-b-u-c-o
surgery 49:8,10,	191:22 198:3		118:21
11 50:7 67:22	243:4,24 253:15		table 116:18
	264:17 266:19		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

128:20 197:1 198:15 Tabulation 250:2 Tacoma 75:9 tag 58:22 take 5:7 44:21 53:6 64:19 71:17 72:22 75:21 78:10 90:15 110:23 115:8 119:25 144:9 146:10 177:18 182:14 190:25 191:19 193:11 200:23 230:14 248:10 258:6 263:12, 15,18 305:2,14 320:8 331:20 352:2,4 357:21 taken 24:25 56:23 92:3 142:24 257:15 284:1 338:2 taking 10:18 46:21 49:23,24 51:2 52:24 181:21 187:14 210:20 257:13 264:8 278:20 282:8 337:20 346:2 350:20 talented 267:1 talk 29:15 31:2, 15 33:2 34:3 43:8 97:9,13 98:18,23 140:11	145:19 156:21 167:5,20,23 168:3 173:19, 20,23 186:15 197:23 204:20, 22 205:15 207:19,20 210:12,19,21 213:7 220:17 221:6 245:16 276:19 293:5,20 295:11,20 298:19 299:2 305:8 317:25 318:15 341:8,11 talked 60:17 96:24 98:19 102:11 139:21 157:25 169:2 177:21 179:17 184:22 185:7 205:8 237:1 242:13 257:2,7 261:25 267:11 276:19 286:12, 18 294:5 324:11 334:20 347:7,9 349:3 talker 33:3 talking 14:8,15 28:13 31:16 33:1 35:13 40:10,22 44:14, 16,19 46:9 53:4, 10 55:24 66:16 72:18 80:20 86:5 94:22 95:10 110:6 115:5 117:15	120:18 122:12 130:16 134:8,23 139:11,25 148:10 150:16 167:17 168:23 176:1 177:16 183:8 184:14 185:24 187:6 193:16,18,20, 21,25 194:16 197:10 198:9 201:19 205:9, 16,19 206:5,9 210:11,17 214:8 216:15 221:8 225:18 226:17 228:2 229:14 238:8,11 239:25 241:7 243:20 245:4,9, 249:10 259:12,13,15 271:1 276:8 297:21 298:23 299:12 300:8 301:6,10 302:8, 10 306:5 308:1 310:25 315:17 317:15 329:8,16 335:23 340:19 341:6 343:2, 346:3 347:18,23 356:6 talks 63:1 255:8 tally 113:2 tallying 112:25 tape 316:25 317:5 318:22 tax 117:1	Tayrac 310:20, 21,23,25 311:15,19 312:3,5 TBN 264:22 teacher 136:7 teaching 49:21 136:5 team 58:22 279:19 tearing 135:10, 11,13 technical 78:6 153:24 161:16 162:17 technically 99:18 100:8 154:12 TECHNICIAN 4:1,11 76:25 78:14,17,22 82:4,7 138:17 139:2 230:11, 13,15,19 248:6 294:1 305:17,24 306:2 309:24 333:10 341:18 357:25 technique 129:19 130:2 247:11 264:18 266:20 337:2 techniques 37:18 131:5 169:10 technology 157:16 television 106:18
--	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

tell 19:4 27:20 38:5,6 40:14 43:9 80:1,13 82:25 85:5,22 92:25 98:7 109:21,22 113:19 114:8 133:1,6 156:20 163:8,19,20 164:2,3,22 165:1,12,19,21, 23 166:21 167:2 169:22 177:23, 25 183:19 186:12 232:10 233:4 248:5 288:3 354:4 357:16	tends 172:9 232:19 tensile 325:21 tension 131:13 317:17 334:7 tension-free 209:4 316:7,25 term 68:5,7 73:19 76:11 261:6 308:11 terminology 167:22 terms 12:6,8 14:19, 88:20 122:4 136:22 143:6 144:5 148:7 156:4 158:14 168:8 184:10,24 211:13 217:22 218:3,6 219:4 224:11 245:20 247:23 265:20 340:23 345:22 tertiary 49:14 52:23 148:21 149:10 175:12 183:7 190:17 195:5 197:6 testament 192:12 tested 94:20 312:9 testified 4:17 63:8 74:24 139:7 349:11 testifying 84:23	testimony 15:15 26:25 27:17 33:5 35:24 40:4 61:8,13 84:10, 18 91:19 166:8, 10 354:22 testing 94:16 96:14,16 99:25 147:22 tests 96:19 303:5 304:19 306:9,19 309:2 text 124:6 than 6:4 12:16, 18 29:22 30:7, 21 31:5,7,13,23 32:13 34:12,23 35:15,19 36:1, 18 41:5 43:15 46:8 73:20 74:15 80:17,18, 24 83:18,20 85:9 89:2 90:22 92:10 93:6 96:13,21 97:5,8 108:22 121:9 124:6 125:12,16 143:9 150:18 153:8 157:5 168:12 173:22 186:1 198:2 202:14 203:2,3 205:9 209:14 210:8 211:1 212:9 214:18 215:6 217:22 224:5 225:1 229:16 232:5 240:22 249:5	251:21 256:20 275:8 297:24 303:13 325:20, 23 330:10 332:20 335:12, 17 339:1 347:25 355:8 thank 17:1 60:12 61:4, 82:20 118:24 180:15 192:16 196:2 203:21 216:10 231:4 273:17 303:3 311:11,19 357:11 thanking 192:19 Thanks 78:13 171:7 324:8 their 9:23 29:4 75:5 85:7 93:1 97:6 112:7 115:4,21,22 117:3 120:19,20 126:12 141:2 142:4 143:15 155:21, 157:22 165:16,17 173:2,9 193:6,7 198:3 204:8 206:19 207:16 208:14 217:6 226:10 227:2 231:8 237:3 238:4 249:3 251:23 255:10 256:9,23 267:24 269:8 271:20 276:11 281:7 282:9 284:8
---	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

289:23 297:4 301:6 338:14,15 343:24,25 344:24 348:22 352:6 353:4 354:6 theirs 173:9 338:8 them 10:4 11:3 13:22,23,25 15:22,23 16:12 17:9,25 28:20, 22,24 29:10 31:19 43:18 44:24 59:10,22 61:18 73:9, 76:10 77:3 79:23 82:19 87:20 89:21 94:13 96:9,11, 12 103:10 104:6,17 106:15 107:25 108:7,8, 11,20 109:8,10 113:2 130:21 138:10 154:23 163:8,19,20 164:2 165:12, 13,21,23 166:15 170:8 177:20 184:4 185:3 187:16 193:6,12 197:20 206:2 211:5,9 214:16 220:2 235:4 240:7 241:16 246:21, 250:22 252:25 254:2,14 256:24 257:7,11 270:23 271:2	274:20,21 278:14,15 283:22 290:17 298:22 306:15 309:3 316:15 334:4 335:1 340:19 345:18 349:7 351:15 themselves 105:23 111:4 192:5 351:17 theories 308:17 theorized 37:21 theory 308:13,22 there's 8:14 10:11,21 13:10 15:21 21:4 25:16 32:11 36:2,3 39:21,24 70:3 88:25 90:3 101:4 117:3 125:6,14 127:21 135:15,18 141:7,17,20,25 145:17 155:6,16 156:23 157:7,8 159:20 164:21 168:20 173:16, 176:17 185:1 186:16 188:21 189:2 192:25 193:14 198:5 202:16,17 210:24 211:11, 21,22 213:1 215:14 219:8 222:2 226:5 233:25 255:24 266:14 270:16	310:18 315:23 325:16 338:4 340:20 357:7 thereabouts 103:6 therefore 318:21 they'd 117:2 226:5 they'll 113:19 176:3 they're 15:18 30:25 54:12 62:10 82:18 104:15 105:3 106:2,4,13,14 107:12,17 115:5,19 117:4, 7 131:10,11 140:21 152:9,21 165:24 183:8 185:19 193:15 200:1,10 201:19 204:8 205:7 209:13 210:3 217:18 232:6 239:16 240:10, 11 245:3 254:1 256:10 257:8,17 258:9 259:12 264:4 265:22, 23,24 266:5 267:1 273:2 283:21 290:18 292:17 301:7,23 302:5 308:23 323:20 327:25 they've 116:25 233:9 240:1	thick 228:16,17 229:15 thicker 229:16 thigh 194:4 214:17 thin 73:24 161:16 162:18 thing 21:21 28:13,14 48:13 50:9,16 62:12 109:9 116:6 119:3 124:12 140:3 142:21 157:20 167:17 192:9 259:25 264:10 266:22 275:1 282:9,21, 22 300:21 302:2 308:6 323:22 325:13,18 326:2 328:3 329:2,5 things 44:16 47:8 60:17 62:7 71:5 90:14 98:23 104:3 121:23 125:15 138:5 141:6 142:24 152:19 168:10 169:14 177:19 189:3 191:16 200:12 205:11 211:1,7 215:21 221:22 226:16 255:25 256:21 264:7 267:5 277:11 280:13 284:11 303:4 304:8 305:5 306:13
--	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

312:5 326:25 340:3 think 16:24 19:16,17 20:21, 23 21:25 24:5,6 25:5 27:9,21 28:7 33:9 40:24 41:5 44:7 56:19 62:25 64:11 67:6 85:14 88:25 97:5, 105:19 106:21 107:11,15,20 108:2,7,8,19 116:23 119:8 124:4 126:22 131:6 135:19 143:14 151:3,9 155:6 156:25 157:6 160:8 161:6 162:8 164:10 165:5 166:2 167:17 168:20 170:25 175:9,21 176:5 179:24 180:2 181:5 184:22 185:1,23 191:11 192:8 202:2 212:17 219:7 220:3,21 222:7, 19,20 223:11 229:2 232:22 234:1 238:6 243:17,19 256:2,22 257:17 258:9 262:22 264:4 266:15,16 267:4 282:14,23 292:22 294:7	295:6,10 301:13 305:2 306:6 307:10,24 308:15 311:8,20 312:3 313:17 315:14 316:16, 17 320:11,12 321:6 326:24 329:8,15 330:1, 18 339:4 340:2, 4 341:16 344:25 346:14,15 348:2 349:11 350:22 357:15 thinking 106:2 170:4,7,12 204:11,13 280:8 307:3 third 28:6 70:16 86:1,20 96:2,9, 12 101:13 224:24 254:21 259:3,4 307:18 thoracic 215:3, 14 thoroughly 29:1 though 16:13 28:15 50:14 56:19 95:6 120:23 125:24 132:10 152:9 160:2 161:10 200:4 201:21 205:13 212:14 218:13 237:16 247:2 297:5 315:8 319:25 322:24 331:21 337:1	thought 22:22 36:11 52:19 87:12 119:17 220:9 258:19 271:13 281:4 305:8 323:24 325:13 326:5 329:4 thoughtful 172:8 175:13 thousand 80:20 284:1 thousands 15:21 188:17 thread 313:2 three 5:13 6:4 37:18 41:13 51:12 58:3 65:17 75:12,18, 24 79:25 85:20 86:21 90:14 105:17,20 132:5 159:2 162:13, 16,24 163:11 164:3,8,14 179:17 193:22 209:3,4,14 223:18,21 224:2,8,15,17 227:24 241:21 242:3,19 250:8 251:6 252:18 253:21 254:22 295:15 303:5,8 304:19 306:9,18 309:1 330:2 348:24 three-year 223:9 227:15 241:13	250:19 thrilled 144:12 through 11:17 13:25 14:9,12 15:2 16:12 17:18 22:1 61:16 65:21 66:25 71:16,22 73:25 104:5 111:23 117:9 120:1,14 133:24 134:4 143:16,17 144:1 153:13 156:18 161:23 169:5 170:18 179:6,22 181:14 199:23,25 203:24 214:15, 16,18 215:17 220:25 221:6 227:1 235:10 237:8 246:13 257:25 269:17 274:15 286:11 289:16,17 293:3 295:11 297:9, 11,12 298:9 309:2 328:8 335:3,6,12 340:17 344:4,18 345:10 throughout 347:12 throw 187:21,22 198:15 221:24 231:4 tide 357:4 time 4:2 7:15 8:18 9:5 10:10
---	--	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

12:1,2 13:3 24:18 41:14 42:6 44:22 56:13 60:1 64:19 66:8 75:1 76:7 78:14,18 79:16 80:13 81:5 82:4,8,12 91:9,25 105:12 107:13 113:11 121:3 122:7,13 124:18 126:17, 23 128:17 131:19 132:12 135:2 136:20 138:17 148:3 152:9 154:8 155:1 156:13 160:1 170:12,22 176:6 178:25 179:1,15,19 184:13 191:19 199:14 207:15 213:4 224:11 227:18,19 229:11,13 230:15,20 232:23 239:3 242:9,18 253:12 260:22,24 262:11,24 266:18 272:10, 17,18 274:3 276:6,10 277:13 280:7 281:14 282:3 287:7 291:17 305:3, 20,24 306:3,12 308:4,16 325:12,22 326:3	333:9 337:10 345:2,10 346:23 347:11 348:2 349:12 352:25 353:2 356:3 357:18 time-dependent 65:23 66:9 329:20 330:16 times 41:13 42:6 64:9 75:10 103:3 108:14 109:3,21 110:14,15 111:16 122:25 125:1 136:13 154:3 164:9 168:6 177:8 178:4 179:18 197:11 207:2,7, 12 237:24 307:10 319:17 330:22 340:5 345:25 Timmons 156:23 tiny 177:14 tired 300:17 tissue 39:14 145:20 147:2,17 148:8,20 149:1, 8,17,25 150:20 151:15,23 152:17 156:4, 13,14 158:1,2, 15 194:5,20 195:15 196:6,14 202:17 203:15 204:7 205:3 206:17 207:1,7,	13 208:1 209:9, 18 210:9 211:15 212:2,9,21 217:4,12,23 218:15,23 219:6,15 221:13 224:19 225:1,24 227:15 231:8,25 234:19 235:25 236:8,16 238:9 241:23 289:8,11 318:22 330:16 333:7 337:15 338:22 357:8 tissues 45:15 46:8,9 48:21 73:24 131:13 213:22 220:25 title 69:16,17 99:5 277:10 283:13 298:8 303:18 today 5:7,10 6:16 19:6 22:20, 25 29:15 32:21 55:18,25 56:3 77:19 79:10 80:11 82:18 84:12,13 91:19 109:21 111:13 112:17 130:12 161:6 164:15 166:2 174:9 177:2 181:3 207:21 213:19 273:16 286:2, 11,13,15,18 293:16 304:17 347:4,18,23	354:22 today's 5:20 122:11 347:12 357:25 together 16:24 84:13 154:16 185:24 224:25 238:15 255:8 257:22,23 316:17 told 4:24 24:5 28:16 53:10 59:6 69:13 76:10 86:25 97:20 98:4 101:11 102:9 105:8 106:22 107:3,20 111:18,21 119:18 131:12 161:7,11 163:9 211:2 269:20 275:2 294:7 300:19,20 318:4 346:16 350:8 353:3 Tom 4:7 175:21 tomorrow 5:12 295:15,21 tongue 304:17 too 16:4 19:18 37:13 72:24 90:2 101:4 108:15 124:17 135:14 161:16 162:18 167:1 207:20 215:12 218:4 222:24
--	---	--	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

223:17 232:23 241:15 249:22 287:9 301:11 took 75:9 100:4, 7 139:10 275:17 285:20 306:6 348:21 351:11, 18 352:6 top 19:16 22:1 31:11 32:8 64:12 151:9 191:22 200:25 222:8 232:15 258:21,22 259:1 263:4 288:11 320:2 topic 11:15,22 13:7 20:6,20 27:7 176:5 topics 20:20 216:12 torquing 214:14 215:18,20 toss 311:18 tossed 258:20 total 9:12 28:17 31:21 75:25 101:17 199:21 totality 49:7 102:1 210:18 309:21 totally 72:2 106:24 107:2 touch 112:11 tough 304:18 towards 127:3 160:10 357:8	toxin 19:15 Trabuco 118:20 119:2 292:13 Trabuto 118:18 track 82:19 87:4 104:2, 111:3,7 112:22 tract 296:22 traditional 71:25 154:1,3 217:7 trained 115:7 152:4 154:6,16 155:8,9 174:19 trainees 176:9 training 49:7,8,9 93:8 101:3 129:12,19 195:4,6 265:2 346:7 347:10 trans- 157:8 transabdominal 71:10 108:22 150:17 155:12 326:16 330:8 transabdominall y 155:14 transcript 14:20 24:18,20 25:22 transcripts 14:3, 18 15:5 transobturator 75:5 112:10 317:18 336:5 transplants 195:9 transvaginal	40:11 50:7 51:13 67:20 68:9 69:5,19,23 72:1 87:25 88:5 90:13 92:8 128:7 129:25 130:12,15,16, 17, 148:18 150:5,18,22 151:5,22 153:8 155:10,24 157:9,11 159:6 168:16 172:10, 15,19 173:1 174:2,11 175:6 176:8,19 177:5, 13 185:8 189:20 193:23 196:7,16 197:18 198:1 205:4,13,20 206:11,12 207:25 209:18 214:13 215:6 217:3 231:6 234:22 236:8 237:20 238:10 245:5,21 247:24 252:11 253:15 261:4,19 265:6 281:8 286:4,8, 22 287:1,4 288:15 289:17, 25 290:8,12 291:5 292:21, 22,23 293:4 300:10 302:11, 15 316:5,6 318:11 348:5 356:13 357:3	transvaginally 37:12 50:22 158:10 317:14 354:18 transverse 312:25 travel 84:20 traveling 84:23 treat 29:23 30:8 68:2 135:22 157:21 159:19 194:20 202:15 225:12 256:7 268:9 287:4 289:1,13 293:3, 8 294:14,20 296:18 322:9,20 treated 253:4 treating 108:10 136:4 155:17 188:18 206:21 225:11 264:15 treatment 65:16 66:3,24 73:7 133:19 155:7 169:13 173:2 191:23 192:1 215:13,14 242:24 243:3 259:7 286:10 288:16 289:21 314:1,20 315:12 317:1 320:4,10 323:4 treatments 67:25 73:9 188:2
--	--	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

treats 176:18	156:1 159:8,13	278:23 287:20	140:5 146:14,19
tremendously 133:3 186:1	163:16 164:17	303:22 308:5	148:10 150:13,
trends 52:18	165:10,11	309:14 312:20	157:15 170:10
trial 6:17 33:21	169:10 185:8	319:11 321:22	193:14 197:10
34:4 35:24	194:23 195:17	324:7 350:21	200:13 205:5
37:18 38:21	202:15 205:25	tunnel 121:22	228:19 243:3
39:3,5,6 41:1,9	209:10 215:9	turn 276:12	249:1 269:24
74:22,24 84:18	225:20 228:7	turned 8:19,20	types 70:3,4 72:7
94:3 223:9	229:4 234:19	turning 357:4	129:13 130:25
232:1 238:8,12	263:13 272:6,25	TV 106:5 276:12	138:5 142:24
260:4 271:21,22	274:5 275:23	TVT 315:24	158:21 173:16
trials 265:19	300:21 301:4	316:4,6 317:9	187:10 194:18
345:2,4	304:21,23	318:10 322:2	199:17 205:11,
tried 154:11	306:25 327:15	twister 304:17	226:16,24
156:15 174:23	328:22 332:15	two 27:5,18 28:2	256:21 277:7
187:13	335:7 336:16,22	29:7 31:6,11	303:5 304:7
trim 149:14	340:12 342:6	39:4 51:12 67:5	324:12,20,23
trocar 127:14,20	347:20,25	80:24 83:3	326:20 329:23
132:22 333:16	trust 283:11	90:14,15 93:10,	330:4 357:8
335:12 336:10,	302:5	15,18 112:8	Typically 134:8
15 337:3	try 33:5 53:9	124:24 132:5	<hr/> U <hr/>
trocar-based 126:18	71:18 72:3	155:6 170:17,23	U.S. 126:18
trocar-guided 203:14,17	156:9 157:4,9	179:10 232:9	127:15
205:19 206:11	193:17 194:11	234:7 236:21	UCLA 89:5
207:25 209:18	230:25 276:3	237:18,23 238:1	Uh-ooh 78:9
trocars 131:13,	337:11 351:2	239:4 240:9,23,	ultimately 142:8
14	trying 10:14,22	24 241:7 251:9	ultra-dense 219:19
true 39:1 40:20	26:24 34:10	253:21 264:7,8	Ultralight 229:21
42:15 51:4 69:6	35:6,23 45:1,4	265:18 272:11	Ultrapro 229:9
97:24 102:17,	61:13 67:12	282:3 284:25	ultrasound 332:4
109:18 114:16,	100:14 109:20	294:22 304:19	Umbreit 65:4
25 134:19	124:3 143:23	306:9 309:1	un- 220:1
141:3,9 143:24	151:13 153:2	two-year 232:4	
145:8 146:19	187:15 198:14	235:12	
148:5 155:22	206:2 208:24	type 14:15 39:7	
	232:18 235:21	51:3,15 56:22	
	241:8 247:23	70:2,5 94:15,16	
	248:4 250:21	111:5 128:23	
	256:19 260:15		

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

unacceptable 269:11	87:10 90:3 93:22 97:16	213:20	250:16 251:8 260:19 261:5
unacceptably 130:9 267:2	98:2 100:6 109:20 117:10	unfamiliar 111:5 unfortunately 37:8 73:7 209:11 271:25	up 12:5,11 22:2 54:7 57:14 72:6 73:2 74:21 91:10 104:16 113:1,2 117:15 123:21 133:22 137:16 142:10 143:12,19 147:13, 152:20 153:5,7,10 155:13 159:1,4 169:23 171:1 176:15 192:7 208:13 213:3 216:11 222:19 226:15 227:23 230:25 232:7 233:24 235:12 239:2 251:1 252:19,25 269:4 276:20 277:12 282:6,19, 288:23 290:14, 20 298:3,17 300:11 318:24 319:11 323:24 325:9 328:15 329:9 337:11 340:7 341:5 342:8 346:23 348:21,23 357:21
unaware 39:2 48:21 111:5 236:17 302:5	125:1 156:11 165:14 166:1,9 173:25 177:21 208:24 211:12 232:21 234:25 260:15 264:2 293:11 298:4 313:13 334:5 344:19 346:6 357:19,24	unique 31:8 114:12 148:18 193:1 260:3 262:7 unit 135:21 United 115:17 116:25 136:18, 24 170:10 173:23 197:7,17 262:9 263:14 353:9 University 187:9 unknown 125:21 126:6,13 unless 6:20 154:23 172:12 214:5 223:23 239:4,12 260:22	
uncover 147:15	understanding 5:10,14 24:8 41:14 88:3 259:16 300:9 340:14 350:24 351:6,19 352:10,17 353:11	unlikely 158:6 159:10 unrealistic 109:18 unreasonably 31:4 193:23 unreliable 211:18 unsafe 333:17 unsupported 39:25 until 8:19,20 170:23 192:9 221:15 239:18	
uncovering 147:18	Understood 33:18 74:7 154:25		
under 124:18 125:25 134:20 155:9 201:3 219:9 259:16 265:15 274:16 275:19 283:13 307:16,18 317:3 334:18,21 335:1	underwent 208:1 238:9 undesirable 343:22 unequivocally 67:16 unethical 238:24 239:13,16 240:1 unexpected 327:14 unfair 11:5 42:4 44:24 59:23 107:4 176:1		
undergo 137:21 163:24			
undergoes 149:8			
undergoing 108:11			
undergone 206:11 231:6,7			
underlining 181:12,13			
underneath 283:15			
underpowered 217:25 219:9 225:8 247:21			
understand 5:7 10:14,24 19:25 24:20 30:3 33:11,21 34:5, 10 35:23 61:13			up-to-date 62:18 update 8:10 212:16 227:20 253:14 updated 7:20,25

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

8:5,17 9:9 11:11,23 13:14 16:9 17:14 22:19,21,24 23:5,10,16 24:17 25:13 90:1 285:13,15 343:20 upon 19:3 21:1 30:14,25 47:23 93:18 107:12 116:4 141:16 151:4 155:7,8 186:2 204:8 212:12 217:18 218:1 234:12 255:5 261:13 264:10 269:1 271:21 296:4 303:18 310:19 338:1 341:2,3 343:12,16,25 344:14 356:18 uptick 105:12 106:19 122:1 urethra 69:25 71:16,22 72:1, 25 73:23 147:19 urethral 72:17 294:13 urgency 140:20 urgent 268:23 278:6 urinary 68:2 147:5 183:1 294:14,20 296:10,22 314:2 317:1 319:7	320:4,11 322:9, 20 323:5 336:22 356:9 urinate 140:16, 19 Urination 140:18 Urodynamics 63:5 319:18 Urogenital 319:18 urogyn 9:19 119:1,2 188:14 199:4 239:15 Urogynecologic 188:9 190:1 331:14 352:20 urogynecologist 100:18,24,25 322:14 331:16 333:20 urogynecology 118:10 119:5 120:22 121:11 122:15 128:5 178:10 287:3 295:1 297:23 322:18 Urologic 68:17 urologic-gyn 90:20 urologist 49:3 100:24,25 101:1 333:20 349:4 urologists 120:25 187:7 330:15	urology 9:20 10:21 29:8 49:13 63:5 66:18 70:23 86:6 94:12 99:7, 14,19 100:11,15 101:3,10 124:25 187:3 272:10 274:13 286:21, 25 292:13 294:21 322:12 Urology's 63:1 us 16:25 33:18 71:15 82:17 99:23 101:2 104:17 115:13 124:4 137:20 168:3 183:19 207:8,9 208:14 209:12 210:13, 22 213:3 227:13 231:16 232:10 233:19 245:6,22 248:5 274:22 287:6,7 293:24 300:20 344:22 355:23 use 35:20,21,22 52:17 66:2 69:5 126:8, 130:12 142:11,19 155:20,25 157:21 172:24 173:7 174:2,11 176:19 177:5 202:20 232:19 259:5 260:6 261:4,15,19 274:24 284:7	287:1,3,8 291:5, 11 292:22,23 294:13,19 295:1 296:24,25 297:1,4 298:3 301:21 302:15 303:22 313:18 320:14 322:11 325:5 333:22,24 334:5,13 335:20 341:14 345:16 349:15 used 10:11 12:6, 8 14:18 24:15 29:23 30:8 34:13 64:17 101:12 117:11 119:21 143:9 152:2 156:12 201:16 202:15 226:22 227:10 229:24 246:17 247:11 266:18 286:8,21 289:1, 7,13 293:3,8 294:21 295:4 296:9,18 297:6 299:15 302:8,25 308:11 313:15 323:7 329:14 333:16 336:9 337:3 354:6 users 111:23 uses 71:12 172:14 205:6 322:12 using 10:12 15:18 31:9 51:17 68:7 73:4
--	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

95:20 96:4 128:6 130:24 147:16 152:10, 17 160:25 161:2,10 162:1, 10 172:17,19 173:1 196:23 201:24 205:7 228:24 232:19 235:25 245:5,21 248:12 251:16 273:15 284:2 291:19,22 294:23,24,25 309:1 322:8 336:15 usual 134:3 usually 64:17 72:2 106:16 113:18 138:7, 10,11 139:19 140:20,21 143:18 148:19 170:23 205:6 218:10 354:1 UT 89:5 108:25 uterine 146:10 uterus 134:9	313:5 326:24 335:7 vaginal 64:22 65:16 66:3,24 120:15 121:5 142:14,25 148:12,20,22 151:2,10,20 156:15 160:5 194:2,5,7 198:19 199:12 200:17 203:15, 18 204:6 216:21 217:7 223:8 225:19 237:2 242:12 244:22 251:2 265:20 297:10 299:15 301:8,22 316:25 Vaginally 119:10 vaginas 200:12 313:11 vague 53:18 vaguely 300:7 valid 131:7 validity 288:8 Valsalva 134:21 value 225:9 valuing 233:1 valve 193:14 valves 328:3 van 257:5 variability 131:15 variance 223:25	variant 12:2 variations 65:23 66:9 264:25 329:20 varied 246:11 266:7 varies 264:19 various 14:13 24:15 200:12 276:21 311:22 339:5 346:1 vary 85:25 varying 266:10, 14 vascular 148:19 vast 11:15 193:2 325:16 vault 65:16 66:3, 24 194:2 verbal 79:3 version 22:19 62:18 versions 21:9,22 versus 29:4 39:8, 22 40:23 45:10, 15,16 75:5 81:19 136:4 137:5 159:6 193:11 196:8 201:17,25 202:21 211:15 212:1, 216:21 217:3 219:6 224:19 225:24 227:14 231:25 271:22 318:12	very 7:16 11:5 18:17 37:9 38:14 41:8 46:18,23 71:11, 16 74:2 89:24 101:5 103:23 105:21 108:19 109:2 113:3,18 114:14 115:21 121:13 123:2,5, 15 125:13 130:2,10 131:16 136:24 137:12 138:7 149:3,12, 19 152:16 154:10,12 156:25 163:10 166:12,14 172:1,8 175:3 176:4,5,22 179:5 181:6 186:12 187:7 193:4,19 194:9 195:21 198:8 207:14,15 208:8 224:16 236:4,19 239:5 245:24 251:10 254:5 256:6,7,25 257:3,8,9 258:12 259:24 261:3 263:9 267:1 270:21 271:6 275:11,14 279:17 282:1 296:20,21 297:13 309:19 310:12 312:22 321:25 325:8,9 335:22 346:4
<hr/> V <hr/>			
vagina 73:23, 139:25 140:7 148:18 153:5,18 158:4,9,10,12 162:18 213:23, 25 215:17 216:7 289:17 293:4 297:9,11 302:9			

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

350:21 356:8 via 152:7 168:23 198:3 214:21 332:3 viable 336:25 video 4:1,3,11 50:8,15 76:25 78:14,17,22 82:4,7 138:17 139:2 230:11, 13,15,19 248:6 294:1 305:17,24 306:2 309:24 322:19,23 333:9,10 341:18 357:25 videographer 248:4 293:24 videos 50:5 Vierhout 211:6 view 131:25 211:13 views 193:10 Virginia 5:1 virtually 353:8 visceral 72:19 visibly 140:6 vision 334:18,21 visiting 275:13 visits 142:23 Visual 210:16 211:21 vitae 62:19 vitro 93:3 vivo 93:3 307:20 331:3	vocal 185:2 187:12 void 140:16 volume 247:15 264:22 317:16 355:12 volumes 197:7 251:22 vouch 317:9 <hr/> W <hr/> W-u 252:6,7 Wahl 89:6 wait 55:11,22 174:4 272:22 300:19 wait-and-see 141:22 walk 108:5 wall 37:12 158:18 215:14 223:8 302:1 Wallace's 91:12 wander 166:15 want 9:7 20:5 27:19,21 33:5 35:20,22 36:6 41:18 43:3 49:15 51:24 52:6 55:7,8 56:10,13 59:16, 20 66:25 91:9 100:14 101:2 110:19 114:4 123:11 124:12, 17 125:24 133:8	135:9 143:15 165:17 166:9 169:23 174:17 176:3 184:21 187:12 190:15, 24 191:9 197:21,23 202:3 207:19,20 211:12,24 216:11 230:25 234:10 239:17, 22 240:19 244:15 245:16 260:12 264:1 269:19,20 270:24 271:4 275:1 292:3,6 293:14,19 296:21 298:5,17 319:9 321:21 328:5 346:15 wanted 18:17 19:13 20:7 21:3, 7,12,16,18,22 25:7,23 26:7 59:5 72:3 76:9 155:12 157:4 178:17 184:20 205:5 207:6 266:24 268:13, 18 278:5,10,14, 15,22 281:20 319:5 357:23 wanting 141:1 wants 143:15 175:21 warn 160:21 296:23 330:15 343:8	warned 340:11 343:4,13 warning 106:1 340:16 342:22 353:1 warnings 49:20 54:21 276:11 290:18 340:15 341:9,11,12 343:21 346:3 washed 307:12 wasn't 35:7 67:18 92:11 152:19 170:14 178:12,20 200:5 250:9 288:8 waste 91:9 124:17 watch 149:11 watched 195:21 wave 176:8,9 way 12:21 19:23 39:20 51:5 59:11 71:25 72:4 76:13 83:22 94:5 129:6 144:17 145:3 153:18 155:15 157:19 162:8 164:13,21 222:7 231:11 272:2 292:21 315:25 320:24 322:8 331:2 ways 136:22 we'd 22:2 109:14 202:10 224:21 237:8
---	--	---	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

244:14 248:22	278:23 290:22	109:12 110:14	101:18 104:11
we'll 5:11,12	291:1 298:23	161:7	106:4, 107:24
29:15 60:2	299:12 302:3,8,	weeks 8:25 9:15	109:7,20 110:6
82:19 203:8	10 305:24 306:2	51:12 75:23	111:2,18 113:25
206:22 213:7	308:5 309:14	108:14 110:15	115:14,21
241:19, 295:20	315:17 317:15	161:8 326:22	116:13 120:11
we're 4:1 5:7	318:10 319:8	330:2,8	121:15 122:18,
6:15 10:12	325:17 329:8	weight 226:24	22 123:4 124:3,
28:13 32:21,22	335:23 341:16,	228:9	16 130:18
35:13 41:16	17 346:11	weird 312:4	131:10,23
42:7 44:13,15,	347:18,23	welcome 273:18	132:19 134:18
19 55:11,18,20	we've 56:12,24	well 5:14,25 7:18	135:7 136:6
56:3,10 68:21	62:2 69:7	8:20 12:6,14	137:3 138:1,4
72:6,18 78:14,	102:11 111:8	15:17 16:14	140:12,16,21
17 82:4,7 84:12	148:10 167:5,20	17:11 18:9 19:3	143:2 144:15
100:10,11	169:2 171:10	20:16 21:15	145:3 148:17
104:3,23,24	176:15 177:2	23:14,18,24	150:1,15,20
107:12,13,18	178:3 185:6	24:5,22 26:24	151:12 152:11,
109:11,12	207:21 221:14	27:16 31:18	13,15,16
110:6,16 122:1	223:4 224:25	32:10,16,23,24	159:13,16
134:8 139:2,24	225:18 228:14	33:8 35:22 36:8	160:11 161:1
147:15,18 159:1	232:22 233:14	41:2 42:22 44:7	164:24 165:13
161:22,23	236:10,11,24	46:16 47:2	167:19 169:25
166:16 167:6,17	244:19 255:14	50:18,20 51:5	170:13,25
170:6 171:1	266:6,15,22	52:20 55:7	171:17 172:1
181:4 183:8	271:1 286:11,12	58:23 59:24	176:20 177:16
185:24 187:6,10	334:20 343:3	61:21 63:18,20	178:7, 179:16
193:16,20	weakened 135:1	64:16 67:2	180:23 181:4,25
194:16 197:10,	289:8	69:17 70:6,11	182:8 186:11
19 200:13	weakness 134:4	71:1 72:16,20,	189:15 191:1
205:9,17,19	135:10 153:2	21 73:19 75:6	192:25 193:4
206:2,5,21	Web 285:1,17	76:4 77:9 79:22	195:10 197:11,
210:17 222:10,	292:16	81:16 83:18	14 198:8 200:16
19,20,21	Website 283:7,9	86:25 87:17	201:22 202:16
226:17,18	284:8 285:1	88:14,16 89:17	204:12,22
230:15,19	290:25	90:10 92:3	205:1,19 206:4,
233:11 236:7	week 73:11	93:18 94:25	8 207:18 209:23
244:9 245:10	103:4,16 105:8,	95:8,10 97:18,	210:10 211:3,5,
246:25 252:17	9,16 108:14	20 98:15 100:25	16 212:14,24
267:4 275:1			217:6 224:17

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

225:20 226:21 227:19 228:15, 25 233:3,5,23 234:4 236:13 237:4,10,17 238:6,24 239:7, 17,24 240:15 241:3,14 243:15 244:25 247:12 248:2,17 249:8 252:21 254:4,21 255:6,14,20,24 256:1,3 257:6 263:18 265:4,24 267:25 268:2,6, 13,21 272:15 273:9 275:24 276:5,7 278:5 279:13 280:10 281:24 284:4 288:2 289:23 291:7,14 292:18 293:1,2,11 295:6,12 296:16,20 297:8 298:16 299:2,20 303:14 304:25 306:21 307:24 309:15 310:10 314:7 316:17 318:3 320:8 321:9,11 322:6, 18 323:8 326:11 327:1,11,13 328:12 329:7,15 330:22 331:4 332:9 335:6 336:2 340:7 343:6,12 344:8 346:9,12 349:23	357:15 well-controlled 350:1,10 well-established 148:14 194:21 195:15 215:8 231:18 well-known 88:5 253:23 254:1,5 276:22 went 45:25 61:16,20 71:16, 21 76:10 122:20 123:3,19 169:5 195:24 199:23 239:15 269:17 315:25 were 5:16 6:13, 17 9:8 11:10,11 15:4 16:20 17:9 18:7,14,20,22 19:7 20:2,9 22:1,3 24:2,25 25:8,24 36:11 37:22 38:1 39:9 40:18 42:14 47:16 61:18 63:20 66:13 67:24 69:1 70:11 71:9,20 75:13,16,24 76:6 82:17 85:1, 5 87:7,20,21 88:4 90:23 91:2, 16 95:22 96:1,4, 12 102:2 111:4, 5 113:6,11,12 119:14,21 120:7,10,20	121:3 122:5,14 124:19 125:3 126:17 128:12, 16 129:2 131:21 132:11,16 139:10 143:12 149:13 152:10 155:11 156:3 157:4,11 161:16 162:1,6,18,19 164:20 170:11 171:19 172:18 173:7 175:13 176:22 178:5,8 179:2 183:12,13 184:12 186:22 191:6,7 193:18 194:13 195:23 200:11,22 201:15,23 205:2,16 207:2, 9, 208:10,11,17 217:19 218:1, 11,20 219:1,15, 221:20 222:24 224:22 226:7,21 227:15 229:12 232:11,19,22,23 234:10 237:4,9 238:2,4 240:22 241:5,11 242:8, 23 243:20 246:6 252:10 256:14 258:19 260:23 261:10 263:17 267:21 272:16, 17 276:6 278:2 281:10 282:14 283:22 284:4, 287:5 290:7	301:16 306:5 309:12 312:15 315:21 316:1,8 318:4,8,9 324:24 330:23 345:9 347:15 348:2,3,17 349:14 351:3,23 352:19 353:13, 18 354:17 355:14 356:2,11 357:17 weren't 10:15 36:10 121:20 246:2 West 5:1 Western 171:20, 23 Wexler 91:12 what's 30:24 31:9 33:13 63:21 71:6 87:13 100:23 103:25 112:19 124:6 147:9 224:12 233:16 242:17 244:12, 16 248:5,21 323:20 331:1,3 339:11,14 349:18 whatever 100:12 109:15 118:6 138:13 146:23 250:10 263:3 264:9 274:21 277:10 whatsoever 39:7
--	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

243:24 318:4	216:15 217:17	102:2 104:3	288:22 292:14,
whenever	219:1,18	105:5 108:3	16 297:24
307:24	220:13,18	109:2,5 113:6	321:12 322:1,13
whereupon 4:14	221:11,12,25	114:10 118:18	323:14 349:6
138:19 139:4	222:1 224:4	120:14 121:4	354:1,2 356:19
whether 14:25	225:20 229:7	123:18 128:6,	who's 329:11
20:8 42:11	232:18,23	16,24 129:2,4,	whoever 22:25
57:20,21 73:23	234:14 235:6,8,	12 130:8,12	98:9 255:15
84:22 91:16	9 237:1 238:19	132:18 135:22	291:1
114:19 130:3	242:12 243:7	140:5 145:25	whole 16:13 20:6
184:4 203:1	245:24 247:15	150:18,24,25	27:15 57:23
240:19 252:21	249:9 255:19	154:15 155:13	66:25 123:11
270:19 306:9,17	264:9 265:10,25	163:24 168:20	124:12 135:19,
308:10 309:16	266:13 267:10	171:14 173:12	21 138:14
315:21 316:1	271:14,21	174:19,20	259:11 271:19
343:4 345:21	273:13 274:7	175:2, 176:18,	wholeheartedly
which 8:5,22	279:17 284:19	19 177:4,25	36:6
14:15 16:20	302:2 304:3	179:1 184:13	whom 282:16
17:15 18:14	309:11 312:21	185:2, 186:25	whose 187:14
19:2 22:12	313:3,6,7,10	187:12 188:17	why 8:10 10:14
23:14 28:25	319:16,20	189:4 193:13	20:12 33:8
29:1 37:22	321:12 330:18	194:19 195:22	59:15 100:6
38:11,13 48:19	341:7 349:3	196:25 198:1,2	105:19 135:12
49:11 50:25	355:9,22	201:15 206:10	143:22 146:18
51:7,21 53:16	while 57:15	207:1,24 208:1	148:2 161:23
57:1 58:11 62:2	59:25 158:13	224:8 226:23	164:24 165:1
65:14 66:11	213:17 252:14	227:2 231:5,7	173:19 205:24
67:23 71:9,16	266:4 277:9	233:12 235:24	206:20 220:21
74:8,11 103:15	294:8 305:15	238:9 241:2	246:24 255:23
104:9,23 125:15	white 299:1	243:23 245:7	258:4 269:15
127:5 134:21	301:7	254:8 255:9,11	271:1 274:15
143:22 153:9	who 4:6 23:1	256:7,11	276:14 280:18
158:10 159:1	49:2 57:21	257:10,22	282:19 308:17,
183:20 188:8	70:19,24 71:4,	258:1,6 263:12	24 309:14,15,
190:3 193:19	15 72:18,23	264:3 269:2,4,5,	16,19,21
195:4,21 199:5	73:7,22 76:17	6,22 270:4,15	317:20,21 343:6
200:17 204:9	77:10 79:4	272:8 277:10	Wilkes 98:5 99:4
205:5,6,24	88:25 89:2 97:4,	278:18,20	
208:25 214:14	6,14 99:23	283:19,24	
		284:17 286:10	

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

Wilkes' 98:11,15 99:3	45:9,21 46:5,12, 47:14,16 48:3, 13 49:24 50:1,4, 7,14 52:2,11,25 53:2 54:7 55:18 56:15,16 57:24 59:8,14 62:8 63:23, 64:24 65:8,9,15 66:6 67:4,7,16,19 68:11,15,20 70:7 71:1,16,17, 18,21,25 72:21, 23 73:1,3,6,8,20 74:1,20 75:7,24 76:13,17,19,21 77:3,18,19 79:6, 7,10 80:11 87:13 89:21,22, 25 90:11,13,16 91:24,25 92:4, 10,19 93:1,5,11, 12,13,25 94:14 95:2 96:13 97:12 98:10,25 99:4,5 101:14 102:2 103:5 104:13 105:17 106:19,23 108:2 109:7,9 111:5 112:11 113:4,6, 11,24 114:6,10 117:15,20 119:3,14 121:11,22 123:5 126:25 127:9,11 128:17,21 129:8,16,25 130:1,7 131:2,7, 21,25 133:4	134:17 135:1,2, 10 136:6,11,14 137:11, 139:19 140:2,15,25 141:2,5,8,13,23 142:1,4 144:10, 12,22 148:9,10, 13,15,17,18,24 149:2,12,15,20, 21,24 150:8,17, 22,24 151:4,5, 13,17,19,22 153:17 154:7,25 155:13,17 156:4,7,12 157:3,10,17,22, 25 158:1,15,19, 24 159:3,6,12, 16,21,25 160:16,18,20 161:12 162:21 163:7,8,17 165:8 166:12, 13,15 167:3 168:5,7 169:9, 16 174:8,20 175:11 177:2, 10,12,18 181:2 182:6 183:14, 20,21 184:12 185:1,12 186:4, 6,18,23,24 188:3 189:24 190:6,8 191:12, 15,17,23 192:2, 7,22 193:3,11, 23 195:14,15, 19,25 196:6,8, 12,16,23 197:3, 8,12,14,25	198:6,19 199:11,19 202:16,25 203:15,18 204:24 205:10 207:1 208:14, 15,22 209:20 210:10,15,24 211:6 212:3 213:4,5,21,22 215:8,21,23,25 216:21 217:7, 10,24 218:9 219:12 220:15 222:10 223:8,9, 14,18,25 224:22 225:10 227:24 228:18 229:5,6 231:12,14,20 232:10,18 235:23 240:6, 13,17,24 241:20 243:11 244:8,22 245:12 246:15 248:17,23 250:7,15,16 251:18,22 252:3 253:15,19,21 255:1,13 256:16 257:21 259:19, 21,22 260:2,7 261:8,14,17 262:4,24 263:13,22 264:12 266:2,8, 14,17,23 267:21 269:4,6 270:17 272:7, 274:14 276:11,19,21 277:4,6,20
---------------------------------	--	---	--

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

278:7,10	212:16 219:11	88:8,13 89:4	130:3 135:16
279:18,20 280:1	223:13 246:4,8	90:9 91:5,23	136:21 138:2
281:10 283:22	247:2 249:4	92:15 107:1,8	139:11 141:13
284:21 285:18	250:7	115:2 121:18	142:10,19
286:1,6,14,17	Withagen's	122:9 123:13	143:22 144:10
287:21,22	207:23	130:14 137:10	145:25 147:1,
288:16 289:4,25	withholds	156:6 164:11,19	19,21 149:8,22
290:16,17,19	191:24	165:4 166:11	159:5,19 193:8
292:21 293:9,23	within 62:20	168:15 171:25	194:19 196:5,12
294:3 297:10,21	129:22 173:3	174:15 175:20	205:2 224:8
298:3 303:2	175:8 187:2	176:2 177:9	233:2,12 256:19
304:15,24	257:3 347:5	186:10 188:24	262:4,6 269:10
307:2,9,25	without 32:8	189:11 194:14,	309:17 316:2
311:6 312:2,21	53:21 104:16	25 208:7 211:4	woman's 136:12
313:1,6,10,14,	107:10 173:16	212:23 215:11	139:25
24 314:21	174:25 175:11	216:20 217:16	women 72:2,18
315:1,14,20,22	177:13,20	219:17 221:18	95:22,25 96:10,
316:1 318:11,	193:15 209:16	225:5 230:10	11 101:13,16,17
13,14 319:2	276:12 277:22	233:22 234:21	102:2 107:21
320:7,20	285:23 287:7	238:15,17,19	113:6,10,22
321:10,22	326:23 340:7	239:11 250:13	114:9,10 116:20
322:1,15,22	withstanding	259:10 262:2	119:14,25 123:7
323:9,22 324:18	275:5	270:10 278:12	128:4,12,16,24
325:12,22	witness 4:12,13,	280:11,15	129:2 131:22
326:13 327:5	16 5:4 6:17	300:6,13 301:3	133:19 134:5,6
328:13,17	14:23 23:4,9	305:12,22	135:22 136:4,25
330:12,25	26:25 30:1,11	316:13 321:24	137:20 140:5,
332:1,21 335:3,	32:19 33:12,14	323:18 327:10,	10,14,24 142:2
8,11,15,18,24	35:1,10 36:5,13,	21 328:11	143:4 176:18
337:3,5 339:7,	16 40:8 42:4,17	332:14,24	177:24,25 179:2
17,18,20 341:2,	45:13 48:8 49:6	333:11 338:13	183:9,12,21
3,4 342:8 343:1	52:5 53:20 54:4,	341:1 344:7	187:14 189:4
344:20,22,23	18 55:14,17	346:18 348:9	190:23,24 192:5
345:4,22 346:19	56:18 59:19,23	350:4,14 351:5,	196:25 198:1,2
351:8 355:25	60:5,22 67:10	21 352:9 353:22	201:15 205:2
356:10,11,19,	74:25 75:11	354:9,15 355:5,	206:10 207:1,
21,24 357:9	77:1 79:14 81:9	20 356:17 357:6	15,24 208:1
Withagen	85:6,13,18	woman 47:10	209:7,9 210:7,8
203:17,20,21	86:21 87:11,23	71:15 72:23	217:10,12
205:6 210:24		73:22 112:8	218:7,13 219:5,

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

14 223:15,18 224:15 225:9 226:1 231:5,7 232:23 234:4,10 235:23,24 238:8 241:21 242:8 243:22 245:7,22 253:24 254:25 255:3,9,13 256:8,19 259:6 260:7,25 261:6 263:13 269:8 270:1 276:24 282:8 313:9 315:12 320:6, 19,22 321:2,10, 12,13 323:4 331:5 336:21 338:4 348:22 349:14,16 350:21 351:24, 25 356:5 women's 190:23 191:16 193:5 196:19 200:12 278:24 won't 35:3 54:11 113:19 146:7 156:22 175:10 261:23 wonderful 272:19 word 13:24 14:6, 16 48:20 52:17 122:25 127:9 164:12 167:14 196:23 200:24 263:15,18 272:1 348:20	Worded 222:7 words 12:4 33:6 35:12,20,22 38:20,23 68:4 84:6 125:10 165:9 207:5 217:18 284:19 297:2 325:19,25 326:20 333:22 334:12 351:1,14 work 53:6 65:18 68:22,24 70:20 71:19 77:10 79:19 83:14 85:6,23 86:21 93:19 117:9 151:22 152:10, 13,15 153:8 154:13 156:23 186:3 233:9 260:6 277:19,21 310:19 324:18 336:2 338:23 workday 8:21 worked 116:9,11 working 10:17 54:19 58:14 59:7 76:1,13,17 77:5 80:1,14 83:20 85:1 153:9 277:4,6 281:10 283:22 346:4 works 70:6 71:14,19 140:20 171:18 world 12:10 69:1 114:11 130:6	162:19 176:25 186:21 290:25 322:3 356:24 world's 336:24 worldwide 320:3,10 worrisome 242:17 worry 86:19 worse 73:12 108:8 212:12,13 217:22 worthless 211:11 wouldn't 13:4,9 26:17 85:14 88:24 90:10 135:7,9,13 156:20 165:21 178:19 185:16 186:4 209:24 212:10 233:23 252:22 270:24 271:4 278:17 323:13 340:8 344:3 wound 198:18 199:10 327:18 wrap 230:25 337:11 write 107:18 226:7 272:9 275:15,19 322:11 writes 218:11 writing 11:15 64:2 159:1 170:17 271:20	281:6 written 93:10 246:19 266:2 276:17,25 282:5 288:23 290:14 305:13 308:16 310:23 342:4,8 353:19 wrong 43:16 57:14 121:15 142:1 167:14 191:3 239:2,3 248:5 274:23 282:9 310:21 329:6 330:21 wrote 65:13 74:21 133:1,22 169:21 269:4,6 272:7,18 273:13,25 275:16 278:25 279:2 282:16 291:1 307:24 308:20 325:13 354:1,2,3 Wu 251:12 252:1 <hr/> Y <hr/> Y-shape 161:21 Y-shaped 161:2, 10 162:1,11 yeah 14:24 15:10 17:21 18:12 21:24 22:20 24:22 25:11 63:9 64:8 68:23 83:3 91:14
--	---	--	---

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

93:10,19 95:3	326:3,22 330:1,	242:4,19 250:9,	19 89:20 90:7
100:4 101:22	7 331:10 332:23	14,17 251:6,8	94:22 97:16
102:7 104:22	335:8 336:23	252:16,18,20	99:7,19 100:8,
106:13 111:2,9	338:14 339:11	254:22 257:25	17 102:16,23
116:17 118:24	341:22 342:23	315:22,24	103:14 110:9
121:13 125:1,5	346:19 348:20	316:2,3,9,	115:17,23
126:7,8 131:6	350:5	318:24 321:13	116:20 117:14
137:23 138:15	year 49:8 68:18	323:21 341:4	123:24 125:9
140:13 143:3	85:25 94:12	347:24 348:25	130:24 144:14
157:23 158:17	108:14 110:15	352:14,18	145:10 147:21
160:18 162:5	112:24 121:10	Yep 7:7 69:3	148:12,24
169:4 171:12	122:6,15 137:21	102:14 222:18	149:15 150:16
179:4,13,25	170:3,13	280:6 289:9	153:1, 158:5,7
180:4 182:18,20	172:16,18	yes-or-no 43:14	160:25 161:6,10
188:19 189:12	176:14 182:11	yesterday 7:18	163:23 165:19
199:13,16,18	213:3 234:25	yet 20:9 64:13	168:16 172:14
200:1 201:2,13	251:7 252:17	69:3,7 95:16	176:18 177:16
203:20 204:8	254:6,8 257:2	114:13 127:19	178:13 180:23
205:7,15 206:14	275:8 277:13	174:6 258:18	184:14 185:21
221:19 222:2,	294:22 314:14	276:8 341:17	186:11 188:3,8
13,22 224:3	322:24 336:7	you'd 26:22	189:2 194:16
230:10,14 232:1	years 12:16 29:7	226:9 305:8	195:13 196:22
237:7 238:14	49:8,13 71:4	you'll 9:24	197:12 202:5
242:16 244:21,	74:11,14 85:20	335:15,18	207:14 212:6,7
23 249:14,23	86:21 99:22	you're 22:11	214:6,8 216:15
250:25 262:16	105:17,20	23:20 29:18,21	226:4,11 227:21
263:23 266:1,22	110:16 121:4,9	33:3,16 35:8,13	228:2,24 229:23
268:14 279:9,24	124:24 132:5	41:12,14, 42:23	230:8 233:4
280:11,15	133:22 148:21	43:22 45:14,24	238:22 239:25
285:10,13	149:10 159:4	48:10 50:25	240:3,9,13
286:5,24 287:20	162:21 170:17,	51:21 52:7,9,16	245:9 259:13
288:7,13 292:11	23 192:24 195:2	53:4,11,16	264:8,10 265:8
298:14 299:6	199:18,21	55:21 57:12,14,	266:5 268:4,7,
300:8 301:23	208:13 209:2	15,18,19 58:11	10 270:11,12
303:2,11,18,25	212:13,17,18	59:7,12,19,	273:9,18
304:5,11 305:19	213:3 214:2	60:23 68:6	282:12,13
308:15,17 310:6	223:18,21	79:16 84:22	288:12 290:22
313:3 315:1,5,	224:2,8,15,17	86:5 88:11,16,	291:10 293:4,17
23 318:7 320:25	227:24 233:12,		295:14 298:20
323:6 324:16	25 234:7 241:21		300:7 315:20

In Re: CR Bard 200

Daniel Elliott, M.D.

11/15/2014

317:10 319:22	Youtube 322:19	
329:16 332:22		
333:2 335:10	<hr/> Z <hr/>	
341:21 345:20		
346:22 357:13	Z-a-k-r-z-e-w-s-	
you've 5:3,13	k-i 25:12 27:3	
6:3 17:24 20:18	Zakrzewski	
22:20 29:16	25:11 27:2	
33:13 34:17	zero 162:21	
42:2 47:1,5 51:3	163:12 164:4,	
56:12 59:25	14,25 165:23,25	
64:15 68:23	166:2,7 177:17	
72:9 83:5,13	243:9 244:11	
85:17 87:6,19	284:24	
94:20 95:5,12	Zhong 298:24	
96:24 98:4	310:16	
102:12 104:21	Zimmerman	
106:18,23	9:22 108:24	
107:6,21 108:10	125:15 187:11,	
109:21 111:16	12	
140:11,24	Zimmerman's	
145:4,25 161:3,	132:7	
11 169:1,12,18	Zimmern 89:5	
180:24 197:11		
209:7 223:12		
291:1 311:19,20		
319:16 325:19		
329:14 330:11		
336:2 342:5		
347:4,7,8,9		
yours 171:6		
322:17		
yourself 17:5		
48:24 49:2,3		
92:6 94:7 96:20		
102:12 152:2		
295:21 296:1		
340:22 345:21		
yourselves 4:5		